UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM N-CSR
CERTIFIED SHAREHOLDER REPORT OF REGISTERED MANAGEMENT
INVESTMENT COMPANIES
Investment Company Act file number: 811-21656
| Name of Fund: | BlackRock Energy and Resources Trust (BGR) |
| Fund Address: | 100 Bellevue Parkway, Wilmington, DE 19809 |
Name and address of agent for service: John M. Perlowski, Chief Executive Officer, BlackRock Energy and Resources Trust, 50 Hudson Yards, New York, NY 10001
Registrant’s telephone number, including area code: (800) 882-0052, Option 4
Date of fiscal year end: 12/31/2024
Date of reporting period: 12/31/2024
Item 1 – Reports to Stockholders
(a) The Reports to Shareholders are attached herewith.
| 2024 Annual Report |
| BlackRock Energy and Resources Trust (BGR) |
| BlackRock Enhanced Equity
Dividend Trust
(BDJ) |
| BlackRock Enhanced Global
Dividend Trust
(BOE) |
| BlackRock Enhanced International Dividend Trust (BGY) |
| BlackRock Enhanced Large Cap Core Fund, Inc. (CII) |
| BlackRock Health Sciences
Term Trust
(BMEZ) |
| BlackRock Health Sciences Trust (BME) |
| BlackRock Innovation and Growth
Term Trust
(BIGZ) |
| BlackRock Resources & Commodities Strategy Trust (BCX) |
| BlackRock Science and Technology
Term Trust
(BSTZ) |
| BlackRock Science and Technology Trust (BST) |
| BlackRock Utilities, Infrastructure & Power Opportunities Trust (BUI) |
| Not FDIC Insured • May Lose Value • No Bank Guarantee |
| |
|
Total Cumulative Distributions for the Fiscal Period |
% Breakdown of the Total Cumulative Distributions for the Fiscal Period | ||||||||
| Trust Name |
|
Net Income |
Net Realized Capital Gains Short-Term |
Net Realized Capital Gains Long-Term |
Return of Capital (a) |
Total Per Common Share |
Net Income |
Net Realized Capital Gains Short-Term |
Net Realized Capital Gains Long-Term |
Return of Capital |
Total Per Common Share |
| BGR |
|
$ 0.347383
|
$ —
|
$ —
|
$ 0.492017
|
$ 0.839400
|
41 % |
— % |
— % |
59 % |
100 % |
| BDJ |
|
0.360710 |
— |
0.319390 |
— |
0.680100 |
53 |
— |
47 |
— |
100 |
| BOE |
|
0.194338 |
— |
— |
0.581362 |
0.775700 |
25 |
— |
— |
75 |
100 |
| BGY |
|
0.089746 |
0.061249 |
0.263405 |
— |
0.414400 |
22 |
14 |
64 |
— |
100 |
| CII |
|
0.064773 |
— |
1.170727 |
— |
1.235500 |
5 |
— |
95 |
— |
100 |
| BMEZ |
|
0.025970 |
— |
— |
1.665080 |
1.691050 |
2 |
— |
— |
98 |
100 |
| BME |
|
0.077993 |
— |
1.902998 |
0.624109 |
2.605100 |
3 |
— |
73 |
24 |
100 |
| BIGZ |
|
— |
— |
— |
0.833900 |
0.833900 |
— |
— |
— |
100 |
100 |
| BCX |
|
0.228555 |
— |
— |
0.410945 |
0.639500 |
36 |
— |
— |
64 |
100 |
| BSTZ |
|
— |
— |
1.117905 |
0.901105 |
2.019010 |
— |
— |
55 |
45 |
100 |
| BST |
|
— |
— |
2.981387 |
0.018613 |
3.000000 |
— |
— |
99 |
1 |
100 |
| BUI |
|
0.295618 |
— |
0.889886 |
0.281496 |
1.467000 |
20 |
— |
61 |
19 |
100 |
| (a) |
Each Trust estimates that it has distributed more than its net income and net realized
capital gains; therefore, a portion of the distribution may be a return of capital. A return of capital may occur, for example, when some or all of the shareholder’s investment in a Trust is returned to the shareholder. A return of capital does not necessarily reflect a
Trust’s investment performance and should not be confused with
“yield” or “income.” When distributions exceed total return performance, the difference will reduce a Trust’s net asset value per share. |
| Trust Name |
Amount Per Common Share |
| BGR |
$ 0.097300
|
| BDJ |
0.061900 |
| BOE |
0.082700 |
| BGY |
0.042600 |
| CII |
0.141000 |
| BMEZ |
0.178090 |
| BME |
0.262100 |
| BIGZ |
0.086760 |
| BCX |
0.069700 |
| BSTZ |
0.218000 |
| BST |
0.250000 |
| BUI |
0.136000 |
| Symbol on New York Stock Exchange |
BGR |
| Initial Offering Date |
December 29, 2004 |
| Current Distribution Rate on Closing Market Price as of December 31, 2024 ($12.61)(a) |
9.26% |
| Current Monthly Distribution per Common
Share(b) |
$0.097300 |
| Current Annualized Distribution per Common Share(b) |
$1.167600 |
| (a) |
Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current
distribution rate may consist of income, net realized gains and/or a return of
capital. Past performance is not an indication of future results. |
| (b) |
The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain. |
| |
12/31/24 |
12/31/23 |
Change |
High |
Low |
| Closing Market Price |
$ 12.61
|
$ 12.45
|
1.29 % |
$ 13.79
|
$ 11.87
|
| Net Asset Value |
13.77 |
14.13 |
(2.55 ) |
15.68 |
13.35 |
| |
Average Annual Total Returns | ||
| |
1 Year |
5 Years |
10 Years |
| Trust at NAV(a)(b) |
3.93 % |
8.37 % |
2.62 % |
| Trust at Market Price(a)(b) |
8.02 |
7.69 |
2.32 |
| MSCI World Energy Call Overwrite Index(c) |
3.79 |
6.37 |
N/A |
| MSCI World Energy Index |
2.70 |
8.10 |
3.57 |
| (a) |
All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices. |
| (b) |
The Trust’s discount to NAV narrowed during the period, which accounts for the difference between performance based on market price and performance based on NAV.
|
| (c) |
An index that incorporates an option overlay component on the MSCI World Energy Index with a 33% overwrite level. The benchmark commenced on December 31, 2018 and
therefore the benchmark does not have 10-year returns. |
| TEN LARGEST HOLDINGS | |
| Security |
Percent of Total Investments(a)
|
| Exxon Mobil Corp. |
20.0 % |
| Shell PLC |
10.5 |
| TotalEnergies SE |
6.7 |
| ConocoPhillips |
5.4 |
| Williams Cos., Inc. |
4.9 |
| EOG Resources, Inc. |
4.2 |
| Cheniere Energy, Inc. |
4.1 |
| Chevron Corp. |
3.9 |
| Targa Resources Corp. |
3.9 |
| Canadian Natural Resources Ltd. |
3.6 |
| INDUSTRY ALLOCATION | |
| Industry(b)
|
Percent of Total Investments(a)
|
| Oil, Gas & Consumable Fuels |
95.5 % |
| Energy Equipment & Services |
4.5 |
| (a) |
Excludes short-term securities, short investments and options, if any. |
| (b) |
For purposes of this report, industry sub-classifications may differ from those utilized by the Trust for compliance purposes. |
| Symbol on New York Stock Exchange |
BDJ |
| Initial Offering Date |
August 31, 2005 |
| Current Distribution Rate on Closing Market Price as of December 31, 2024 ($8.28)(a) |
8.97% |
| Current Monthly Distribution per Common
Share(b) |
$0.061900 |
| Current Annualized Distribution per Common Share(b) |
$0.742800 |
| (a) |
Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current
distribution rate may consist of income, net realized gains and/or a return of
capital. Past performance is not an indication of future results. |
| (b) |
The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain. |
| |
12/31/24 |
12/31/23 |
Change |
High |
Low |
| Closing Market Price |
$ 8.28
|
$ 7.69
|
7.67 % |
$ 9.04
|
$ 7.69
|
| Net Asset Value |
9.02 |
8.82 |
2.27 |
9.58 |
8.68 |
| |
Average Annual Total Returns | ||
| |
1 Year |
5 Years |
10 Years |
| Trust at NAV(a)(b) |
10.89 % |
7.22 % |
8.12 % |
| Trust at Market Price(a)(b) |
16.76 |
5.63 |
8.60 |
| MSCI USA Value Call Overwrite Index(c) |
13.48 |
6.00 |
N/A |
| Russell 1000® Value Index |
14.37 |
8.68 |
8.49 |
| (a) |
All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices. |
| (b) |
The Trust’s discount to NAV narrowed during the period, which accounts for the difference between performance based on market price and performance based on NAV.
|
| (c) |
An index that incorporates an option overlay component on the MSCI USA Value Index with a 55% overwrite level. The benchmark commenced on December 31, 2018 and therefore
the benchmark does not have 10-year returns. |
| TEN LARGEST HOLDINGS | |
| Security |
Percent of Total Investments(a)
|
| Wells Fargo & Co. |
4.1 % |
| Citigroup, Inc. |
3.3 |
| First Citizens BancShares, Inc. |
2.9 |
| SS&C Technologies Holdings, Inc. |
2.8 |
| Cardinal Health, Inc. |
2.6 |
| Microsoft Corp. |
2.4 |
| L3Harris Technologies, Inc. |
2.2 |
| Willis Towers Watson PLC |
2.1 |
| Medtronic PLC |
2.1 |
| CVS Health Corp. |
2.0 |
| SECTOR ALLOCATION | |
| Sector(b)
|
Percent of Total Investments(a)
|
| Financials |
23.6 % |
| Health Care |
16.0 |
| Industrials |
13.3 |
| Information Technology |
10.4 |
| Communication Services |
6.8 |
| Energy |
6.5 |
| Consumer Discretionary |
6.0 |
| Consumer Staples |
5.5 |
| Materials |
5.3 |
| Utilities |
4.8 |
| Real Estate |
1.8 |
| (a) |
Excludes short-term securities, short investments and options, if any. |
| (b) |
For purposes of this report, sector sub-classifications may differ from those utilized by the Trust for compliance purposes. |
| Symbol on New York Stock Exchange |
BOE |
| Initial Offering Date |
May 31, 2005 |
| Current Distribution Rate on Closing Market Price as of December 31, 2024 ($10.77)(a) |
9.21% |
| Current Monthly Distribution per Common
Share(b) |
$0.082700 |
| Current Annualized Distribution per Common Share(b) |
$0.992400 |
| (a) |
Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current
distribution rate may consist of income, net realized gains and/or a return of
capital. Past performance is not an indication of future results. |
| (b) |
The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain. |
| |
12/31/24 |
12/31/23 |
Change |
High |
Low |
| Closing Market Price |
$ 10.77
|
$ 9.92
|
8.57 % |
$ 11.42
|
$ 9.81
|
| Net Asset Value |
12.05 |
11.81 |
2.03 |
12.83 |
11.53 |
| |
Average Annual Total Returns | ||
| |
1 Year |
5 Years |
10 Years |
| Trust at NAV(a)(b) |
9.67 % |
7.03 % |
6.44 % |
| Trust at Market Price(a)(b) |
16.70 |
7.07 |
6.80 |
| MSCI ACWI Call Overwrite Index(c) |
17.30 |
7.82 |
N/A |
| MSCI ACWI |
17.49 |
10.06 |
9.23 |
| (a) |
All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices. |
| (b) |
The Trust’s discount to NAV narrowed during the period, which accounts for the difference between performance based on market price and performance based on NAV.
|
| (c) |
An index that incorporates an option overlay component on the MSCI ACWI Index with a 45% overwrite level. The benchmark commenced on December 31, 2018 and therefore the
benchmark does not have 10-year returns. |
| TEN LARGEST HOLDINGS | |
| Security |
Percent of Total Investments(a)
|
| Microsoft Corp. |
4.8 % |
| Taiwan Semiconductor Manufacturing Co. Ltd. |
3.5 |
| Accenture PLC |
3.2 |
| Broadcom, Inc. |
3.1 |
| AstraZeneca PLC |
3.1 |
| Texas Instruments, Inc. |
3.0 |
| AbbVie, Inc. |
2.6 |
| RELX PLC |
2.6 |
| UnitedHealth Group, Inc. |
2.6 |
| Apple, Inc. |
2.6 |
| GEOGRAPHIC ALLOCATION | |
| Country/Geographic Region |
Percent of Total Investments |
| United States |
73.1 % |
| United Kingdom |
10.6 |
| France |
3.9 |
| Taiwan |
3.5 |
| Denmark |
2.4 |
| Spain |
2.0 |
| Switzerland |
1.6 |
| Netherlands |
1.5 |
| Canada |
1.4 |
| India |
— (b) |
| (a) |
Excludes short-term securities, short investments and options, if any. |
| (b) |
Rounds to less than 0.1%. |
| Symbol on New York Stock Exchange |
BGY |
| Initial Offering Date |
May 30, 2007 |
| Current Distribution Rate on Closing Market Price as of December 31, 2024 ($5.31)(a) |
9.63% |
| Current Monthly Distribution per Common
Share(b) |
$0.042600 |
| Current Annualized Distribution per Common Share(b) |
$0.511200 |
| (a) |
Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current
distribution rate may consist of income, net realized gains and/or a return of
capital. Past performance is not an indication of future results. |
| (b) |
The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain. |
| |
12/31/24 |
12/31/23 |
Change |
High |
Low |
| Closing Market Price |
$ 5.31
|
$ 5.27
|
0.76 % |
$ 5.82
|
$ 5.13
|
| Net Asset Value |
5.91 |
6.21 |
(4.83 ) |
6.60 |
5.89 |
| |
Average Annual Total Returns | ||
| |
1 Year |
5 Years |
10 Years |
| Trust at NAV(a)(b) |
2.55 % |
5.70 % |
5.27 % |
| Trust at Market Price(a)(b) |
8.58 |
5.43 |
5.42 |
| MSCI ACWI ex USA Call Overwrite Index(c) |
5.65 |
2.02 |
N/A |
| MSCI ACWI ex USA Index |
5.53 |
4.10 |
4.80 |
| (a) |
All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices. |
| (b) |
The Trust’s discount to NAV narrowed during the period, which accounts for the difference between performance based on market price and performance based on NAV.
|
| (c) |
An index that incorporates an option overlay component on the MSCI ACWI ex USA Index with a 45% overwrite level. The benchmark commenced on December 31, 2018 and
therefore the benchmark does not have 10-year returns. |
| TEN LARGEST HOLDINGS | |
| Security |
Percent of Total Investments(a)
|
| Taiwan Semiconductor Manufacturing Co. Ltd. |
6.2 % |
| Novo Nordisk A/S |
4.2 |
| RELX PLC |
3.7 |
| LVMH Moet Hennessy Louis Vuitton SE |
3.5 |
| Air Liquide SA |
3.4 |
| HDFC Bank Ltd. |
3.3 |
| Tencent Holdings Ltd. |
3.2 |
| Shell PLC |
3.1 |
| Sony Group Corp. |
3.1 |
| Texas Instruments, Inc. |
3.1 |
| GEOGRAPHIC ALLOCATION | |
| Country/Geographic Region |
Percent of Total Investments |
| United States |
19.8 % |
| United Kingdom |
10.7 |
| Germany |
9.2 |
| France |
8.8 |
| Japan |
7.6 |
| Taiwan |
6.1 |
| Canada |
6.0 |
| Sweden |
5.2 |
| Netherlands |
5.1 |
| Denmark |
4.1 |
| India |
3.3 |
| China |
3.2 |
| Italy |
3.0 |
| Spain |
2.7 |
| Singapore |
2.5 |
| Switzerland |
1.5 |
| Indonesia |
1.2 |
| (a) |
Excludes short-term securities, short investments and options, if any. |
| Symbol on New York Stock Exchange |
CII |
| Initial Offering Date |
April 30, 2004 |
| Current Distribution Rate on Closing Market Price as of December 31, 2024 ($20.10)(a) |
8.42% |
| Current Monthly Distribution per Common
Share(b) |
$0.141000 |
| Current Annualized Distribution per Common Share(b) |
$1.692000 |
| (a) |
Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current
distribution rate may consist of income, net realized gains and/or a return of
capital. Past performance is not an indication of future results. |
| (b) |
The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain. |
| |
12/31/24 |
12/31/23 |
Change |
High |
Low |
| Closing Market Price |
$ 20.10
|
$ 19.00
|
5.79 % |
$ 20.44
|
$ 18.29
|
| Net Asset Value |
21.43 |
19.81 |
8.18 |
22.15 |
19.57 |
| |
Average Annual Total Returns | ||
| |
1 Year |
5 Years |
10 Years |
| Trust at NAV(a)(b) |
15.21 % |
11.41 % |
10.89 % |
| Trust at Market Price(a)(b) |
12.66 |
10.90 |
11.45 |
| MSCI USA Call Overwrite Index(c) |
23.86 |
11.25 |
N/A |
| Russell 1000® Index |
24.51 |
14.28 |
12.87 |
| (a) |
All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices. |
| (b) |
The Trust’s discount to NAV widened during the period, which accounts for the difference between performance based on market price and performance based on NAV.
|
| (c) |
An index that incorporates an option overlay component on the MSCI USA Index with a 55% overwrite level. The benchmark commenced on December 31, 2018 and therefore the
benchmark does not have 10-year returns. |
| TEN LARGEST HOLDINGS | |
| Security |
Percent of Total Investments(a)
|
| Microsoft Corp. |
8.5 % |
| Amazon.com, Inc. |
7.5 |
| Meta Platforms, Inc. |
5.6 |
| NVIDIA Corp. |
4.6 |
| Ciena Corp. |
4.4 |
| Visa, Inc. |
4.1 |
| Alphabet, Inc. |
3.6 |
| Cardinal Health, Inc. |
3.4 |
| Apple, Inc. |
3.4 |
| S&P Global, Inc. |
3.1 |
| SECTOR ALLOCATION | |
| Sector(b)
|
Percent of Total Investments(a)
|
| Information Technology |
33.8 % |
| Financials |
16.1 |
| Communication Services |
13.0 |
| Industrials |
11.1 |
| Consumer Discretionary |
10.4 |
| Health Care |
10.1 |
| Materials |
3.1 |
| Energy |
2.4 |
| (a) |
Excludes short-term securities, short investments and options, if any. |
| (b) |
For purposes of this report, sector sub-classifications may differ from those utilized by the Trust for compliance purposes. |
| Symbol on New York Stock Exchange |
BMEZ |
| Initial Offering Date |
January 30, 2020 |
| Current Distribution Rate on Closing Market Price as of December 31, 2024 ($14.40)(a) |
14.84% |
| Current Monthly Distribution per Common
Share(b) |
$0.178090 |
| Current Annualized Distribution per Common Share(b) |
$2.137080 |
| (a) |
Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current
distribution rate may consist of income, net realized gains and/or a return of
capital. Past performance is not an indication of future results. |
| (b) |
The monthly distribution per Common Share, declared on February 3, 2025, was decreased to $0.177300 per share. The current distribution rate on closing market
price, current monthly distribution per Common Share, and current annualized
distribution per Common Share do not reflect the new distribution rate. The new distribution rate is not constant and is subject to change in the future. A portion of the distribution may be deemed a return of capital or net realized gain. |
| |
12/31/24 |
12/31/23 |
Change |
High |
Low |
| Closing Market Price |
$ 14.40
|
$ 14.65
|
(1.71 )% |
$ 16.54
|
$ 14.40
|
| Net Asset Value |
16.43 |
17.91 |
(8.26 ) |
18.94 |
16.43 |
| |
Average Annual Total Returns | |
| |
1 Year |
Since Inception(a)
|
| Trust at NAV(b)(c) |
2.11 % |
4.41 % |
| Trust at Market Price(b)(c) |
9.40 |
1.64 |
| MSCI Custom ACWI SMID Growth HC Call Overwrite Index(d) |
1.32 |
(3.97 ) |
| MSCI ACWI |
17.49 |
10.22 |
| (a) |
BMEZ commenced operations on January 30, 2020. |
| (b) |
All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices. |
| (c) |
The Trust’s discount to NAV narrowed during the period, which accounts for the difference between performance based on market price and performance based on NAV.
|
| (d) |
An index representing the Health Care sector stocks within the MSCI ACWI SMID Cap Growth Index and incorporating an option overlay component with a 25% overwrite
level. The MSCI ACWI SMID Cap Growth Index captures mid- and small-cap
securities exhibiting overall growth style characteristics across certain developed and emerging markets countries. The index commenced on March 31, 2022 and therefore the since inception return presented is for the period March 31, 2022 through the current reporting
period. |
| TEN LARGEST HOLDINGS | |
| Security |
Percent of Total Investments(a)
|
| Intuitive Surgical, Inc. |
4.9 % |
| Argenx SE |
4.0 |
| Alnylam Pharmaceuticals, Inc. |
3.8 |
| West Pharmaceutical Services, Inc. |
3.3 |
| Waters Corp. |
2.9 |
| Boston Scientific Corp. |
2.7 |
| Mettler-Toledo International, Inc. |
2.5 |
| Rhythm Pharmaceuticals, Inc. |
2.2 |
| Roche Holding AG |
2.2 |
| Bio-Techne Corp. |
2.0 |
| INDUSTRY ALLOCATION | |
| Industry(b)
|
Percent of Total Investments(a)
|
| Biotechnology |
46.0 % |
| Health Care Equipment & Supplies |
22.5 |
| Life Sciences Tools & Services |
17.3 |
| Pharmaceuticals |
5.5 |
| Health Care Providers & Services |
4.9 |
| Health Care Technology |
2.0 |
| Semiconductors & Semiconductor Equipment |
1.3 |
| Other* |
0.5 |
| (a) |
Excludes short-term securities, short investments and options, if any. |
| (b) |
For purposes of this report, industry sub-classifications may differ from those utilized by the Trust for compliance purposes. |
| * |
Includes one or more investment categories that individually represents less than 1.0% of the Trust’s total investments. Please refer to the Schedule of Investments for
details. |
| Symbol on New York Stock Exchange |
BME |
| Initial Offering Date |
March 31, 2005 |
| Current Distribution Rate on Closing Market Price as of December 31, 2024 ($37.93)(a) |
8.29% |
| Current Monthly Distribution per Common
Share(b) |
$0.262100 |
| Current Annualized Distribution per Common Share(b) |
$3.145200 |
| (a) |
Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current
distribution rate may consist of income, net realized gains and/or a return of
capital. Past performance is not an indication of future results. |
| (b) |
The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain. |
| |
12/31/24 |
12/31/23 |
Change |
High |
Low |
| Closing Market Price |
$ 37.93
|
$ 40.46
|
(6.25 )% |
$ 42.71
|
$ 36.92
|
| Net Asset Value |
41.20 |
42.18 |
(2.32 ) |
46.00 |
40.83 |
| |
Average Annual Total Returns | ||
| |
1 Year |
5 Years |
10 Years |
| Trust at NAV(a)(b) |
4.09 % |
6.12 % |
8.50 % |
| Trust at Market Price(a)(b) |
(0.09 ) |
3.74 |
6.53 |
| MSCI USA Investable Market Index Health Care Call Overwrite Index(c) |
1.32 |
5.14 |
N/A |
| Russell 3000® Health Care Index |
3.48 |
7.18 |
8.81 |
| (a) |
All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices. |
| (b) |
The Trust’s discount to NAV widened during the period, which accounts for the difference between performance based on market price and performance based on NAV.
|
| (c) |
An index that incorporates an option overlay component on the MSCI USA IMI Health Care Index with a 33% overwrite level. The benchmark commenced on December 31, 2018 and
therefore the benchmark does not have 10-year returns. |
| TEN LARGEST HOLDINGS | |
| Security |
Percent of Total Investments(a)
|
| Eli Lilly & Co. |
9.1 % |
| Boston Scientific Corp. |
7.6 |
| Intuitive Surgical, Inc. |
5.3 |
| AbbVie, Inc. |
4.8 |
| UnitedHealth Group, Inc. |
4.6 |
| Abbott Laboratories |
4.2 |
| Stryker Corp. |
3.4 |
| Danaher Corp. |
3.2 |
| Thermo Fisher Scientific, Inc. |
3.0 |
| Gilead Sciences, Inc. |
2.6 |
| INDUSTRY ALLOCATION | |
| Industry(b)
|
Percent of Total Investments(a)
|
| Health Care Equipment & Supplies |
31.1 % |
| Biotechnology |
27.3 |
| Pharmaceuticals |
21.0 |
| Health Care Providers & Services |
10.4 |
| Life Sciences Tools & Services |
10.1 |
| Other* |
0.1 |
| (a) |
Excludes short-term securities, short investments and options, if any. |
| (b) |
For purposes of this report, industry sub-classifications may differ from those utilized by the Trust for compliance purposes. |
| * |
Includes one or more investment categories that individually represents less than 1.0% of the Trust’s total investments. Please refer to the Schedule of Investments for
details. |
| Symbol on New York Stock Exchange |
BIGZ |
| Initial Offering Date |
March 29, 2021 |
| Current Distribution Rate on Closing Market Price as of December 31, 2024 ($7.44)(a) |
13.99% |
| Current Monthly Distribution per Common
Share(b) |
$0.086760 |
| Current Annualized Distribution per Common Share(b) |
$1.041120 |
| (a) |
Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current
distribution rate may consist of income, net realized gains and/or a return of
capital. Past performance is not an indication of future results. |
| (b) |
The monthly distribution per Common Share, declared on February 3, 2025, was decreased to $0.086570 per share. The current distribution rate on closing market
price, current monthly distribution per Common Share, and current annualized
distribution per Common Share do not reflect the new distribution rate. The new distribution rate is not constant and is subject to change in the future. A portion of the distribution may be deemed a return of capital or net realized gain. |
| |
12/31/24 |
12/31/23 |
Change |
High |
Low |
| Closing Market Price |
$ 7.44
|
$ 7.33
|
1.50 % |
$ 8.20
|
$ 6.75
|
| Net Asset Value |
8.37 |
9.03 |
(7.31 ) |
9.36 |
7.84 |
| |
Average Annual Total Returns | |
| |
1 Year |
Since Inception(a)
|
| Trust at NAV(b)(c) |
3.39 % |
(12.73 )% |
| Trust at Market Price(b)(c) |
13.22 |
(15.42 ) |
| MSCI USA SMID Growth Call Overwrite Index(d) |
14.67 |
4.21 |
| Russell 2500™ Growth Index |
13.90 |
1.56 |
| (a) |
BIGZ commenced operations on March 29, 2021. |
| (b) |
All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices. |
| (c) |
The Trust’s discount to NAV narrowed during the period, which accounts for the difference between performance based on market price and performance based on NAV.
|
| (d) |
A custom benchmark that is made up of the MSCI USA SMID Growth Index, MSCI USA SMID Growth 25% Call Overwrite Cash and MSCI USA SMID Growth 25% Call Overwrite Option.
The MSCI USA SMID Growth Index captures mid and small cap representations of
securities exhibiting overall growth style characteristics in the U.S. |
| TEN LARGEST HOLDINGS | |
| Security |
Percent of Total Investments(a)
|
| Axon Enterprise, Inc. |
3.9 % |
| Vertiv Holdings Co. |
3.4 |
| PsiQuantum Corp. |
3.2 |
| Comfort Systems USA, Inc. |
2.6 |
| Liberty Media Corp.-Liberty Formula One |
2.6 |
| Tradeweb Markets, Inc. |
2.5 |
| TPG, Inc. |
2.3 |
| Saia, Inc. |
2.3 |
| CoStar Group, Inc. |
2.2 |
| DraftKings, Inc. |
2.2 |
| INDUSTRY ALLOCATION | |
| Industry(b)
|
Percent of Total Investments(a)
|
| Software |
17.2 % |
| Semiconductors & Semiconductor Equipment |
12.7 |
| Capital Markets |
7.4 |
| Hotels, Restaurants & Leisure |
6.4 |
| Aerospace & Defense |
5.8 |
| IT Services |
5.0 |
| Health Care Equipment & Supplies |
3.7 |
| Electrical Equipment |
3.4 |
| Entertainment |
3.0 |
| Life Sciences Tools & Services |
3.0 |
| Interactive Media & Services |
2.9 |
| Construction & Engineering |
2.6 |
| Textiles, Apparel & Luxury Goods |
2.6 |
| Diversified Consumer Services |
2.3 |
| Ground Transportation |
2.3 |
| Real Estate Management & Development |
2.2 |
| Specialty Retail |
2.2 |
| Building Products |
1.7 |
| Wireless Telecommunication Services |
1.7 |
| Biotechnology |
1.6 |
| Technology Hardware, Storage & Peripherals |
1.5 |
| Pharmaceuticals |
1.5 |
| Food Products |
1.4 |
| Electronic Equipment, Instruments & Components |
1.3 |
| Financial Services |
1.3 |
| Other* |
3.3 |
| (a) |
Excludes short-term securities, short investments and options, if any. |
| (b) |
For purposes of this report, industry sub-classifications may differ from those utilized by the Trust for compliance purposes. |
| * |
Includes one or more investment categories that individually represents less than 1.0% of the Trust’s total investments. Please refer to the Schedule of Investments for
details. |
| Symbol on New York Stock Exchange |
BCX |
| Initial Offering Date |
March 30, 2011 |
| Current Distribution Rate on Closing Market Price as of December 31, 2024 ($8.54)(a) |
9.79% |
| Current Monthly Distribution per Common
Share(b) |
$0.069700 |
| Current Annualized Distribution per Common Share(b) |
$0.836400 |
| (a) |
Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current
distribution rate may consist of income, net realized gains and/or a return of
capital. Past performance is not an indication of future results. |
| (b) |
The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain. |
| |
12/31/24 |
12/31/23 |
Change |
High |
Low |
| Closing Market Price |
$ 8.54
|
$ 8.88
|
(3.83 )% |
$ 9.68
|
$ 8.30
|
| Net Asset Value |
9.58 |
10.57 |
(9.37 ) |
11.01 |
9.43 |
| |
Average Annual Total Returns | ||
| |
1 Year |
5 Years |
10 Years |
| Trust at NAV(a)(b) |
(2.80 )% |
7.99 % |
5.32 % |
| Trust at Market Price(a)(b) |
3.14 |
7.96 |
6.04 |
| MSCI ACWI Select Liquidity Natural Resources Call Overwrite Index(c) |
(9.71 ) |
3.48 |
N/A |
| S&P Global Natural Resources Net Index |
(8.86 ) |
5.13 |
4.63 |
| (a) |
All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices. |
| (b) |
The Trust’s discount to NAV narrowed during the period, which accounts for the difference between performance based on market price and performance based on NAV.
|
| (c) |
An index that incorporates an option overlay component on the MSCI ACWI Select Liquidity Natural Resources Index with a 33% overwrite level. The benchmark commenced on
December 31, 2018 and therefore the benchmark does not have 10-year
returns. |
| TEN LARGEST HOLDINGS | |
| Security |
Percent of Total Investments(a)
|
| Shell PLC |
8.9 % |
| Exxon Mobil Corp. |
7.7 |
| Smurfit WestRock PLC |
4.9 |
| Wheaton Precious Metals Corp. |
4.8 |
| TotalEnergies SE |
4.6 |
| Glencore PLC |
4.0 |
| Anglo American PLC |
4.0 |
| Nutrien Ltd. |
4.0 |
| Corteva, Inc. |
3.7 |
| Norsk Hydro ASA |
3.6 |
| INDUSTRY ALLOCATION | |
| Industry(b)
|
Percent of Total Investments(a)
|
| Oil, Gas & Consumable Fuels |
35.4 % |
| Metals & Mining |
35.2 |
| Containers & Packaging |
12.5 |
| Chemicals |
10.3 |
| Food Products |
2.1 |
| Construction Materials |
1.9 |
| Energy Equipment & Services |
1.5 |
| Paper & Forest Products |
1.1 |
| (a) |
Excludes short-term securities, short investments and options, if any. |
| (b) |
For purposes of this report, industry sub-classifications may differ from those utilized by the Trust for compliance purposes. |
| Symbol on New York Stock Exchange |
BSTZ |
| Initial Offering Date |
June 27, 2019 |
| Current Distribution Rate on Closing Market Price as of December 31, 2024 ($20.71)(a) |
12.63% |
| Current Monthly Distribution per Common
Share(b) |
$0.218000 |
| Current Annualized Distribution per Common Share(b) |
$2.616000 |
| (a) |
Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current
distribution rate may consist of income, net realized gains and/or a return of
capital. Past performance is not an indication of future results. |
| (b) |
The monthly distribution per Common Share, declared on February 3, 2025, was increased to $0.221780 per share. The current distribution rate on closing market
price, current monthly distribution per Common Share, and current annualized
distribution per Common Share do not reflect the new distribution rate. The new distribution rate is not constant and is subject to change in the future. A portion of the distribution may be deemed a return of capital or net realized gain. |
| |
12/31/24 |
12/31/23 |
Change |
High |
Low |
| Closing Market Price |
$ 20.71
|
$ 16.71
|
23.94 % |
$ 22.13
|
$ 16.36
|
| Net Asset Value |
23.14 |
21.43 |
7.98 |
24.33 |
19.82 |
| |
Average Annual Total Returns | ||
| |
1 Year |
5 Years |
Since Inception(a)
|
| Trust at NAV(b)(c) |
19.60 % |
11.47 % |
11.79 % |
| Trust at Market Price(b)(c) |
37.27 |
9.50 |
9.56 |
| MSCI Custom ACWI SMID Growth IT Call Overwrite Index(d) |
10.93 |
N/A |
5.38 |
| MSCI ACWI |
17.49 |
10.06 |
10.90 |
| (a) |
BSTZ commenced operations on June 27, 2019. |
| (b) |
All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices. |
| (c) |
The Trust’s discount to NAV narrowed during the period, which accounts for the difference between performance based on market price and performance based on NAV.
|
| (d) |
An index representing the Information Technology sector stocks within the MSCI ACWI SMID Cap Growth Index and incorporating an option overlay component with a 25%
overwrite level. An index that captures mid- and small-cap securities
exhibiting overall growth style characteristics across certain developed and emerging markets. The index commenced on March 31, 2022 and therefore the since inception return presented is for the period March 31, 2022 through the current reporting period. |
| TEN LARGEST HOLDINGS | |
| Security |
Percent of Total Investments(a)
|
| NVIDIA Corp. |
9.0 % |
| Databricks, Inc. |
5.0 |
| Astera Labs, Inc. |
4.2 |
| PsiQuantum Corp. |
4.0 |
| Credo Technology Group Holding Ltd. |
3.2 |
| Reddit, Inc. |
3.1 |
| Klarna Holdings AB |
2.6 |
| Tesla, Inc. |
2.5 |
| SambaNova Systems, Inc. |
2.1 |
| Spotify Technology SA |
2.0 |
| INDUSTRY ALLOCATION | |
| Industry(b)
|
Percent of Total Investments(a)
|
| Semiconductors & Semiconductor Equipment |
31.8 % |
| Software |
28.0 |
| IT Services |
6.8 |
| Interactive Media & Services |
4.7 |
| Electronic Equipment, Instruments & Components |
4.4 |
| Entertainment |
4.2 |
| Professional Services |
3.5 |
| Technology Hardware, Storage & Peripherals |
3.0 |
| Automobiles |
2.5 |
| Financial Services |
2.5 |
| Consumer Staples Distribution & Retail |
1.9 |
| Communications Equipment |
1.5 |
| Industrial Conglomerates |
1.2 |
| Broadline Retail |
1.1 |
| Other* |
2.9 |
| (a) |
Excludes short-term securities, short investments and options, if any. |
| (b) |
For purposes of this report, industry sub-classifications may differ from those utilized by the Trust for compliance purposes. |
| * |
Includes one or more investment categories that individually represents less than 1.0% of the Trust’s total investments. Please refer to the Consolidated Schedule of
Investments for details. |
| Symbol on New York Stock Exchange |
BST |
| Initial Offering Date |
October 30, 2014 |
| Current Distribution Rate on Closing Market Price as of December 31, 2024 ($36.56)(a) |
8.21% |
| Current Monthly Distribution per Common
Share(b) |
$0.250000 |
| Current Annualized Distribution per Common Share(b) |
$3.000000 |
| (a) |
Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current
distribution rate may consist of income, net realized gains and/or a return of
capital. Past performance is not an indication of future results. |
| (b) |
The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain. |
| |
12/31/24 |
12/31/23 |
Change |
High |
Low |
| Closing Market Price |
$ 36.56
|
$ 33.66
|
8.62 % |
$ 38.95
|
$ 32.92
|
| Net Asset Value |
39.60 |
34.74 |
13.99 |
40.78 |
33.76 |
| |
Average Annual Total Returns | ||
| |
1 Year |
5 Years |
10 Years |
| Trust at NAV(a)(b) |
23.84 % |
12.58 % |
15.76 % |
| Trust at Market Price(a)(b) |
18.01 |
10.24 |
15.99 |
| MSCI ACWI Information Technology Call Overwrite Index(c) |
31.00 |
16.62 |
N/A |
| MSCI ACWI Information Technology Index |
31.59 |
20.50 |
19.16 |
| (a) |
All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices. |
| (b) |
The Trust’s discount to NAV widened during the period, which accounts for the difference between performance based on market price and performance based on NAV.
|
| (c) |
An index that incorporates an option overlay component on the MSCI ACWI IT Index with a 33% overwrite level. The benchmark commenced on December 31, 2018 and therefore
the benchmark does not have 10-year returns. |
| TEN LARGEST HOLDINGS | |
| Security |
Percent of Total Investments(a)
|
| NVIDIA Corp. |
13.3 % |
| Microsoft Corp. |
8.5 |
| Apple, Inc. |
8.2 |
| Broadcom, Inc. |
6.1 |
| Meta Platforms, Inc. |
3.2 |
| Cadence Design Systems, Inc. |
2.7 |
| Amazon.com, Inc. |
2.7 |
| Tesla, Inc. |
2.4 |
| Oracle Corp. |
2.0 |
| Credo Technology Group Holding Ltd. |
2.0 |
| INDUSTRY ALLOCATION | |
| Industry(b)
|
Percent of Total Investments(a)
|
| Semiconductors & Semiconductor Equipment |
33.3 % |
| Software |
26.7 |
| Technology Hardware, Storage & Peripherals |
8.2 |
| IT Services |
5.8 |
| Interactive Media & Services |
5.1 |
| Broadline Retail |
3.6 |
| Entertainment |
2.9 |
| Financial Services |
2.4 |
| Automobiles |
2.4 |
| Aerospace & Defense |
1.5 |
| Communications Equipment |
1.4 |
| Professional Services |
1.3 |
| Diversified Consumer Services |
1.1 |
| Consumer Staples Distribution & Retail |
1.0 |
| Other* |
3.3 |
| (a) |
Excludes short-term securities, short investments and options, if any. |
| (b) |
For purposes of this report, industry sub-classifications may differ from those utilized by the Trust for compliance purposes. |
| * |
Includes one or more investment categories that individually represents less than 1.0% of the Trust’s total investments. Please refer to the Consolidated Schedule of
Investments for details. |
| Symbol on New York Stock Exchange |
BUI |
| Initial Offering Date |
November 25, 2011 |
| Current Distribution Rate on Closing Market Price as of December 31, 2024 ($23.43)(a) |
6.97% |
| Current Monthly Distribution per Common
Share(b) |
$0.136000 |
| Current Annualized Distribution per Common Share(b) |
$1.632000 |
| (a) |
Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current
distribution rate may consist of income, net realized gains and/or a return of
capital. Past performance is not an indication of future results. |
| (b) |
The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain. |
| |
12/31/24 |
12/31/23 |
Change |
High |
Low |
| Closing Market Price |
$ 23.43
|
$ 21.82
|
7.38 % |
$ 24.83
|
$ 20.20
|
| Net Asset Value |
22.65 |
22.53 |
0.53 |
24.49 |
21.12 |
| |
Average Annual Total Returns | ||
| |
1 Year |
5 Years |
10 Years |
| Trust at NAV(a)(b) |
7.28 % |
7.29 % |
7.24 % |
| Trust at Market Price(a)(b) |
14.58 |
7.73 |
8.47 |
| MSCI World Select Energy, Utilities and Industry Call Overwrite Index(c) |
12.93 |
4.20 |
N/A |
| MSCI ACWI |
17.49 |
10.06 |
9.23 |
| (a) |
All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices. |
| (b) |
The Trust moved from a discount to NAV to a premium during the period, which accounts for the difference between performance based on market price and performance based on
NAV. |
| (c) |
An index that incorporates an option overlay component on the MSCI World Select Energy, Utilities and Industry Index with a 33% overwrite level.The benchmark commenced
on December 31, 2018 and therefore the benchmark does not have 10-year
returns. |
| TEN LARGEST HOLDINGS | |
| Security |
Percent of Total Investments(a)
|
| NextEra Energy, Inc. |
5.6 % |
| GE Vernova, Inc. |
4.2 |
| National Grid PLC |
3.5 |
| Trane Technologies PLC |
3.4 |
| Sempra |
3.2 |
| Williams Cos., Inc. |
3.2 |
| Enel SpA |
3.1 |
| Vinci SA |
2.9 |
| Cheniere Energy, Inc. |
2.9 |
| Cie de Saint-Gobain SA |
2.8 |
| INDUSTRY ALLOCATION | |
| Industry(b)
|
Percent of Total Investments(a)
|
| Electric Utilities |
26.6 % |
| Electrical Equipment |
14.8 |
| Multi-Utilities |
13.5 |
| Oil, Gas & Consumable Fuels |
11.8 |
| Building Products |
9.3 |
| Construction & Engineering |
5.6 |
| Independent Power and Renewable Electricity Producers |
5.1 |
| Commercial Services & Supplies |
4.5 |
| Chemicals |
2.8 |
| Ground Transportation |
2.6 |
| Machinery |
1.9 |
| Semiconductors & Semiconductor Equipment |
1.5 |
| (a) |
Excludes short-term securities, short investments and options, if any. |
| (b) |
For purposes of this report, industry sub-classifications may differ from those utilized by the Trust for compliance purposes. |
| Security |
|
Shares |
Value |
| Common Stocks | |||
| Energy Equipment & Services — 4.4% |
| ||
| Saipem SpA(a) |
|
2,413,799 |
$ 6,313,861
|
| TechnipFMC PLC |
|
206,352 |
5,971,827 |
| Tenaris SA |
|
187,428 |
3,538,348 |
| |
|
|
15,824,036 |
| Oil, Gas & Consumable Fuels — 94.0% |
| ||
| ARC Resources Ltd. |
|
497,638 |
9,025,304 |
| Cameco Corp. |
|
111,150 |
5,715,048 |
| Canadian Natural Resources Ltd. |
|
409,511 |
12,643,291 |
| Cheniere Energy, Inc. |
|
67,354 |
14,472,354 |
| Chevron Corp.(b) |
|
95,822 |
13,878,858 |
| ConocoPhillips(c) |
|
193,788 |
19,217,918 |
| Diamondback Energy, Inc. |
|
53,467 |
8,759,499 |
| Eni SpA |
|
577,386 |
7,897,680 |
| EOG Resources, Inc. |
|
121,900 |
14,942,502 |
| Exxon Mobil Corp.(b)(c) |
|
659,194 |
70,909,499 |
| Gazprom PJSC(a)(d) |
|
879,200 |
77 |
| Gaztransport Et Technigaz SA |
|
26,800 |
3,589,089 |
| Hess Corp. |
|
78,573 |
10,450,995 |
| Keyera Corp. |
|
185,700 |
5,679,065 |
| Kosmos Energy Ltd.(a) |
|
883,380 |
3,021,160 |
| Marathon Petroleum Corp. |
|
72,097 |
10,057,531 |
| Pembina Pipeline Corp. |
|
299,691 |
11,072,795 |
| Permian Resources Corp., Class A |
|
513,102 |
7,378,407 |
| Shell PLC, ADR |
|
595,551 |
37,311,270 |
| South Bow Corp. |
|
29,425 |
694,352 |
| Targa Resources Corp. |
|
77,020 |
13,748,070 |
| TC Energy Corp. |
|
143,879 |
6,705,245 |
| TotalEnergies SE |
|
425,978 |
23,733,296 |
| Tourmaline Oil Corp. |
|
214,959 |
9,947,527 |
| Williams Cos., Inc. |
|
316,839 |
17,147,327 |
| |
|
|
337,998,159 |
| Total Long-Term Investments — 98.4% (Cost: $241,326,966) |
353,822,195 | ||
| Security |
|
Shares |
Value |
| Short-Term Securities | |||
| Money Market Funds — 2.1% |
| ||
| BlackRock Liquidity Funds, T-Fund, Institutional Shares, 4.36%(e)(f) |
|
7,583,996 |
$ 7,583,996 |
| Total Short-Term Securities — 2.1% (Cost: $7,583,996) |
7,583,996 | ||
| Total Investments Before Options Written — 100.5% (Cost: $248,910,962) |
361,406,191 | ||
| Options Written — (0.4)% (Premiums Received: $(2,551,928)) |
(1,632,661 ) | ||
| Total Investments, Net of Options Written — 100.1% (Cost: $246,359,034) |
359,773,530 | ||
| Liabilities in Excess of Other Assets — (0.1)% |
(203,755 ) | ||
| Net Assets — 100.0% |
$ 359,569,775 | ||
| (a) |
Non-income producing security. |
| (b) |
All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives. |
| (c) |
All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written. |
| (d) |
Security is valued using significant unobservable inputs and is classified as Level 3 in the
fair value hierarchy. |
| (e) |
Affiliate of the Trust. |
| (f) |
Annualized 7-day yield as of period end. |
| Affiliated Issuer |
Value at 12/31/23 |
Purchases at Cost |
Proceeds from Sales |
Net Realized Gain (Loss) |
Change in Unrealized Appreciation (Depreciation) |
Value at 12/31/24 |
Shares Held at 12/31/24 |
Income |
Capital Gain Distributions from Underlying Funds |
| BlackRock Liquidity Funds, T-Fund, Institutional Shares |
$ 3,612,320 |
$ 3,971,676 (a) |
$ — |
$ — |
$ — |
$ 7,583,996 |
7,583,996 |
$ 368,659 |
$ — |
| (a) |
Represents net amount purchased (sold). |
| Description |
Number of Contracts |
Expiration Date |
Exercise Price |
Notional Amount (000) |
Value | ||
| Call |
|
|
|
|
|
|
|
| Chevron Corp. |
169 |
01/10/25 |
USD |
165.00 |
USD |
2,448 |
$ (676
) |
| ConocoPhillips |
163 |
01/10/25 |
USD |
109.00 |
USD |
1,616 |
(1,467 ) |
| Diamondback Energy, Inc. |
45 |
01/10/25 |
USD |
185.00 |
USD |
737 |
(675 ) |
| Description |
Number of Contracts |
Expiration Date |
Exercise Price |
Notional Amount (000) |
Value | ||
| Call (continued) |
|
|
|
|
|
|
|
| Exxon Mobil Corp. |
737 |
01/10/25 |
USD |
120.00 |
USD |
7,928 |
$ (1,474
) |
| Shell PLC, ADR |
380 |
01/10/25 |
USD |
67.00 |
USD |
2,381 |
(1,900 ) |
| ARC Resources Ltd. |
1,074 |
01/17/25 |
CAD |
26.00 |
CAD |
2,800 |
(46,697 ) |
| Canadian Natural Resources Ltd. |
685 |
01/17/25 |
CAD |
49.00 |
CAD |
3,040 |
(2,859 ) |
| Cheniere Energy, Inc. |
80 |
01/17/25 |
USD |
200.00 |
USD |
1,719 |
(129,200 ) |
| Cheniere Energy, Inc. |
62 |
01/17/25 |
USD |
210.00 |
USD |
1,332 |
(48,980 ) |
| Chevron Corp. |
135 |
01/17/25 |
USD |
165.00 |
USD |
1,955 |
(338 ) |
| EOG Resources, Inc. |
125 |
01/17/25 |
USD |
136.00 |
USD |
1,532 |
(3,125 ) |
| Exxon Mobil Corp. |
447 |
01/17/25 |
USD |
125.00 |
USD |
4,808 |
(1,341 ) |
| Hess Corp. |
71 |
01/17/25 |
USD |
150.00 |
USD |
944 |
(1,775 ) |
| Keyera Corp. |
323 |
01/17/25 |
CAD |
46.00 |
CAD |
1,420 |
(1,685 ) |
| Keyera Corp. |
144 |
01/17/25 |
CAD |
43.00 |
CAD |
633 |
(13,524 ) |
| Marathon Petroleum Corp. |
140 |
01/17/25 |
USD |
165.00 |
USD |
1,953 |
(2,590 ) |
| Permian Resources Corp., Class A |
987 |
01/17/25 |
USD |
15.20 |
USD |
1,419 |
(48,628 ) |
| Shell PLC, ADR |
199 |
01/17/25 |
USD |
70.00 |
USD |
1,247 |
(995 ) |
| Shell PLC, ADR |
162 |
01/17/25 |
USD |
67.50 |
USD |
1,015 |
(1,620 ) |
| Targa Resources Corp. |
150 |
01/17/25 |
USD |
195.00 |
USD |
2,678 |
(9,375 ) |
| TC Energy Corp. |
357 |
01/17/25 |
CAD |
68.00 |
CAD |
2,392 |
(12,790 ) |
| TechnipFMC PLC |
330 |
01/17/25 |
USD |
29.00 |
USD |
955 |
(26,400 ) |
| Tourmaline Oil Corp. |
99 |
01/17/25 |
CAD |
65.50 |
CAD |
659 |
(13,706 ) |
| Williams Cos., Inc. |
569 |
01/17/25 |
USD |
60.00 |
USD |
3,079 |
(4,267 ) |
| ARC Resources Ltd. |
568 |
01/24/25 |
CAD |
25.00 |
CAD |
1,481 |
(57,098 ) |
| Canadian Natural Resources Ltd. |
333 |
01/24/25 |
CAD |
45.50 |
CAD |
1,478 |
(15,174 ) |
| ConocoPhillips |
220 |
01/24/25 |
USD |
108.00 |
USD |
2,182 |
(7,040 ) |
| Diamondback Energy, Inc. |
131 |
01/24/25 |
USD |
175.00 |
USD |
2,146 |
(16,375 ) |
| EOG Resources, Inc. |
186 |
01/24/25 |
USD |
131.00 |
USD |
2,280 |
(42,780 ) |
| Exxon Mobil Corp. |
233 |
01/24/25 |
USD |
118.00 |
USD |
2,506 |
(3,029 ) |
| Hess Corp. |
188 |
01/24/25 |
USD |
130.00 |
USD |
2,501 |
(82,720 ) |
| Marathon Petroleum Corp. |
102 |
01/24/25 |
USD |
145.00 |
USD |
1,423 |
(21,318 ) |
| Shell PLC, ADR |
500 |
01/24/25 |
USD |
64.00 |
USD |
3,133 |
(37,500 ) |
| Tourmaline Oil Corp. |
517 |
01/24/25 |
CAD |
62.00 |
CAD |
3,439 |
(175,338 ) |
| Williams Cos., Inc. |
476 |
01/24/25 |
USD |
54.00 |
USD |
2,576 |
(145,180 ) |
| Canadian Natural Resources Ltd. |
333 |
01/31/25 |
CAD |
45.50 |
CAD |
1,478 |
(18,764 ) |
| ConocoPhillips |
256 |
01/31/25 |
USD |
101.00 |
USD |
2,539 |
(50,432 ) |
| EOG Resources, Inc. |
91 |
01/31/25 |
USD |
128.00 |
USD |
1,115 |
(11,375 ) |
| Exxon Mobil Corp. |
332 |
01/31/25 |
USD |
112.00 |
USD |
3,571 |
(45,484 ) |
| Shell PLC, ADR |
297 |
01/31/25 |
USD |
66.00 |
USD |
1,861 |
(13,365 ) |
| Shell PLC, ADR |
427 |
02/07/25 |
USD |
64.00 |
USD |
2,675 |
(71,522 ) |
| Cheniere Energy, Inc. |
80 |
02/21/25 |
USD |
220.00 |
USD |
1,719 |
(47,600 ) |
| Exxon Mobil Corp. |
426 |
02/21/25 |
USD |
120.00 |
USD |
4,582 |
(21,726 ) |
| Keyera Corp. |
144 |
02/21/25 |
CAD |
43.00 |
CAD |
633 |
(18,984 ) |
| Permian Resources Corp., Class A |
706 |
02/21/25 |
USD |
15.00 |
USD |
1,015 |
(35,300 ) |
| TechnipFMC PLC |
350 |
02/21/25 |
USD |
32.86 |
USD |
1,013 |
(20,641 ) |
| Tourmaline Oil Corp. |
99 |
02/21/25 |
CAD |
65.50 |
CAD |
659 |
(20,972 ) |
| |
|
|
|
|
|
|
$ (1,355,804 ) |
| Description |
Counterparty |
Number of Contracts |
Expiration Date |
Exercise Price |
Notional Amount (000) |
Value | ||
| Call |
|
|
|
|
|
|
|
|
| Eni SpA |
Goldman Sachs International |
92,800 |
01/09/25 |
EUR |
14.43 |
EUR |
1,225 |
$ (62
) |
| Saipem SpA |
Bank of America N.A. |
239,400 |
01/14/25 |
EUR |
2.43 |
EUR |
605 |
(27,402 ) |
| Tenaris SA |
Goldman Sachs International |
67,000 |
01/14/25 |
EUR |
17.98 |
EUR |
1,221 |
(26,737 ) |
| TotalEnergies SE |
Bank of America N.A. |
82,600 |
01/14/25 |
EUR |
58.71 |
EUR |
4,443 |
(2,671 ) |
| Gaztransport Et Technigaz SA |
Goldman Sachs International |
9,000 |
01/15/25 |
EUR |
144.13 |
EUR |
1,164 |
(21 ) |
| Saipem SpA |
UBS AG |
586,200 |
01/16/25 |
EUR |
2.46 |
EUR |
1,480 |
(59,355 ) |
| TotalEnergies SE |
Goldman Sachs International |
13,700 |
01/22/25 |
EUR |
54.70 |
EUR |
737 |
(5,069 ) |
| Eni SpA |
UBS AG |
97,700 |
01/24/25 |
EUR |
13.91 |
EUR |
1,290 |
(3,881 ) |
| TotalEnergies SE |
Goldman Sachs International |
46,400 |
01/28/25 |
EUR |
54.27 |
EUR |
2,476 |
(27,126 ) |
| Targa Resources Corp. |
Morgan Stanley & Co. International PLC |
10,400 |
02/07/25 |
USD |
184.62 |
USD |
1,856 |
(51,634 ) |
| Description |
Counterparty |
Number of Contracts |
Expiration Date |
Exercise Price |
Notional Amount (000) |
Value | ||
| Call (continued) |
|
|
|
|
|
|
|
|
| TC Energy Corp. |
Morgan Stanley & Co. International PLC |
11,700 |
02/10/25 |
CAD |
68.76 |
CAD |
784 |
$ (9,241
) |
| Pembina Pipeline Corp. |
Royal Bank of Canada |
102,600 |
02/27/25 |
CAD |
54.25 |
CAD |
5,449 |
(63,658 ) |
| |
|
|
|
|
|
|
|
$ (276,857 ) |
| Description |
Premiums Paid |
Premiums Received |
Unrealized Appreciation |
Unrealized Depreciation |
Value |
| Options Written |
$ N/A
|
$ (2,551,928
) |
$ 1,397,520
|
$ (478,253
) |
$ (1,632,661
) |
| |
Commodity Contracts |
Credit Contracts |
Equity Contracts |
Foreign Currency Exchange Contracts |
Interest Rate Contracts |
Other Contracts |
Total |
| Liabilities — Derivative Financial Instruments |
|
|
|
|
|
|
|
| Options written Options written at value |
$ — |
$ — |
$ 1,632,661 |
$ — |
$ — |
$ — |
$ 1,632,661 |
| |
Commodity Contracts |
Credit Contracts |
Equity Contracts |
Foreign Currency Exchange Contracts |
Interest Rate Contracts |
Other Contracts |
Total |
| Net Realized Gain (Loss) from: |
|
|
|
|
|
|
|
| Options purchased(a) |
$ —
|
$ —
|
$ (104,176
) |
$ —
|
$ —
|
$ —
|
$ (104,176
) |
| Options written |
— |
— |
(2,739,126 ) |
— |
— |
— |
(2,739,126 ) |
| |
$ — |
$ — |
$ (2,843,302 ) |
$ — |
$ — |
$ — |
$ (2,843,302 ) |
| Net Change in Unrealized Appreciation (Depreciation) on: |
|
|
|
|
|
|
|
| Options written |
$ — |
$ — |
$ 206,038 |
$ — |
$ — |
$ — |
$ 206,038 |
| (a) |
Options purchased are included in net realized gain (loss) from investments —
unaffiliated. |
| Options: |
|
| Average value of option contracts purchased |
$—
(a) |
| Average value of option contracts written |
3,495,273 |
| (a) |
Derivative financial instrument not held at any quarter-end. The risk exposure table serves as an
indicator of activity during the period. |
| |
Assets |
Liabilities |
| Derivative Financial Instruments |
|
|
| Options |
$ — |
$ 1,632,661 |
| Total derivative assets and liabilities in the Statements of Assets and Liabilities |
— |
1,632,661 |
| Derivatives not subject to a Master Netting Agreement or similar agreement (“MNA”) |
— |
(1,355,804 ) |
| Total derivative assets and liabilities subject to an MNA |
$ — |
$ 276,857 |
| Counterparty |
Derivative Liabilities Subject to an MNA by Counterparty |
Derivatives Available for Offset(a)
|
Non-Cash Collateral Pledged(b)
|
Cash Collateral Pledged(b)
|
Net Amount of Derivative Liabilities(c)
|
| Bank of America N.A. |
$ 30,073
|
$ —
|
$ —
|
$ —
|
$ 30,073
|
| Goldman Sachs International |
59,015 |
— |
(59,015 ) |
— |
— |
| Morgan Stanley & Co. International PLC |
60,875 |
— |
(60,875 ) |
— |
— |
| Royal Bank of Canada |
63,658 |
— |
— |
— |
63,658 |
| UBS AG |
63,236 |
— |
— |
— |
63,236 |
| |
$ 276,857 |
$ — |
$ (119,890 ) |
$ — |
$ 156,967 |
| (a) |
The amount of derivatives available for offset is limited to the amount of derivative assets and/or liabilities that are subject to an MNA. |
| (b) |
Excess of collateral received/pledged, if any, from the individual counterparty is not shown for financial reporting purposes. |
| (c) |
Net amount represents the net amount payable due to the counterparty in the event of default. Net amount may be offset further by the options written
receivable/payable on the Statements of Assets and Liabilities. |
| |
Level 1 |
Level 2 |
Level 3 |
Total |
| Assets |
|
|
|
|
| Investments |
|
|
|
|
| Long-Term Investments |
|
|
|
|
| Common Stocks |
|
|
|
|
| Energy Equipment & Services |
$ 5,971,827
|
$ 9,852,209
|
$ —
|
$ 15,824,036 |
| Oil, Gas & Consumable Fuels |
302,778,017 |
35,220,065 |
77 |
337,998,159 |
| Short-Term Securities |
|
|
|
|
| Money Market Funds |
7,583,996 |
— |
— |
7,583,996 |
| |
$316,333,840 |
$45,072,274 |
$77 |
$361,406,191 |
| Derivative Financial Instruments(a)
|
|
|
|
|
| Liabilities |
|
|
|
|
| Equity Contracts |
$ (1,286,535 ) |
$ (346,126 ) |
$ — |
$ (1,632,661 ) |
| (a) |
Derivative financial instruments are options written. Options written are shown at
value. |
| Security |
|
Shares |
Value |
| Common Stocks | |||
| Aerospace & Defense — 4.4% |
| ||
| Airbus SE |
|
45,674 |
$ 7,313,815
|
| Boeing Co.(a) |
|
62,141 |
10,998,957 |
| L3Harris Technologies, Inc.(b)(c)
|
|
162,139 |
34,094,589 |
| RTX Corp.(c) |
|
154,868 |
17,921,325 |
| |
|
|
70,328,686 |
| Automobile Components — 0.4% |
| ||
| Lear Corp. |
|
74,548 |
7,059,696 |
| Automobiles — 1.2% |
| ||
| General Motors Co.(b)(c) |
|
358,669 |
19,106,298 |
| Banks — 12.6% |
| ||
| Bank of America Corp. |
|
298,162 |
13,104,220 |
| Citigroup, Inc.(c) |
|
734,441 |
51,697,302 |
| First Citizens BancShares, Inc., Class A |
|
21,149 |
44,688,260 |
| JPMorgan Chase & Co.(c) |
|
109,917 |
26,348,204 |
| Wells Fargo & Co.(c) |
|
922,423 |
64,790,992 |
| |
|
|
200,628,978 |
| Beverages — 0.6% |
| ||
| Constellation Brands, Inc., Class A |
|
21,695 |
4,794,595 |
| Keurig Dr. Pepper, Inc. |
|
168,263 |
5,404,608 |
| |
|
|
10,199,203 |
| Broadline Retail — 1.6% |
| ||
| Alibaba Group Holding Ltd. |
|
637,400 |
6,745,830 |
| Amazon.com, Inc.(a) |
|
82,514 |
18,102,747 |
| |
|
|
24,848,577 |
| Building Products — 1.1% |
| ||
| Johnson Controls International PLC |
|
227,539 |
17,959,653 |
| Capital Markets — 1.9% |
| ||
| Carlyle Group, Inc. |
|
102,817 |
5,191,230 |
| Intercontinental Exchange, Inc. |
|
172,693 |
25,732,984 |
| |
|
|
30,924,214 |
| Chemicals — 3.3% |
| ||
| Air Products and Chemicals, Inc. |
|
67,451 |
19,563,488 |
| Albemarle Corp. |
|
67,793 |
5,835,622 |
| Corteva, Inc. |
|
62,106 |
3,537,558 |
| International Flavors & Fragrances, Inc. |
|
124,117 |
10,494,092 |
| PPG Industries, Inc. |
|
113,347 |
13,539,299 |
| |
|
|
52,970,059 |
| Commercial Services & Supplies — 0.3% |
| ||
| Rentokil Initial PLC |
|
914,208 |
4,563,244 |
| Communications Equipment — 1.7% |
| ||
| Cisco Systems, Inc.(c) |
|
462,777 |
27,396,398 |
| Consumer Staples Distribution & Retail — 0.7% |
| ||
| Dollar General Corp. |
|
153,639 |
11,648,909 |
| Containers & Packaging — 1.4% |
| ||
| Crown Holdings, Inc. |
|
47,729 |
3,946,711 |
| Sealed Air Corp.(b) |
|
536,195 |
18,139,477 |
| |
|
|
22,086,188 |
| Diversified Telecommunication Services — 1.5% |
| ||
| AT&T, Inc. |
|
185,831 |
4,231,372 |
| Verizon Communications, Inc.(b) |
|
502,160 |
20,081,378 |
| |
|
|
24,312,750 |
| Electric Utilities — 3.1% |
| ||
| American Electric Power Co., Inc. |
|
97,655 |
9,006,721 |
| Security |
|
Shares |
Value |
| Electric Utilities (continued) |
| ||
| Entergy Corp. |
|
152,704 |
$ 11,578,017
|
| Exelon Corp. |
|
282,006 |
10,614,706 |
| PG&E Corp. |
|
911,803 |
18,400,184 |
| |
|
|
49,599,628 |
| Electrical Equipment — 0.3% |
| ||
| Acuity Brands, Inc. |
|
14,356 |
4,193,818 |
| Entertainment — 2.5% |
| ||
| Electronic Arts, Inc. |
|
179,070 |
26,197,941 |
| Walt Disney Co. |
|
126,644 |
14,101,809 |
| |
|
|
40,299,750 |
| Financial Services — 3.9% |
| ||
| AP Arsenal Co. Invest LP(a)(d)
|
|
15,830,106 |
16,305,009 |
| Fidelity National Information Services, Inc.(b) |
|
369,590 |
29,851,785 |
| Visa, Inc., Class A |
|
50,677 |
16,015,959 |
| |
|
|
62,172,753 |
| Food Products — 2.3% |
| ||
| Kraft Heinz Co.(b)(c) |
|
957,335 |
29,399,758 |
| Lamb Weston Holdings, Inc. |
|
116,326 |
7,774,066 |
| |
|
|
37,173,824 |
| Ground Transportation — 0.2% |
| ||
| Norfolk Southern Corp. |
|
13,776 |
3,233,227 |
| Health Care Equipment & Supplies — 4.6% |
| ||
| Baxter International, Inc.(c) |
|
943,659 |
27,517,096 |
| Becton Dickinson & Co. |
|
20,929 |
4,748,162 |
| Koninklijke Philips NV(a) |
|
332,980 |
8,434,807 |
| Medtronic PLC |
|
415,585 |
33,196,930 |
| |
|
|
73,896,995 |
| Health Care Providers & Services — 8.6% |
| ||
| Cardinal Health, Inc. |
|
338,263 |
40,006,365 |
| Cigna Group |
|
46,101 |
12,730,330 |
| CVS Health Corp.(b)(c) |
|
696,142 |
31,249,814 |
| Elevance Health, Inc.(c) |
|
41,393 |
15,269,878 |
| Humana, Inc. |
|
55,789 |
14,154,227 |
| Labcorp Holdings, Inc. |
|
101,702 |
23,322,303 |
| |
|
|
136,732,917 |
| Household Durables — 1.8% |
| ||
| Sony Group Corp. |
|
1,334,000 |
28,114,765 |
| Household Products — 0.5% |
| ||
| Kimberly-Clark Corp. |
|
59,807 |
7,837,109 |
| Industrial Conglomerates — 0.5% |
| ||
| Honeywell International, Inc. |
|
38,091 |
8,604,376 |
| Insurance — 4.7% |
| ||
| American International Group, Inc.(c) |
|
338,408 |
24,636,102 |
| Fidelity National Financial, Inc., Class A |
|
313,242 |
17,585,406 |
| Willis Towers Watson PLC |
|
106,544 |
33,373,843 |
| |
|
|
75,595,351 |
| IT Services — 1.6% |
| ||
| Cognizant Technology Solutions Corp., Class
A(c) |
|
336,328 |
25,863,623 |
| Leisure Products — 0.9% |
| ||
| Hasbro, Inc. |
|
269,066 |
15,043,480 |
| Life Sciences Tools & Services — 0.3% |
| ||
| Fortrea Holdings, Inc.(a) |
|
261,935 |
4,885,088 |
| Machinery — 2.4% |
| ||
| CNH Industrial NV |
|
1,152,798 |
13,061,201 |
| Security |
|
Shares |
Value |
| Machinery (continued) |
| ||
| Fortive Corp. |
|
110,747 |
$ 8,306,025
|
| Komatsu Ltd. |
|
155,800 |
4,244,357 |
| Westinghouse Air Brake Technologies Corp. |
|
65,084 |
12,339,276 |
| |
|
|
37,950,859 |
| Media — 2.6% |
| ||
| Comcast Corp., Class A(c) |
|
744,506 |
27,941,310 |
| WPP PLC |
|
1,357,685 |
13,994,794 |
| |
|
|
41,936,104 |
| Metals & Mining — 0.5% |
| ||
| Teck Resources Ltd., Class B |
|
208,585 |
8,453,950 |
| Multi-Utilities — 1.6% |
| ||
| Dominion Energy, Inc. |
|
128,068 |
6,897,743 |
| Sempra |
|
213,652 |
18,741,553 |
| |
|
|
25,639,296 |
| Oil, Gas & Consumable Fuels — 6.4% |
| ||
| BP PLC |
|
4,911,365 |
24,276,710 |
| Enterprise Products Partners LP(c) |
|
557,347 |
17,478,402 |
| Formentera Partners Fund II
LP(a)(d)(e) |
|
— (f) |
14,785,475 |
| Hess Corp. |
|
126,542 |
16,831,351 |
| Shell PLC |
|
806,146 |
25,128,372 |
| Suncor Energy, Inc. |
|
83,663 |
2,985,096 |
| |
|
|
101,485,406 |
| Pharmaceuticals — 2.2% |
| ||
| AstraZeneca PLC |
|
68,790 |
8,968,813 |
| Eli Lilly & Co. |
|
12,149 |
9,379,028 |
| Sanofi SA |
|
167,683 |
16,300,592 |
| |
|
|
34,648,433 |
| Professional Services — 3.8% |
| ||
| Leidos Holdings, Inc.(c) |
|
111,537 |
16,068,020 |
| SS&C Technologies Holdings, Inc. |
|
585,000 |
44,331,300 |
| |
|
|
60,399,320 |
| Residential REITs — 0.7% |
| ||
| Mid-America Apartment Communities, Inc. |
|
66,441 |
10,269,785 |
| Semiconductors & Semiconductor Equipment — 1.7% |
| ||
| Applied Materials, Inc. |
|
26,435 |
4,299,124 |
| Intel Corp. |
|
340,257 |
6,822,153 |
| Micron Technology, Inc.(b) |
|
44,325 |
3,730,392 |
| Taiwan Semiconductor Manufacturing Co. Ltd., ADR |
|
59,196 |
11,690,618 |
| |
|
|
26,542,287 |
| Software — 2.4% |
| ||
| Microsoft Corp. |
|
89,334 |
37,654,281 |
| Specialized REITs — 1.1% |
| ||
| Crown Castle, Inc.(b)(c) |
|
190,018 |
17,246,034 |
| Technology Hardware, Storage & Peripherals — 2.9% |
| ||
| HP, Inc.(b) |
|
787,720 |
25,703,304 |
| Samsung Electronics Co. Ltd.,
GDR(g) |
|
22,170 |
20,021,150 |
| |
|
|
45,724,454 |
| Security |
|
Shares |
Value |
| Tobacco — 1.0% |
| ||
| British American Tobacco PLC, ADR |
|
420,387 |
$ 15,268,456 |
| Total Common Stocks — 97.8% (Cost: $1,273,037,563) |
1,560,498,222 | ||
| Preferred Securities | |||
| Preferred Stocks — 0.2% | |||
| Household Products — 0.2% |
| ||
| Henkel AG & Co. KGaA |
|
39,028 |
3,424,179 |
| |
3,424,179 | ||
| Total Preferred Securities — 0.2% (Cost: $3,075,151) |
3,424,179 | ||
| Total Long-Term Investments — 98.0% (Cost: $1,276,112,714) |
1,563,922,401 | ||
| Short-Term Securities | |||
| Money Market Funds — 2.9% |
| ||
| BlackRock Liquidity Funds, T-Fund, Institutional Shares, 4.36%(h)(i) |
|
46,597,729 |
46,597,729 |
| Total Short-Term Securities — 2.9% (Cost: $46,597,729) |
46,597,729 | ||
| Total Investments Before Options Written — 100.9% (Cost: $1,322,710,443) |
1,610,520,130 | ||
| Options Written — (0.7)% (Premiums Received: $(20,123,825)) |
(10,489,212 ) | ||
| Total Investments, Net of Options Written — 100.2% (Cost: $1,302,586,618) |
1,600,030,918 | ||
| Liabilities in Excess of Other Assets — (0.2)% |
(3,422,473 ) | ||
| Net Assets — 100.0% |
$ 1,596,608,445 | ||
| (a) |
Non-income producing security. |
| (b) |
All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives. |
| (c) |
All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written. |
| (d) |
Security is valued using significant unobservable inputs and is classified as Level 3 in the
fair value hierarchy. |
| (e) |
All or a portion of the security is held by a wholly-owned subsidiary. See Note 1 of the
Notes to Financial Statements for details on the wholly-owned subsidiary. |
| (f) |
Investment does not issue shares. |
| (g) |
This security may be resold to qualified foreign investors and foreign institutional buyers
under Regulation S of the Securities Act of 1933. |
| (h) |
Affiliate of the Trust. |
| (i) |
Annualized 7-day yield as of period end. |
| Affiliated Issuer |
Value at 12/31/23 |
Purchases at Cost |
Proceeds from Sales |
Net Realized Gain (Loss) |
Change in Unrealized Appreciation (Depreciation) |
Value at 12/31/24 |
Shares Held at 12/31/24 |
Income |
Capital Gain Distributions from Underlying Funds |
| BlackRock Cash Funds: Institutional, SL Agency Shares(a) |
$ — |
$ 896 (b) |
$ — |
$ (896 ) |
$ — |
$ — |
— |
$ 464 (c) |
$ — |
| BlackRock Liquidity Funds, T-Fund, Institutional Shares |
5,204,534 |
41,393,195 (b) |
— |
— |
— |
46,597,729 |
46,597,729 |
1,687,407 |
— |
| |
|
|
|
$ (896 ) |
$ — |
$ 46,597,729 |
|
$ 1,687,871 |
$ — |
| (a) |
As of period end, the entity is no longer held. |
| (b) |
Represents net amount purchased (sold). |
| (c) |
All or a portion represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of collateral investment fees, and
other payments to and from borrowers of securities. |
| Description |
Number of Contracts |
Expiration Date |
Exercise Price |
Notional Amount (000) |
Value | ||
| Call |
|
|
|
|
|
|
|
| Boeing Co. |
173 |
01/03/25 |
USD |
180.00 |
USD |
3,062 |
$ (17,473
) |
| Electronic Arts, Inc. |
526 |
01/03/25 |
USD |
165.00 |
USD |
7,695 |
(52,600 ) |
| Honeywell International, Inc. |
106 |
01/03/25 |
USD |
230.00 |
USD |
2,394 |
(4,240 ) |
| HP, Inc. |
296 |
01/03/25 |
USD |
37.00 |
USD |
966 |
(6,216 ) |
| Humana, Inc. |
182 |
01/03/25 |
USD |
315.00 |
USD |
4,618 |
(27,300 ) |
| JPMorgan Chase & Co. |
164 |
01/03/25 |
USD |
245.00 |
USD |
3,931 |
(3,608 ) |
| PG&E Corp. |
1,175 |
01/03/25 |
USD |
21.50 |
USD |
2,371 |
(17,625 ) |
| Taiwan Semiconductor Manufacturing Co. Ltd., ADR |
61 |
01/03/25 |
USD |
200.00 |
USD |
1,205 |
(8,296 ) |
| Teck Resources Ltd., Class B |
281 |
01/03/25 |
USD |
48.00 |
USD |
1,139 |
(18,265 ) |
| Cognizant Technology Solutions Corp., Class A |
1,074 |
01/08/25 |
USD |
78.50 |
USD |
8,259 |
(50,068 ) |
| Amazon.com, Inc. |
56 |
01/10/25 |
USD |
230.00 |
USD |
1,229 |
(3,556 ) |
| American International Group, Inc. |
100 |
01/10/25 |
USD |
77.00 |
USD |
728 |
(1,500 ) |
| Bank of America Corp. |
526 |
01/10/25 |
USD |
47.00 |
USD |
2,312 |
(1,315 ) |
| Baxter International, Inc. |
1,479 |
01/10/25 |
USD |
35.00 |
USD |
4,313 |
(199,665 ) |
| Boeing Co. |
173 |
01/10/25 |
USD |
170.00 |
USD |
3,062 |
(150,510 ) |
| Cardinal Health, Inc. |
449 |
01/10/25 |
USD |
122.91 |
USD |
5,310 |
(7,184 ) |
| Cisco Systems, Inc. |
1,583 |
01/10/25 |
USD |
60.00 |
USD |
9,371 |
(34,826 ) |
| Citigroup, Inc. |
530 |
01/10/25 |
USD |
74.00 |
USD |
3,731 |
(6,095 ) |
| Enterprise Products Partners LP |
1,050 |
01/10/25 |
USD |
33.00 |
USD |
3,293 |
(13,650 ) |
| HP, Inc. |
859 |
01/10/25 |
USD |
40.71 |
USD |
2,803 |
— |
| JPMorgan Chase & Co. |
154 |
01/10/25 |
USD |
255.00 |
USD |
3,692 |
(847 ) |
| Kimberly-Clark Corp. |
208 |
01/10/25 |
USD |
138.48 |
USD |
2,726 |
(3,087 ) |
| Kraft Heinz Co. |
886 |
01/10/25 |
USD |
31.63 |
USD |
2,721 |
(9,668 ) |
| Medtronic PLC |
427 |
01/10/25 |
USD |
86.00 |
USD |
3,411 |
(49,105 ) |
| Microsoft Corp. |
250 |
01/10/25 |
USD |
445.00 |
USD |
10,538 |
(6,500 ) |
| PG&E Corp. |
625 |
01/10/25 |
USD |
21.32 |
USD |
1,261 |
(1,219 ) |
| PPG Industries, Inc. |
195 |
01/10/25 |
USD |
131.00 |
USD |
2,329 |
(9,750 ) |
| Verizon Communications, Inc. |
537 |
01/10/25 |
USD |
44.00 |
USD |
2,147 |
(1,074 ) |
| Visa, Inc., Class A |
35 |
01/10/25 |
USD |
320.00 |
USD |
1,106 |
(6,405 ) |
| Wells Fargo & Co. |
1,775 |
01/10/25 |
USD |
73.00 |
USD |
12,468 |
(48,812 ) |
| Acuity Brands, Inc. |
79 |
01/17/25 |
USD |
340.00 |
USD |
2,308 |
(14,615 ) |
| Air Products and Chemicals, Inc. |
131 |
01/17/25 |
USD |
310.00 |
USD |
3,800 |
(4,585 ) |
| Albemarle Corp. |
129 |
01/17/25 |
USD |
110.00 |
USD |
1,110 |
(1,484 ) |
| Amazon.com, Inc. |
64 |
01/17/25 |
USD |
215.00 |
USD |
1,404 |
(51,520 ) |
| Amazon.com, Inc. |
214 |
01/17/25 |
USD |
230.00 |
USD |
4,695 |
(30,816 ) |
| American Electric Power Co., Inc. |
280 |
01/17/25 |
USD |
97.50 |
USD |
2,582 |
(3,500 ) |
| American International Group, Inc. |
1,089 |
01/17/25 |
USD |
77.50 |
USD |
7,928 |
(13,613 ) |
| AT&T, Inc. |
895 |
01/17/25 |
USD |
23.00 |
USD |
2,038 |
(18,348 ) |
| Bank of America Corp. |
1,134 |
01/17/25 |
USD |
47.00 |
USD |
4,984 |
(30,051 ) |
| Description |
Number of Contracts |
Expiration Date |
Exercise Price |
Notional Amount (000) |
Value | ||
| Call (continued) |
|
|
|
|
|
|
|
| Baxter International, Inc. |
1,242 |
01/17/25 |
USD |
35.00 |
USD |
3,622 |
$ (12,420
) |
| Becton Dickinson & Co. |
58 |
01/17/25 |
USD |
235.00 |
USD |
1,316 |
(7,250 ) |
| Cardinal Health, Inc. |
295 |
01/17/25 |
USD |
120.00 |
USD |
3,489 |
(38,350 ) |
| Carlyle Group, Inc. |
282 |
01/17/25 |
USD |
52.50 |
USD |
1,424 |
(16,920 ) |
| Cigna Group |
78 |
01/17/25 |
USD |
360.00 |
USD |
2,154 |
(1,950 ) |
| Cisco Systems, Inc. |
497 |
01/17/25 |
USD |
60.00 |
USD |
2,942 |
(21,371 ) |
| Citigroup, Inc. |
748 |
01/17/25 |
USD |
70.00 |
USD |
5,265 |
(157,828 ) |
| CNH Industrial NV |
3,122 |
01/17/25 |
USD |
10.85 |
USD |
3,537 |
(222,105 ) |
| Cognizant Technology Solutions Corp., Class A |
775 |
01/17/25 |
USD |
82.50 |
USD |
5,960 |
(11,625 ) |
| Comcast Corp., Class A |
1,314 |
01/17/25 |
USD |
45.00 |
USD |
4,931 |
(2,628 ) |
| Corteva, Inc. |
170 |
01/17/25 |
USD |
60.00 |
USD |
968 |
(5,100 ) |
| Crown Holdings, Inc. |
137 |
01/17/25 |
USD |
97.50 |
USD |
1,133 |
(11,645 ) |
| Crown Holdings, Inc. |
62 |
01/17/25 |
USD |
85.00 |
USD |
513 |
(3,720 ) |
| CVS Health Corp. |
528 |
01/17/25 |
USD |
60.00 |
USD |
2,370 |
(792 ) |
| CVS Health Corp. |
1,259 |
01/17/25 |
USD |
57.50 |
USD |
5,652 |
(3,777 ) |
| Dollar General Corp. |
393 |
01/17/25 |
USD |
85.00 |
USD |
2,980 |
(6,681 ) |
| Dominion Energy, Inc. |
282 |
01/17/25 |
USD |
57.50 |
USD |
1,519 |
(2,115 ) |
| Electronic Arts, Inc. |
181 |
01/17/25 |
USD |
165.00 |
USD |
2,648 |
(905 ) |
| Elevance Health, Inc. |
118 |
01/17/25 |
USD |
440.00 |
USD |
4,353 |
(6,490 ) |
| Eli Lilly & Co. |
51 |
01/17/25 |
USD |
780.00 |
USD |
3,937 |
(79,432 ) |
| Entergy Corp. |
560 |
01/17/25 |
USD |
75.18 |
USD |
4,246 |
(97,339 ) |
| Enterprise Products Partners LP |
1,110 |
01/17/25 |
USD |
31.00 |
USD |
3,481 |
(77,700 ) |
| Exelon Corp. |
493 |
01/17/25 |
USD |
40.00 |
USD |
1,856 |
(2,465 ) |
| Exelon Corp. |
529 |
01/17/25 |
USD |
37.00 |
USD |
1,991 |
(55,545 ) |
| Fidelity National Financial, Inc., Class A |
901 |
01/17/25 |
USD |
62.00 |
USD |
5,058 |
(254 ) |
| Fidelity National Information Services, Inc. |
361 |
01/17/25 |
USD |
90.00 |
USD |
2,916 |
(1,805 ) |
| First Citizens BancShares, Inc., Class A |
56 |
01/17/25 |
USD |
2,250.00 |
USD |
11,833 |
(60,760 ) |
| Fortive Corp. |
308 |
01/17/25 |
USD |
80.00 |
USD |
2,310 |
(13,860 ) |
| Fortrea Holdings, Inc. |
931 |
01/17/25 |
USD |
22.50 |
USD |
1,736 |
(32,585 ) |
| General Motors Co. |
1,000 |
01/17/25 |
USD |
57.50 |
USD |
5,327 |
(33,500 ) |
| General Motors Co. |
125 |
01/17/25 |
USD |
55.00 |
USD |
666 |
(10,063 ) |
| Hasbro, Inc. |
625 |
01/17/25 |
USD |
67.50 |
USD |
3,494 |
(18,750 ) |
| Honeywell International, Inc. |
106 |
01/17/25 |
USD |
240.00 |
USD |
2,394 |
(5,035 ) |
| Intercontinental Exchange, Inc. |
277 |
01/17/25 |
USD |
165.00 |
USD |
4,128 |
(4,155 ) |
| International Flavors & Fragrances, Inc. |
335 |
01/17/25 |
USD |
95.00 |
USD |
2,832 |
(16,750 ) |
| Johnson Controls International PLC |
764 |
01/17/25 |
USD |
85.00 |
USD |
6,030 |
(34,380 ) |
| JPMorgan Chase & Co. |
159 |
01/17/25 |
USD |
240.00 |
USD |
3,811 |
(83,077 ) |
| Keurig Dr. Pepper, Inc. |
797 |
01/17/25 |
USD |
33.00 |
USD |
2,560 |
(9,963 ) |
| Keurig Dr. Pepper, Inc. |
140 |
01/17/25 |
USD |
34.00 |
USD |
450 |
(1,400 ) |
| Kraft Heinz Co. |
1,342 |
01/17/25 |
USD |
33.29 |
USD |
4,121 |
(2,315 ) |
| L3Harris Technologies, Inc. |
404 |
01/17/25 |
USD |
250.00 |
USD |
8,495 |
(2,020 ) |
| Labcorp Holdings, Inc. |
289 |
01/17/25 |
USD |
240.00 |
USD |
6,627 |
(22,397 ) |
| Lamb Weston Holdings, Inc. |
260 |
01/17/25 |
USD |
82.50 |
USD |
1,738 |
(7,800 ) |
| Lear Corp. |
205 |
01/17/25 |
USD |
100.00 |
USD |
1,941 |
(20,500 ) |
| Leidos Holdings, Inc. |
178 |
01/17/25 |
USD |
202.50 |
USD |
2,564 |
(430 ) |
| Medtronic PLC |
424 |
01/17/25 |
USD |
90.00 |
USD |
3,387 |
(848 ) |
| Medtronic PLC |
458 |
01/17/25 |
USD |
87.50 |
USD |
3,659 |
(2,977 ) |
| Mid-America Apartment Communities, Inc. |
170 |
01/17/25 |
USD |
165.00 |
USD |
2,628 |
(22,950 ) |
| Mid-America Apartment Communities, Inc. |
97 |
01/17/25 |
USD |
152.75 |
USD |
1,499 |
(26,792 ) |
| PG&E Corp. |
1,143 |
01/17/25 |
USD |
22.00 |
USD |
2,307 |
(4,572 ) |
| RTX Corp. |
425 |
01/17/25 |
USD |
120.00 |
USD |
4,918 |
(31,025 ) |
| Sealed Air Corp. |
1,132 |
01/17/25 |
USD |
37.50 |
USD |
3,830 |
(33,960 ) |
| Sempra |
159 |
01/17/25 |
USD |
91.25 |
USD |
1,395 |
(4,533 ) |
| SS&C Technologies Holdings, Inc. |
1,450 |
01/17/25 |
USD |
75.00 |
USD |
10,988 |
(246,500 ) |
| Suncor Energy, Inc. |
431 |
01/17/25 |
USD |
42.00 |
USD |
1,538 |
(20,257 ) |
| Teck Resources Ltd., Class B |
343 |
01/17/25 |
USD |
49.00 |
USD |
1,390 |
(6,346 ) |
| Verizon Communications, Inc. |
658 |
01/17/25 |
USD |
42.00 |
USD |
2,631 |
(2,961 ) |
| Visa, Inc., Class A |
162 |
01/17/25 |
USD |
315.00 |
USD |
5,120 |
(93,150 ) |
| Walt Disney Co. |
459 |
01/17/25 |
USD |
120.00 |
USD |
5,111 |
(7,344 ) |
| Wells Fargo & Co. |
1,961 |
01/17/25 |
USD |
77.50 |
USD |
13,774 |
(52,947 ) |
| Westinghouse Air Brake Technologies Corp. |
84 |
01/17/25 |
USD |
202.34 |
USD |
1,593 |
(2,038 ) |
| Willis Towers Watson PLC |
317 |
01/17/25 |
USD |
320.00 |
USD |
9,930 |
(74,495 ) |
| Description |
Number of Contracts |
Expiration Date |
Exercise Price |
Notional Amount (000) |
Value | ||
| Call (continued) |
|
|
|
|
|
|
|
| Amazon.com, Inc. |
63 |
01/24/25 |
USD |
235.00 |
USD |
1,382 |
$ (7,403
) |
| American International Group, Inc. |
672 |
01/24/25 |
USD |
75.00 |
USD |
4,892 |
(35,280 ) |
| AT&T, Inc. |
127 |
01/24/25 |
USD |
23.00 |
USD |
289 |
(3,556 ) |
| Baxter International, Inc. |
1,053 |
01/24/25 |
USD |
30.00 |
USD |
3,071 |
(52,650 ) |
| Cardinal Health, Inc. |
339 |
01/24/25 |
USD |
124.00 |
USD |
4,009 |
(15,255 ) |
| Cardinal Health, Inc. |
292 |
01/24/25 |
USD |
120.00 |
USD |
3,453 |
(44,530 ) |
| Citigroup, Inc. |
1,115 |
01/24/25 |
USD |
75.00 |
USD |
7,848 |
(57,422 ) |
| Comcast Corp., Class A |
487 |
01/24/25 |
USD |
44.00 |
USD |
1,828 |
(1,461 ) |
| Comcast Corp., Class A |
568 |
01/24/25 |
USD |
40.00 |
USD |
2,132 |
(5,396 ) |
| Electronic Arts, Inc. |
277 |
01/24/25 |
USD |
157.50 |
USD |
4,053 |
(65,095 ) |
| Enterprise Products Partners LP |
944 |
01/24/25 |
USD |
33.00 |
USD |
2,960 |
(6,136 ) |
| Fidelity National Information Services, Inc. |
562 |
01/24/25 |
USD |
87.00 |
USD |
4,539 |
(7,025 ) |
| General Motors Co. |
309 |
01/24/25 |
USD |
53.00 |
USD |
1,646 |
(63,654 ) |
| HP, Inc. |
1,106 |
01/24/25 |
USD |
37.00 |
USD |
3,609 |
(8,295 ) |
| Intel Corp. |
1,198 |
01/24/25 |
USD |
22.50 |
USD |
2,402 |
(33,544 ) |
| JPMorgan Chase & Co. |
135 |
01/24/25 |
USD |
250.00 |
USD |
3,236 |
(29,025 ) |
| Kimberly-Clark Corp. |
125 |
01/24/25 |
USD |
138.00 |
USD |
1,638 |
(60,000 ) |
| Kraft Heinz Co. |
1,047 |
01/24/25 |
USD |
33.00 |
USD |
3,215 |
(8,376 ) |
| Micron Technology, Inc. |
443 |
01/24/25 |
USD |
112.00 |
USD |
3,728 |
(3,323 ) |
| Microsoft Corp. |
57 |
01/24/25 |
USD |
465.00 |
USD |
2,403 |
(1,824 ) |
| PG&E Corp. |
993 |
01/24/25 |
USD |
21.00 |
USD |
2,004 |
(17,378 ) |
| PPG Industries, Inc. |
428 |
01/24/25 |
USD |
126.00 |
USD |
5,112 |
(87,740 ) |
| Suncor Energy, Inc. |
29 |
01/24/25 |
USD |
37.00 |
USD |
103 |
(1,204 ) |
| Taiwan Semiconductor Manufacturing Co. Ltd., ADR |
200 |
01/24/25 |
USD |
210.00 |
USD |
3,950 |
(83,500 ) |
| Verizon Communications, Inc. |
595 |
01/24/25 |
USD |
43.00 |
USD |
2,379 |
(18,445 ) |
| Verizon Communications, Inc. |
80 |
01/24/25 |
USD |
42.00 |
USD |
320 |
(1,520 ) |
| Visa, Inc., Class A |
81 |
01/24/25 |
USD |
325.00 |
USD |
2,560 |
(21,465 ) |
| Applied Materials, Inc. |
73 |
01/31/25 |
USD |
175.00 |
USD |
1,187 |
(19,455 ) |
| Citigroup, Inc. |
919 |
01/31/25 |
USD |
75.00 |
USD |
6,469 |
(63,870 ) |
| Comcast Corp., Class A |
692 |
01/31/25 |
USD |
42.00 |
USD |
2,597 |
(10,726 ) |
| Comcast Corp., Class A |
207 |
01/31/25 |
USD |
41.00 |
USD |
777 |
(6,003 ) |
| Constellation Brands, Inc., Class A |
119 |
01/31/25 |
USD |
245.00 |
USD |
2,630 |
(10,115 ) |
| Dollar General Corp. |
462 |
01/31/25 |
USD |
80.00 |
USD |
3,503 |
(63,063 ) |
| Humana, Inc. |
128 |
01/31/25 |
USD |
295.00 |
USD |
3,247 |
(53,120 ) |
| Kraft Heinz Co. |
1,454 |
01/31/25 |
USD |
33.00 |
USD |
4,465 |
(13,086 ) |
| Medtronic PLC |
267 |
01/31/25 |
USD |
84.00 |
USD |
2,133 |
(8,544 ) |
| Microsoft Corp. |
53 |
01/31/25 |
USD |
470.00 |
USD |
2,234 |
(6,440 ) |
| PG&E Corp. |
1,078 |
01/31/25 |
USD |
20.50 |
USD |
2,175 |
(38,269 ) |
| RTX Corp. |
425 |
01/31/25 |
USD |
119.00 |
USD |
4,918 |
(87,125 ) |
| Verizon Communications, Inc. |
616 |
01/31/25 |
USD |
43.00 |
USD |
2,463 |
(8,316 ) |
| Verizon Communications, Inc. |
80 |
01/31/25 |
USD |
42.00 |
USD |
320 |
(2,000 ) |
| Wells Fargo & Co. |
668 |
01/31/25 |
USD |
75.00 |
USD |
4,692 |
(61,790 ) |
| Becton Dickinson & Co. |
58 |
02/05/25 |
USD |
233.94 |
USD |
1,316 |
(14,632 ) |
| Albemarle Corp. |
243 |
02/21/25 |
USD |
100.00 |
USD |
2,092 |
(59,656 ) |
| Amazon.com, Inc. |
56 |
02/21/25 |
USD |
230.00 |
USD |
1,229 |
(39,480 ) |
| American Electric Power Co., Inc. |
257 |
02/21/25 |
USD |
95.00 |
USD |
2,370 |
(32,767 ) |
| Applied Materials, Inc. |
73 |
02/21/25 |
USD |
180.00 |
USD |
1,187 |
(27,010 ) |
| British American Tobacco PLC, ADR |
840 |
02/21/25 |
USD |
37.00 |
USD |
3,051 |
(69,300 ) |
| Cardinal Health, Inc. |
485 |
02/21/25 |
USD |
120.00 |
USD |
5,736 |
(177,025 ) |
| Carlyle Group, Inc. |
283 |
02/21/25 |
USD |
55.00 |
USD |
1,429 |
(30,422 ) |
| Cisco Systems, Inc. |
497 |
02/21/25 |
USD |
60.00 |
USD |
2,942 |
(87,969 ) |
| CNH Industrial NV |
2,144 |
02/21/25 |
USD |
11.55 |
USD |
2,429 |
(96,489 ) |
| Corteva, Inc. |
170 |
02/21/25 |
USD |
60.00 |
USD |
968 |
(22,950 ) |
| Crown Holdings, Inc. |
62 |
02/21/25 |
USD |
85.00 |
USD |
513 |
(15,035 ) |
| CVS Health Corp. |
470 |
02/21/25 |
USD |
50.00 |
USD |
2,110 |
(60,160 ) |
| Dominion Energy, Inc. |
422 |
02/21/25 |
USD |
55.25 |
USD |
2,273 |
(49,862 ) |
| Elevance Health, Inc. |
109 |
02/21/25 |
USD |
389.00 |
USD |
4,021 |
(128,085 ) |
| Eli Lilly & Co. |
16 |
02/21/25 |
USD |
870.00 |
USD |
1,235 |
(20,400 ) |
| Exelon Corp. |
529 |
02/21/25 |
USD |
37.04 |
USD |
1,991 |
(80,926 ) |
| First Citizens BancShares, Inc., Class A |
60 |
02/21/25 |
USD |
2,200.00 |
USD |
12,678 |
(449,100 ) |
| Fortive Corp. |
301 |
02/21/25 |
USD |
75.00 |
USD |
2,258 |
(81,270 ) |
| Fortrea Holdings, Inc. |
510 |
02/21/25 |
USD |
22.50 |
USD |
951 |
(33,150 ) |
| Description |
Number of Contracts |
Expiration Date |
Exercise Price |
Notional Amount (000) |
Value | ||
| Call (continued) |
|
|
|
|
|
|
|
| Hasbro, Inc. |
854 |
02/21/25 |
USD |
62.75 |
USD |
4,775 |
$ (53,670
) |
| Intercontinental Exchange, Inc. |
260 |
02/21/25 |
USD |
157.00 |
USD |
3,874 |
(42,563 ) |
| International Flavors & Fragrances, Inc. |
347 |
02/21/25 |
USD |
87.50 |
USD |
2,934 |
(96,292 ) |
| Johnson Controls International PLC |
487 |
02/21/25 |
USD |
80.00 |
USD |
3,844 |
(176,537 ) |
| Kraft Heinz Co. |
536 |
02/21/25 |
USD |
32.50 |
USD |
1,646 |
(24,120 ) |
| L3Harris Technologies, Inc. |
499 |
02/21/25 |
USD |
240.00 |
USD |
10,493 |
(39,920 ) |
| Labcorp Holdings, Inc. |
270 |
02/21/25 |
USD |
240.00 |
USD |
6,192 |
(113,400 ) |
| Lamb Weston Holdings, Inc. |
379 |
02/21/25 |
USD |
70.00 |
USD |
2,533 |
(79,590 ) |
| Lear Corp. |
205 |
02/21/25 |
USD |
100.00 |
USD |
1,941 |
(58,937 ) |
| Leidos Holdings, Inc. |
435 |
02/21/25 |
USD |
160.00 |
USD |
6,267 |
(90,262 ) |
| Medtronic PLC |
738 |
02/21/25 |
USD |
85.00 |
USD |
5,895 |
(54,243 ) |
| Microsoft Corp. |
131 |
02/21/25 |
USD |
460.00 |
USD |
5,522 |
(51,417 ) |
| Mid-America Apartment Communities, Inc. |
97 |
02/21/25 |
USD |
152.75 |
USD |
1,499 |
(50,607 ) |
| Sealed Air Corp. |
1,012 |
02/21/25 |
USD |
36.00 |
USD |
3,424 |
(72,537 ) |
| Sempra |
1,016 |
02/21/25 |
USD |
86.50 |
USD |
8,912 |
(369,558 ) |
| SS&C Technologies Holdings, Inc. |
1,770 |
02/21/25 |
USD |
80.00 |
USD |
13,413 |
(203,550 ) |
| Taiwan Semiconductor Manufacturing Co. Ltd., ADR |
64 |
02/21/25 |
USD |
220.00 |
USD |
1,264 |
(29,760 ) |
| Teck Resources Ltd., Class B |
268 |
02/21/25 |
USD |
49.00 |
USD |
1,086 |
(11,658 ) |
| Teck Resources Ltd., Class B |
270 |
02/21/25 |
USD |
47.00 |
USD |
1,094 |
(14,985 ) |
| Walt Disney Co. |
250 |
02/21/25 |
USD |
120.00 |
USD |
2,784 |
(47,500 ) |
| Wells Fargo & Co. |
668 |
02/21/25 |
USD |
75.00 |
USD |
4,692 |
(91,850 ) |
| Westinghouse Air Brake Technologies Corp. |
273 |
02/21/25 |
USD |
195.00 |
USD |
5,176 |
(143,325 ) |
| Willis Towers Watson PLC |
268 |
02/21/25 |
USD |
330.00 |
USD |
8,395 |
(113,230 ) |
| British American Tobacco PLC, ADR |
840 |
03/21/25 |
USD |
38.00 |
USD |
3,051 |
(58,800 ) |
| |
|
|
|
|
|
|
$ (7,647,061 ) |
| Description |
Counterparty |
Number of Contracts |
Expiration Date |
Exercise Price |
Notional Amount (000) |
Value | ||
| Call |
|
|
|
|
|
|
|
|
| Comcast Corp., Class A |
Bank of America N.A. |
41,300 |
01/08/25 |
USD |
43.30 |
USD |
1,550 |
$ (12
) |
| Comcast Corp., Class A |
Bank of America N.A. |
41,300 |
01/08/25 |
USD |
44.46 |
USD |
1,550 |
(36 ) |
| CVS Health Corp. |
Citibank N.A. |
52,700 |
01/08/25 |
USD |
58.59 |
USD |
2,366 |
(22 ) |
| Fidelity National Information Services, Inc. |
JPMorgan Chase Bank N.A. |
30,100 |
01/08/25 |
USD |
87.97 |
USD |
2,431 |
(583 ) |
| Sony Group Corp. |
JPMorgan Chase Bank N.A. |
426,500 |
01/08/25 |
JPY |
2,993.85 |
JPY |
1,414,330 |
(1,033,638 ) |
| Komatsu Ltd. |
Nomura International, Inc. |
57,400 |
01/09/25 |
JPY |
4,323.94 |
JPY |
246,042 |
(35,906 ) |
| Alibaba Group Holding Ltd. |
Bank of America N.A. |
128,000 |
01/14/25 |
HKD |
95.86 |
HKD |
10,521 |
(1,296 ) |
| AstraZeneca PLC |
Bank of America N.A. |
5,900 |
01/14/25 |
GBP |
107.15 |
GBP |
614 |
(6,942 ) |
| BP PLC |
Bank of America N.A. |
1,976,000 |
01/14/25 |
GBP |
3.97 |
GBP |
7,802 |
(141,375 ) |
| Henkel AG & Co. KGaA, Preference Shares |
Bank of America N.A. |
31,300 |
01/14/25 |
EUR |
81.29 |
EUR |
2,651 |
(122,181 ) |
| Sanofi SA |
BNP Paribas SA |
116,500 |
01/14/25 |
EUR |
96.64 |
EUR |
10,933 |
(43,016 ) |
| WPP PLC |
BNP Paribas SA |
262,400 |
01/14/25 |
GBP |
8.64 |
GBP |
2,161 |
(7,161 ) |
| Crown Castle, Inc. |
Barclays Bank PLC |
22,400 |
01/15/25 |
USD |
106.35 |
USD |
2,033 |
(2,360 ) |
| Shell PLC |
Goldman Sachs International |
112,700 |
01/15/25 |
GBP |
26.19 |
GBP |
2,806 |
(3,153 ) |
| AstraZeneca PLC |
Citibank N.A. |
32,400 |
01/16/25 |
GBP |
103.59 |
GBP |
3,374 |
(112,409 ) |
| Koninklijke Philips NV |
Goldman Sachs International |
210,000 |
01/16/25 |
EUR |
26.39 |
EUR |
5,135 |
(8,790 ) |
| Sony Group Corp. |
UBS AG |
316,500 |
01/16/25 |
JPY |
3,083.64 |
JPY |
1,049,555 |
(625,054 ) |
| Alibaba Group Holding Ltd. |
Citibank N.A. |
130,200 |
01/22/25 |
HKD |
85.88 |
HKD |
10,702 |
(22,857 ) |
| BP PLC |
Barclays Bank PLC |
79,800 |
01/22/25 |
GBP |
3.86 |
GBP |
315 |
(12,960 ) |
| Fidelity National Information Services, Inc. |
Citibank N.A. |
41,700 |
01/23/25 |
USD |
87.43 |
USD |
3,368 |
(15,311 ) |
| Shell PLC |
Goldman Sachs International |
245,700 |
01/23/25 |
GBP |
25.33 |
GBP |
6,084 |
(70,531 ) |
| WPP PLC |
Goldman Sachs International |
308,000 |
01/23/25 |
GBP |
8.95 |
GBP |
2,548 |
(4,014 ) |
| Airbus SE |
Bank of America N.A. |
8,500 |
01/28/25 |
EUR |
162.62 |
EUR |
1,316 |
(11,358 ) |
| BP PLC |
Bank of America N.A. |
645,400 |
01/28/25 |
GBP |
3.86 |
GBP |
2,536 |
(116,744 ) |
| Shell PLC |
Goldman Sachs International |
90,700 |
01/28/25 |
GBP |
25.40 |
GBP |
2,246 |
(29,442 ) |
| WPP PLC |
Morgan Stanley & Co. International PLC |
185,900 |
01/28/25 |
GBP |
9.03 |
GBP |
1,538 |
(2,732 ) |
| Intercontinental Exchange, Inc. |
BNP Paribas SA |
41,200 |
01/29/25 |
USD |
159.14 |
USD |
6,139 |
(19,122 ) |
| Rentokil Initial PLC |
Goldman Sachs International |
251,000 |
01/29/25 |
GBP |
4.08 |
GBP |
1,006 |
(41,425 ) |
| Fidelity National Information Services, Inc. |
Citibank N.A. |
41,700 |
01/30/25 |
USD |
86.58 |
USD |
3,368 |
(7,396 ) |
| Crown Castle, Inc. |
UBS AG |
17,200 |
02/04/25 |
USD |
104.10 |
USD |
1,561 |
(7,866 ) |
| Description |
Counterparty |
Number of Contracts |
Expiration Date |
Exercise Price |
Notional Amount (000) |
Value | ||
| Call (continued) |
|
|
|
|
|
|
|
|
| Komatsu Ltd. |
JPMorgan Chase Bank N.A. |
29,400 |
02/04/25 |
JPY |
4,346.00 |
JPY |
127,890 |
$ (30,358
) |
| Fidelity National Financial, Inc., Class A |
Morgan Stanley & Co. International PLC |
82,100 |
02/05/25 |
USD |
59.32 |
USD |
4,609 |
(49,148 ) |
| Airbus SE |
Bank of America N.A. |
17,000 |
02/06/25 |
EUR |
159.65 |
EUR |
2,631 |
(46,670 ) |
| Rentokil Initial PLC |
Goldman Sachs International |
251,000 |
02/06/25 |
GBP |
4.08 |
GBP |
1,006 |
(48,466 ) |
| Entergy Corp. |
Citibank N.A. |
27,900 |
02/19/25 |
USD |
76.41 |
USD |
2,115 |
(62,243 ) |
| Crown Castle, Inc. |
Bank of America N.A. |
64,800 |
02/24/25 |
USD |
96.93 |
USD |
5,881 |
(99,574 ) |
| |
|
|
|
|
|
|
|
$ (2,842,151 ) |
| Description |
Premiums Paid |
Premiums Received |
Unrealized Appreciation |
Unrealized Depreciation |
Value |
| Options Written |
$ N/A
|
$ (20,123,825
) |
$ 11,735,024
|
$ (2,100,411
) |
$ (10,489,212
) |
| |
Commodity Contracts |
Credit Contracts |
Equity Contracts |
Foreign Currency Exchange Contracts |
Interest Rate Contracts |
Other Contracts |
Total |
| Liabilities — Derivative Financial Instruments |
|
|
|
|
|
|
|
| Options written Options written at value |
$ — |
$ — |
$ 10,489,212 |
$ — |
$ — |
$ — |
$ 10,489,212 |
| |
Commodity Contracts |
Credit Contracts |
Equity Contracts |
Foreign Currency Exchange Contracts |
Interest Rate Contracts |
Other Contracts |
Total |
| Net Realized Gain (Loss) from: |
|
|
|
|
|
|
|
| Options written |
$ — |
$ — |
$ (53,221,661 ) |
$ — |
$ — |
$ — |
$ (53,221,661 ) |
| Net Change in Unrealized Appreciation (Depreciation) on: |
|
|
|
|
|
|
|
| Options written |
$ — |
$ — |
$ 25,508,715 |
$ — |
$ — |
$ — |
$ 25,508,715 |
| Options: |
|
| Average value of option contracts written |
$21,825,196
|
| |
Assets |
Liabilities |
| Derivative Financial Instruments |
|
|
| Options |
$ — |
$ 10,489,212 |
| Total derivative assets and liabilities in the Statements of Assets and Liabilities |
— |
10,489,212 |
| Derivatives not subject to a Master Netting Agreement or similar agreement (“MNA”) |
— |
(7,647,061 ) |
| Total derivative assets and liabilities subject to an MNA |
$ — |
$ 2,842,151 |
| Counterparty |
Derivative Liabilities Subject to an MNA by Counterparty |
Derivatives Available for Offset(a)
|
Non-Cash Collateral Pledged(b)
|
Cash Collateral Pledged(b)
|
Net Amount of Derivative Liabilities(c)
|
| Bank of America N.A. |
$ 546,188
|
$ —
|
$ (546,188
) |
$ —
|
$ —
|
| Barclays Bank PLC |
15,320 |
— |
(15,320 ) |
— |
— |
| BNP Paribas SA |
69,299 |
— |
(69,299 ) |
— |
— |
| Citibank N.A. |
220,238 |
— |
(220,238 ) |
— |
— |
| Goldman Sachs International |
205,821 |
— |
(205,821 ) |
— |
— |
| JPMorgan Chase Bank N.A. |
1,064,579 |
— |
(1,064,579 ) |
— |
— |
| Morgan Stanley & Co. International PLC |
51,880 |
— |
(51,880 ) |
— |
— |
| Nomura International, Inc. |
35,906 |
— |
— |
— |
35,906 |
| UBS AG |
632,920 |
— |
(632,920 ) |
— |
— |
| |
$ 2,842,151 |
$ — |
$ (2,806,245 ) |
$ — |
$ 35,906 |
| (a) |
The amount of derivatives available for offset is limited to the amount of derivative assets and/or liabilities that are subject to an MNA. |
| (b) |
Excess of collateral received/pledged, if any, from the individual counterparty is not shown for financial reporting purposes. |
| (c) |
Net amount represents the net amount payable due to the counterparty in the event of default. Net amount may be offset further by the options written
receivable/payable on the Statements of Assets and Liabilities. |
| |
Level 1 |
Level 2 |
Level 3 |
Total |
| Assets |
|
|
|
|
| Investments |
|
|
|
|
| Long-Term Investments |
|
|
|
|
| Common Stocks |
|
|
|
|
| Aerospace & Defense |
$ 63,014,871
|
$ 7,313,815
|
$ —
|
$ 70,328,686 |
| Automobile Components |
7,059,696 |
— |
— |
7,059,696 |
| Automobiles |
19,106,298 |
— |
— |
19,106,298 |
| Banks |
200,628,978 |
— |
— |
200,628,978 |
| Beverages |
10,199,203 |
— |
— |
10,199,203 |
| Broadline Retail |
18,102,747 |
6,745,830 |
— |
24,848,577 |
| Building Products |
17,959,653 |
— |
— |
17,959,653 |
| Capital Markets |
30,924,214 |
— |
— |
30,924,214 |
| Chemicals |
52,970,059 |
— |
— |
52,970,059 |
| Commercial Services & Supplies |
— |
4,563,244 |
— |
4,563,244 |
| Communications Equipment |
27,396,398 |
— |
— |
27,396,398 |
| Consumer Staples Distribution & Retail |
11,648,909 |
— |
— |
11,648,909 |
| Containers & Packaging |
22,086,188 |
— |
— |
22,086,188 |
| Diversified Telecommunication Services |
24,312,750 |
— |
— |
24,312,750 |
| Electric Utilities |
49,599,628 |
— |
— |
49,599,628 |
| Electrical Equipment |
4,193,818 |
— |
— |
4,193,818 |
| Entertainment |
40,299,750 |
— |
— |
40,299,750 |
| Financial Services |
45,867,744 |
— |
16,305,009 |
62,172,753 |
| Food Products |
37,173,824 |
— |
— |
37,173,824 |
| Ground Transportation |
3,233,227 |
— |
— |
3,233,227 |
| Health Care Equipment & Supplies |
65,462,188 |
8,434,807 |
— |
73,896,995 |
| Health Care Providers & Services |
136,732,917 |
— |
— |
136,732,917 |
| Household Durables |
— |
28,114,765 |
— |
28,114,765 |
| Household Products |
7,837,109 |
— |
— |
7,837,109 |
| Industrial Conglomerates |
8,604,376 |
— |
— |
8,604,376 |
| Insurance |
75,595,351 |
— |
— |
75,595,351 |
| IT Services |
25,863,623 |
— |
— |
25,863,623 |
| Leisure Products |
15,043,480 |
— |
— |
15,043,480 |
| |
Level 1 |
Level 2 |
Level 3 |
Total |
| Common Stocks (continued) |
|
|
|
|
| Life Sciences Tools & Services |
$ 4,885,088
|
$ —
|
$ —
|
$ 4,885,088
|
| Machinery |
33,706,502 |
4,244,357 |
— |
37,950,859 |
| Media |
27,941,310 |
13,994,794 |
— |
41,936,104 |
| Metals & Mining |
8,453,950 |
— |
— |
8,453,950 |
| Multi-Utilities |
25,639,296 |
— |
— |
25,639,296 |
| Oil, Gas & Consumable Fuels |
37,294,849 |
49,405,082 |
14,785,475 |
101,485,406 |
| Pharmaceuticals |
9,379,028 |
25,269,405 |
— |
34,648,433 |
| Professional Services |
60,399,320 |
— |
— |
60,399,320 |
| Residential REITs |
10,269,785 |
— |
— |
10,269,785 |
| Semiconductors & Semiconductor Equipment |
26,542,287 |
— |
— |
26,542,287 |
| Software |
37,654,281 |
— |
— |
37,654,281 |
| Specialized REITs |
17,246,034 |
— |
— |
17,246,034 |
| Technology Hardware, Storage & Peripherals |
25,703,304 |
20,021,150 |
— |
45,724,454 |
| Tobacco |
15,268,456 |
— |
— |
15,268,456 |
| Preferred Securities |
|
|
|
|
| Preferred Stocks |
3,424,179 |
— |
— |
3,424,179 |
| Short-Term Securities |
|
|
|
|
| Money Market Funds |
46,597,729 |
— |
— |
46,597,729 |
| |
$1,411,322,397 |
$168,107,249 |
$31,090,484 |
$1,610,520,130 |
| Derivative Financial Instruments(a)
|
|
|
|
|
| Liabilities |
|
|
|
|
| Equity Contracts |
$ (6,261,100 ) |
$ (4,228,112 ) |
$ — |
$ (10,489,212 ) |
| (a) |
Derivative financial instruments are options written. Options written are shown at
value. |
| |
Common Stocks |
| Assets |
|
| Opening balance, as of December 31, 2023 |
$ 26,546,732
|
| Transfers into Level 3 |
— |
| Transfers out of Level 3 |
— |
| Accrued discounts/premiums |
— |
| Net realized gain (loss) |
— |
| Net change in unrealized appreciation (depreciation)(a)(b) |
3,991,985 |
| Purchases |
4,400,506 |
| Sales |
(3,848,739 ) |
| Closing balance, as of December 31, 2024 |
$ 31,090,484 |
| Net change in unrealized appreciation (depreciation) on investments still held at December 31, 2024(b) |
$ 3,991,985 |
| (a) |
Included in the related net change in unrealized appreciation (depreciation) in the Statements of Operations. |
| (b) |
Any difference between net change in unrealized appreciation (depreciation) and net change in unrealized appreciation (depreciation) on investments still held at
December 31, 2024 is generally due to investments no longer held or categorized as
Level 3 at period end. |
| |
Value |
Valuation Approach |
Unobservable Inputs |
Range of Unobservable Inputs Utilized(a) |
Weighted Average of Unobservable Inputs Based on Fair Value |
| Assets |
|
|
|
|
|
| Common Stocks |
$31,090,484
|
Income |
Discount Rate |
10% |
— |
| |
|
Market |
EBITDA Multiple |
7.00x |
— |
| |
$31,090,484 |
|
|
|
|
| (a) |
A
significant change in unobservable input could result in a correlated or inverse change in value. |
| Security |
|
Shares |
Value |
| Common Stocks | |||
| Canada — 1.4% |
| ||
| TELUS Corp. |
|
713,921 |
$ 9,679,864 |
| Denmark — 2.4% |
| ||
| Novo Nordisk A/S, Class B |
|
196,600 |
16,963,008 |
| France — 3.9% |
| ||
| Air Liquide SA |
|
81,613 |
13,266,983 |
| LVMH Moet Hennessy Louis Vuitton SE |
|
21,915 |
14,415,528 |
| |
|
|
27,682,511 |
| India — 0.0% |
| ||
| AceVector Limited, Series I, (Acquired 08/31/18, Cost: $2,637,143)(a)(b)(c) |
|
566,400 |
217,196 |
| Netherlands — 1.5% |
| ||
| Koninklijke KPN NV |
|
2,900,038 |
10,574,805 |
| Spain — 2.0% |
| ||
| Banco Bilbao Vizcaya Argentaria SA |
|
1,453,111 |
14,217,860 |
| Switzerland — 1.7% |
| ||
| Zurich Insurance Group AG, Class N |
|
19,740 |
11,740,673 |
| Taiwan — 3.5% |
| ||
| Taiwan Semiconductor Manufacturing Co. Ltd. |
|
754,000 |
24,505,017 |
| United Kingdom — 10.7% |
| ||
| AstraZeneca PLC |
|
166,609 |
21,722,415 |
| BAE Systems PLC |
|
698,996 |
10,027,287 |
| Diageo PLC |
|
469,963 |
14,934,400 |
| RELX PLC |
|
402,150 |
18,211,670 |
| Taylor Wimpey PLC |
|
6,771,171 |
10,305,745 |
| |
|
|
75,201,517 |
| United States — 72.4% |
| ||
| AbbVie, Inc.(d) |
|
102,937 |
18,291,905 |
| Accenture PLC, Class A |
|
62,792 |
22,089,598 |
| Allegion PLC |
|
103,069 |
13,469,057 |
| Alphabet, Inc., Class A |
|
92,589 |
17,527,098 |
| AMETEK, Inc. |
|
55,370 |
9,980,996 |
| Apple, Inc.(d)(e) |
|
71,432 |
17,888,001 |
| Applied Materials, Inc. |
|
65,297 |
10,619,251 |
| Assurant, Inc.(d) |
|
39,472 |
8,416,220 |
| Baker Hughes Co., Class A |
|
246,980 |
10,131,120 |
| Broadcom, Inc. |
|
94,199 |
21,839,096 |
| Charles Schwab Corp. |
|
145,813 |
10,791,620 |
| Citizens Financial Group, Inc.(e)
|
|
315,548 |
13,808,380 |
| CMS Energy Corp. |
|
171,335 |
11,419,478 |
| Coca-Cola Co. |
|
232,736 |
14,490,143 |
| General Electric Co. |
|
85,712 |
14,295,904 |
| Home Depot, Inc. |
|
34,647 |
13,477,336 |
| Hubbell, Inc. |
|
31,622 |
13,246,140 |
| Intercontinental Exchange,
Inc.(d) |
|
96,885 |
14,436,834 |
| M&T Bank Corp. |
|
53,051 |
9,974,118 |
| Security |
|
Shares |
Value |
| United States (continued) |
| ||
| Mastercard, Inc., Class A |
|
15,561 |
$ 8,193,956
|
| Meta Platforms, Inc., Class A(e)
|
|
29,143 |
17,063,518 |
| Microsoft Corp.(d) |
|
80,339 |
33,862,888 |
| Moody’s Corp. |
|
23,730 |
11,233,070 |
| Oracle Corp. |
|
85,803 |
14,298,212 |
| Otis Worldwide Corp.(d) |
|
181,442 |
16,803,344 |
| Philip Morris International, Inc.(d)(e) |
|
110,477 |
13,295,907 |
| Republic Services, Inc.(e) |
|
36,967 |
7,437,021 |
| Salesforce, Inc. |
|
38,999 |
13,038,536 |
| Sanofi SA |
|
153,206 |
14,893,272 |
| Shell PLC |
|
442,059 |
13,873,220 |
| Texas Instruments, Inc.(d)(e)
|
|
113,718 |
21,323,262 |
| Union Pacific Corp. |
|
61,931 |
14,122,745 |
| UnitedHealth Group, Inc.(e)
|
|
35,502 |
17,959,042 |
| Walmart, Inc.(d) |
|
116,140 |
10,493,249 |
| Williams Cos., Inc.(d) |
|
183,217 |
9,915,704 |
| Zoetis, Inc., Class A |
|
40,803 |
6,648,033 |
| |
|
|
510,647,274 |
| Total Long-Term Investments — 99.5% (Cost: $550,585,379) |
701,429,725 | ||
| Short-Term Securities | |||
| Money Market Funds — 1.0% |
| ||
| BlackRock Liquidity Funds, T-Fund, Institutional Shares, 4.36%(f)(g) |
|
7,033,278 |
7,033,278 |
| Total Short-Term Securities — 1.0% (Cost: $7,033,278) |
7,033,278 | ||
| Total Investments Before Options Written — 100.5% (Cost: $557,618,657) |
708,463,003 | ||
| Options Written — (0.6)% (Premiums Received: $(7,687,194)) |
(4,114,542 ) | ||
| Total Investments, Net of Options Written — 99.9% (Cost: $549,931,463) |
704,348,461 | ||
| Other Assets Less Liabilities — 0.1% |
360,738 | ||
| Net Assets — 100.0% |
$ 704,709,199 | ||
| (a) |
Security is valued using significant unobservable inputs and is classified as Level 3 in the
fair value hierarchy. |
| (b) |
Non-income producing security. |
| (c) |
Restricted security as to resale, excluding 144A securities. The Trust held restricted
securities with a current value of $217,196, representing less than 0.05% of its net
assets as of period end, and an original cost of $2,637,143. |
| (d) |
All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written. |
| (e) |
All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives. |
| (f) |
Affiliate of the Trust. |
| (g) |
Annualized 7-day yield as of period end. |
| Affiliated Issuer |
Value at 12/31/23 |
Purchases at Cost |
Proceeds from Sales |
Net Realized Gain (Loss) |
Change in Unrealized Appreciation (Depreciation) |
Value at 12/31/24 |
Shares Held at 12/31/24 |
Income |
Capital Gain Distributions from Underlying Funds |
| BlackRock Cash Funds: Institutional, SL Agency Shares(a) |
$ — |
$ — |
$ (98 )(b) |
$ 98 |
$ — |
$ — |
— |
$ 23 (c) |
$ — |
| BlackRock Liquidity Funds, T-Fund, Institutional Shares |
2,668,223 |
4,365,055 (b) |
— |
— |
— |
7,033,278 |
7,033,278 |
348,611 |
— |
| |
|
|
|
$ 98 |
$ — |
$ 7,033,278 |
|
$ 348,634 |
$ — |
| (a) |
As of period end, the entity is no longer held. |
| (b) |
Represents net amount purchased (sold). |
| (c) |
All or a portion represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of collateral investment fees, and
other payments to and from borrowers of securities. |
| Description |
Number of Contracts |
Expiration Date |
Exercise Price |
Notional Amount (000) |
Value | ||
| Call |
|
|
|
|
|
|
|
| UnitedHealth Group, Inc. |
42 |
01/03/25 |
USD |
615.00 |
USD |
2,125 |
$ (7,140
) |
| Alphabet, Inc., Class A |
191 |
01/10/25 |
USD |
180.00 |
USD |
3,616 |
(195,297 ) |
| Coca-Cola Co. |
433 |
01/10/25 |
USD |
65.00 |
USD |
2,696 |
(866 ) |
| Microsoft Corp. |
97 |
01/10/25 |
USD |
445.00 |
USD |
4,089 |
(2,522 ) |
| Oracle Corp. |
107 |
01/10/25 |
USD |
185.00 |
USD |
1,783 |
(1,124 ) |
| Philip Morris International, Inc. |
197 |
01/10/25 |
USD |
132.00 |
USD |
2,371 |
(14,775 ) |
| Texas Instruments, Inc. |
87 |
01/10/25 |
USD |
205.00 |
USD |
1,631 |
(914 ) |
| Texas Instruments, Inc. |
97 |
01/10/25 |
USD |
195.00 |
USD |
1,819 |
(5,772 ) |
| Union Pacific Corp. |
45 |
01/10/25 |
USD |
240.00 |
USD |
1,026 |
(1,575 ) |
| UnitedHealth Group, Inc. |
54 |
01/10/25 |
USD |
585.00 |
USD |
2,732 |
(594 ) |
| AbbVie, Inc. |
114 |
01/17/25 |
USD |
185.00 |
USD |
2,026 |
(8,721 ) |
| AbbVie, Inc. |
114 |
01/17/25 |
USD |
170.00 |
USD |
2,026 |
(103,455 ) |
| Accenture PLC, Class A |
86 |
01/17/25 |
USD |
370.00 |
USD |
3,025 |
(7,525 ) |
| Allegion PLC |
253 |
01/17/25 |
USD |
145.00 |
USD |
3,306 |
(7,590 ) |
| Alphabet, Inc., Class A |
39 |
01/17/25 |
USD |
180.00 |
USD |
738 |
(43,290 ) |
| AMETEK, Inc. |
151 |
01/17/25 |
USD |
200.00 |
USD |
2,722 |
(20,385 ) |
| Apple, Inc. |
81 |
01/17/25 |
USD |
235.00 |
USD |
2,028 |
(131,827 ) |
| Applied Materials, Inc. |
159 |
01/17/25 |
USD |
185.00 |
USD |
2,586 |
(4,134 ) |
| Assurant, Inc. |
87 |
01/17/25 |
USD |
220.00 |
USD |
1,855 |
(10,440 ) |
| Baker Hughes Co., Class A |
257 |
01/17/25 |
USD |
42.00 |
USD |
1,054 |
(14,135 ) |
| Charles Schwab Corp. |
381 |
01/17/25 |
USD |
82.50 |
USD |
2,820 |
(2,858 ) |
| Citizens Financial Group, Inc. |
1,050 |
01/17/25 |
USD |
47.50 |
USD |
4,595 |
(21,000 ) |
| CMS Energy Corp. |
368 |
01/17/25 |
USD |
70.00 |
USD |
2,453 |
(49,680 ) |
| Coca-Cola Co. |
433 |
01/17/25 |
USD |
65.00 |
USD |
2,696 |
(5,846 ) |
| General Electric Co. |
180 |
01/17/25 |
USD |
185.00 |
USD |
3,002 |
(2,700 ) |
| Home Depot, Inc. |
90 |
01/17/25 |
USD |
415.00 |
USD |
3,501 |
(4,725 ) |
| Hubbell, Inc. |
74 |
01/17/25 |
USD |
450.00 |
USD |
3,100 |
(21,090 ) |
| M&T Bank Corp. |
145 |
01/17/25 |
USD |
220.00 |
USD |
2,726 |
(4,350 ) |
| Mastercard, Inc., Class A |
33 |
01/17/25 |
USD |
525.00 |
USD |
1,738 |
(30,443 ) |
| Meta Platforms, Inc., Class A |
26 |
01/17/25 |
USD |
600.00 |
USD |
1,522 |
(24,765 ) |
| Oracle Corp. |
108 |
01/17/25 |
USD |
185.00 |
USD |
1,800 |
(1,188 ) |
| Otis Worldwide Corp. |
223 |
01/17/25 |
USD |
100.00 |
USD |
2,065 |
(3,345 ) |
| Otis Worldwide Corp. |
50 |
01/17/25 |
USD |
105.00 |
USD |
463 |
(250 ) |
| Republic Services, Inc. |
117 |
01/17/25 |
USD |
220.00 |
USD |
2,354 |
(1,463 ) |
| Salesforce, Inc. |
95 |
01/17/25 |
USD |
350.00 |
USD |
3,176 |
(22,515 ) |
| Texas Instruments, Inc. |
87 |
01/17/25 |
USD |
220.00 |
USD |
1,631 |
(1,131 ) |
| Texas Instruments, Inc. |
32 |
01/17/25 |
USD |
210.00 |
USD |
600 |
(464 ) |
| Union Pacific Corp. |
130 |
01/17/25 |
USD |
250.00 |
USD |
2,965 |
(3,900 ) |
| Williams Cos., Inc. |
345 |
01/17/25 |
USD |
60.00 |
USD |
1,867 |
(2,588 ) |
| Zoetis, Inc., Class A |
46 |
01/17/25 |
USD |
185.00 |
USD |
749 |
(1,150 ) |
| Description |
Number of Contracts |
Expiration Date |
Exercise Price |
Notional Amount (000) |
Value | ||
| Call (continued) |
|
|
|
|
|
|
|
| Accenture PLC, Class A |
86 |
01/24/25 |
USD |
375.00 |
USD |
3,025 |
$ (9,890
) |
| Alphabet, Inc., Class A |
95 |
01/24/25 |
USD |
205.00 |
USD |
1,798 |
(7,030 ) |
| Apple, Inc. |
72 |
01/24/25 |
USD |
255.00 |
USD |
1,803 |
(21,492 ) |
| Assurant, Inc. |
86 |
01/24/25 |
USD |
224.72 |
USD |
1,834 |
(6,758 ) |
| Broadcom, Inc. |
180 |
01/24/25 |
USD |
235.00 |
USD |
4,173 |
(147,150 ) |
| General Electric Co. |
197 |
01/24/25 |
USD |
180.00 |
USD |
3,286 |
(39,104 ) |
| Mastercard, Inc., Class A |
19 |
01/24/25 |
USD |
540.00 |
USD |
1,000 |
(7,315 ) |
| Meta Platforms, Inc., Class A |
41 |
01/24/25 |
USD |
680.00 |
USD |
2,401 |
(2,747 ) |
| Microsoft Corp. |
96 |
01/24/25 |
USD |
465.00 |
USD |
4,046 |
(3,072 ) |
| Philip Morris International, Inc. |
205 |
01/24/25 |
USD |
129.00 |
USD |
2,467 |
(7,175 ) |
| Salesforce, Inc. |
76 |
01/24/25 |
USD |
370.00 |
USD |
2,541 |
(4,636 ) |
| TELUS Corp. |
1,447 |
01/24/25 |
CAD |
22.50 |
CAD |
2,820 |
(5,033 ) |
| UnitedHealth Group, Inc. |
73 |
01/24/25 |
USD |
525.00 |
USD |
3,693 |
(73,547 ) |
| Williams Cos., Inc. |
662 |
01/24/25 |
USD |
54.00 |
USD |
3,583 |
(201,910 ) |
| Applied Materials, Inc. |
64 |
01/31/25 |
USD |
175.00 |
USD |
1,041 |
(17,056 ) |
| Broadcom, Inc. |
72 |
01/31/25 |
USD |
240.00 |
USD |
1,669 |
(55,440 ) |
| Broadcom, Inc. |
45 |
01/31/25 |
USD |
230.00 |
USD |
1,043 |
(57,937 ) |
| Meta Platforms, Inc., Class A |
61 |
01/31/25 |
USD |
660.00 |
USD |
3,572 |
(38,888 ) |
| Microsoft Corp. |
173 |
01/31/25 |
USD |
470.00 |
USD |
7,292 |
(21,020 ) |
| Oracle Corp. |
50 |
01/31/25 |
USD |
180.00 |
USD |
833 |
(4,275 ) |
| Texas Instruments, Inc. |
185 |
01/31/25 |
USD |
200.00 |
USD |
3,469 |
(40,237 ) |
| Accenture PLC, Class A |
47 |
02/07/25 |
USD |
360.00 |
USD |
1,653 |
(25,145 ) |
| Alphabet, Inc., Class A |
82 |
02/07/25 |
USD |
205.00 |
USD |
1,552 |
(23,534 ) |
| Coca-Cola Co. |
420 |
02/07/25 |
USD |
64.00 |
USD |
2,615 |
(32,760 ) |
| AbbVie, Inc. |
224 |
02/21/25 |
USD |
185.00 |
USD |
3,980 |
(69,328 ) |
| Allegion PLC |
200 |
02/21/25 |
USD |
140.25 |
USD |
2,614 |
(24,452 ) |
| AMETEK, Inc. |
95 |
02/21/25 |
USD |
195.50 |
USD |
1,712 |
(8,906 ) |
| Apple, Inc. |
205 |
02/21/25 |
USD |
250.00 |
USD |
5,134 |
(195,262 ) |
| Applied Materials, Inc. |
64 |
02/21/25 |
USD |
180.00 |
USD |
1,041 |
(23,680 ) |
| Baker Hughes Co., Class A |
1,101 |
02/21/25 |
USD |
44.00 |
USD |
4,516 |
(77,070 ) |
| Broadcom, Inc. |
72 |
02/21/25 |
USD |
240.00 |
USD |
1,669 |
(85,320 ) |
| Broadcom, Inc. |
45 |
02/21/25 |
USD |
230.00 |
USD |
1,043 |
(68,962 ) |
| Charles Schwab Corp. |
260 |
02/21/25 |
USD |
82.50 |
USD |
1,924 |
(15,340 ) |
| Citizens Financial Group, Inc. |
338 |
02/21/25 |
USD |
45.00 |
USD |
1,479 |
(47,320 ) |
| Home Depot, Inc. |
65 |
02/21/25 |
USD |
415.00 |
USD |
2,528 |
(25,513 ) |
| Hubbell, Inc. |
65 |
02/21/25 |
USD |
460.00 |
USD |
2,723 |
(42,412 ) |
| Intercontinental Exchange, Inc. |
67 |
02/21/25 |
USD |
157.00 |
USD |
998 |
(10,968 ) |
| M&T Bank Corp. |
88 |
02/21/25 |
USD |
195.00 |
USD |
1,654 |
(47,960 ) |
| Mastercard, Inc., Class A |
16 |
02/21/25 |
USD |
530.00 |
USD |
843 |
(25,640 ) |
| Microsoft Corp. |
21 |
02/21/25 |
USD |
460.00 |
USD |
885 |
(8,243 ) |
| Moody’s Corp. |
104 |
02/21/25 |
USD |
490.00 |
USD |
4,923 |
(104,520 ) |
| Otis Worldwide Corp. |
524 |
02/21/25 |
USD |
99.00 |
USD |
4,853 |
(48,096 ) |
| Republic Services, Inc. |
45 |
02/21/25 |
USD |
210.00 |
USD |
905 |
(11,250 ) |
| TELUS Corp. |
1,031 |
02/21/25 |
CAD |
22.00 |
CAD |
2,009 |
(5,021 ) |
| Union Pacific Corp. |
97 |
02/21/25 |
USD |
245.00 |
USD |
2,212 |
(16,005 ) |
| Zoetis, Inc., Class A |
133 |
02/21/25 |
USD |
177.00 |
USD |
2,167 |
(26,507 ) |
| TELUS Corp. |
1,448 |
03/21/25 |
CAD |
23.00 |
CAD |
2,822 |
(5,540 ) |
| |
|
|
|
|
|
|
$ (2,633,998 ) |
| Description |
Counterparty |
Number of Contracts |
Expiration Date |
Exercise Price |
Notional Amount (000) |
Value | ||
| Call |
|
|
|
|
|
|
|
|
| Air Liquide SA |
Bank of America N.A. |
13,800 |
01/07/25 |
EUR |
170.59 |
EUR |
2,166 |
$ (59
) |
| BAE Systems PLC |
Morgan Stanley & Co. International PLC |
135,200 |
01/07/25 |
GBP |
13.09 |
GBP |
1,549 |
(85 ) |
| Novo Nordisk A/S, Class B |
Bank of America N.A. |
12,300 |
01/07/25 |
DKK |
803.84 |
DKK |
7,640 |
— |
| Taiwan Semiconductor Manufacturing Co. Ltd. |
Bank of America N.A. |
227,000 |
01/08/25 |
TWD |
1,102.40 |
TWD |
241,868 |
(48,412 ) |
| Banco Bilbao Vizcaya Argentaria SA |
Bank of America N.A. |
237,000 |
01/09/25 |
EUR |
9.25 |
EUR |
2,239 |
(70,146 ) |
| Koninklijke KPN NV |
UBS AG |
342,000 |
01/09/25 |
EUR |
3.60 |
EUR |
1,204 |
(3,355 ) |
| LVMH Moet Hennessy Louis Vuitton SE |
UBS AG |
5,650 |
01/09/25 |
EUR |
593.34 |
EUR |
3,588 |
(253,909 ) |
| Description |
Counterparty |
Number of Contracts |
Expiration Date |
Exercise Price |
Notional Amount (000) |
Value | ||
| Call (continued) |
|
|
|
|
|
|
|
|
| Novo Nordisk A/S, Class B |
BNP Paribas SA |
27,300 |
01/09/25 |
DKK |
789.45 |
DKK |
16,958 |
$ —
|
| RELX PLC |
BNP Paribas SA |
105,500 |
01/09/25 |
EUR |
44.70 |
EUR |
4,612 |
(14,485 ) |
| Shell PLC |
BNP Paribas SA |
32,700 |
01/09/25 |
EUR |
31.54 |
EUR |
991 |
(857 ) |
| Air Liquide SA |
Goldman Sachs International |
22,100 |
01/14/25 |
EUR |
166.18 |
EUR |
3,468 |
(4,745 ) |
| AstraZeneca PLC |
Bank of America N.A. |
30,400 |
01/14/25 |
GBP |
107.15 |
GBP |
3,166 |
(35,768 ) |
| BAE Systems PLC |
Goldman Sachs International |
76,800 |
01/14/25 |
GBP |
13.68 |
GBP |
880 |
(308 ) |
| Diageo PLC |
BNP Paribas SA |
111,400 |
01/14/25 |
GBP |
24.67 |
GBP |
2,828 |
(120,436 ) |
| Koninklijke KPN NV |
Morgan Stanley & Co. International PLC |
254,400 |
01/14/25 |
EUR |
3.61 |
EUR |
896 |
(4,253 ) |
| Sanofi SA |
BNP Paribas SA |
19,000 |
01/14/25 |
EUR |
96.64 |
EUR |
1,783 |
(7,016 ) |
| Taiwan Semiconductor Manufacturing Co. Ltd. |
Bank of America N.A. |
123,000 |
01/14/25 |
TWD |
1,086.75 |
TWD |
131,056 |
(64,557 ) |
| Taylor Wimpey PLC |
Goldman Sachs International |
754,100 |
01/14/25 |
GBP |
1.34 |
GBP |
917 |
(925 ) |
| Banco Bilbao Vizcaya Argentaria SA |
Goldman Sachs International |
239,550 |
01/15/25 |
EUR |
9.70 |
EUR |
2,264 |
(21,930 ) |
| Koninklijke KPN NV |
Morgan Stanley & Co. International PLC |
254,000 |
01/15/25 |
EUR |
3.64 |
EUR |
894 |
(4,446 ) |
| Taylor Wimpey PLC |
Morgan Stanley & Co. International PLC |
397,000 |
01/15/25 |
GBP |
1.31 |
GBP |
483 |
(1,869 ) |
| AstraZeneca PLC |
Citibank N.A. |
27,600 |
01/16/25 |
GBP |
103.59 |
GBP |
2,874 |
(95,755 ) |
| AstraZeneca PLC |
UBS AG |
15,300 |
01/16/25 |
GBP |
108.06 |
GBP |
1,593 |
(15,193 ) |
| Novo Nordisk A/S, Class B |
Morgan Stanley & Co. International PLC |
17,700 |
01/16/25 |
DKK |
780.34 |
DKK |
10,995 |
(10 ) |
| RELX PLC |
Citibank N.A. |
52,500 |
01/16/25 |
EUR |
44.00 |
EUR |
2,295 |
(26,818 ) |
| Diageo PLC |
Goldman Sachs International |
65,500 |
01/22/25 |
GBP |
24.28 |
GBP |
1,663 |
(105,750 ) |
| Koninklijke KPN NV |
Morgan Stanley & Co. International PLC |
394,500 |
01/22/25 |
EUR |
3.71 |
EUR |
1,389 |
(9,587 ) |
| LVMH Moet Hennessy Louis Vuitton SE |
Bank of America N.A. |
5,650 |
01/22/25 |
EUR |
617.72 |
EUR |
3,588 |
(160,763 ) |
| Novo Nordisk A/S, Class B |
Goldman Sachs International |
11,500 |
01/22/25 |
DKK |
780.44 |
DKK |
7,143 |
(84 ) |
| RELX PLC |
Barclays Bank PLC |
19,000 |
01/22/25 |
EUR |
46.12 |
EUR |
831 |
(2,663 ) |
| Sanofi SA |
Goldman Sachs International |
41,300 |
01/22/25 |
EUR |
92.07 |
EUR |
3,876 |
(116,186 ) |
| BAE Systems PLC |
UBS AG |
172,400 |
01/23/25 |
GBP |
12.02 |
GBP |
1,980 |
(24,883 ) |
| Zurich Insurance Group AG, Class N |
Morgan Stanley & Co. International PLC |
8,700 |
01/23/25 |
CHF |
553.96 |
CHF |
2,566 |
(27,889 ) |
| Shell PLC |
Goldman Sachs International |
161,800 |
01/28/25 |
EUR |
31.19 |
EUR |
4,873 |
(39,524 ) |
| Intercontinental Exchange, Inc. |
BNP Paribas SA |
35,900 |
01/29/25 |
USD |
159.14 |
USD |
5,349 |
(16,662 ) |
| Koninklijke KPN NV |
Morgan Stanley & Co. International PLC |
160,600 |
01/29/25 |
EUR |
3.58 |
EUR |
565 |
(5,764 ) |
| Koninklijke KPN NV |
Morgan Stanley & Co. International PLC |
189,500 |
02/04/25 |
EUR |
3.66 |
EUR |
666 |
(6,537 ) |
| Banco Bilbao Vizcaya Argentaria SA |
BNP Paribas SA |
162,800 |
02/06/25 |
EUR |
9.72 |
EUR |
2,232 |
(33,914 ) |
| Taylor Wimpey PLC |
Morgan Stanley & Co. International PLC |
1,828,200 |
02/06/25 |
GBP |
1.24 |
GBP |
1,539 |
(81,891 ) |
| CMS Energy Corp. |
Barclays Bank PLC |
38,500 |
02/24/25 |
USD |
67.99 |
USD |
4,688 |
(53,110 ) |
| |
|
|
|
|
|
|
|
$ (1,480,544 ) |
| Description |
Premiums Paid |
Premiums Received |
Unrealized Appreciation |
Unrealized Depreciation |
Value |
| Options Written |
$ N/A
|
$ (7,687,194
) |
$ 4,439,945
|
$ (867,293
) |
$ (4,114,542
) |
| |
Commodity Contracts |
Credit Contracts |
Equity Contracts |
Foreign Currency Exchange Contracts |
Interest Rate Contracts |
Other Contracts |
Total |
| Liabilities — Derivative Financial Instruments |
|
|
|
|
|
|
|
| Options written Options written at value |
$ — |
$ — |
$ 4,114,542 |
$ — |
$ — |
$ — |
$ 4,114,542 |
| |
Commodity Contracts |
Credit Contracts |
Equity Contracts |
Foreign Currency Exchange Contracts |
Interest Rate Contracts |
Other Contracts |
Total |
| Net Realized Gain (Loss) from: |
|
|
|
|
|
|
|
| Options purchased(a) |
$ —
|
$ —
|
$ (7,534
) |
$ —
|
$ —
|
$ —
|
$ (7,534
) |
| Options written |
— |
— |
(15,973,502 ) |
— |
— |
— |
(15,973,502 ) |
| |
$ — |
$ — |
$ (15,981,036 ) |
$ — |
$ — |
$ — |
$ (15,981,036 ) |
| Net Change in Unrealized Appreciation (Depreciation) on: |
|
|
|
|
|
|
|
| Options written |
$ — |
$ — |
$ 7,740,032 |
$ — |
$ — |
$ — |
$ 7,740,032 |
| (a) |
Options purchased are included in net realized gain (loss) from investments —
unaffiliated. |
| Options: |
|
| Average value of option contracts purchased |
$—
(a) |
| Average value of option contracts written |
8,180,000 |
| (a) |
Derivative financial instrument not held at any quarter-end. The risk exposure table serves as an
indicator of activity during the period. |
| |
Assets |
Liabilities |
| Derivative Financial Instruments |
|
|
| Options |
$ — |
$ 4,114,542 |
| Total derivative assets and liabilities in the Statements of Assets and Liabilities |
— |
4,114,542 |
| Derivatives not subject to a Master Netting Agreement or similar agreement (“MNA”) |
— |
(2,633,998 ) |
| Total derivative assets and liabilities subject to an MNA |
$ — |
$ 1,480,544 |
| Counterparty |
Derivative Liabilities Subject to an MNA by Counterparty |
Derivatives Available for Offset(a)
|
Non-Cash Collateral Pledged(b)
|
Cash Collateral Pledged(b)
|
Net Amount of Derivative Liabilities(c)
|
| Bank of America N.A. |
$ 379,705
|
$ —
|
$ (379,705
) |
$ —
|
$ —
|
| Barclays Bank PLC |
55,773 |
— |
— |
— |
55,773 |
| BNP Paribas SA |
193,370 |
— |
(193,370 ) |
— |
— |
| Citibank N.A. |
122,573 |
— |
(122,573 ) |
— |
— |
| Goldman Sachs International |
289,452 |
— |
— |
— |
289,452 |
| Morgan Stanley & Co. International PLC |
142,331 |
— |
(142,331 ) |
— |
— |
| UBS AG |
297,340 |
— |
(297,340 ) |
— |
— |
| |
$ 1,480,544 |
$ — |
$ (1,135,319 ) |
$ — |
$ 345,225 |
| (a) |
The amount of derivatives available for offset is limited to the amount of derivative assets and/or liabilities that are subject to an MNA. |
| (b) |
Excess of collateral received/pledged, if any, from the individual counterparty is not shown for financial reporting purposes. |
| (c) |
Net amount represents the net amount payable due to the counterparty in the event of default. Net amount may be offset further by the options written
receivable/payable on the Statements of Assets and Liabilities. |
| |
Level 1 |
Level 2 |
Level 3 |
Total |
| Assets |
|
|
|
|
| Investments |
|
|
|
|
| Long-Term Investments |
|
|
|
|
| Common Stocks |
|
|
|
|
| Canada |
$ 9,679,864
|
$ —
|
$ —
|
$ 9,679,864 |
| Denmark |
— |
16,963,008 |
— |
16,963,008 |
| France |
— |
27,682,511 |
— |
27,682,511 |
| India |
— |
— |
217,196 |
217,196 |
| Netherlands |
— |
10,574,805 |
— |
10,574,805 |
| Spain |
— |
14,217,860 |
— |
14,217,860 |
| Switzerland |
— |
11,740,673 |
— |
11,740,673 |
| Taiwan |
— |
24,505,017 |
— |
24,505,017 |
| United Kingdom |
— |
75,201,517 |
— |
75,201,517 |
| United States |
481,880,782 |
28,766,492 |
— |
510,647,274 |
| Short-Term Securities |
|
|
|
|
| Money Market Funds |
7,033,278 |
— |
— |
7,033,278 |
| |
$ 498,593,924 |
$ 209,651,883 |
$ 217,196 |
$ 708,463,003 |
| Derivative Financial Instruments(a)
|
|
|
|
|
| Liabilities |
|
|
|
|
| Equity Contracts |
$ (2,508,311 ) |
$ (1,606,231 ) |
$ — |
$ (4,114,542 ) |
| (a) |
Derivative financial instruments are options written. Options written are shown at
value. |
| Security |
|
Shares |
Value |
| Common Stocks | |||
| Canada — 6.0% |
| ||
| Canadian National Railway Co. |
|
134,092 |
$ 13,616,759
|
| Teck Resources Ltd., Class B |
|
244,652 |
9,919,175 |
| TELUS Corp. |
|
764,482 |
10,365,407 |
| |
|
|
33,901,341 |
| China — 3.2% |
| ||
| Tencent Holdings Ltd., ADR(a) |
|
341,471 |
18,159,428 |
| Denmark — 4.2% |
| ||
| Novo Nordisk A/S, Class B |
|
273,134 |
23,566,501 |
| France — 8.9% |
| ||
| Air Liquide SA |
|
116,518 |
18,941,129 |
| Cie de Saint-Gobain SA |
|
127,745 |
11,351,628 |
| LVMH Moet Hennessy Louis Vuitton SE |
|
30,111 |
19,806,797 |
| |
|
|
50,099,554 |
| Germany — 9.3% |
| ||
| adidas AG, Class N |
|
48,445 |
11,915,738 |
| Beiersdorf AG |
|
122,485 |
15,732,631 |
| Deutsche Telekom AG, Class N, Registered Shares |
|
302,117 |
9,052,354 |
| SAP SE |
|
64,445 |
15,851,801 |
| |
|
|
52,552,524 |
| India — 3.4% |
| ||
| AceVector Limited, Series I, (Acquired 01/25/22, Cost: $3,948,600)(b)(c)(d) |
|
848,000 |
325,180 |
| HDFC Bank Ltd. |
|
895,320 |
18,515,493 |
| |
|
|
18,840,673 |
| Indonesia — 1.3% |
| ||
| Bank Rakyat Indonesia Persero Tbk PT |
|
27,670,000 |
6,985,248 |
| Italy — 3.0% |
| ||
| FinecoBank Banca Fineco SpA |
|
975,056 |
17,017,395 |
| Japan — 7.6% |
| ||
| Keyence Corp. |
|
41,200 |
16,746,619 |
| SMC Corp. |
|
22,200 |
8,620,735 |
| Sony Group Corp. |
|
832,500 |
17,545,384 |
| |
|
|
42,912,738 |
| Netherlands — 5.1% |
| ||
| ASML Holding NV |
|
21,751 |
15,235,144 |
| Koninklijke KPN NV |
|
3,748,439 |
13,668,445 |
| |
|
|
28,903,589 |
| Singapore — 2.5% |
| ||
| United Overseas Bank Ltd. |
|
537,900 |
14,284,402 |
| Spain — 2.7% |
| ||
| Banco Bilbao Vizcaya Argentaria SA |
|
1,570,401 |
15,365,476 |
| Sweden — 5.3% |
| ||
| Assa Abloy AB, Class B |
|
575,076 |
16,985,605 |
| Atlas Copco AB, Class A |
|
823,904 |
12,574,129 |
| |
|
|
29,559,734 |
| Switzerland — 1.5% |
| ||
| Zurich Insurance Group AG, Class N |
|
13,867 |
8,247,615 |
| Security |
|
Shares |
Value |
| Taiwan — 6.2% |
| ||
| Taiwan Semiconductor Manufacturing Co. Ltd. |
|
1,068,000 |
$ 34,710,024 |
| United Kingdom — 10.9% |
| ||
| AstraZeneca PLC |
|
129,940 |
16,941,525 |
| Diageo PLC |
|
500,084 |
15,891,580 |
| RELX PLC |
|
464,973 |
21,056,658 |
| Taylor Wimpey PLC |
|
4,738,790 |
7,212,454 |
| |
|
|
61,102,217 |
| United States — 19.3% |
| ||
| Baker Hughes Co., Class A(a)(e) |
|
206,682 |
8,478,096 |
| General Electric Co.(e) |
|
68,405 |
11,409,270 |
| Haleon PLC |
|
1,813,323 |
8,550,088 |
| Mastercard, Inc., Class A(e)
|
|
22,743 |
11,975,782 |
| Nestle SA, Class N, Registered Shares |
|
89,894 |
7,375,188 |
| Otis Worldwide Corp.(a)(e) |
|
120,604 |
11,169,137 |
| Sanofi SA |
|
153,355 |
14,907,756 |
| Shell PLC |
|
563,203 |
17,675,104 |
| Texas Instruments, Inc.(a)(e) |
|
91,875 |
17,227,481 |
| |
|
|
108,767,902 |
| Total Long-Term Investments — 100.4% (Cost: $494,250,581) |
564,976,361 | ||
| Short-Term Securities | |||
| Money Market Funds — 0.7% |
| ||
| BlackRock Liquidity Funds, T-Fund, Institutional Shares, 4.36%(f)(g) |
|
3,742,337 |
3,742,337 |
| Total Short-Term Securities — 0.7% (Cost: $3,742,337) |
3,742,337 | ||
| Total Investments Before Options Written — 101.1% (Cost: $497,992,918) |
568,718,698 | ||
| Options Written — (0.8)% (Premiums Received: $(5,915,885)) |
(4,331,111 ) | ||
| Total Investments, Net of Options Written — 100.3% (Cost: $492,077,033) |
564,387,587 | ||
| Liabilities in Excess of Other Assets — (0.3)% |
(1,428,556 ) | ||
| Net Assets — 100.0% |
$ 562,959,031 | ||
| (a) |
All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written. |
| (b) |
Security is valued using significant unobservable inputs and is classified as Level 3 in the
fair value hierarchy. |
| (c) |
Non-income producing security. |
| (d) |
Restricted security as to resale, excluding 144A securities. The Trust held restricted
securities with a current value of $325,180, representing 0.1% of its net assets as of
period end, and an original cost of $3,948,600. |
| (e) |
All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives. |
| (f) |
Affiliate of the Trust. |
| (g) |
Annualized 7-day yield as of period end. |
| Affiliated Issuer |
Value at 12/31/23 |
Purchases at Cost |
Proceeds from Sales |
Net Realized Gain (Loss) |
Change in Unrealized Appreciation (Depreciation) |
Value at 12/31/24 |
Shares Held at 12/31/24 |
Income |
Capital Gain Distributions from Underlying Funds |
| BlackRock Liquidity Funds, T-Fund, Institutional Shares |
$ 8,260,103 |
$ — |
$ (4,517,766 )(a) |
$ — |
$ — |
$ 3,742,337 |
3,742,337 |
$ 352,353 |
$ — |
| (a) |
Represents net amount purchased (sold). |
| Description |
Number of Contracts |
Expiration Date |
Exercise Price |
Notional Amount (000) |
Value | ||
| Call |
|
|
|
|
|
|
|
| Texas Instruments, Inc. |
78 |
01/10/25 |
USD |
205.00 |
USD |
1,463 |
$ (819
) |
| Baker Hughes Co., Class A |
568 |
01/17/25 |
USD |
44.00 |
USD |
2,330 |
(8,520 ) |
| Canadian National Railway Co. |
283 |
01/17/25 |
CAD |
160.00 |
CAD |
4,131 |
(1,575 ) |
| General Electric Co. |
140 |
01/17/25 |
USD |
185.00 |
USD |
2,335 |
(2,100 ) |
| Mastercard, Inc., Class A |
45 |
01/17/25 |
USD |
525.00 |
USD |
2,370 |
(41,512 ) |
| Otis Worldwide Corp. |
322 |
01/17/25 |
USD |
100.00 |
USD |
2,982 |
(4,830 ) |
| Otis Worldwide Corp. |
19 |
01/17/25 |
USD |
105.00 |
USD |
176 |
(95 ) |
| Teck Resources Ltd., Class B |
489 |
01/17/25 |
CAD |
66.00 |
CAD |
2,850 |
(4,933 ) |
| Texas Instruments, Inc. |
78 |
01/17/25 |
USD |
220.00 |
USD |
1,463 |
(1,014 ) |
| Texas Instruments, Inc. |
102 |
01/17/25 |
USD |
210.00 |
USD |
1,913 |
(1,479 ) |
| Canadian National Railway Co. |
320 |
01/24/25 |
CAD |
150.00 |
CAD |
4,671 |
(21,705 ) |
| General Electric Co. |
167 |
01/24/25 |
USD |
180.00 |
USD |
2,785 |
(33,150 ) |
| Mastercard, Inc., Class A |
57 |
01/24/25 |
USD |
540.00 |
USD |
3,001 |
(21,945 ) |
| TELUS Corp. |
1,475 |
01/24/25 |
CAD |
22.50 |
CAD |
2,875 |
(5,131 ) |
| Texas Instruments, Inc. |
155 |
01/31/25 |
USD |
200.00 |
USD |
2,906 |
(33,712 ) |
| Baker Hughes Co., Class A |
568 |
02/21/25 |
USD |
44.00 |
USD |
2,330 |
(39,760 ) |
| Otis Worldwide Corp. |
201 |
02/21/25 |
USD |
99.00 |
USD |
1,861 |
(18,449 ) |
| Teck Resources Ltd., Class B |
367 |
02/21/25 |
CAD |
66.00 |
CAD |
2,139 |
(18,510 ) |
| TELUS Corp. |
1,254 |
02/21/25 |
CAD |
22.00 |
CAD |
2,444 |
(6,107 ) |
| TELUS Corp. |
1,475 |
03/21/25 |
CAD |
23.00 |
CAD |
2,875 |
(5,644 ) |
| |
|
|
|
|
|
|
$ (270,990 ) |
| Description |
Counterparty |
Number of Contracts |
Expiration Date |
Exercise Price |
Notional Amount (000) |
Value | ||
| Call |
|
|
|
|
|
|
|
|
| Air Liquide SA |
Bank of America N.A. |
23,100 |
01/07/25 |
EUR |
170.59 |
EUR |
3,625 |
$ (99
) |
| ASML Holding NV |
Goldman Sachs International |
6,600 |
01/07/25 |
EUR |
691.14 |
EUR |
4,463 |
(49,110 ) |
| Cie de Saint-Gobain SA |
Bank of America N.A. |
35,300 |
01/07/25 |
EUR |
87.65 |
EUR |
3,028 |
(17,713 ) |
| FinecoBank Banca Fineco SpA |
Bank of America N.A. |
147,800 |
01/07/25 |
EUR |
15.44 |
EUR |
2,490 |
(209,477 ) |
| Novo Nordisk A/S, Class B |
Bank of America N.A. |
25,700 |
01/07/25 |
DKK |
803.84 |
DKK |
15,964 |
— |
| Sony Group Corp. |
JPMorgan Chase Bank N.A. |
67,000 |
01/08/25 |
JPY |
2,993.85 |
JPY |
222,181 |
(162,377 ) |
| Taiwan Semiconductor Manufacturing Co. Ltd. |
Bank of America N.A. |
144,000 |
01/08/25 |
TWD |
1,102.40 |
TWD |
153,432 |
(30,711 ) |
| Banco Bilbao Vizcaya Argentaria SA |
Bank of America N.A. |
440,200 |
01/09/25 |
EUR |
9.26 |
EUR |
4,158 |
(130,287 ) |
| Haleon PLC |
BNP Paribas SA |
498,000 |
01/09/25 |
GBP |
3.64 |
GBP |
1,876 |
(88,448 ) |
| Keyence Corp. |
JPMorgan Chase Bank N.A. |
12,000 |
01/09/25 |
JPY |
69,344.17 |
JPY |
767,475 |
(13,442 ) |
| Koninklijke KPN NV |
UBS AG |
156,300 |
01/09/25 |
EUR |
3.60 |
EUR |
550 |
(1,533 ) |
| LVMH Moet Hennessy Louis Vuitton SE |
UBS AG |
6,750 |
01/09/25 |
EUR |
593.34 |
EUR |
4,286 |
(303,342 ) |
| RELX PLC |
BNP Paribas SA |
104,500 |
01/09/25 |
EUR |
44.70 |
EUR |
4,569 |
(14,348 ) |
| SAP SE |
BNP Paribas SA |
14,500 |
01/09/25 |
EUR |
228.04 |
EUR |
3,443 |
(137,843 ) |
| Shell PLC |
BNP Paribas SA |
114,700 |
01/09/25 |
EUR |
31.54 |
EUR |
3,475 |
(3,005 ) |
| Air Liquide SA |
Goldman Sachs International |
29,400 |
01/14/25 |
EUR |
166.18 |
EUR |
4,614 |
(6,312 ) |
| AstraZeneca PLC |
Bank of America N.A. |
28,700 |
01/14/25 |
GBP |
107.15 |
GBP |
2,989 |
(33,768 ) |
| Description |
Counterparty |
Number of Contracts |
Expiration Date |
Exercise Price |
Notional Amount (000) |
Value | ||
| Call (continued) |
|
|
|
|
|
|
|
|
| Atlas Copco AB, Class A |
UBS AG |
69,100 |
01/14/25 |
SEK |
186.16 |
SEK |
11,668 |
$ (164
) |
| Beiersdorf AG |
BNP Paribas SA |
28,000 |
01/14/25 |
EUR |
127.67 |
EUR |
3,472 |
(12,969 ) |
| Diageo PLC |
BNP Paribas SA |
109,800 |
01/14/25 |
GBP |
24.67 |
GBP |
2,787 |
(118,706 ) |
| FinecoBank Banca Fineco SpA |
Morgan Stanley & Co. International PLC |
210,400 |
01/14/25 |
EUR |
15.68 |
EUR |
3,545 |
(259,206 ) |
| Koninklijke KPN NV |
Morgan Stanley & Co. International PLC |
359,000 |
01/14/25 |
EUR |
3.61 |
EUR |
1,264 |
(6,002 ) |
| Nestle SA, Class N, Registered Shares |
Bank of America N.A. |
21,800 |
01/14/25 |
CHF |
81.37 |
CHF |
1,623 |
(656 ) |
| Taiwan Semiconductor Manufacturing Co. Ltd. |
Bank of America N.A. |
229,000 |
01/14/25 |
TWD |
1,086.75 |
TWD |
243,999 |
(120,191 ) |
| Taylor Wimpey PLC |
Goldman Sachs International |
795,500 |
01/14/25 |
GBP |
1.34 |
GBP |
967 |
(976 ) |
| Banco Bilbao Vizcaya Argentaria SA |
Goldman Sachs International |
266,450 |
01/15/25 |
EUR |
9.70 |
EUR |
2,264 |
(24,393 ) |
| Deutsche Telekom AG, Class N, Registered Shares |
BNP Paribas SA |
48,200 |
01/15/25 |
EUR |
29.38 |
EUR |
1,394 |
(6,953 ) |
| Koninklijke KPN NV |
Morgan Stanley & Co. International PLC |
360,000 |
01/15/25 |
EUR |
3.64 |
EUR |
1,267 |
(6,302 ) |
| SAP SE |
Morgan Stanley & Co. International PLC |
14,500 |
01/15/25 |
EUR |
240.99 |
EUR |
3,426 |
(37,250 ) |
| Taylor Wimpey PLC |
Morgan Stanley & Co. International PLC |
375,900 |
01/15/25 |
GBP |
1.31 |
GBP |
457 |
(1,769 ) |
| Tencent Holdings Ltd., ADR |
Barclays Bank PLC |
38,400 |
01/15/25 |
USD |
53.59 |
USD |
2,042 |
(64,381 ) |
| United Overseas Bank Ltd. |
HSBC Bank PLC |
11,300 |
01/15/25 |
SGD |
36.95 |
SGD |
410 |
(2,711 ) |
| Assa Abloy AB, Class B |
Bank of America N.A. |
165,000 |
01/16/25 |
SEK |
332.59 |
SEK |
53,920 |
(38,238 ) |
| AstraZeneca PLC |
Citibank N.A. |
25,500 |
01/16/25 |
GBP |
103.59 |
GBP |
2,656 |
(88,470 ) |
| FinecoBank Banca Fineco SpA |
UBS AG |
140,800 |
01/16/25 |
EUR |
14.90 |
EUR |
2,372 |
(282,749 ) |
| Novo Nordisk A/S, Class B |
Morgan Stanley & Co. International PLC |
46,400 |
01/16/25 |
DKK |
780.34 |
DKK |
28,822 |
(27 ) |
| RELX PLC |
Citibank N.A. |
76,700 |
01/16/25 |
EUR |
44.00 |
EUR |
3,353 |
(39,180 ) |
| Sony Group Corp. |
UBS AG |
120,600 |
01/16/25 |
JPY |
3,132.15 |
JPY |
399,925 |
(204,021 ) |
| Taiwan Semiconductor Manufacturing Co. Ltd. |
Morgan Stanley & Co. International PLC |
135,000 |
01/16/25 |
TWD |
1,118.25 |
TWD |
143,842 |
(37,425 ) |
| Assa Abloy AB, Class B |
Goldman Sachs International |
93,800 |
01/22/25 |
SEK |
348.45 |
SEK |
30,652 |
(4,037 ) |
| Diageo PLC |
Goldman Sachs International |
38,600 |
01/22/25 |
GBP |
24.28 |
GBP |
980 |
(62,320 ) |
| Koninklijke KPN NV |
Morgan Stanley & Co. International PLC |
468,500 |
01/22/25 |
EUR |
3.71 |
EUR |
1,649 |
(11,385 ) |
| LVMH Moet Hennessy Louis Vuitton SE |
Bank of America N.A. |
6,750 |
01/22/25 |
EUR |
617.72 |
EUR |
4,286 |
(192,062 ) |
| Nestle SA, Class N, Registered Shares |
Goldman Sachs International |
18,700 |
01/22/25 |
CHF |
76.33 |
CHF |
1,392 |
(10,848 ) |
| Novo Nordisk A/S, Class B |
Goldman Sachs International |
23,400 |
01/22/25 |
DKK |
780.44 |
DKK |
14,535 |
(172 ) |
| RELX PLC |
Barclays Bank PLC |
28,000 |
01/22/25 |
EUR |
46.12 |
EUR |
1,224 |
(3,925 ) |
| Sanofi SA |
Goldman Sachs International |
62,900 |
01/22/25 |
EUR |
92.07 |
EUR |
5,903 |
(176,952 ) |
| Sony Group Corp. |
UBS AG |
187,000 |
01/22/25 |
JPY |
3,246.17 |
JPY |
620,116 |
(214,021 ) |
| Tencent Holdings Ltd., ADR |
Morgan Stanley & Co. International PLC |
37,200 |
01/22/25 |
USD |
55.61 |
USD |
1,978 |
(47,874 ) |
| Atlas Copco AB, Class A |
Goldman Sachs International |
103,100 |
01/23/25 |
SEK |
179.49 |
SEK |
17,408 |
(4,275 ) |
| Beiersdorf AG |
BNP Paribas SA |
27,200 |
01/23/25 |
EUR |
125.90 |
EUR |
3,373 |
(37,744 ) |
| Cie de Saint-Gobain SA |
Bank of America N.A. |
22,200 |
01/23/25 |
EUR |
87.91 |
EUR |
1,903 |
(29,825 ) |
| SMC Corp. |
UBS AG |
5,000 |
01/23/25 |
JPY |
64,008.69 |
JPY |
310,900 |
(35,788 ) |
| United Overseas Bank Ltd. |
Citibank N.A. |
74,200 |
01/23/25 |
SGD |
37.84 |
SGD |
2,696 |
(11,734 ) |
| Zurich Insurance Group AG, Class N |
Morgan Stanley & Co. International PLC |
6,300 |
01/23/25 |
CHF |
553.96 |
CHF |
4,688 |
(20,195 ) |
| adidas AG, Class N |
Bank of America N.A. |
10,600 |
01/28/25 |
EUR |
243.60 |
EUR |
2,510 |
(40,331 ) |
| Diageo PLC |
Bank of America N.A. |
76,600 |
01/28/25 |
GBP |
26.30 |
GBP |
1,944 |
(32,041 ) |
| Shell PLC |
Goldman Sachs International |
138,700 |
01/28/25 |
EUR |
31.19 |
EUR |
4,873 |
(33,881 ) |
| Koninklijke KPN NV |
Morgan Stanley & Co. International PLC |
560,900 |
01/29/25 |
EUR |
3.59 |
EUR |
565 |
(20,132 ) |
| Tencent Holdings Ltd., ADR |
Morgan Stanley & Co. International PLC |
39,000 |
01/29/25 |
USD |
54.95 |
USD |
2,074 |
(72,489 ) |
| Keyence Corp. |
JPMorgan Chase Bank N.A. |
6,600 |
02/04/25 |
JPY |
66,333.51 |
JPY |
426,558 |
(71,150 ) |
| Koninklijke KPN NV |
Morgan Stanley & Co. International PLC |
156,900 |
02/04/25 |
EUR |
3.66 |
EUR |
666 |
(5,412 ) |
| SMC Corp. |
JPMorgan Chase Bank N.A. |
4,900 |
02/04/25 |
JPY |
63,242.26 |
JPY |
304,682 |
(57,975 ) |
| United Overseas Bank Ltd. |
UBS AG |
156,600 |
02/04/25 |
SGD |
38.10 |
SGD |
5,689 |
(33,497 ) |
| adidas AG, Class N |
BNP Paribas SA |
11,300 |
02/06/25 |
EUR |
240.82 |
EUR |
2,676 |
(70,377 ) |
| Atlas Copco AB, Class A |
Goldman Sachs International |
198,600 |
02/06/25 |
SEK |
177.89 |
SEK |
33,534 |
(29,962 ) |
| Deutsche Telekom AG, Class N, Registered Shares |
Bank of America N.A. |
87,700 |
02/06/25 |
EUR |
29.82 |
EUR |
2,534 |
(19,786 ) |
| Haleon PLC |
Morgan Stanley & Co. International PLC |
498,000 |
02/06/25 |
GBP |
3.88 |
GBP |
1,879 |
(32,918 ) |
| Taylor Wimpey PLC |
Morgan Stanley & Co. International PLC |
788,000 |
02/06/25 |
GBP |
1.24 |
GBP |
2,232 |
(35,297 ) |
| Tencent Holdings Ltd., ADR |
Morgan Stanley & Co. International PLC |
39,000 |
02/12/25 |
USD |
55.47 |
USD |
2,074 |
(87,162 ) |
| |
|
|
|
|
|
|
|
$ (4,060,121 ) |
| Description |
Premiums Paid |
Premiums Received |
Unrealized Appreciation |
Unrealized Depreciation |
Value |
| Options Written |
$ N/A
|
$ (5,915,885
) |
$ 2,989,566
|
$ (1,404,792
) |
$ (4,331,111
) |
| |
Commodity Contracts |
Credit Contracts |
Equity Contracts |
Foreign Currency Exchange Contracts |
Interest Rate Contracts |
Other Contracts |
Total |
| Liabilities — Derivative Financial Instruments |
|
|
|
|
|
|
|
| Options written Options written at value |
$ — |
$ — |
$ 4,331,111 |
$ — |
$ — |
$ — |
$ 4,331,111 |
| |
Commodity Contracts |
Credit Contracts |
Equity Contracts |
Foreign Currency Exchange Contracts |
Interest Rate Contracts |
Other Contracts |
Total |
| Net Realized Gain (Loss) from: |
|
|
|
|
|
|
|
| Options purchased(a) |
$ —
|
$ —
|
$ (6,308
) |
$ —
|
$ —
|
$ —
|
$ (6,308
) |
| Options written |
— |
— |
(6,055,084 ) |
— |
— |
— |
(6,055,084 ) |
| |
$ — |
$ — |
$ (6,061,392 ) |
$ — |
$ — |
$ — |
$ (6,061,392 ) |
| Net Change in Unrealized Appreciation (Depreciation) on: |
|
|
|
|
|
|
|
| Options written |
$ — |
$ — |
$ 6,032,978 |
$ — |
$ — |
$ — |
$ 6,032,978 |
| (a) |
Options purchased are included in net realized gain (loss) from investments —
unaffiliated. |
| Options: |
|
| Average value of option contracts purchased |
$—
(a) |
| Average value of option contracts written |
6,962,585 |
| (a) |
Derivative financial instrument not held at any quarter-end. The risk exposure table serves as an
indicator of activity during the period. |
| |
Assets |
Liabilities |
| Derivative Financial Instruments |
|
|
| Options |
$ — |
$ 4,331,111 |
| Total derivative assets and liabilities in the Statements of Assets and Liabilities |
— |
4,331,111 |
| Derivatives not subject to a Master Netting Agreement or similar agreement (“MNA”) |
— |
(270,990 ) |
| Total derivative assets and liabilities subject to an MNA |
$ — |
$ 4,060,121 |
| Counterparty |
Derivative Liabilities Subject to an MNA by Counterparty |
Derivatives Available for Offset(a)
|
Non-Cash Collateral Pledged(b)
|
Cash Collateral Pledged(b)
|
Net Amount of Derivative Liabilities(c)
|
| Bank of America N.A. |
$ 895,185
|
$ —
|
$ (895,185
) |
$ —
|
$ —
|
| Counterparty |
Derivative Liabilities Subject to an MNA by Counterparty |
Derivatives Available for Offset(a) |
Non-Cash Collateral Pledged(b) |
Cash Collateral Pledged(b) |
Net Amount of Derivative Liabilities(c) |
| Barclays Bank PLC |
$ 68,306
|
$ —
|
$ —
|
$ —
|
$ 68,306
|
| BNP Paribas SA |
490,393 |
— |
(490,393 ) |
— |
— |
| Citibank N.A. |
139,384 |
— |
(139,384 ) |
— |
— |
| Goldman Sachs International |
403,238 |
— |
(403,238 ) |
— |
— |
| HSBC Bank PLC |
2,711 |
— |
— |
— |
2,711 |
| JPMorgan Chase Bank N.A. |
304,944 |
— |
(304,944 ) |
— |
— |
| Morgan Stanley & Co. International PLC |
680,845 |
— |
(680,845 ) |
— |
— |
| UBS AG |
1,075,115 |
— |
(1,075,115 ) |
— |
— |
| |
$ 4,060,121 |
$ — |
$ (3,989,104 ) |
$ — |
$ 71,017 |
| (a) |
The amount of derivatives available for offset is limited to the amount of derivative assets and/or liabilities that are subject to an MNA. |
| (b) |
Excess of collateral received/pledged, if any, from the individual counterparty is not shown for financial reporting purposes. |
| (c) |
Net amount represents the net amount payable due to the counterparty in the event of default. Net amount may be offset further by the options written
receivable/payable on the Statements of Assets and Liabilities. |
| |
Level 1 |
Level 2 |
Level 3 |
Total |
| Assets |
|
|
|
|
| Investments |
|
|
|
|
| Long-Term Investments |
|
|
|
|
| Common Stocks |
|
|
|
|
| Canada |
$ 33,901,341
|
$ —
|
$ —
|
$ 33,901,341 |
| China |
18,159,428 |
— |
— |
18,159,428 |
| Denmark |
— |
23,566,501 |
— |
23,566,501 |
| France |
— |
50,099,554 |
— |
50,099,554 |
| Germany |
15,732,631 |
36,819,893 |
— |
52,552,524 |
| India |
— |
18,515,493 |
325,180 |
18,840,673 |
| Indonesia |
— |
6,985,248 |
— |
6,985,248 |
| Italy |
— |
17,017,395 |
— |
17,017,395 |
| Japan |
— |
42,912,738 |
— |
42,912,738 |
| Netherlands |
— |
28,903,589 |
— |
28,903,589 |
| Singapore |
— |
14,284,402 |
— |
14,284,402 |
| Spain |
— |
15,365,476 |
— |
15,365,476 |
| Sweden |
— |
29,559,734 |
— |
29,559,734 |
| Switzerland |
— |
8,247,615 |
— |
8,247,615 |
| Taiwan |
— |
34,710,024 |
— |
34,710,024 |
| United Kingdom |
— |
61,102,217 |
— |
61,102,217 |
| United States |
60,259,766 |
48,508,136 |
— |
108,767,902 |
| Short-Term Securities |
|
|
|
|
| Money Market Funds |
3,742,337 |
— |
— |
3,742,337 |
| |
$ 131,795,503 |
$ 436,598,015 |
$ 325,180 |
$ 568,718,698 |
| Derivative Financial Instruments(a)
|
|
|
|
|
| Liabilities |
|
|
|
|
| Equity Contracts |
$ (252,541 ) |
$ (4,078,570 ) |
$ — |
$ (4,331,111 ) |
| (a) |
Derivative financial instruments are options written. Options written are shown at
value. |
| Security |
|
Shares |
Value |
| Common Stocks | |||
| Aerospace & Defense — 1.5% |
| ||
| Howmet Aerospace, Inc. |
|
120,992 |
$ 13,232,895 |
| Banks — 3.3% |
| ||
| JPMorgan Chase & Co.(a)
|
|
86,574 |
20,752,654 |
| Wells Fargo & Co. |
|
129,551 |
9,099,662 |
| |
|
|
29,852,316 |
| Broadline Retail — 7.5% |
| ||
| Amazon.com, Inc.(a)(b) |
|
307,740 |
67,515,079 |
| Building Products — 1.5% |
| ||
| Johnson Controls International PLC |
|
166,814 |
13,166,629 |
| Capital Markets — 7.0% |
| ||
| Intercontinental Exchange,
Inc.(a) |
|
147,339 |
21,954,984 |
| KKR & Co., Inc., Class A |
|
88,225 |
13,049,360 |
| S&P Global, Inc. |
|
56,897 |
28,336,413 |
| |
|
|
63,340,757 |
| Chemicals — 3.1% |
| ||
| Air Products and Chemicals, Inc. |
|
96,126 |
27,880,385 |
| Communications Equipment — 4.4% |
| ||
| Ciena Corp.(b) |
|
468,378 |
39,723,138 |
| Electronic Equipment, Instruments & Components — 1.7% |
| ||
| Zebra Technologies Corp., Class A(b) |
|
38,576 |
14,898,823 |
| Entertainment — 1.2% |
| ||
| TKO Group Holdings, Inc., Class A(b) |
|
79,102 |
11,241,185 |
| Financial Services — 4.1% |
| ||
| Visa, Inc., Class A |
|
117,753 |
37,214,658 |
| Health Care Providers & Services — 8.9% |
| ||
| Cardinal Health, Inc. |
|
261,873 |
30,971,720 |
| Elevance Health, Inc. |
|
23,728 |
8,753,259 |
| Humana, Inc. |
|
65,017 |
16,495,463 |
| Tenet Healthcare Corp.(b) |
|
119,934 |
15,139,269 |
| UnitedHealth Group, Inc. |
|
17,047 |
8,623,395 |
| |
|
|
79,983,106 |
| Household Durables — 0.7% |
| ||
| Sony Group Corp., ADR(c) |
|
318,130 |
6,731,631 |
| Industrial Conglomerates — 2.2% |
| ||
| Honeywell International, Inc. |
|
85,744 |
19,368,712 |
| Insurance — 1.7% |
| ||
| Fidelity National Financial, Inc., Class A |
|
75,000 |
4,210,500 |
| Reinsurance Group of America, Inc.(a) |
|
50,682 |
10,827,196 |
| |
|
|
15,037,696 |
| Interactive Media & Services — 11.8% |
| ||
| Alphabet, Inc., Class A |
|
170,532 |
32,281,708 |
| Meta Platforms, Inc., Class A(a) |
|
86,113 |
50,420,023 |
| Reddit, Inc., Class A(b) |
|
145,599 |
23,796,700 |
| |
|
|
106,498,431 |
| IT Services — 1.1% |
| ||
| Cognizant Technology Solutions Corp., Class A |
|
131,307 |
10,097,508 |
| Security |
|
Shares |
Value |
| Machinery — 2.1% |
| ||
| Otis Worldwide Corp.(a) |
|
67,390 |
$ 6,240,988
|
| Westinghouse Air Brake Technologies Corp. |
|
68,904 |
13,063,509 |
| |
|
|
19,304,497 |
| Oil, Gas & Consumable Fuels — 2.5% |
| ||
| ConocoPhillips(a) |
|
90,304 |
8,955,448 |
| Hess Corp. |
|
98,663 |
13,123,165 |
| |
|
|
22,078,613 |
| Pharmaceuticals — 1.3% |
| ||
| Eli Lilly & Co. |
|
5,930 |
4,577,960 |
| Novo Nordisk A/S, Class B, ADR |
|
79,305 |
6,821,816 |
| |
|
|
11,399,776 |
| Professional Services — 3.9% |
| ||
| Dun & Bradstreet Holdings, Inc. |
|
926,496 |
11,544,140 |
| SS&C Technologies Holdings, Inc. |
|
315,266 |
23,890,858 |
| |
|
|
35,434,998 |
| Semiconductors & Semiconductor Equipment — 13.5% |
| ||
| Advanced Micro Devices, Inc.(b) |
|
117,679 |
14,214,446 |
| Astera Labs, Inc.(b) |
|
93,944 |
12,442,883 |
| Broadcom, Inc. |
|
108,378 |
25,126,356 |
| Marvell Technology, Inc. |
|
248,842 |
27,484,599 |
| NVIDIA Corp.(a) |
|
312,498 |
41,965,356 |
| |
|
|
121,233,640 |
| Software — 9.5% |
| ||
| Intuit, Inc. |
|
13,800 |
8,673,300 |
| Microsoft Corp.(a)(d) |
|
181,899 |
76,670,428 |
| |
|
|
85,343,728 |
| Specialty Retail — 0.8% |
| ||
| Ross Stores, Inc. |
|
44,959 |
6,800,948 |
| Technology Hardware, Storage & Peripherals — 3.9% |
| ||
| Apple, Inc.(a) |
|
121,954 |
30,539,721 |
| Western Digital Corp.(b) |
|
70,097 |
4,179,884 |
| |
|
|
34,719,605 |
| Textiles, Apparel & Luxury Goods — 1.5% |
| ||
| LVMH Moet Hennessy Louis Vuitton SE |
|
20,654 |
13,586,051 |
| Total Long-Term Investments — 100.7% (Cost: $599,221,066) |
905,684,805 | ||
| Security |
|
Shares |
Value |
| Short-Term Securities | |||
| Money Market Funds — 0.8% |
| ||
| BlackRock Cash Funds: Institutional, SL Agency Shares, 4.63%(e)(f)(g) |
|
434,910 |
$ 435,128
|
| BlackRock Liquidity Funds, T-Fund, Institutional Shares,
4.36%(e)(f) |
|
6,320,794 |
6,320,794 |
| Total Short-Term Securities — 0.8% (Cost: $6,755,963) |
6,755,922 | ||
| Total Investments Before Options Written — 101.5% (Cost: $605,977,029) |
912,440,727 | ||
| Options Written — (1.3)% (Premiums Received: $(14,633,458)) |
(11,480,390 ) | ||
| Total Investments, Net of Options Written — 100.2% (Cost: $591,343,571) |
900,960,337 | ||
| Liabilities in Excess of Other Assets — (0.2)% |
(1,409,029 ) | ||
| Net Assets — 100.0% |
$ 899,551,308 | ||
| (a) |
All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written. |
| (b) |
Non-income producing security. |
| (c) |
All or a portion of this security is on loan. |
| (d) |
All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives. |
| (e) |
Affiliate of the Trust. |
| (f) |
Annualized 7-day yield as of period end. |
| (g) |
All or a portion of this security was purchased with the cash collateral from loaned securities. |
| Affiliated Issuer |
Value at 12/31/23 |
Purchases at Cost |
Proceeds from Sales |
Net Realized Gain (Loss) |
Change in Unrealized Appreciation (Depreciation) |
Value at 12/31/24 |
Shares Held at 12/31/24 |
Income |
Capital Gain Distributions from Underlying Funds |
| BlackRock Cash Funds: Institutional, SL Agency Shares |
$ — |
$ 435,466 (a) |
$ — |
$ (298 ) |
$ (40 ) |
$ 435,128 |
434,910 |
$ 2,660 (b) |
$ — |
| BlackRock Liquidity Funds, T-Fund, Institutional Shares |
12,932,953 |
— |
(6,612,159 )(a) |
— |
— |
6,320,794 |
6,320,794 |
550,353 |
— |
| SL Liquidity Series, LLC, Money Market
Series(c) |
397,512 |
— |
(397,856
)(a) |
305 |
39 |
— |
— |
215
(b) |
— |
| |
|
|
|
$ 7 |
$ (1 ) |
$ 6,755,922 |
|
$ 553,228 |
$ — |
| (a) |
Represents net amount purchased (sold). |
| (b) |
All or a portion represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of collateral investment fees, and
other payments to and from borrowers of securities. |
| (c) |
As of period end, the entity is no longer held. |
| Description |
Number of Contracts |
Expiration Date |
Exercise Price |
Notional Amount (000) |
Value | ||
| Call |
|
|
|
|
|
|
|
| Honeywell International, Inc. |
217 |
01/03/25 |
USD |
235.25 |
USD |
4,902 |
$ (335
) |
| Honeywell International, Inc. |
300 |
01/03/25 |
USD |
230.00 |
USD |
6,777 |
(12,000 ) |
| Humana, Inc. |
42 |
01/03/25 |
USD |
315.00 |
USD |
1,066 |
(6,300 ) |
| JPMorgan Chase & Co. |
267 |
01/03/25 |
USD |
245.00 |
USD |
6,400 |
(5,874 ) |
| KKR & Co., Inc., Class A |
190 |
01/03/25 |
USD |
165.00 |
USD |
2,810 |
(24,700 ) |
| Novo Nordisk A/S, Class B, ADR |
300 |
01/03/25 |
USD |
116.00 |
USD |
2,581 |
(15,000 ) |
| Reddit, Inc., Class A |
227 |
01/03/25 |
USD |
180.00 |
USD |
3,710 |
(7,605 ) |
| Sony Group Corp., ADR |
983 |
01/03/25 |
USD |
22.00 |
USD |
2,080 |
(4,915 ) |
| UnitedHealth Group, Inc. |
50 |
01/03/25 |
USD |
615.00 |
USD |
2,529 |
(8,500 ) |
| Cognizant Technology Solutions Corp., Class A |
196 |
01/08/25 |
USD |
78.50 |
USD |
1,507 |
(9,137 ) |
| Advanced Micro Devices, Inc. |
59 |
01/10/25 |
USD |
150.00 |
USD |
713 |
(207 ) |
| Alphabet, Inc., Class A |
58 |
01/10/25 |
USD |
180.00 |
USD |
1,098 |
(59,305 ) |
| Amazon.com, Inc. |
384 |
01/10/25 |
USD |
230.00 |
USD |
8,425 |
(24,384 ) |
| Broadcom, Inc. |
251 |
01/10/25 |
USD |
178.30 |
USD |
5,819 |
(1,350,388 ) |
| Description |
Number of Contracts |
Expiration Date |
Exercise Price |
Notional Amount (000) |
Value | ||
| Call (continued) |
|
|
|
|
|
|
|
| Cardinal Health, Inc. |
3 |
01/10/25 |
USD |
122.91 |
USD |
35 |
$ (48
) |
| ConocoPhillips |
377 |
01/10/25 |
USD |
109.00 |
USD |
3,739 |
(3,393 ) |
| JPMorgan Chase & Co. |
156 |
01/10/25 |
USD |
255.00 |
USD |
3,739 |
(858 ) |
| Marvell Technology, Inc. |
571 |
01/10/25 |
USD |
125.00 |
USD |
6,307 |
(8,851 ) |
| Meta Platforms, Inc., Class A |
120 |
01/10/25 |
USD |
635.00 |
USD |
7,026 |
(6,840 ) |
| Microsoft Corp. |
127 |
01/10/25 |
USD |
445.00 |
USD |
5,353 |
(3,302 ) |
| NVIDIA Corp. |
132 |
01/10/25 |
USD |
160.32 |
USD |
1,773 |
(327 ) |
| NVIDIA Corp. |
233 |
01/10/25 |
USD |
165.08 |
USD |
3,129 |
(191 ) |
| Sony Group Corp., ADR |
1,099 |
01/10/25 |
USD |
22.00 |
USD |
2,325 |
(8,243 ) |
| UnitedHealth Group, Inc. |
16 |
01/10/25 |
USD |
585.00 |
USD |
809 |
(176 ) |
| Visa, Inc., Class A |
287 |
01/10/25 |
USD |
320.00 |
USD |
9,070 |
(52,521 ) |
| Advanced Micro Devices, Inc. |
58 |
01/17/25 |
USD |
155.00 |
USD |
701 |
(435 ) |
| Alphabet, Inc., Class A |
600 |
01/17/25 |
USD |
180.00 |
USD |
11,358 |
(666,000 ) |
| Amazon.com, Inc. |
388 |
01/17/25 |
USD |
215.00 |
USD |
8,512 |
(312,340 ) |
| Amazon.com, Inc. |
376 |
01/17/25 |
USD |
230.00 |
USD |
8,249 |
(54,144 ) |
| Apple, Inc. |
289 |
01/17/25 |
USD |
235.00 |
USD |
7,237 |
(470,347 ) |
| Astera Labs, Inc. |
490 |
01/17/25 |
USD |
145.00 |
USD |
6,490 |
(154,350 ) |
| Broadcom, Inc. |
272 |
01/17/25 |
USD |
185.00 |
USD |
6,306 |
(1,319,880 ) |
| Cardinal Health, Inc. |
159 |
01/17/25 |
USD |
120.00 |
USD |
1,880 |
(20,670 ) |
| Ciena Corp. |
660 |
01/17/25 |
USD |
72.50 |
USD |
5,597 |
(778,800 ) |
| Elevance Health, Inc. |
58 |
01/17/25 |
USD |
440.00 |
USD |
2,140 |
(3,190 ) |
| Fidelity National Financial, Inc., Class A |
403 |
01/17/25 |
USD |
62.00 |
USD |
2,262 |
(114 ) |
| Hess Corp. |
641 |
01/17/25 |
USD |
150.00 |
USD |
8,526 |
(16,025 ) |
| Honeywell International, Inc. |
217 |
01/17/25 |
USD |
235.25 |
USD |
4,902 |
(21,159 ) |
| Howmet Aerospace, Inc. |
260 |
01/17/25 |
USD |
125.00 |
USD |
2,844 |
(9,100 ) |
| Intercontinental Exchange, Inc. |
278 |
01/17/25 |
USD |
165.00 |
USD |
4,142 |
(4,170 ) |
| Johnson Controls International PLC |
542 |
01/17/25 |
USD |
82.50 |
USD |
4,278 |
(17,615 ) |
| JPMorgan Chase & Co. |
139 |
01/17/25 |
USD |
240.00 |
USD |
3,332 |
(72,627 ) |
| KKR & Co., Inc., Class A |
190 |
01/17/25 |
USD |
165.00 |
USD |
2,810 |
(4,750 ) |
| Marvell Technology, Inc. |
309 |
01/17/25 |
USD |
92.50 |
USD |
3,413 |
(554,655 ) |
| Meta Platforms, Inc., Class A |
93 |
01/17/25 |
USD |
600.00 |
USD |
5,445 |
(88,582 ) |
| Novo Nordisk A/S, Class B, ADR |
318 |
01/17/25 |
USD |
115.00 |
USD |
2,735 |
(2,385 ) |
| NVIDIA Corp. |
45 |
01/17/25 |
USD |
140.00 |
USD |
604 |
(12,803 ) |
| NVIDIA Corp. |
132 |
01/17/25 |
USD |
158.00 |
USD |
1,773 |
(3,498 ) |
| Otis Worldwide Corp. |
341 |
01/17/25 |
USD |
100.00 |
USD |
3,158 |
(5,115 ) |
| Otis Worldwide Corp. |
24 |
01/17/25 |
USD |
105.00 |
USD |
222 |
(120 ) |
| Reddit, Inc., Class A |
227 |
01/17/25 |
USD |
175.00 |
USD |
3,710 |
(120,877 ) |
| Reinsurance Group of America, Inc. |
174 |
01/17/25 |
USD |
230.00 |
USD |
3,717 |
(55,680 ) |
| S&P Global, Inc. |
145 |
01/17/25 |
USD |
530.00 |
USD |
7,221 |
(8,700 ) |
| Sony Group Corp., ADR |
1,099 |
01/17/25 |
USD |
22.00 |
USD |
2,325 |
(13,738 ) |
| SS&C Technologies Holdings, Inc. |
411 |
01/17/25 |
USD |
75.00 |
USD |
3,115 |
(69,870 ) |
| SS&C Technologies Holdings, Inc. |
822 |
01/17/25 |
USD |
77.50 |
USD |
6,229 |
(60,664 ) |
| Tenet Healthcare Corp. |
375 |
01/17/25 |
USD |
175.00 |
USD |
4,734 |
(28,125 ) |
| TKO Group Holdings, Inc., Class A |
257 |
01/17/25 |
USD |
125.00 |
USD |
3,652 |
(453,605 ) |
| Visa, Inc., Class A |
286 |
01/17/25 |
USD |
320.00 |
USD |
9,039 |
(94,380 ) |
| Westinghouse Air Brake Technologies Corp. |
232 |
01/17/25 |
USD |
202.34 |
USD |
4,398 |
(5,628 ) |
| Alphabet, Inc., Class A |
450 |
01/24/25 |
USD |
205.00 |
USD |
8,519 |
(33,300 ) |
| Amazon.com, Inc. |
348 |
01/24/25 |
USD |
220.00 |
USD |
7,635 |
(205,320 ) |
| Apple, Inc. |
217 |
01/24/25 |
USD |
255.00 |
USD |
5,434 |
(64,774 ) |
| Broadcom, Inc. |
117 |
01/24/25 |
USD |
235.00 |
USD |
2,713 |
(95,647 ) |
| Cardinal Health, Inc. |
276 |
01/24/25 |
USD |
124.00 |
USD |
3,264 |
(12,420 ) |
| Cardinal Health, Inc. |
78 |
01/24/25 |
USD |
120.00 |
USD |
923 |
(11,895 ) |
| ConocoPhillips |
115 |
01/24/25 |
USD |
108.00 |
USD |
1,140 |
(3,680 ) |
| Meta Platforms, Inc., Class A |
199 |
01/24/25 |
USD |
680.00 |
USD |
11,652 |
(13,333 ) |
| Microsoft Corp. |
494 |
01/24/25 |
USD |
465.00 |
USD |
20,822 |
(15,808 ) |
| NVIDIA Corp. |
223 |
01/24/25 |
USD |
144.00 |
USD |
2,995 |
(54,523 ) |
| NVIDIA Corp. |
38 |
01/24/25 |
USD |
135.00 |
USD |
510 |
(21,945 ) |
| Reddit, Inc., Class A |
185 |
01/24/25 |
USD |
185.00 |
USD |
3,024 |
(74,925 ) |
| UnitedHealth Group, Inc. |
44 |
01/24/25 |
USD |
525.00 |
USD |
2,226 |
(44,330 ) |
| Visa, Inc., Class A |
192 |
01/24/25 |
USD |
325.00 |
USD |
6,068 |
(50,880 ) |
| Amazon.com, Inc. |
120 |
01/31/25 |
USD |
245.00 |
USD |
2,633 |
(13,680 ) |
| Broadcom, Inc. |
32 |
01/31/25 |
USD |
240.00 |
USD |
742 |
(24,640 ) |
| Description |
Number of Contracts |
Expiration Date |
Exercise Price |
Notional Amount (000) |
Value | ||
| Call (continued) |
|
|
|
|
|
|
|
| ConocoPhillips |
94 |
01/31/25 |
USD |
101.00 |
USD |
932 |
$ (18,518
) |
| Humana, Inc. |
88 |
01/31/25 |
USD |
295.00 |
USD |
2,233 |
(36,520 ) |
| Marvell Technology, Inc. |
62 |
01/31/25 |
USD |
123.00 |
USD |
685 |
(11,315 ) |
| Meta Platforms, Inc., Class A |
147 |
01/31/25 |
USD |
660.00 |
USD |
8,607 |
(93,712 ) |
| Microsoft Corp. |
259 |
01/31/25 |
USD |
470.00 |
USD |
10,917 |
(31,469 ) |
| NVIDIA Corp. |
130 |
01/31/25 |
USD |
131.00 |
USD |
1,746 |
(120,900 ) |
| NVIDIA Corp. |
112 |
01/31/25 |
USD |
152.50 |
USD |
1,504 |
(18,256 ) |
| Reddit, Inc., Class A |
186 |
01/31/25 |
USD |
195.00 |
USD |
3,040 |
(71,889 ) |
| Ross Stores, Inc. |
146 |
01/31/25 |
USD |
155.00 |
USD |
2,209 |
(32,850 ) |
| Wells Fargo & Co. |
421 |
01/31/25 |
USD |
75.00 |
USD |
2,957 |
(38,943 ) |
| Western Digital Corp. |
227 |
01/31/25 |
USD |
66.00 |
USD |
1,354 |
(26,105 ) |
| NVIDIA Corp. |
112 |
02/07/25 |
USD |
152.50 |
USD |
1,504 |
(25,088 ) |
| NVIDIA Corp. |
112 |
02/14/25 |
USD |
152.51 |
USD |
1,504 |
(29,997 ) |
| Advanced Micro Devices, Inc. |
353 |
02/21/25 |
USD |
145.00 |
USD |
4,264 |
(79,425 ) |
| Amazon.com, Inc. |
384 |
02/21/25 |
USD |
230.00 |
USD |
8,425 |
(270,720 ) |
| Apple, Inc. |
286 |
02/21/25 |
USD |
250.00 |
USD |
7,162 |
(272,415 ) |
| Broadcom, Inc. |
32 |
02/21/25 |
USD |
240.00 |
USD |
742 |
(37,920 ) |
| Cardinal Health, Inc. |
7 |
02/21/25 |
USD |
120.00 |
USD |
83 |
(2,555 ) |
| Ciena Corp. |
793 |
02/21/25 |
USD |
92.50 |
USD |
6,725 |
(128,862 ) |
| Elevance Health, Inc. |
55 |
02/21/25 |
USD |
389.00 |
USD |
2,029 |
(64,630 ) |
| Eli Lilly & Co. |
38 |
02/21/25 |
USD |
870.00 |
USD |
2,934 |
(48,450 ) |
| Intercontinental Exchange, Inc. |
353 |
02/21/25 |
USD |
157.00 |
USD |
5,260 |
(57,787 ) |
| Johnson Controls International PLC |
542 |
02/21/25 |
USD |
80.00 |
USD |
4,278 |
(196,475 ) |
| Marvell Technology, Inc. |
53 |
02/21/25 |
USD |
120.00 |
USD |
585 |
(20,935 ) |
| Microsoft Corp. |
302 |
02/21/25 |
USD |
460.00 |
USD |
12,729 |
(118,535 ) |
| NVIDIA Corp. |
166 |
02/21/25 |
USD |
148.00 |
USD |
2,229 |
(70,965 ) |
| Otis Worldwide Corp. |
235 |
02/21/25 |
USD |
99.00 |
USD |
2,176 |
(21,570 ) |
| Reddit, Inc., Class A |
121 |
02/21/25 |
USD |
170.00 |
USD |
1,978 |
(221,430 ) |
| Ross Stores, Inc. |
146 |
02/21/25 |
USD |
160.00 |
USD |
2,209 |
(26,280 ) |
| S&P Global, Inc. |
224 |
02/21/25 |
USD |
510.00 |
USD |
11,156 |
(263,200 ) |
| SS&C Technologies Holdings, Inc. |
817 |
02/21/25 |
USD |
80.00 |
USD |
6,191 |
(93,955 ) |
| Tenet Healthcare Corp. |
181 |
02/21/25 |
USD |
155.00 |
USD |
2,285 |
(18,100 ) |
| Wells Fargo & Co. |
421 |
02/21/25 |
USD |
75.00 |
USD |
2,957 |
(57,887 ) |
| Western Digital Corp. |
227 |
02/21/25 |
USD |
67.50 |
USD |
1,354 |
(33,937 ) |
| Zebra Technologies Corp., Class A |
130 |
02/21/25 |
USD |
400.00 |
USD |
5,021 |
(183,300 ) |
| |
|
|
|
|
|
|
$ (10,703,536 ) |
| Description |
Counterparty |
Number of Contracts |
Expiration Date |
Exercise Price |
Notional Amount (000) |
Value | ||
| Call |
|
|
|
|
|
|
|
|
| Cognizant Technology Solutions Corp., Class A |
Citibank N.A. |
30,000 |
01/06/25 |
USD |
82.00 |
USD |
2,307 |
$ (448
) |
| Dun & Bradstreet Holdings, Inc. |
Goldman Sachs International |
92,600 |
01/06/25 |
USD |
12.46 |
USD |
1,154 |
(16,361 ) |
| Reinsurance Group of America, Inc. |
Goldman Sachs International |
15,000 |
01/06/25 |
USD |
212.55 |
USD |
3,204 |
(48,349 ) |
| TKO Group Holdings, Inc., Class A |
Morgan Stanley & Co. International PLC |
30,000 |
01/06/25 |
USD |
145.96 |
USD |
4,263 |
(37,863 ) |
| Westinghouse Air Brake Technologies Corp. |
Citibank N.A. |
25,000 |
01/06/25 |
USD |
195.28 |
USD |
4,740 |
(7,462 ) |
| Ciena Corp. |
Citibank N.A. |
42,000 |
01/08/25 |
USD |
75.05 |
USD |
3,562 |
(413,326 ) |
| NVIDIA Corp. |
Barclays Bank PLC |
6,400 |
01/08/25 |
USD |
149.60 |
USD |
859 |
(955 ) |
| Dun & Bradstreet Holdings, Inc. |
Goldman Sachs International |
92,600 |
01/10/25 |
USD |
12.53 |
USD |
1,154 |
(17,124 ) |
| Zebra Technologies Corp., Class A |
Citibank N.A. |
12,000 |
01/10/25 |
USD |
415.09 |
USD |
4,635 |
(2,353 ) |
| LVMH Moet Hennessy Louis Vuitton SE |
Morgan Stanley & Co. International PLC |
13,400 |
01/22/25 |
EUR |
641.33 |
EUR |
8,516 |
(192,088 ) |
| Howmet Aerospace, Inc. |
Morgan Stanley & Co. International PLC |
26,000 |
01/29/25 |
USD |
122.89 |
USD |
2,844 |
(4,622 ) |
| Intercontinental Exchange, Inc. |
BNP Paribas SA |
32,600 |
01/29/25 |
USD |
159.14 |
USD |
4,858 |
(15,130 ) |
| Fidelity National Financial, Inc., Class A |
Morgan Stanley & Co. International PLC |
34,700 |
02/05/25 |
USD |
59.32 |
USD |
1,948 |
(20,773 ) |
| |
|
|
|
|
|
|
|
$ (776,854 ) |
| Description |
Premiums Paid |
Premiums Received |
Unrealized Appreciation |
Unrealized Depreciation |
Value |
| Options Written |
$ N/A
|
$ (14,633,458
) |
$ 7,831,390
|
$ (4,678,322
) |
$ (11,480,390
) |
| |
Commodity Contracts |
Credit Contracts |
Equity Contracts |
Foreign Currency Exchange Contracts |
Interest Rate Contracts |
Other Contracts |
Total |
| Liabilities — Derivative Financial Instruments |
|
|
|
|
|
|
|
| Options written Options written at value |
$ — |
$ — |
$ 11,480,390 |
$ — |
$ — |
$ — |
$ 11,480,390 |
| |
Commodity Contracts |
Credit Contracts |
Equity Contracts |
Foreign Currency Exchange Contracts |
Interest Rate Contracts |
Other Contracts |
Total |
| Net Realized Gain (Loss) from: |
|
|
|
|
|
|
|
| Options written |
$ — |
$ — |
$ (35,047,640 ) |
$ — |
$ — |
$ — |
$ (35,047,640 ) |
| Net Change in Unrealized Appreciation (Depreciation) on: |
|
|
|
|
|
|
|
| Options written |
$ — |
$ — |
$ 11,435,274 |
$ — |
$ — |
$ — |
$ 11,435,274 |
| Options: |
|
| Average value of option contracts written |
$14,936,859
|
| |
Assets |
Liabilities |
| Derivative Financial Instruments |
|
|
| Options |
$ — |
$ 11,480,390 |
| Total derivative assets and liabilities in the Statements of Assets and Liabilities |
— |
11,480,390 |
| Derivatives not subject to a Master Netting Agreement or similar agreement (“MNA”) |
— |
(10,703,536 ) |
| Total derivative assets and liabilities subject to an MNA |
$ — |
$ 776,854 |
| Counterparty |
Derivative Liabilities Subject to an MNA by Counterparty |
Derivatives Available for Offset(a)
|
Non-Cash Collateral Pledged(b)
|
Cash Collateral Pledged(b)
|
Net Amount of Derivative Liabilities(c)
|
| Barclays Bank PLC |
$ 955
|
$ —
|
$ —
|
$ —
|
$ 955
|
| BNP Paribas SA |
15,130 |
— |
— |
— |
15,130 |
| Citibank N.A. |
423,589 |
— |
(423,589 ) |
— |
— |
| Counterparty |
Derivative Liabilities Subject to an MNA by Counterparty |
Derivatives Available for Offset(a) |
Non-Cash Collateral Pledged(b) |
Cash Collateral Pledged(b) |
Net Amount of Derivative Liabilities(c) |
| Goldman Sachs International |
$ 81,834
|
$ —
|
$ —
|
$ —
|
$ 81,834
|
| Morgan Stanley & Co. International PLC |
255,346 |
— |
(255,346 ) |
— |
— |
| |
$ 776,854 |
$ — |
$ (678,935 ) |
$ — |
$ 97,919 |
| (a) |
The amount of derivatives available for offset is limited to the amount of derivative assets and/or liabilities that are subject to an MNA. |
| (b) |
Excess of collateral received/pledged, if any, from the individual counterparty is not shown for financial reporting purposes. |
| (c) |
Net amount represents the net amount payable due to the counterparty in the event of default. Net amount may be offset further by the options written
receivable/payable on the Statements of Assets and Liabilities. |
| |
Level 1 |
Level 2 |
Level 3 |
Total |
| Assets |
|
|
|
|
| Investments |
|
|
|
|
| Long-Term Investments |
|
|
|
|
| Common Stocks |
|
|
|
|
| Aerospace & Defense |
$ 13,232,895
|
$ —
|
$ —
|
$ 13,232,895 |
| Banks |
29,852,316 |
— |
— |
29,852,316 |
| Broadline Retail |
67,515,079 |
— |
— |
67,515,079 |
| Building Products |
13,166,629 |
— |
— |
13,166,629 |
| Capital Markets |
63,340,757 |
— |
— |
63,340,757 |
| Chemicals |
27,880,385 |
— |
— |
27,880,385 |
| Communications Equipment |
39,723,138 |
— |
— |
39,723,138 |
| Electronic Equipment, Instruments & Components |
14,898,823 |
— |
— |
14,898,823 |
| Entertainment |
11,241,185 |
— |
— |
11,241,185 |
| Financial Services |
37,214,658 |
— |
— |
37,214,658 |
| Health Care Providers & Services |
79,983,106 |
— |
— |
79,983,106 |
| Household Durables |
6,731,631 |
— |
— |
6,731,631 |
| Industrial Conglomerates |
19,368,712 |
— |
— |
19,368,712 |
| Insurance |
15,037,696 |
— |
— |
15,037,696 |
| Interactive Media & Services |
106,498,431 |
— |
— |
106,498,431 |
| IT Services |
10,097,508 |
— |
— |
10,097,508 |
| Machinery |
19,304,497 |
— |
— |
19,304,497 |
| Oil, Gas & Consumable Fuels |
22,078,613 |
— |
— |
22,078,613 |
| Pharmaceuticals |
11,399,776 |
— |
— |
11,399,776 |
| Professional Services |
35,434,998 |
— |
— |
35,434,998 |
| Semiconductors & Semiconductor Equipment |
121,233,640 |
— |
— |
121,233,640 |
| Software |
85,343,728 |
— |
— |
85,343,728 |
| Specialty Retail |
6,800,948 |
— |
— |
6,800,948 |
| Technology Hardware, Storage & Peripherals |
34,719,605 |
— |
— |
34,719,605 |
| Textiles, Apparel & Luxury Goods |
— |
13,586,051 |
— |
13,586,051 |
| Short-Term Securities |
|
|
|
|
| Money Market Funds |
6,755,922 |
— |
— |
6,755,922 |
| |
$898,854,676 |
$13,586,051 |
$— |
$912,440,727 |
| Derivative Financial Instruments(a)
|
|
|
|
|
| Liabilities |
|
|
|
|
| Equity Contracts |
$ (9,081,561 ) |
$ (2,398,829 ) |
$ — |
$ (11,480,390 ) |
| (a) |
Derivative financial instruments are options written. Options written are shown at
value. |
| Security |
|
Shares |
Value |
| Common Stocks | |||
| Biotechnology — 41.0% |
| ||
| 4D Molecular Therapeutics,
Inc.(a) |
|
109,215 |
$ 608,328
|
| Abbisko Cayman Ltd.(a) |
|
10,378,250 |
6,108,843 |
| AC Immune SA(a) |
|
628,829 |
1,697,838 |
| Alkermes PLC(a) |
|
190,629 |
5,482,490 |
| Allogene Therapeutics, Inc.(a)
|
|
729,560 |
1,553,963 |
| Alnylam Pharmaceuticals, Inc.(a)(b) |
|
262,673 |
61,809,584 |
| Annexon, Inc.(a) |
|
247,095 |
1,267,597 |
| Apellis Pharmaceuticals, Inc.(a) |
|
53,391 |
1,703,707 |
| Arcellx, Inc.(a) |
|
20,900 |
1,602,820 |
| Arcturus Therapeutics Holdings, Inc.(a) |
|
84,144 |
1,427,924 |
| Arcus Biosciences, Inc.(a)(c)
|
|
169,790 |
2,528,173 |
| Argenx SE, ADR(a) |
|
104,599 |
64,328,385 |
| Arrowhead Pharmaceuticals,
Inc.(a) |
|
88,016 |
1,654,701 |
| Ascendis Pharma A/S, ADR(a) |
|
48,265 |
6,644,643 |
| Autolus Therapeutics PLC, ADR(a)
|
|
795,718 |
1,869,937 |
| Avidity Biosciences, Inc.(a) |
|
124,955 |
3,633,691 |
| Beam Therapeutics, Inc.(a) |
|
290,752 |
7,210,650 |
| BeiGene Ltd., ADR(a)(c) |
|
74,469 |
13,755,169 |
| Bicycle Therapeutics PLC,
ADR(a)(c) |
|
91,006 |
1,274,084 |
| Biohaven Ltd.(a) |
|
151,959 |
5,675,669 |
| BioMarin Pharmaceutical, Inc.(a)
|
|
253,011 |
16,630,413 |
| BioNTech SE, ADR(a) |
|
61,595 |
7,018,750 |
| Black Diamond Therapeutics,
Inc.(a) |
|
866,005 |
1,853,251 |
| Blueprint Medicines Corp.(a) |
|
171,956 |
14,998,002 |
| Bridgebio Pharma, Inc.(a) |
|
176,043 |
4,830,620 |
| CG oncology, Inc.(a) |
|
43,008 |
1,233,469 |
| Denali Therapeutics, Inc.(a)
|
|
511,840 |
10,431,299 |
| Disc Medicine, Inc.(a) |
|
48,054 |
3,046,624 |
| Dyne Therapeutics, Inc.(a) |
|
200,089 |
4,714,097 |
| Everest Medicines Ltd.(a)(c)(d) |
|
3,113,667 |
19,314,157 |
| Exact Sciences Corp.(a) |
|
270,089 |
15,176,301 |
| Exelixis, Inc.(a) |
|
344,845 |
11,483,338 |
| Gilead Sciences, Inc. |
|
176,216 |
16,277,072 |
| Halozyme Therapeutics, Inc.(a) |
|
171,850 |
8,216,148 |
| Immatics NV(a) |
|
278,934 |
1,983,221 |
| Immunocore Holdings PLC, Series C, ADR(a) |
|
321,900 |
9,496,050 |
| Incyte Corp.(a) |
|
114,060 |
7,878,124 |
| Insmed, Inc.(a) |
|
300,764 |
20,764,747 |
| Ionis Pharmaceuticals, Inc.(a)
|
|
173,321 |
6,059,302 |
| Legend Biotech Corp., ADR(a) |
|
72,722 |
2,366,374 |
| Lexeo Therapeutics, Inc.(a)
|
|
28,330 |
186,411 |
| Merus NV(a) |
|
401,993 |
16,903,806 |
| Monte Rosa Therapeutics,
Inc.(a)(c) |
|
266,168 |
1,847,206 |
| MoonLake Immunotherapeutics(a) |
|
121,107 |
6,557,944 |
| Natera, Inc.(a) |
|
115,865 |
18,341,429 |
| Neurocrine Biosciences, Inc.(a) |
|
177,015 |
24,162,547 |
| Neurogene, Inc.(a) |
|
234,672 |
5,364,602 |
| Nurix Therapeutics, Inc.(a)(c) |
|
420,409 |
7,920,506 |
| Nuvalent, Inc., Class A(a) |
|
230,634 |
18,054,029 |
| Onkure Therapeutic, Inc., (Acquired 03/24/23, Cost:
$7,022,594)(a)(e) |
|
367,976 |
3,164,594 |
| ORIC Pharmaceuticals, Inc.(a)
|
|
237,559 |
1,917,101 |
| Protagonist Therapeutics, Inc.(a) |
|
158,867 |
6,132,266 |
| PTC Therapeutics, Inc.(a) |
|
234,545 |
10,587,361 |
| REGENXBIO, Inc.(a) |
|
111,333 |
860,604 |
| Renagade Therapeutics, Series
A-2(a)(f) |
|
3,584,906 |
8,818,869 |
| REVOLUTION Medicines, Inc.(a)(c) |
|
66,825 |
2,922,925 |
| Rhythm Pharmaceuticals, Inc.(a)
|
|
630,459 |
35,293,095 |
| Rocket Pharmaceuticals, Inc.(a) |
|
273,849 |
3,442,282 |
| Roivant Sciences Ltd.(a) |
|
899,035 |
10,635,584 |
| Security |
|
Shares |
Value |
| Biotechnology (continued) |
| ||
| RPHM Onkure Pipe(a) |
|
95,610 |
$ 796,431
|
| Sagimet Biosciences, Inc., Series
A(a) |
|
408,120 |
1,836,540 |
| Sarepta Therapeutics, Inc.(a) |
|
228,161 |
27,742,096 |
| Scholar Rock Holding Corp.(a)
|
|
115,917 |
5,009,933 |
| Spyre Therapeutics, Inc.(a) |
|
31,295 |
728,548 |
| Stoke Therapeutics, Inc.(a)
|
|
530,092 |
5,846,915 |
| TScan Therapeutics, Inc.(a) |
|
1,045,767 |
3,179,132 |
| Twist Bioscience Corp.(a) |
|
138,215 |
6,422,851 |
| Ultragenyx Pharmaceutical, Inc.(a) |
|
120,654 |
5,075,914 |
| United Therapeutics Corp.(a)
|
|
60,511 |
21,350,701 |
| Vaxcyte, Inc.(a) |
|
127,504 |
10,437,477 |
| Vertex Pharmaceuticals, Inc.(a)
|
|
9,507 |
3,828,469 |
| Vigil Neuroscience, Inc.(a) |
|
225,247 |
382,920 |
| Viking Therapeutics, Inc.(a)(c)
|
|
42,180 |
1,697,323 |
| Voyager Therapeutics, Inc.(a) |
|
363,321 |
2,060,030 |
| Xenon Pharmaceuticals, Inc.(a)
|
|
456,329 |
17,888,097 |
| Zealand Pharma A/S(a) |
|
90,332 |
8,985,775 |
| |
|
|
681,991,868 |
| Capital Markets — 0.3% |
| ||
| Helix Acquisition Corp. II, Class
A(a) |
|
544,465 |
5,716,883 |
| Health Care Equipment & Supplies — 21.6% |
| ||
| Abbott Laboratories |
|
117,320 |
13,270,065 |
| Alcon AG |
|
101,475 |
8,614,213 |
| Align Technology, Inc.(a) |
|
116,423 |
24,275,360 |
| Becton Dickinson & Co. |
|
42,593 |
9,663,074 |
| Boston Scientific Corp.(a)(b)(g)
|
|
495,160 |
44,227,691 |
| Cooper Cos., Inc.(a) |
|
104,912 |
9,644,560 |
| Dexcom, Inc.(a) |
|
119,854 |
9,321,045 |
| Edwards Lifesciences Corp.(a) |
|
113,306 |
8,388,043 |
| GE HealthCare Technologies,
Inc.(a)(c) |
|
118,855 |
9,292,084 |
| Glaukos Corp.(a) |
|
44,674 |
6,698,419 |
| Inari Medical, Inc.(a) |
|
87,520 |
4,467,896 |
| Inspire Medical Systems, Inc.(a) |
|
89,190 |
16,534,042 |
| Insulet Corp.(a) |
|
97,595 |
25,479,127 |
| Intuitive Surgical, Inc.(a)(b) |
|
152,850 |
79,781,586 |
| Novocure Ltd.(a) |
|
231,742 |
6,905,912 |
| Nucleix Ltd., (Acquired 04/10/24, Cost:
$1,300,000)(a)(e)(f)(h) |
|
1,300 |
1,161,485 |
| Nyxoah SA(a) |
|
648,041 |
5,184,328 |
| Orchestra BioMed Holdings, Inc.(a) |
|
233,344 |
933,376 |
| Penumbra, Inc.(a) |
|
62,727 |
14,896,408 |
| Sonova Holding AG, Registered Shares |
|
98,780 |
32,302,016 |
| STERIS PLC |
|
47,732 |
9,811,790 |
| Stryker Corp. |
|
50,474 |
18,173,164 |
| |
|
|
359,025,684 |
| Health Care Providers & Services — 3.6% |
| ||
| Chemed Corp. |
|
11,582 |
6,136,144 |
| Encompass Health Corp. |
|
164,829 |
15,221,958 |
| Guardant Health, Inc.(a) |
|
372,391 |
11,376,545 |
| Molina Healthcare, Inc.(a)(c) |
|
77,120 |
22,445,776 |
| RadNet, Inc.(a) |
|
66,127 |
4,618,310 |
| |
|
|
59,798,733 |
| Health Care Technology — 1.9% |
| ||
| Veeva Systems, Inc., Class A(a) |
|
151,305 |
31,811,876 |
| Life Sciences Tools & Services — 16.3% |
| ||
| Bio-Techne Corp.(g) |
|
451,301 |
32,507,211 |
| Danaher Corp. |
|
89,673 |
20,584,437 |
| Gerresheimer AG |
|
50,949 |
3,750,793 |
| Illumina, Inc.(a) |
|
90,520 |
12,096,188 |
| Lonza Group AG, Registered Shares |
|
25,381 |
14,980,841 |
| Security |
|
Shares |
Value |
| Life Sciences Tools & Services (continued) |
| ||
| Mettler-Toledo International, Inc.(a)(g) |
|
33,037 |
$ 40,426,716
|
| QIAGEN NV |
|
302,727 |
13,480,433 |
| Rapid Micro Biosystems, Inc., Class A(a) |
|
571,184 |
514,066 |
| Repligen Corp.(a) |
|
218,335 |
31,427,140 |
| Waters Corp.(a)(b)(g) |
|
128,848 |
47,800,031 |
| West Pharmaceutical Services,
Inc.(b) |
|
161,486 |
52,896,354 |
| |
|
|
270,464,210 |
| Pharmaceuticals — 4.8% |
| ||
| Antengene Corp. Ltd.(a)(d) |
|
5,019,274 |
414,852 |
| Arvinas, Inc.(a) |
|
253,060 |
4,851,160 |
| Axsome Therapeutics, Inc.(a) |
|
39,899 |
3,375,854 |
| Daiichi Sankyo Co. Ltd. |
|
207,700 |
5,683,344 |
| Edgewise Therapeutics, Inc.(a) |
|
136,782 |
3,652,080 |
| Neumora Therapeutics, Inc.(a)
|
|
112,071 |
1,187,953 |
| Nuvation Bio, Inc., Class A(a) |
|
328,466 |
873,720 |
| Roche Holding AG |
|
124,794 |
34,893,227 |
| Sanofi SA, ADR |
|
272,403 |
13,137,997 |
| Septerna, Inc.(a) |
|
19,466 |
445,771 |
| Structure Therapeutics, Inc., ADR(a)(c) |
|
66,435 |
1,801,717 |
| Tarsus Pharmaceuticals, Inc.(a)
|
|
156,604 |
8,671,164 |
| WaVe Life Sciences Ltd.(a) |
|
114,714 |
1,419,012 |
| |
|
|
80,407,851 |
| Total Common Stocks — 89.5% (Cost: $1,396,866,799) |
1,489,217,105 | ||
| |
|
Par (000) |
|
| Corporate Bonds | |||
| Health Care Equipment & Supplies — 0.0% | |||
| Exo Imaging, Inc., (Acquired 07/24/24, Cost: $640,450), 8.00%, 08/14/25(e)(f)
|
$ |
641 |
885,422 |
| Software — 0.1% | |||
| Carbon Health Technologies, Inc., Series D2, (Acquired 02/27/24, Cost: $1,226,000), 12.00%, 02/28/26(e)(f) |
|
1 |
1,300,222 |
| Total Corporate Bonds — 0.1% (Cost: $1,866,450) |
2,185,644 | ||
| |
|
Benefical Interest (000) |
|
| Other Interests | |||
| Biotechnology(e)(f)(i)
— 0.2% |
| ||
| Affinivax, Inc., (Acquired 08/18/22, Cost: $ —) |
$ |
183 |
1,736,395 |
| Amunix Pharmaceuticals, Inc., (Acquired 02/08/22,
Cost: $ —) |
|
5,657 |
1,470,837 |
| Total Other Interests — 0.2% (Cost: $ — ) |
3,207,232 | ||
| Security |
|
Shares |
Value |
| Preferred Securities | |||
| Preferred Stocks — 7.8% | |||
| Biotechnology(a)(f)
— 3.8% |
| ||
| ABCURO, Series B |
|
1,092,954 |
$ 6,514,006
|
| Adarx Pharamaceuticals, Inc., Series C, (Acquired 08/02/23, Cost: $7,160,001)(e)
|
|
860,577 |
7,667,741 |
| Bright Peak Therapeutics, Inc., Series B, (Acquired
05/14/21, Cost: $8,000,004)(e) |
|
3,191,830 |
3,287,585 |
| Cellarity, Inc., Series B, (Acquired 01/15/21, Cost: $14,584,998)(e) |
|
2,430,833 |
4,861,666 |
| Genesis Therapeutics, Inc., Series B, (Acquired
08/10/23, Cost: $6,999,996)(e) |
|
1,370,506 |
7,976,345 |
| Goldfinch Bio, Inc., Series B, (Acquired 06/26/20, Cost: $4,543,847)(e) |
|
3,850,718 |
1,501,780 |
| Kartos Therapeutics, Inc., Series C, (Acquired
08/22/23, Cost: $7,539,875)(e) |
|
1,333,783 |
7,829,306 |
| Laronde, Inc., Series B, (Acquired 07/28/21, Cost: $13,498,156)(e) |
|
482,077 |
12,856,994 |
| Mirvie, Inc., Series B, (Acquired 10/15/21, Cost:
$6,250,000)(e) |
|
2,793,833 |
5,168,591 |
| NiKang Therapeutics, Inc., Series C, (Acquired 05/20/21, Cost: $7,999,996)(e)
|
|
1,394,189 |
4,921,487 |
| |
|
|
62,585,501 |
| Health Care Equipment & Supplies(a)(e)(f)
— 0.3% |
| ||
| Exo Imaging, Inc., Series C, (Acquired 06/24/21,
Cost: $13,225,003) |
|
2,257,597 |
135,456 |
| Nucleix Ltd., Series AA, (Acquired 03/25/21, Cost: $6,929,998) |
|
2,379,480 |
5,044,497 |
| Swift Health Systems, Inc., Series D, (Acquired
08/27/21, Cost: $6,441,930) |
|
2,078 |
4,634 |
| |
|
|
5,184,587 |
| Health Care Providers & Services(e)(f)
— 1.1% |
| ||
| Everly Well, Inc., Series D, (Acquired 11/25/20, Cost: $9,999,986)(a) |
|
382,775 |
3,487,080 |
| Numab Therapeutics AG, Series C, (Acquired
05/07/21, Cost: $7,770,441) |
|
815,851 |
6,337,667 |
| Quanta Dialysis Technologies Ltd., Series D, (Acquired 06/18/21, Cost:
$14,071,890)(a) |
|
115,766,240 |
9,275,375 |
| |
|
|
19,100,122 |
| Life Sciences Tools & Services — 0.7% |
| ||
| Sartorius AG |
|
48,949 |
10,878,114 |
| Pharmaceuticals(a)(e)(f)
— 0.5% |
| ||
| Insitro, Inc. |
|
|
|
| Series B, (Acquired 05/21/20, Cost: $5,000,000) |
|
802,478 |
6,788,964 |
| Series C, (Acquired 03/10/21, Cost: $3,600,018) |
|
196,818 |
1,665,080 |
| |
|
|
8,454,044 |
| Semiconductors & Semiconductor Equipment — 1.3% |
| ||
| PsiQuantum Corp., Series D, (Acquired 05/21/21, Cost: $14,999,996)(a)(e)(f) |
|
571,947 |
21,802,620 |
| Software — 0.1% |
| ||
| Carbon Health Technologies, Inc., Series D2, (Acquired 02/02/23, Cost:
$17,100,000)(a)(e)(f) |
|
1,694,781 |
1,593,094 |
| |
129,598,082 | ||
| Total Preferred Securities — 7.8% (Cost: $199,337,033) |
129,598,082 | ||
| Security |
|
Shares |
Value |
| Rights | |||
| Biotechnology(f)
— 0.0% |
| ||
| Korro Bio, Inc., CVR |
|
231,775 |
$ 2
|
| Mirati Therapeutics, Inc. CVR(c) |
|
180,175 |
133,330 |
| |
|
|
133,332 |
| Health Care Equipment & Supplies — 0.0% |
| ||
| Abiomed, Inc., CVR(a)(f) |
|
98,636 |
213,054 |
| Total Rights — 0.0% (Cost: $226,731) |
346,386 | ||
| Warrants | |||
| Health Care Equipment & Supplies — 0.0% |
| ||
| Nucleix Ltd., (Acquired 04/10/24, Cost: $—), (Issued 04/10/24, Expires 04/10/34, Strike Price USD 3.35)(a)(e)(f) |
|
1,552,563 |
217,359 |
| Health Care Providers & Services — 0.0% |
| ||
| CareMax, Inc., (Issued/Exercisable 09/15/20, 1 Share for 1 Warrant, Expires 08/06/26, Strike Price USD 11.50)(a) |
|
63,808 |
290 |
| Pharmaceuticals — 0.0% |
| ||
| Nuvation Bio, Inc., (Issued/Exercisable 08/17/20, 1 Share for 1 Warrant, Expires 07/07/27, Strike Price USD 11.50)(a) |
|
68,880 |
15,842 |
| Total Warrants — 0.0% (Cost: $227,724) |
233,491 | ||
| Total Long-Term Investments — 97.6% (Cost: $1,598,524,737) |
1,624,787,940 | ||
| Short-Term Securities | |||
| Money Market Funds — 3.7% |
| ||
| BlackRock Cash Funds: Institutional, SL Agency
Shares, 4.63%(j)(k)(l) |
|
10,223,001 |
10,228,113 |
| BlackRock Liquidity Funds, T-Fund, Institutional Shares, 4.36%(j)(k) |
|
51,121,570 |
51,121,570 |
| Total Short-Term Securities — 3.7% (Cost: $61,350,462) |
61,349,683 | ||
| Total Investments Before Options Written — 101.3% (Cost: $1,659,875,199) |
1,686,137,623 | ||
| Options Written — (0.6)% (Premiums Received: $(15,891,589)) |
(10,440,970 ) | ||
| Total Investments, Net of Options Written — 100.7% (Cost: $1,643,983,610) |
1,675,696,653 | ||
| Liabilities in Excess of Other Assets — (0.7)% |
(11,814,398 ) | ||
| Net Assets — 100.0% |
$ 1,663,882,255 | ||
| (a) |
Non-income producing security. |
| (b) |
All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written. |
| (c) |
All or a portion of this security is on loan. |
| (d) |
Security exempt from registration pursuant to Rule 144A under the Securities Act of 1933,
as amended. These securities may be resold in transactions exempt from registration to
qualified institutional investors. |
| (e) |
Restricted security as to resale, excluding 144A securities. The Trust held restricted
securities with a current value of $122,142,276, representing 7.3% of its net assets as of
period end, and an original cost of $185,905,179. |
| (f) |
Security is valued using significant unobservable inputs and is classified as Level 3 in the
fair value hierarchy. |
| (g) |
All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives. |
| (h) |
Convertible security. |
| (i) |
Other interests represent beneficial interests in liquidation trusts and other reorganization
or private entities. |
| (j) |
Affiliate of the Trust. |
| (k) |
Annualized 7-day yield as of period end. |
| (l) |
All or a portion of this security was purchased with the cash collateral from loaned securities. |
| Affiliated Issuer |
Value at 12/31/23 |
Purchases at Cost |
Proceeds from Sales |
Net Realized Gain (Loss) |
Change in Unrealized Appreciation (Depreciation) |
Value at 12/31/24 |
Shares Held at 12/31/24 |
Income |
Capital Gain Distributions from Underlying Funds |
| BlackRock Cash Funds: Institutional, SL Agency Shares |
$ — |
$ 10,228,332 (a) |
$ — |
$ 560 |
$ (779 ) |
$ 10,228,113 |
10,223,001 |
$ 59,935 (b) |
$ — |
| BlackRock Liquidity Funds, T-Fund, Institutional Shares |
40,473,813 |
10,647,757 (a) |
— |
— |
— |
51,121,570 |
51,121,570 |
2,809,759 |
— |
| SL Liquidity Series, LLC, Money Market
Series(c) |
12,308,246 |
— |
(12,309,250
)(a) |
424 |
580 |
— |
— |
29,603
(b) |
— |
| |
|
|
|
$ 984 |
$ (199 ) |
$ 61,349,683 |
|
$ 2,899,297 |
$ — |
| (a) |
Represents net amount purchased (sold). |
| (b) |
All or a portion represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of collateral investment fees, and
other payments to and from borrowers of securities. |
| (c) |
As of period end, the entity is no longer held. |
| Description |
Number of Contracts |
Expiration Date |
Exercise Price |
Notional Amount (000) |
Value | ||
| Call |
|
|
|
|
|
|
|
| Danaher Corp. |
113 |
01/03/25 |
USD |
235.00 |
USD |
2,594 |
$ (1,978
) |
| Intuitive Surgical, Inc. |
122 |
01/03/25 |
USD |
564.03 |
USD |
6,368 |
(101 ) |
| Abbott Laboratories |
188 |
01/10/25 |
USD |
117.00 |
USD |
2,126 |
(3,948 ) |
| Dexcom, Inc. |
245 |
01/10/25 |
USD |
82.00 |
USD |
1,905 |
(9,800 ) |
| GE HealthCare Technologies, Inc. |
181 |
01/10/25 |
USD |
85.00 |
USD |
1,415 |
(6,335 ) |
| Gilead Sciences, Inc. |
269 |
01/10/25 |
USD |
95.00 |
USD |
2,485 |
(12,374 ) |
| Align Technology, Inc. |
110 |
01/17/25 |
USD |
250.00 |
USD |
2,294 |
(2,200 ) |
| Align Technology, Inc. |
147 |
01/17/25 |
USD |
260.00 |
USD |
3,065 |
(5,145 ) |
| Alkermes PLC |
305 |
01/17/25 |
USD |
30.00 |
USD |
877 |
(16,013 ) |
| Alnylam Pharmaceuticals, Inc. |
361 |
01/17/25 |
USD |
270.00 |
USD |
8,495 |
(79,420 ) |
| Arcellx, Inc. |
66 |
01/17/25 |
USD |
95.00 |
USD |
506 |
(32,340 ) |
| Arcturus Therapeutics Holdings, Inc. |
269 |
01/17/25 |
USD |
20.00 |
USD |
456 |
(12,105 ) |
| Argenx SE, ADR |
160 |
01/17/25 |
USD |
620.00 |
USD |
9,840 |
(332,000 ) |
| Arvinas, Inc. |
374 |
01/17/25 |
USD |
30.00 |
USD |
717 |
(28,050 ) |
| Arvinas, Inc. |
435 |
01/17/25 |
USD |
22.50 |
USD |
834 |
(26,100 ) |
| Avidity Biosciences, Inc. |
399 |
01/17/25 |
USD |
35.00 |
USD |
1,160 |
(13,965 ) |
| Axsome Therapeutics, Inc. |
63 |
01/17/25 |
USD |
105.00 |
USD |
533 |
(1,890 ) |
| Beam Therapeutics, Inc. |
930 |
01/17/25 |
USD |
29.00 |
USD |
2,306 |
(34,875 ) |
| Becton Dickinson & Co. |
67 |
01/17/25 |
USD |
240.00 |
USD |
1,520 |
(2,010 ) |
| BeiGene Ltd., ADR |
238 |
01/17/25 |
USD |
203.90 |
USD |
4,396 |
(23,042 ) |
| Biohaven Ltd. |
328 |
01/17/25 |
USD |
60.00 |
USD |
1,225 |
(3,280 ) |
| BioMarin Pharmaceutical, Inc. |
250 |
01/17/25 |
USD |
70.00 |
USD |
1,643 |
(10,625 ) |
| BioNTech SE, ADR |
99 |
01/17/25 |
USD |
120.00 |
USD |
1,128 |
(25,493 ) |
| Bio-Techne Corp. |
857 |
01/17/25 |
USD |
75.00 |
USD |
6,173 |
(244,245 ) |
| Blueprint Medicines Corp. |
275 |
01/17/25 |
USD |
100.00 |
USD |
2,399 |
(27,500 ) |
| Boston Scientific Corp. |
528 |
01/17/25 |
USD |
92.50 |
USD |
4,716 |
(33,000 ) |
| Bridgebio Pharma, Inc. |
281 |
01/17/25 |
USD |
30.00 |
USD |
771 |
(18,265 ) |
| Cooper Cos., Inc. |
334 |
01/17/25 |
USD |
105.00 |
USD |
3,070 |
(31,730 ) |
| Danaher Corp. |
90 |
01/17/25 |
USD |
240.00 |
USD |
2,066 |
(10,575 ) |
| Disc Medicine, Inc. |
153 |
01/17/25 |
USD |
70.00 |
USD |
970 |
(74,970 ) |
| Edgewise Therapeutics, Inc. |
437 |
01/17/25 |
USD |
35.00 |
USD |
1,167 |
(28,405 ) |
| Edwards Lifesciences Corp. |
286 |
01/17/25 |
USD |
70.00 |
USD |
2,117 |
(155,870 ) |
| Encompass Health Corp. |
242 |
01/17/25 |
USD |
100.00 |
USD |
2,235 |
(61,105 ) |
| Exact Sciences Corp. |
466 |
01/17/25 |
USD |
55.00 |
USD |
2,618 |
(172,420 ) |
| Exelixis, Inc. |
547 |
01/17/25 |
USD |
37.00 |
USD |
1,822 |
(27,350 ) |
| GE HealthCare Technologies, Inc. |
199 |
01/17/25 |
USD |
87.50 |
USD |
1,556 |
(1,493 ) |
| Gilead Sciences, Inc. |
269 |
01/17/25 |
USD |
97.50 |
USD |
2,485 |
(13,450 ) |
| Description |
Number of Contracts |
Expiration Date |
Exercise Price |
Notional Amount (000) |
Value | ||
| Call (continued) |
|
|
|
|
|
|
|
| Glaukos Corp. |
71 |
01/17/25 |
USD |
150.00 |
USD |
1,065 |
$ (44,730
) |
| Guardant Health, Inc. |
595 |
01/17/25 |
USD |
33.46 |
USD |
1,818 |
(42,769 ) |
| Halozyme Therapeutics, Inc. |
288 |
01/17/25 |
USD |
50.00 |
USD |
1,377 |
(24,480 ) |
| Inari Medical, Inc. |
140 |
01/17/25 |
USD |
65.00 |
USD |
715 |
(27,300 ) |
| Incyte Corp. |
364 |
01/17/25 |
USD |
77.50 |
USD |
2,514 |
(100,100 ) |
| Insmed, Inc. |
481 |
01/17/25 |
USD |
77.50 |
USD |
3,321 |
(51,707 ) |
| Inspire Medical Systems, Inc. |
142 |
01/17/25 |
USD |
200.00 |
USD |
2,632 |
(49,345 ) |
| Insulet Corp. |
156 |
01/17/25 |
USD |
280.00 |
USD |
4,073 |
(21,060 ) |
| Intuitive Surgical, Inc. |
122 |
01/17/25 |
USD |
540.00 |
USD |
6,368 |
(89,060 ) |
| Ionis Pharmaceuticals, Inc. |
554 |
01/17/25 |
USD |
40.00 |
USD |
1,937 |
(9,695 ) |
| Merus NV |
625 |
01/17/25 |
USD |
55.00 |
USD |
2,628 |
(25,000 ) |
| Mettler-Toledo International, Inc. |
51 |
01/17/25 |
USD |
1,320.00 |
USD |
6,241 |
(25,755 ) |
| Molina Healthcare, Inc. |
118 |
01/17/25 |
USD |
330.00 |
USD |
3,434 |
(17,405 ) |
| Natera, Inc. |
370 |
01/17/25 |
USD |
165.00 |
USD |
5,857 |
(244,200 ) |
| Neurocrine Biosciences, Inc. |
221 |
01/17/25 |
USD |
130.00 |
USD |
3,017 |
(176,800 ) |
| Novocure Ltd. |
370 |
01/17/25 |
USD |
35.00 |
USD |
1,103 |
(9,250 ) |
| Nurix Therapeutics, Inc. |
448 |
01/17/25 |
USD |
30.00 |
USD |
844 |
(147,840 ) |
| Nuvalent, Inc., Class A |
412 |
01/17/25 |
USD |
100.00 |
USD |
3,225 |
(201,880 ) |
| Penumbra, Inc. |
96 |
01/17/25 |
USD |
250.00 |
USD |
2,280 |
(30,480 ) |
| PTC Therapeutics, Inc. |
377 |
01/17/25 |
USD |
45.00 |
USD |
1,702 |
(115,927 ) |
| QIAGEN NV |
484 |
01/17/25 |
USD |
45.27 |
USD |
2,155 |
(41,563 ) |
| RadNet, Inc. |
211 |
01/17/25 |
USD |
80.00 |
USD |
1,474 |
(8,440 ) |
| Repligen Corp. |
273 |
01/17/25 |
USD |
140.00 |
USD |
3,930 |
(222,495 ) |
| REVOLUTION Medicines, Inc. |
184 |
01/17/25 |
USD |
65.00 |
USD |
805 |
(88,320 ) |
| Rhythm Pharmaceuticals, Inc. |
917 |
01/17/25 |
USD |
60.00 |
USD |
5,133 |
(105,455 ) |
| Rocket Pharmaceuticals, Inc. |
435 |
01/17/25 |
USD |
20.00 |
USD |
547 |
(8,700 ) |
| Sanofi SA, ADR |
1,077 |
01/17/25 |
USD |
52.50 |
USD |
5,194 |
(16,155 ) |
| Scholar Rock Holding Corp. |
370 |
01/17/25 |
USD |
45.00 |
USD |
1,599 |
(84,175 ) |
| Structure Therapeutics, Inc., ADR |
106 |
01/17/25 |
USD |
45.00 |
USD |
287 |
(3,180 ) |
| Stryker Corp. |
78 |
01/17/25 |
USD |
390.00 |
USD |
2,808 |
(975 ) |
| Tarsus Pharmaceuticals, Inc. |
501 |
01/17/25 |
USD |
55.00 |
USD |
2,774 |
(237,975 ) |
| Twist Bioscience Corp. |
225 |
01/17/25 |
USD |
57.50 |
USD |
1,046 |
(64,125 ) |
| Ultragenyx Pharmaceutical, Inc. |
386 |
01/17/25 |
USD |
55.00 |
USD |
1,624 |
(27,020 ) |
| United Therapeutics Corp. |
91 |
01/17/25 |
USD |
400.00 |
USD |
3,211 |
(21,840 ) |
| Vaxcyte, Inc. |
204 |
01/17/25 |
USD |
105.00 |
USD |
1,670 |
(15,300 ) |
| Veeva Systems, Inc., Class A |
450 |
01/17/25 |
USD |
260.00 |
USD |
9,461 |
(11,250 ) |
| Vertex Pharmaceuticals, Inc. |
16 |
01/17/25 |
USD |
490.00 |
USD |
644 |
(2,240 ) |
| Viking Therapeutics, Inc. |
134 |
01/17/25 |
USD |
55.00 |
USD |
539 |
(6,365 ) |
| Waters Corp. |
155 |
01/17/25 |
USD |
397.49 |
USD |
5,750 |
(24,988 ) |
| WaVe Life Sciences Ltd. |
183 |
01/17/25 |
USD |
17.50 |
USD |
226 |
(3,660 ) |
| West Pharmaceutical Services, Inc. |
188 |
01/17/25 |
USD |
340.00 |
USD |
6,158 |
(56,400 ) |
| Xenon Pharmaceuticals, Inc. |
219 |
01/17/25 |
USD |
42.50 |
USD |
858 |
(21,900 ) |
| Abbott Laboratories |
187 |
01/24/25 |
USD |
118.00 |
USD |
2,115 |
(14,493 ) |
| Align Technology, Inc. |
115 |
01/24/25 |
USD |
235.00 |
USD |
2,398 |
(14,088 ) |
| Dexcom, Inc. |
138 |
01/24/25 |
USD |
81.00 |
USD |
1,073 |
(37,260 ) |
| Gilead Sciences, Inc. |
25 |
01/24/25 |
USD |
93.00 |
USD |
231 |
(4,850 ) |
| Sarepta Therapeutics, Inc. |
182 |
01/24/25 |
USD |
130.00 |
USD |
2,213 |
(65,975 ) |
| Boston Scientific Corp. |
528 |
01/31/25 |
USD |
90.00 |
USD |
4,716 |
(175,560 ) |
| Danaher Corp. |
83 |
01/31/25 |
USD |
245.00 |
USD |
1,905 |
(18,260 ) |
| Intuitive Surgical, Inc. |
79 |
01/31/25 |
USD |
540.00 |
USD |
4,123 |
(124,425 ) |
| Vertex Pharmaceuticals, Inc. |
14 |
01/31/25 |
USD |
420.00 |
USD |
564 |
(7,560 ) |
| Becton Dickinson & Co. |
69 |
02/05/25 |
USD |
233.94 |
USD |
1,565 |
(17,407 ) |
| Boston Scientific Corp. |
528 |
02/07/25 |
USD |
93.00 |
USD |
4,716 |
(81,840 ) |
| Penumbra, Inc. |
104 |
02/07/25 |
USD |
248.00 |
USD |
2,470 |
(81,275 ) |
| Halozyme Therapeutics, Inc. |
261 |
02/10/25 |
USD |
50.25 |
USD |
1,248 |
(44,934 ) |
| Alkermes PLC |
305 |
02/21/25 |
USD |
32.00 |
USD |
877 |
(46,512 ) |
| Alnylam Pharmaceuticals, Inc. |
479 |
02/21/25 |
USD |
259.00 |
USD |
11,271 |
(230,947 ) |
| Argenx SE, ADR |
174 |
02/21/25 |
USD |
640.00 |
USD |
10,701 |
(339,300 ) |
| Axsome Therapeutics, Inc. |
63 |
02/21/25 |
USD |
105.00 |
USD |
533 |
(9,135 ) |
| BioMarin Pharmaceutical, Inc. |
757 |
02/21/25 |
USD |
71.25 |
USD |
4,976 |
(98,359 ) |
| BioNTech SE, ADR |
98 |
02/21/25 |
USD |
125.00 |
USD |
1,117 |
(38,220 ) |
| Bio-Techne Corp. |
587 |
02/21/25 |
USD |
75.00 |
USD |
4,228 |
(193,710 ) |
| Description |
Number of Contracts |
Expiration Date |
Exercise Price |
Notional Amount (000) |
Value | ||
| Call (continued) |
|
|
|
|
|
|
|
| Bridgebio Pharma, Inc. |
281 |
02/21/25 |
USD |
30.00 |
USD |
771 |
$ (40,043
) |
| Edwards Lifesciences Corp. |
76 |
02/21/25 |
USD |
82.50 |
USD |
563 |
(8,550 ) |
| Encompass Health Corp. |
285 |
02/21/25 |
USD |
95.00 |
USD |
2,632 |
(90,487 ) |
| Exact Sciences Corp. |
398 |
02/21/25 |
USD |
70.00 |
USD |
2,236 |
(51,740 ) |
| Exelixis, Inc. |
556 |
02/21/25 |
USD |
37.00 |
USD |
1,851 |
(37,530 ) |
| Glaukos Corp. |
71 |
02/21/25 |
USD |
155.00 |
USD |
1,065 |
(54,315 ) |
| Guardant Health, Inc. |
595 |
02/21/25 |
USD |
34.00 |
USD |
1,818 |
(84,787 ) |
| Inari Medical, Inc. |
140 |
02/21/25 |
USD |
65.00 |
USD |
715 |
(19,600 ) |
| Insmed, Inc. |
481 |
02/21/25 |
USD |
77.50 |
USD |
3,321 |
(122,655 ) |
| Inspire Medical Systems, Inc. |
143 |
02/21/25 |
USD |
220.00 |
USD |
2,651 |
(88,660 ) |
| Insulet Corp. |
156 |
02/21/25 |
USD |
280.00 |
USD |
4,073 |
(83,460 ) |
| Intuitive Surgical, Inc. |
166 |
02/21/25 |
USD |
555.00 |
USD |
8,665 |
(206,670 ) |
| Mettler-Toledo International, Inc. |
54 |
02/21/25 |
USD |
1,330.00 |
USD |
6,608 |
(91,800 ) |
| Neurocrine Biosciences, Inc. |
345 |
02/21/25 |
USD |
145.00 |
USD |
4,709 |
(81,075 ) |
| Nuvalent, Inc., Class A |
326 |
02/21/25 |
USD |
90.00 |
USD |
2,552 |
(37,490 ) |
| PTC Therapeutics, Inc. |
373 |
02/21/25 |
USD |
45.00 |
USD |
1,684 |
(139,875 ) |
| QIAGEN NV |
484 |
02/21/25 |
USD |
45.27 |
USD |
2,155 |
(85,715 ) |
| Repligen Corp. |
426 |
02/21/25 |
USD |
165.00 |
USD |
6,132 |
(173,595 ) |
| REVOLUTION Medicines, Inc. |
29 |
02/21/25 |
USD |
44.00 |
USD |
127 |
(8,918 ) |
| Rhythm Pharmaceuticals, Inc. |
1,097 |
02/21/25 |
USD |
60.00 |
USD |
6,141 |
(315,387 ) |
| STERIS PLC |
152 |
02/21/25 |
USD |
220.00 |
USD |
3,125 |
(49,020 ) |
| Structure Therapeutics, Inc., ADR |
106 |
02/21/25 |
USD |
35.00 |
USD |
287 |
(6,625 ) |
| Stryker Corp. |
83 |
02/21/25 |
USD |
370.00 |
USD |
2,988 |
(71,380 ) |
| Twist Bioscience Corp. |
217 |
02/21/25 |
USD |
50.00 |
USD |
1,008 |
(81,375 ) |
| Waters Corp. |
257 |
02/21/25 |
USD |
380.00 |
USD |
9,534 |
(371,365 ) |
| WaVe Life Sciences Ltd. |
184 |
02/21/25 |
USD |
15.51 |
USD |
228 |
(8,778 ) |
| West Pharmaceutical Services, Inc. |
328 |
02/21/25 |
USD |
350.00 |
USD |
10,744 |
(309,960 ) |
| Xenon Pharmaceuticals, Inc. |
645 |
02/21/25 |
USD |
44.50 |
USD |
2,528 |
(215,099 ) |
| |
|
|
|
|
|
|
$ (8,690,835 ) |
| Description |
Counterparty |
Number of Contracts |
Expiration Date |
Exercise Price |
Notional Amount (000) |
Value | ||
| Call |
|
|
|
|
|
|
|
|
| Denali Therapeutics, Inc. |
Citibank N.A. |
78,300 |
01/06/25 |
USD |
29.80 |
USD |
1,596 |
$ (46
) |
| Abbisko Cayman Ltd. |
Morgan Stanley & Co. International PLC |
1,250,000 |
01/09/25 |
HKD |
5.11 |
HKD |
5,715 |
(7,883 ) |
| Everest Medicines Ltd. |
Goldman Sachs International |
498,000 |
01/09/25 |
HKD |
36.93 |
HKD |
23,992 |
(741,576 ) |
| Zealand Pharma A/S |
Bank of America N.A. |
25,300 |
01/09/25 |
DKK |
874.12 |
DKK |
18,118 |
(19 ) |
| Abbisko Cayman Ltd. |
JPMorgan Chase Bank N.A. |
1,241,000 |
01/16/25 |
HKD |
5.32 |
HKD |
5,673 |
(9,709 ) |
| Everest Medicines Ltd. |
Morgan Stanley & Co. International PLC |
498,000 |
01/16/25 |
HKD |
50.94 |
HKD |
23,992 |
(168,817 ) |
| Zealand Pharma A/S |
Bank of America N.A. |
3,700 |
01/16/25 |
DKK |
753.50 |
DKK |
2,650 |
(5,028 ) |
| Sonova Holding AG, Registered Shares |
UBS AG |
18,200 |
01/22/25 |
CHF |
301.29 |
CHF |
5,401 |
(76,762 ) |
| Lonza Group AG, Registered Shares |
Bank of America N.A. |
8,100 |
01/28/25 |
CHF |
549.23 |
CHF |
4,340 |
(81,904 ) |
| Sonova Holding AG, Registered Shares |
BNP Paribas SA |
13,400 |
01/28/25 |
CHF |
299.70 |
CHF |
3,970 |
(77,694 ) |
| Sartorius AG, Preference Shares |
BNP Paribas SA |
15,600 |
02/05/25 |
EUR |
225.45 |
EUR |
3,357 |
(135,716 ) |
| United Therapeutics Corp. |
Goldman Sachs International |
10,200 |
02/05/25 |
USD |
369.88 |
USD |
3,599 |
(83,795 ) |
| Abbisko Cayman Ltd. |
JPMorgan Chase Bank N.A. |
830,000 |
02/06/25 |
HKD |
4.59 |
HKD |
3,818 |
(44,936 ) |
| Gerresheimer AG |
Bank of America N.A. |
16,300 |
02/06/25 |
EUR |
76.86 |
EUR |
1,157 |
(16,740 ) |
| Roche Holding AG |
BNP Paribas SA |
38,400 |
02/06/25 |
CHF |
253.66 |
CHF |
9,811 |
(299,510 ) |
| |
|
|
|
|
|
|
|
$ (1,750,135 ) |
| Description |
Premiums Paid |
Premiums Received |
Unrealized Appreciation |
Unrealized Depreciation |
Value |
| Options Written |
$ N/A
|
$ (15,891,589
) |
$ 7,178,894
|
$ (1,728,275
) |
$ (10,440,970
) |
| |
Commodity Contracts |
Credit Contracts |
Equity Contracts |
Foreign Currency Exchange Contracts |
Interest Rate Contracts |
Other Contracts |
Total |
| Liabilities — Derivative Financial Instruments |
|
|
|
|
|
|
|
| Options written Options written at value |
$ — |
$ — |
$ 10,440,970 |
$ — |
$ — |
$ — |
$ 10,440,970 |
| |
Commodity Contracts |
Credit Contracts |
Equity Contracts |
Foreign Currency Exchange Contracts |
Interest Rate Contracts |
Other Contracts |
Total |
| Net Realized Gain (Loss) from: |
|
|
|
|
|
|
|
| Forward foreign currency exchange contracts |
$ —
|
$ —
|
$ —
|
$ (3,753,243
) |
$ —
|
$ —
|
$ (3,753,243
) |
| Options written |
— |
— |
(4,293,260 ) |
— |
— |
— |
(4,293,260 ) |
| |
$ — |
$ — |
$ (4,293,260 ) |
$ (3,753,243 ) |
$ — |
$ — |
$ (8,046,503 ) |
| Net Change in Unrealized Appreciation (Depreciation) on: |
|
|
|
|
|
|
|
| Forward foreign currency exchange contracts |
$ —
|
$ —
|
$ —
|
$ (1,429,095
) |
$ —
|
$ —
|
$ (1,429,095
) |
| Options written |
— |
— |
22,155,749 |
— |
— |
— |
22,155,749 |
| |
$ — |
$ — |
$ 22,155,749 |
$ (1,429,095 ) |
$ — |
$ — |
$ 20,726,654 |
| Forward foreign currency exchange contracts: |
|
| Average amounts purchased — in USD |
$—
(a) |
| Average amounts sold — in USD |
6,835,182 |
| Options: |
|
| Average value of option contracts written |
16,850,477 |
| (a) |
Derivative financial instrument not held at any quarter-end. The risk exposure table serves as an
indicator of activity during the period. |
| |
Assets |
Liabilities |
| Derivative Financial Instruments |
|
|
| Options |
$ — |
$ 10,440,970 |
| Total derivative assets and liabilities in the Statements of Assets and Liabilities |
— |
10,440,970 |
| Derivatives not subject to a Master Netting Agreement or similar agreement (“MNA”) |
— |
(8,690,835 ) |
| Total derivative assets and liabilities subject to an MNA |
$ — |
$ 1,750,135 |
| Counterparty |
Derivative Liabilities Subject to an MNA by Counterparty |
Derivatives Available for Offset(a)
|
Non-Cash Collateral Pledged(b)
|
Cash Collateral Pledged(b)
|
Net Amount of Derivative Liabilities(c)
|
| Bank of America N.A. |
$ 103,691
|
$ —
|
$ —
|
$ —
|
$ 103,691
|
| BNP Paribas SA |
512,920 |
— |
(512,920 ) |
— |
— |
| Citibank N.A. |
46 |
— |
(46 ) |
— |
— |
| Goldman Sachs International |
825,371 |
— |
(825,371 ) |
— |
— |
| JPMorgan Chase Bank N.A. |
54,645 |
— |
— |
— |
54,645 |
| Counterparty |
Derivative Liabilities Subject to an MNA by Counterparty |
Derivatives Available for Offset(a) |
Non-Cash Collateral Pledged(b) |
Cash Collateral Pledged(b) |
Net Amount of Derivative Liabilities(c) |
| Morgan Stanley & Co. International PLC |
$ 176,700
|
$ —
|
$ —
|
$ —
|
$ 176,700
|
| UBS AG |
76,762 |
— |
— |
— |
76,762 |
| |
$ 1,750,135 |
$ — |
$ (1,338,337 ) |
$ — |
$ 411,798 |
| (a) |
The amount of derivatives available for offset is limited to the amount of derivative assets and/or liabilities that are subject to an MNA. |
| (b) |
Excess of collateral received/pledged, if any, from the individual counterparty is not shown for financial reporting purposes. |
| (c) |
Net amount represents the net amount payable due to the counterparty in the event of default. Net amount may be offset further by the options written
receivable/payable on the Statements of Assets and Liabilities. |
| |
Level 1 |
Level 2 |
Level 3 |
Total |
| Assets |
|
|
|
|
| Investments |
|
|
|
|
| Long-Term Investments |
|
|
|
|
| Common Stocks |
|
|
|
|
| Biotechnology |
$ 625,307,149
|
$ 47,865,850
|
$ 8,818,869
|
$ 681,991,868 |
| Capital Markets |
5,716,883 |
— |
— |
5,716,883 |
| Health Care Equipment & Supplies |
325,562,183 |
32,302,016 |
1,161,485 |
359,025,684 |
| Health Care Providers & Services |
59,798,733 |
— |
— |
59,798,733 |
| Health Care Technology |
31,811,876 |
— |
— |
31,811,876 |
| Life Sciences Tools & Services |
251,732,576 |
18,731,634 |
— |
270,464,210 |
| Pharmaceuticals |
39,416,428 |
40,991,423 |
— |
80,407,851 |
| Corporate Bonds |
— |
— |
2,185,644 |
2,185,644 |
| Other Interests |
— |
— |
3,207,232 |
3,207,232 |
| Preferred Securities |
|
|
|
|
| Preferred Stocks |
— |
10,878,114 |
118,719,968 |
129,598,082 |
| Rights |
— |
— |
346,386 |
346,386 |
| Warrants |
16,132 |
— |
217,359 |
233,491 |
| Short-Term Securities |
|
|
|
|
| Money Market Funds |
61,349,683 |
— |
— |
61,349,683 |
| |
$1,400,711,643 |
$150,769,037 |
$134,656,943 |
$1,686,137,623 |
| Derivative Financial Instruments(a)
|
|
|
|
|
| Liabilities |
|
|
|
|
| Equity Contracts |
$ (7,775,858 ) |
$ (2,665,112 ) |
$ — |
$ (10,440,970 ) |
| (a) |
Derivative financial instruments are options written. Options written are shown at
value. |
| |
Common Stocks |
Corporate Bonds |
Other Interests |
Preferred Stocks |
Rights |
Warrants |
Total |
| Assets |
|
|
|
|
|
|
|
| Opening balance, as of December 31, 2023 |
$ —
|
$ —
|
$ 4,664,318
|
$ 143,543,684
|
$ 268,290
|
$ —
|
$ 148,476,292
|
| Transfers into Level 3 |
— |
— |
— |
— |
3,152 |
— |
3,152 |
| Transfers out of Level 3 |
— |
— |
— |
— |
— |
— |
— |
| Accrued discounts/premiums |
— |
— |
— |
— |
— |
— |
— |
| Net realized gain (loss) |
— |
— |
— |
— |
4,394 |
— |
4,394 |
| Net change in unrealized appreciation (depreciation)(a)(b) |
680,354 |
319,194 |
(1,457,086
) |
(17,801,121
) |
(51,179
) |
217,359 |
(18,092,479 ) |
| |
Common Stocks |
Corporate Bonds |
Other Interests |
Preferred Stocks |
Rights |
Warrants |
Total |
| Purchases |
$ 9,300,000
|
$ 1,866,450 |
$ — |
$ — |
$ 126,123 |
$ — |
$ 11,292,573
|
| Sales |
— |
— |
— |
(7,022,595 ) |
(4,394 ) |
— |
(7,026,989
) |
| Closing balance, as of December 31, 2024 |
$ 9,980,354 |
$ 2,185,644 |
$ 3,207,232 |
$ 118,719,968 |
$ 346,386 |
$ 217,359 |
$ 134,656,943 |
| Net change in unrealized appreciation (depreciation) on investments still held at December 31, 2024(b) |
$ 680,354 |
$ 319,194 |
$ (1,457,086 ) |
$ (19,283,508 ) |
$ (51,179 ) |
$ 217,359 |
$ (19,574,866 ) |
| (a) |
Included in the related net change in unrealized appreciation (depreciation) in the Statements of Operations. |
| (b) |
Any difference between net change in unrealized appreciation (depreciation) and net change in unrealized appreciation (depreciation) on investments still held at
December 31, 2024 is generally due to investments no longer held or categorized as
Level 3 at period end. |
| |
Value |
Valuation Approach |
Unobservable Inputs |
Range of Unobservable Inputs Utilized(a) |
Weighted Average of Unobservable Inputs Based on Fair Value |
| Assets |
|
|
|
|
|
| Preferred Stocks |
$118,719,968
|
Market |
Revenue Multiple |
1.13x - 8.86x |
3.88x |
| |
|
|
Volatility |
50% - 95% |
70% |
| |
|
|
Time to Exit |
1.0 - 4.0 years |
2.9 years |
| |
|
|
Market Adjustment Multiple |
0.50x - 1.80x |
0.94x |
| |
|
Income |
Discount Rate |
5% |
— |
| |
|
|
|
|
|
| Common Stocks |
9,980,354 |
Market |
Volatility |
60% - 80% |
78% |
| |
|
|
Time to Exit |
1.5 - 3.0 years |
2.8 years |
| |
|
|
Market Adjustment Multiple |
0.85x - 1.10x |
1.07x |
| |
|
|
|
|
|
| Corporate Bonds |
2,185,644 |
Market |
Revenue Multiple |
1.13x - 1.65x |
1.44x |
| |
|
|
Volatility |
80% - 95% |
86% |
| |
|
|
Time to Exit |
1.0- 3.0 years |
2.2 years |
| |
|
|
|
|
|
| Other Interests |
3,207,232 |
Income |
Discount Rate |
5% - 5% |
5% |
| |
|
|
|
|
|
| Rights |
346,386 |
Income |
Discount Rate |
4% - 5% |
4% |
| |
|
|
|
|
|
| Warrants |
217,359 |
Market |
Volatility |
60% |
— |
| |
|
|
Time to Exit |
1.5 years |
— |
| |
|
|
Market Adjustment Multiple |
0.85x |
— |
| |
|
|
|
|
|
| |
$134,656,943 |
|
|
|
|
| (a) |
A
significant change in unobservable input could result in a correlated or inverse change in value. |
| Security |
|
Shares |
Value |
| Common Stocks | |||
| Biotechnology — 25.8% |
| ||
| 4D Molecular Therapeutics,
Inc.(a) |
|
11,778 |
$ 65,603
|
| AbbVie, Inc.(b) |
|
141,396 |
25,126,069 |
| AC Immune SA(a) |
|
62,903 |
169,838 |
| Allogene Therapeutics, Inc.(a) |
|
108,101 |
230,255 |
| Alnylam Pharmaceuticals, Inc.(a)
|
|
35,881 |
8,443,158 |
| Amgen, Inc.(b) |
|
52,296 |
13,630,429 |
| Arcellx, Inc.(a) |
|
6,764 |
518,731 |
| Argenx SE, ADR(a) |
|
16,263 |
10,001,745 |
| Ascendis Pharma A/S, ADR(a)
|
|
9,459 |
1,302,221 |
| Autolus Therapeutics PLC, ADR(a) |
|
64,258 |
151,006 |
| Avidity Biosciences, Inc.(a)
|
|
17,918 |
521,055 |
| Beam Therapeutics, Inc.(a) |
|
20,739 |
514,327 |
| BeiGene Ltd., ADR(a) |
|
6,675 |
1,232,939 |
| Biogen, Inc.(a) |
|
32,751 |
5,008,283 |
| Biohaven Ltd.(a) |
|
24,215 |
904,430 |
| BioMarin Pharmaceutical, Inc.(a) |
|
21,076 |
1,385,325 |
| BioNTech SE, ADR(a) |
|
7,725 |
880,264 |
| Blueprint Medicines Corp.(a) |
|
26,672 |
2,326,332 |
| Bridgebio Pharma, Inc.(a) |
|
16,735 |
459,208 |
| CG oncology, Inc.(a) |
|
5,223 |
149,796 |
| Denali Therapeutics, Inc.(a)
|
|
35,343 |
720,290 |
| Disc Medicine, Inc.(a) |
|
7,440 |
471,696 |
| Dyne Therapeutics, Inc.(a) |
|
24,506 |
577,361 |
| Exact Sciences Corp.(a) |
|
31,331 |
1,760,489 |
| Gilead Sciences, Inc. |
|
149,750 |
13,832,408 |
| Immatics NV(a) |
|
21,538 |
153,135 |
| Incyte Corp.(a) |
|
15,306 |
1,057,185 |
| Insmed, Inc.(a) |
|
45,410 |
3,135,106 |
| Ionis Pharmaceuticals, Inc.(a)
|
|
18,725 |
654,626 |
| Legend Biotech Corp., ADR(a) |
|
10,574 |
344,078 |
| Merus NV(a) |
|
22,655 |
952,643 |
| MoonLake Immunotherapeutics(a)(c) |
|
8,382 |
453,885 |
| Natera, Inc.(a) |
|
27,665 |
4,379,370 |
| Neurocrine Biosciences, Inc.(a) |
|
20,208 |
2,758,392 |
| Neurogene, Inc.(a) |
|
19,342 |
442,158 |
| Nurix Therapeutics, Inc.(a) |
|
45,062 |
848,968 |
| Nuvalent, Inc., Class A(a) |
|
28,266 |
2,212,663 |
| Protagonist Therapeutics, Inc.(a) |
|
19,831 |
765,477 |
| PTC Therapeutics, Inc.(a) |
|
19,817 |
894,539 |
| Regeneron Pharmaceuticals, Inc.(a) |
|
7,337 |
5,226,365 |
| REGENXBIO, Inc.(a) |
|
18,875 |
145,904 |
| REVOLUTION Medicines, Inc.(a) |
|
10,844 |
474,317 |
| Rhythm Pharmaceuticals, Inc.(a)
|
|
49,466 |
2,769,107 |
| Rocket Pharmaceuticals, Inc.(a) |
|
18,343 |
230,572 |
| Roivant Sciences Ltd.(a) |
|
57,525 |
680,521 |
| Sagimet Biosciences, Inc., Series A(a) |
|
21,965 |
98,843 |
| Sarepta Therapeutics, Inc.(a)
|
|
34,288 |
4,169,078 |
| Scholar Rock Holding Corp.(a) |
|
17,280 |
746,842 |
| Stoke Therapeutics, Inc.(a)
|
|
70,495 |
777,560 |
| TScan Therapeutics, Inc.(a) |
|
49,480 |
150,419 |
| Ultragenyx Pharmaceutical,
Inc.(a) |
|
14,268 |
600,255 |
| Vaxcyte, Inc.(a) |
|
15,795 |
1,292,979 |
| Vertex Pharmaceuticals, Inc.(a)
|
|
28,074 |
11,305,400 |
| Viking Therapeutics, Inc.(a) |
|
9,142 |
367,874 |
| Voyager Therapeutics, Inc.(a)
|
|
32,205 |
182,602 |
| Xenon Pharmaceuticals, Inc.(a) |
|
35,726 |
1,400,459 |
| Zealand Pharma A/S(a) |
|
8,499 |
845,438 |
| |
|
|
140,900,018 |
| Security |
|
Shares |
Value |
| Capital Markets — 0.1% |
| ||
| Helix Acquisition Corp. II, Class A(a) |
|
61,530 |
$ 646,065 |
| Health Care Equipment & Supplies — 29.6% |
| ||
| Abbott Laboratories(b) |
|
191,997 |
21,716,781 |
| Alcon AG |
|
32,610 |
2,768,263 |
| Align Technology, Inc.(a) |
|
8,170 |
1,703,527 |
| Becton Dickinson & Co. |
|
42,696 |
9,686,442 |
| Boston Scientific Corp.(a) |
|
442,329 |
39,508,826 |
| Cooper Cos., Inc.(a) |
|
46,363 |
4,262,151 |
| Dexcom, Inc.(a) |
|
58,668 |
4,562,610 |
| Edwards Lifesciences Corp.(a)
|
|
101,760 |
7,533,293 |
| GE HealthCare Technologies, Inc.(a) |
|
75,498 |
5,902,434 |
| Glaukos Corp.(a) |
|
14,615 |
2,191,373 |
| IDEXX Laboratories, Inc.(a) |
|
6,691 |
2,766,327 |
| Inari Medical, Inc.(a) |
|
7,005 |
357,605 |
| Inspire Medical Systems, Inc.(a) |
|
5,782 |
1,071,867 |
| Intuitive Surgical, Inc.(a)
|
|
53,465 |
27,906,591 |
| Medtronic PLC |
|
71,671 |
5,725,079 |
| Novocure Ltd.(a) |
|
43,718 |
1,302,796 |
| Nucleix Ltd., (Acquired 04/10/24, Cost:
$200,000)(a)(d)(e)(f) |
|
200 |
178,690 |
| Nyxoah SA(a) |
|
29,870 |
238,960 |
| Orchestra BioMed Holdings, Inc.(a)(c) |
|
18,076 |
72,304 |
| Penumbra, Inc.(a) |
|
12,105 |
2,874,695 |
| STERIS PLC |
|
9,642 |
1,982,010 |
| Stryker Corp. |
|
48,820 |
17,577,641 |
| |
|
|
161,890,265 |
| Health Care Providers & Services — 9.9% |
| ||
| Cencora, Inc. |
|
24,158 |
5,427,819 |
| Cigna Group |
|
10,161 |
2,805,859 |
| Elevance Health, Inc. |
|
14,908 |
5,499,561 |
| Guardant Health, Inc.(a) |
|
24,415 |
745,878 |
| HCA Healthcare, Inc. |
|
6,153 |
1,846,823 |
| Humana, Inc. |
|
18,525 |
4,699,978 |
| Labcorp Holdings, Inc. |
|
6,745 |
1,546,763 |
| McKesson Corp. |
|
9,738 |
5,549,784 |
| Quest Diagnostics, Inc. |
|
11,479 |
1,731,722 |
| UnitedHealth Group, Inc.(b)
|
|
47,333 |
23,943,871 |
| |
|
|
53,798,058 |
| Life Sciences Tools & Services — 9.7% |
| ||
| Agilent Technologies, Inc. |
|
15,171 |
2,038,072 |
| Bio-Techne Corp. |
|
16,718 |
1,204,198 |
| Danaher Corp. |
|
72,831 |
16,718,356 |
| Illumina, Inc.(a) |
|
12,070 |
1,612,914 |
| IQVIA Holdings, Inc.(a) |
|
6,738 |
1,324,084 |
| Mettler-Toledo International,
Inc.(a) |
|
1,170 |
1,431,706 |
| Repligen Corp.(a) |
|
13,935 |
2,005,804 |
| Thermo Fisher Scientific, Inc. |
|
30,324 |
15,775,454 |
| Waters Corp.(a) |
|
20,065 |
7,443,714 |
| West Pharmaceutical Services, Inc. |
|
10,207 |
3,343,405 |
| |
|
|
52,897,707 |
| Pharmaceuticals — 20.0% |
| ||
| AstraZeneca PLC |
|
31,854 |
4,153,112 |
| Bristol-Myers Squibb Co. |
|
143,710 |
8,128,238 |
| Daiichi Sankyo Co. Ltd. |
|
57,800 |
1,581,595 |
| Edgewise Therapeutics, Inc.(a)
|
|
8,490 |
226,683 |
| Eli Lilly & Co.(b)(g) |
|
61,764 |
47,681,808 |
| Johnson & Johnson |
|
83,583 |
12,087,773 |
| Merck & Co., Inc.(b) |
|
83,142 |
8,270,966 |
| Neumora Therapeutics, Inc.(a)
|
|
24,235 |
256,891 |
| Security |
|
Shares |
Value |
| Pharmaceuticals (continued) |
| ||
| Pfizer, Inc. |
|
219,920 |
$ 5,834,478
|
| Roche Holding AG |
|
14,080 |
3,936,861 |
| Sanofi SA |
|
44,338 |
4,310,131 |
| Septerna, Inc.(a) |
|
6,451 |
147,728 |
| Structure Therapeutics, Inc., ADR(a)(c) |
|
14,399 |
390,501 |
| Teva Pharmaceutical Industries Ltd.,
ADR(a) |
|
182,264 |
4,017,099 |
| UCB SA |
|
8,455 |
1,683,083 |
| WaVe Life Sciences Ltd.(a) |
|
19,104 |
236,316 |
| Zoetis, Inc., Class A |
|
39,924 |
6,504,817 |
| |
|
|
109,448,080 |
| Total Common Stocks — 95.1% (Cost: $347,519,099) |
519,580,193 | ||
| |
|
Par (000) |
|
| Corporate Bonds | |||
| Health Care Equipment & Supplies — 0.0% | |||
| Exo Imaging, Inc., (Acquired 07/24/24, Cost: $28,863), 8.00%, 08/14/25(e)(f) |
$ |
29 |
39,903 |
| Software — 0.0% | |||
| Carbon Health Technologies, Inc., Series D2, (Acquired 02/27/24, Cost: $65,000), 12.00%,
02/28/26(e)(f) |
|
— (h) |
68,935 |
| Total Corporate Bonds — 0.0% (Cost: $93,863) |
108,838 | ||
| |
|
Benefical Interest (000) |
|
| Other Interests | |||
| Biotechnology — 0.0% |
| ||
| Affinivax, Inc., (Acquired 08/18/22, Cost: $ —)(e)(f)(i) |
$ |
6 |
60,018 |
| Health Care Providers & Services — 0.0% |
| ||
| Afferent Pharmaceuticals, Inc., (Acquired 09/30/15, Cost: $ —)(e)(f)(i) |
|
190 |
2 |
| Total Other Interests — 0.0% (Cost: $ — ) |
60,020 | ||
| |
|
Shares |
|
| Preferred Securities | |||
| Preferred Stocks — 0.7%(a)(e)(f) | |||
| Biotechnology — 0.4% |
| ||
| Adarx Pharamaceuticals, Inc., Series C, (Acquired
08/02/23, Cost: $440,003) |
|
52,885 |
471,205 |
| Cellarity, Inc., Series B, (Acquired 01/15/21, Cost: $265,002) |
|
44,167 |
88,334 |
| Genesis Therapeutics, Inc., Series B, (Acquired
08/10/23, Cost: $292,001) |
|
57,170 |
332,730 |
| Goldfinch Bio, Inc., Series B, (Acquired 06/26/20, Cost: $224,200) |
|
190,000 |
74,100 |
| Security |
|
Shares |
Value |
| Biotechnology (continued) |
| ||
| Kartos Therapeutics, Inc., Series C, (Acquired
08/22/23, Cost: $485,124) |
|
85,817 |
$ 503,746
|
| Laronde, Inc., Series B, (Acquired 07/28/21, Cost: $590,800) |
|
21,100 |
562,737 |
| |
|
|
2,032,852 |
| Health Care Equipment & Supplies — 0.1% |
| ||
| Exo Imaging, Inc., Series C, (Acquired 06/24/21, Cost:
$595,999) |
|
101,741 |
6,105 |
| Nucleix Ltd., Series AA, (Acquired 03/25/21, Cost: $1,070,001) |
|
367,395 |
778,877 |
| Swift Health Systems, Inc., Series D, (Acquired
08/27/21, Cost: $286,998) |
|
93 |
206 |
| |
|
|
785,188 |
| Health Care Providers & Services — 0.1% |
| ||
| Quanta Dialysis Technologies Ltd., Series D, (Acquired 06/18/21, Cost: $515,759) |
|
4,243,029 |
339,958 |
| Pharmaceuticals — 0.1% |
| ||
| Insitro, Inc., Series C, (Acquired 03/10/21, Cost: $560,000) |
|
30,616 |
259,011 |
| Software — 0.0% |
| ||
| Carbon Health Technologies, Inc., Series D2, (Acquired 02/02/23, Cost: $907,000) |
|
89,892 |
84,499 |
| |
3,501,508 | ||
| Total Preferred Securities — 0.7% (Cost: $6,232,887) |
3,501,508 | ||
| Rights | |||
| Biotechnology(e)
— 0.0% |
| ||
| Korro Bio, Inc., CVR |
|
28,060 |
— |
| Mirati Therapeutics, Inc. CVR |
|
15,747 |
11,653 |
| |
|
|
11,653 |
| Health Care Equipment & Supplies — 0.0% |
| ||
| Abiomed, Inc., CVR(a)(e) |
|
14,359 |
31,016 |
| Total Rights — 0.0% (Cost: $25,669) |
42,669 | ||
| Warrants | |||
| Health Care Equipment & Supplies — 0.0% |
| ||
| Nucleix Ltd., (Acquired 04/10/24, Cost: $—), (Issued
04/10/24, Expires 04/10/34, Strike Price USD
3.35)(a)(e)(f) |
|
238,856 |
33,440 |
| Health Care Providers & Services — 0.0% |
| ||
| CareMax, Inc., (Issued/Exercisable 09/15/20, 1 Share
for 1 Warrant, Expires 08/06/26, Strike Price USD
11.50)(a) |
|
4,201 |
19 |
| Security |
|
Shares |
Value |
| Pharmaceuticals — 0.0% |
| ||
| Nuvation Bio, Inc., (Issued/Exercisable 08/17/20,
1 Share for 1 Warrant, Expires 07/07/27, Strike Price
USD 11.50)(a) |
|
4,050 |
$ 931 |
| Total Warrants — 0.0% (Cost: $14,030) |
34,390 | ||
| Total Long-Term Investments — 95.8% (Cost: $353,885,548) |
523,327,618 | ||
| Short-Term Securities | |||
| Money Market Funds — 4.9% |
| ||
| BlackRock Cash Funds: Institutional, SL Agency Shares, 4.63%(j)(k)(l) |
|
277,571 |
277,709 |
| BlackRock Liquidity Funds, T-Fund, Institutional
Shares, 4.36%(j)(k) |
|
26,275,044 |
26,275,044 |
| Total Short-Term Securities — 4.9% (Cost: $26,552,737) |
26,552,753 | ||
| Total Investments Before Options Written — 100.7% (Cost: $380,438,285) |
549,880,371 | ||
| Options Written — (0.5)% (Premiums Received: $(5,345,930)) |
(2,822,101 ) | ||
| Total Investments, Net of Options Written — 100.2% (Cost: $375,092,355) |
547,058,270 | ||
| Liabilities in Excess of Other Assets — (0.2)% |
(923,006 ) | ||
| Net Assets — 100.0% |
$ 546,135,264 | ||
| (a) |
Non-income producing security. |
| (b) |
All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written. |
| (c) |
All or a portion of this security is on loan. |
| (d) |
Convertible security. |
| (e) |
Security is valued using significant unobservable inputs and is classified as Level 3 in the
fair value hierarchy. |
| (f) |
Restricted security as to resale, excluding 144A securities. The Trust held restricted
securities with a current value of $3,882,496, representing 0.7% of its net assets as of
period end, and an original cost of $6,526,750. |
| (g) |
All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives. |
| (h) |
Rounds to less than 1,000. |
| (i) |
Other interests represent beneficial interests in liquidation trusts and other reorganization
or private entities. |
| (j) |
Affiliate of the Trust. |
| (k) |
Annualized 7-day yield as of period end. |
| (l) |
All or a portion of this security was purchased with the cash collateral from loaned securities. |
| Affiliated Issuer |
Value at 12/31/23 |
Purchases at Cost |
Proceeds from Sales |
Net Realized Gain (Loss) |
Change in Unrealized Appreciation (Depreciation) |
Value at 12/31/24 |
Shares Held at 12/31/24 |
Income |
Capital Gain Distributions from Underlying Funds |
| BlackRock Cash Funds: Institutional, SL Agency Shares |
$ — |
$ 277,965 (a) |
$ — |
$ (272 ) |
$ 16 |
$ 277,709 |
277,571 |
$ 2,935 (b) |
$ — |
| BlackRock Liquidity Funds, T-Fund, Institutional Shares |
31,396,977 |
— |
(5,121,933 )(a) |
— |
— |
26,275,044 |
26,275,044 |
1,061,011 |
— |
| SL Liquidity Series, LLC, Money Market
Series(c) |
— |
463 (a) |
— |
(463 ) |
— |
— |
— |
690
(b) |
— |
| |
|
|
|
$ (735 ) |
$ 16 |
$ 26,552,753 |
|
$ 1,064,636 |
$ — |
| (a) |
Represents net amount purchased (sold). |
| (b) |
All or a portion represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of collateral investment fees, and
other payments to and from borrowers of securities. |
| (c) |
As of period end, the entity is no longer held. |
| Description |
Number of Contracts |
Expiration Date |
Exercise Price |
Notional Amount (000) |
Value | ||
| Call |
|
|
|
|
|
|
|
| Abbott Laboratories |
174 |
01/03/25 |
USD |
117.00 |
USD |
1,968 |
$ (1,914
) |
| Danaher Corp. |
107 |
01/03/25 |
USD |
235.00 |
USD |
2,456 |
(1,873 ) |
| Description |
Number of Contracts |
Expiration Date |
Exercise Price |
Notional Amount (000) |
Value | ||
| Call (continued) |
|
|
|
|
|
|
|
| Humana, Inc. |
4 |
01/03/25 |
USD |
315.00 |
USD |
101 |
$ (600
) |
| Intuitive Surgical, Inc. |
36 |
01/03/25 |
USD |
564.03 |
USD |
1,879 |
(30 ) |
| UnitedHealth Group, Inc. |
161 |
01/03/25 |
USD |
615.00 |
USD |
8,144 |
(27,370 ) |
| Abbott Laboratories |
192 |
01/10/25 |
USD |
117.00 |
USD |
2,172 |
(4,032 ) |
| Amgen, Inc. |
99 |
01/10/25 |
USD |
285.00 |
USD |
2,580 |
(1,980 ) |
| Dexcom, Inc. |
145 |
01/10/25 |
USD |
82.00 |
USD |
1,128 |
(5,800 ) |
| GE HealthCare Technologies, Inc. |
48 |
01/10/25 |
USD |
85.00 |
USD |
375 |
(1,680 ) |
| Gilead Sciences, Inc. |
136 |
01/10/25 |
USD |
95.00 |
USD |
1,256 |
(6,256 ) |
| Medtronic PLC |
68 |
01/10/25 |
USD |
86.00 |
USD |
543 |
(7,820 ) |
| UnitedHealth Group, Inc. |
131 |
01/10/25 |
USD |
585.00 |
USD |
6,627 |
(1,441 ) |
| Abbott Laboratories |
152 |
01/17/25 |
USD |
120.00 |
USD |
1,719 |
(3,724 ) |
| AbbVie, Inc. |
138 |
01/17/25 |
USD |
185.00 |
USD |
2,452 |
(10,557 ) |
| AbbVie, Inc. |
138 |
01/17/25 |
USD |
170.00 |
USD |
2,452 |
(125,235 ) |
| Agilent Technologies, Inc. |
57 |
01/17/25 |
USD |
140.00 |
USD |
766 |
(4,418 ) |
| Align Technology, Inc. |
11 |
01/17/25 |
USD |
250.00 |
USD |
229 |
(220 ) |
| Align Technology, Inc. |
9 |
01/17/25 |
USD |
260.00 |
USD |
188 |
(315 ) |
| Alnylam Pharmaceuticals, Inc. |
69 |
01/17/25 |
USD |
270.00 |
USD |
1,624 |
(15,180 ) |
| Arcellx, Inc. |
25 |
01/17/25 |
USD |
95.00 |
USD |
192 |
(12,250 ) |
| Argenx SE, ADR |
31 |
01/17/25 |
USD |
620.00 |
USD |
1,907 |
(64,325 ) |
| Avidity Biosciences, Inc. |
68 |
01/17/25 |
USD |
35.00 |
USD |
198 |
(2,380 ) |
| Beam Therapeutics, Inc. |
78 |
01/17/25 |
USD |
29.00 |
USD |
193 |
(2,925 ) |
| Becton Dickinson & Co. |
64 |
01/17/25 |
USD |
240.00 |
USD |
1,452 |
(1,920 ) |
| BeiGene Ltd., ADR |
25 |
01/17/25 |
USD |
203.90 |
USD |
462 |
(2,420 ) |
| Biogen, Inc. |
57 |
01/17/25 |
USD |
170.00 |
USD |
872 |
(4,275 ) |
| BioMarin Pharmaceutical, Inc. |
40 |
01/17/25 |
USD |
70.00 |
USD |
263 |
(1,700 ) |
| BioNTech SE, ADR |
14 |
01/17/25 |
USD |
120.00 |
USD |
160 |
(3,605 ) |
| Bio-Techne Corp. |
40 |
01/17/25 |
USD |
75.00 |
USD |
288 |
(11,400 ) |
| Blueprint Medicines Corp. |
51 |
01/17/25 |
USD |
100.00 |
USD |
445 |
(5,100 ) |
| Boston Scientific Corp. |
561 |
01/17/25 |
USD |
92.50 |
USD |
5,011 |
(35,062 ) |
| Bridgebio Pharma, Inc. |
32 |
01/17/25 |
USD |
30.00 |
USD |
88 |
(2,080 ) |
| Cencora, Inc. |
52 |
01/17/25 |
USD |
250.00 |
USD |
1,168 |
(520 ) |
| Cigna Group |
62 |
01/17/25 |
USD |
360.00 |
USD |
1,712 |
(1,550 ) |
| Cooper Cos., Inc. |
176 |
01/17/25 |
USD |
105.00 |
USD |
1,618 |
(16,720 ) |
| Danaher Corp. |
78 |
01/17/25 |
USD |
240.00 |
USD |
1,790 |
(9,165 ) |
| Disc Medicine, Inc. |
28 |
01/17/25 |
USD |
70.00 |
USD |
178 |
(13,720 ) |
| Edgewise Therapeutics, Inc. |
33 |
01/17/25 |
USD |
35.00 |
USD |
88 |
(2,145 ) |
| Edwards Lifesciences Corp. |
232 |
01/17/25 |
USD |
70.00 |
USD |
1,717 |
(126,440 ) |
| Elevance Health, Inc. |
44 |
01/17/25 |
USD |
440.00 |
USD |
1,623 |
(2,420 ) |
| Eli Lilly & Co. |
63 |
01/17/25 |
USD |
780.00 |
USD |
4,864 |
(98,122 ) |
| Exact Sciences Corp. |
36 |
01/17/25 |
USD |
55.00 |
USD |
202 |
(13,320 ) |
| GE HealthCare Technologies, Inc. |
238 |
01/17/25 |
USD |
87.50 |
USD |
1,861 |
(1,785 ) |
| Gilead Sciences, Inc. |
284 |
01/17/25 |
USD |
97.50 |
USD |
2,623 |
(14,200 ) |
| Glaukos Corp. |
42 |
01/17/25 |
USD |
150.00 |
USD |
630 |
(26,460 ) |
| Guardant Health, Inc. |
46 |
01/17/25 |
USD |
33.46 |
USD |
141 |
(3,306 ) |
| HCA Healthcare, Inc. |
24 |
01/17/25 |
USD |
380.00 |
USD |
720 |
(120 ) |
| IDEXX Laboratories, Inc. |
12 |
01/17/25 |
USD |
450.00 |
USD |
496 |
(1,440 ) |
| Inari Medical, Inc. |
13 |
01/17/25 |
USD |
65.00 |
USD |
66 |
(2,535 ) |
| Incyte Corp. |
58 |
01/17/25 |
USD |
77.50 |
USD |
401 |
(15,950 ) |
| Insmed, Inc. |
86 |
01/17/25 |
USD |
77.50 |
USD |
594 |
(9,245 ) |
| Inspire Medical Systems, Inc. |
11 |
01/17/25 |
USD |
200.00 |
USD |
204 |
(3,823 ) |
| Intuitive Surgical, Inc. |
41 |
01/17/25 |
USD |
540.00 |
USD |
2,140 |
(29,930 ) |
| Ionis Pharmaceuticals, Inc. |
71 |
01/17/25 |
USD |
40.00 |
USD |
248 |
(1,243 ) |
| IQVIA Holdings, Inc. |
25 |
01/17/25 |
USD |
210.00 |
USD |
491 |
(2,313 ) |
| Johnson & Johnson |
159 |
01/17/25 |
USD |
160.00 |
USD |
2,299 |
(795 ) |
| Labcorp Holdings, Inc. |
13 |
01/17/25 |
USD |
240.00 |
USD |
298 |
(1,008 ) |
| McKesson Corp. |
46 |
01/17/25 |
USD |
620.00 |
USD |
2,622 |
(7,475 ) |
| Medtronic PLC |
95 |
01/17/25 |
USD |
90.00 |
USD |
759 |
(190 ) |
| Merck & Co., Inc. |
158 |
01/17/25 |
USD |
105.00 |
USD |
1,572 |
(6,557 ) |
| Merus NV |
43 |
01/17/25 |
USD |
55.00 |
USD |
181 |
(1,720 ) |
| Mettler-Toledo International, Inc. |
4 |
01/17/25 |
USD |
1,320.00 |
USD |
489 |
(2,020 ) |
| Natera, Inc. |
105 |
01/17/25 |
USD |
165.00 |
USD |
1,662 |
(69,300 ) |
| Neurocrine Biosciences, Inc. |
22 |
01/17/25 |
USD |
130.00 |
USD |
300 |
(17,600 ) |
| Description |
Number of Contracts |
Expiration Date |
Exercise Price |
Notional Amount (000) |
Value | ||
| Call (continued) |
|
|
|
|
|
|
|
| Novocure Ltd. |
55 |
01/17/25 |
USD |
35.00 |
USD |
164 |
$ (1,375
) |
| Nurix Therapeutics, Inc. |
57 |
01/17/25 |
USD |
30.00 |
USD |
107 |
(18,810 ) |
| Nuvalent, Inc., Class A |
53 |
01/17/25 |
USD |
100.00 |
USD |
415 |
(25,970 ) |
| Penumbra, Inc. |
23 |
01/17/25 |
USD |
250.00 |
USD |
546 |
(7,303 ) |
| Pfizer, Inc. |
428 |
01/17/25 |
USD |
26.00 |
USD |
1,135 |
(37,236 ) |
| PTC Therapeutics, Inc. |
38 |
01/17/25 |
USD |
45.00 |
USD |
172 |
(11,685 ) |
| Quest Diagnostics, Inc. |
43 |
01/17/25 |
USD |
155.00 |
USD |
649 |
(3,763 ) |
| Regeneron Pharmaceuticals, Inc. |
28 |
01/17/25 |
USD |
840.00 |
USD |
1,995 |
(7,910 ) |
| Repligen Corp. |
21 |
01/17/25 |
USD |
140.00 |
USD |
302 |
(17,115 ) |
| REVOLUTION Medicines, Inc. |
27 |
01/17/25 |
USD |
65.00 |
USD |
118 |
(12,960 ) |
| Rhythm Pharmaceuticals, Inc. |
84 |
01/17/25 |
USD |
60.00 |
USD |
470 |
(9,660 ) |
| Rocket Pharmaceuticals, Inc. |
34 |
01/17/25 |
USD |
20.00 |
USD |
43 |
(680 ) |
| Scholar Rock Holding Corp. |
65 |
01/17/25 |
USD |
45.00 |
USD |
281 |
(14,787 ) |
| Structure Therapeutics, Inc., ADR |
27 |
01/17/25 |
USD |
45.00 |
USD |
73 |
(810 ) |
| Stryker Corp. |
126 |
01/17/25 |
USD |
390.00 |
USD |
4,537 |
(1,575 ) |
| Thermo Fisher Scientific, Inc. |
46 |
01/17/25 |
USD |
540.00 |
USD |
2,393 |
(14,145 ) |
| Ultragenyx Pharmaceutical, Inc. |
54 |
01/17/25 |
USD |
55.00 |
USD |
227 |
(3,780 ) |
| Vaxcyte, Inc. |
60 |
01/17/25 |
USD |
105.00 |
USD |
491 |
(4,500 ) |
| Vertex Pharmaceuticals, Inc. |
34 |
01/17/25 |
USD |
490.00 |
USD |
1,369 |
(4,760 ) |
| Viking Therapeutics, Inc. |
34 |
01/17/25 |
USD |
55.00 |
USD |
137 |
(1,615 ) |
| WaVe Life Sciences Ltd. |
36 |
01/17/25 |
USD |
17.50 |
USD |
45 |
(720 ) |
| West Pharmaceutical Services, Inc. |
18 |
01/17/25 |
USD |
340.00 |
USD |
590 |
(5,400 ) |
| Xenon Pharmaceuticals, Inc. |
22 |
01/17/25 |
USD |
42.50 |
USD |
86 |
(2,200 ) |
| Zoetis, Inc., Class A |
151 |
01/17/25 |
USD |
185.00 |
USD |
2,460 |
(3,775 ) |
| Abbott Laboratories |
192 |
01/24/25 |
USD |
118.00 |
USD |
2,172 |
(14,880 ) |
| Align Technology, Inc. |
11 |
01/24/25 |
USD |
235.00 |
USD |
229 |
(1,348 ) |
| Biogen, Inc. |
67 |
01/24/25 |
USD |
150.45 |
USD |
1,025 |
(46,277 ) |
| Dexcom, Inc. |
77 |
01/24/25 |
USD |
81.00 |
USD |
599 |
(20,790 ) |
| Gilead Sciences, Inc. |
149 |
01/24/25 |
USD |
93.00 |
USD |
1,376 |
(28,906 ) |
| Johnson & Johnson |
158 |
01/24/25 |
USD |
150.00 |
USD |
2,285 |
(17,696 ) |
| Merck & Co., Inc. |
157 |
01/24/25 |
USD |
103.00 |
USD |
1,562 |
(28,966 ) |
| Pfizer, Inc. |
407 |
01/24/25 |
USD |
27.00 |
USD |
1,080 |
(15,466 ) |
| Sarepta Therapeutics, Inc. |
51 |
01/24/25 |
USD |
130.00 |
USD |
620 |
(18,487 ) |
| Thermo Fisher Scientific, Inc. |
69 |
01/24/25 |
USD |
550.00 |
USD |
3,590 |
(29,152 ) |
| Amgen, Inc. |
99 |
01/31/25 |
USD |
285.00 |
USD |
2,580 |
(7,623 ) |
| Boston Scientific Corp. |
557 |
01/31/25 |
USD |
90.00 |
USD |
4,975 |
(185,202 ) |
| Danaher Corp. |
91 |
01/31/25 |
USD |
245.00 |
USD |
2,089 |
(20,020 ) |
| Humana, Inc. |
23 |
01/31/25 |
USD |
295.00 |
USD |
584 |
(9,545 ) |
| Intuitive Surgical, Inc. |
61 |
01/31/25 |
USD |
540.00 |
USD |
3,184 |
(96,075 ) |
| Medtronic PLC |
68 |
01/31/25 |
USD |
84.00 |
USD |
543 |
(2,176 ) |
| Vertex Pharmaceuticals, Inc. |
73 |
01/31/25 |
USD |
420.00 |
USD |
2,940 |
(39,420 ) |
| Becton Dickinson & Co. |
91 |
02/05/25 |
USD |
233.94 |
USD |
2,065 |
(22,957 ) |
| Boston Scientific Corp. |
562 |
02/07/25 |
USD |
93.00 |
USD |
5,020 |
(87,110 ) |
| Penumbra, Inc. |
22 |
02/07/25 |
USD |
248.00 |
USD |
522 |
(17,193 ) |
| AbbVie, Inc. |
248 |
02/21/25 |
USD |
185.00 |
USD |
4,407 |
(76,756 ) |
| Alnylam Pharmaceuticals, Inc. |
67 |
02/21/25 |
USD |
259.00 |
USD |
1,577 |
(32,304 ) |
| Argenx SE, ADR |
30 |
02/21/25 |
USD |
640.00 |
USD |
1,845 |
(58,500 ) |
| BioMarin Pharmaceutical, Inc. |
40 |
02/21/25 |
USD |
71.25 |
USD |
263 |
(5,197 ) |
| BioNTech SE, ADR |
15 |
02/21/25 |
USD |
125.00 |
USD |
171 |
(5,850 ) |
| Bio-Techne Corp. |
23 |
02/21/25 |
USD |
75.00 |
USD |
166 |
(7,590 ) |
| Bridgebio Pharma, Inc. |
32 |
02/21/25 |
USD |
30.00 |
USD |
88 |
(4,560 ) |
| Cencora, Inc. |
39 |
02/21/25 |
USD |
240.00 |
USD |
876 |
(9,653 ) |
| Edwards Lifesciences Corp. |
154 |
02/21/25 |
USD |
82.50 |
USD |
1,140 |
(17,325 ) |
| Elevance Health, Inc. |
12 |
02/21/25 |
USD |
389.00 |
USD |
443 |
(14,101 ) |
| Eli Lilly & Co. |
179 |
02/21/25 |
USD |
870.00 |
USD |
13,819 |
(228,225 ) |
| Exact Sciences Corp. |
83 |
02/21/25 |
USD |
70.00 |
USD |
466 |
(10,790 ) |
| Glaukos Corp. |
13 |
02/21/25 |
USD |
155.00 |
USD |
195 |
(9,945 ) |
| Guardant Health, Inc. |
46 |
02/21/25 |
USD |
34.00 |
USD |
141 |
(6,555 ) |
| IDEXX Laboratories, Inc. |
13 |
02/21/25 |
USD |
440.00 |
USD |
537 |
(15,470 ) |
| Inari Medical, Inc. |
13 |
02/21/25 |
USD |
65.00 |
USD |
66 |
(1,820 ) |
| Insmed, Inc. |
86 |
02/21/25 |
USD |
77.50 |
USD |
594 |
(21,930 ) |
| Inspire Medical Systems, Inc. |
10 |
02/21/25 |
USD |
220.00 |
USD |
185 |
(6,200 ) |
| Description |
Number of Contracts |
Expiration Date |
Exercise Price |
Notional Amount (000) |
Value | ||
| Call (continued) |
|
|
|
|
|
|
|
| Intuitive Surgical, Inc. |
65 |
02/21/25 |
USD |
555.00 |
USD |
3,393 |
$ (80,925
) |
| Labcorp Holdings, Inc. |
12 |
02/21/25 |
USD |
240.00 |
USD |
275 |
(5,040 ) |
| Medtronic PLC |
41 |
02/21/25 |
USD |
85.00 |
USD |
328 |
(3,014 ) |
| Neurocrine Biosciences, Inc. |
41 |
02/21/25 |
USD |
145.00 |
USD |
560 |
(9,635 ) |
| Nuvalent, Inc., Class A |
54 |
02/21/25 |
USD |
90.00 |
USD |
423 |
(6,210 ) |
| PTC Therapeutics, Inc. |
37 |
02/21/25 |
USD |
45.00 |
USD |
167 |
(13,875 ) |
| Repligen Corp. |
31 |
02/21/25 |
USD |
165.00 |
USD |
446 |
(12,632 ) |
| REVOLUTION Medicines, Inc. |
14 |
02/21/25 |
USD |
44.00 |
USD |
61 |
(4,305 ) |
| Rhythm Pharmaceuticals, Inc. |
103 |
02/21/25 |
USD |
60.00 |
USD |
577 |
(29,612 ) |
| STERIS PLC |
36 |
02/21/25 |
USD |
220.00 |
USD |
740 |
(11,610 ) |
| Structure Therapeutics, Inc., ADR |
27 |
02/21/25 |
USD |
35.00 |
USD |
73 |
(1,688 ) |
| Stryker Corp. |
59 |
02/21/25 |
USD |
370.00 |
USD |
2,124 |
(50,740 ) |
| Waters Corp. |
55 |
02/21/25 |
USD |
380.00 |
USD |
2,040 |
(79,475 ) |
| WaVe Life Sciences Ltd. |
36 |
02/21/25 |
USD |
15.51 |
USD |
45 |
(1,717 ) |
| West Pharmaceutical Services, Inc. |
20 |
02/21/25 |
USD |
350.00 |
USD |
655 |
(18,900 ) |
| Xenon Pharmaceuticals, Inc. |
55 |
02/21/25 |
USD |
44.50 |
USD |
216 |
(18,342 ) |
| |
|
|
|
|
|
|
$ (2,675,338 ) |
| Description |
Counterparty |
Number of Contracts |
Expiration Date |
Exercise Price |
Notional Amount (000) |
Value | ||
| Call |
|
|
|
|
|
|
|
|
| Denali Therapeutics, Inc. |
Citibank N.A. |
6,700 |
01/06/25 |
USD |
29.81 |
USD |
137 |
$ (4
) |
| Zealand Pharma A/S |
Bank of America N.A. |
3,000 |
01/09/25 |
DKK |
874.12 |
DKK |
2,148 |
(2 ) |
| AstraZeneca PLC |
Bank of America N.A. |
6,400 |
01/14/25 |
GBP |
107.15 |
GBP |
667 |
(7,530 ) |
| Sanofi SA |
BNP Paribas SA |
5,400 |
01/14/25 |
EUR |
96.64 |
EUR |
507 |
(1,994 ) |
| AstraZeneca PLC |
Citibank N.A. |
3,300 |
01/16/25 |
GBP |
103.59 |
GBP |
344 |
(11,449 ) |
| Zealand Pharma A/S |
Bank of America N.A. |
300 |
01/16/25 |
DKK |
753.50 |
DKK |
215 |
(408 ) |
| Sanofi SA |
Goldman Sachs International |
11,500 |
01/22/25 |
EUR |
92.07 |
EUR |
1,079 |
(32,352 ) |
| Daiichi Sankyo Co. Ltd. |
Citibank N.A. |
13,200 |
02/04/25 |
JPY |
4,403.80 |
JPY |
57,446 |
(13,224 ) |
| Roche Holding AG |
BNP Paribas SA |
5,300 |
02/06/25 |
CHF |
253.66 |
CHF |
1,354 |
(41,338 ) |
| UCB SA |
Citibank N.A. |
3,200 |
02/06/25 |
EUR |
188.50 |
EUR |
615 |
(38,462 ) |
| |
|
|
|
|
|
|
|
$ (146,763 ) |
| Description |
Premiums Paid |
Premiums Received |
Unrealized Appreciation |
Unrealized Depreciation |
Value |
| Options Written |
$ N/A
|
$ (5,345,930
) |
$ 2,859,538
|
$ (335,709
) |
$ (2,822,101
) |
| |
Commodity Contracts |
Credit Contracts |
Equity Contracts |
Foreign Currency Exchange Contracts |
Interest Rate Contracts |
Other Contracts |
Total |
| Liabilities — Derivative Financial Instruments |
|
|
|
|
|
|
|
| Options written Options written at value |
$ — |
$ — |
$ 2,822,101 |
$ — |
$ — |
$ — |
$ 2,822,101 |
| |
Commodity Contracts |
Credit Contracts |
Equity Contracts |
Foreign Currency Exchange Contracts |
Interest Rate Contracts |
Other Contracts |
Total |
| Net Realized Gain (Loss) from: |
|
|
|
|
|
|
|
| Options purchased(a) |
$ —
|
$ —
|
$ (6,226
) |
$ —
|
$ —
|
$ —
|
$ (6,226
) |
| Options written |
— |
— |
(7,907,613 ) |
— |
— |
— |
(7,907,613 ) |
| |
$ — |
$ — |
$ (7,913,839 ) |
$ — |
$ — |
$ — |
$ (7,913,839 ) |
| Net Change in Unrealized Appreciation (Depreciation) on: |
|
|
|
|
|
|
|
| Options written |
$ — |
$ — |
$ 5,003,236 |
$ — |
$ — |
$ — |
$ 5,003,236 |
| (a) |
Options purchased are included in net realized gain (loss) from investments —
unaffiliated. |
| Options: |
|
| Average value of option contracts purchased |
$—
(a) |
| Average value of option contracts written |
5,489,276 |
| (a) |
Derivative financial instrument not held at any quarter-end. The risk exposure table serves as an
indicator of activity during the period. |
| |
Assets |
Liabilities |
| Derivative Financial Instruments |
|
|
| Options |
$ — |
$ 2,822,101 |
| Total derivative assets and liabilities in the Statements of Assets and Liabilities |
— |
2,822,101 |
| Derivatives not subject to a Master Netting Agreement or similar agreement (“MNA”) |
— |
(2,675,338 ) |
| Total derivative assets and liabilities subject to an MNA |
$ — |
$ 146,763 |
| Counterparty |
Derivative Liabilities Subject to an MNA by Counterparty |
Derivatives Available for Offset(a)
|
Non-Cash Collateral Pledged(b)
|
Cash Collateral Pledged(b)
|
Net Amount of Derivative Liabilities(c)
|
| Bank of America N.A. |
$ 7,940
|
$ —
|
$ —
|
$ —
|
$ 7,940
|
| BNP Paribas SA |
43,332 |
— |
— |
— |
43,332 |
| Citibank N.A. |
63,139 |
— |
(39,372 ) |
— |
23,767 |
| Goldman Sachs International |
32,352 |
— |
— |
— |
32,352 |
| |
$ 146,763 |
$ — |
$ (39,372 ) |
$ — |
$ 107,391 |
| (a) |
The amount of derivatives available for offset is limited to the amount of derivative assets and/or liabilities that are subject to an MNA. |
| (b) |
Excess of collateral received/pledged, if any, from the individual counterparty is not shown for financial reporting purposes. |
| (c) |
Net amount represents the net amount payable due to the counterparty in the event of default. Net amount may be offset further by the options written
receivable/payable on the Statements of Assets and Liabilities. |
| |
Level 1 |
Level 2 |
Level 3 |
Total |
| Assets |
|
|
|
|
| Investments |
|
|
|
|
| Long-Term Investments |
|
|
|
|
| Common Stocks |
|
|
|
|
| Biotechnology |
$ 140,054,580
|
$ 845,438
|
$ —
|
$ 140,900,018 |
| Capital Markets |
646,065 |
— |
— |
646,065 |
| Health Care Equipment & Supplies |
161,711,575 |
— |
178,690 |
161,890,265 |
| Health Care Providers & Services |
53,798,058 |
— |
— |
53,798,058 |
| Life Sciences Tools & Services |
52,897,707 |
— |
— |
52,897,707 |
| Pharmaceuticals |
93,783,298 |
15,664,782 |
— |
109,448,080 |
| Corporate Bonds |
— |
— |
108,838 |
108,838 |
| Other Interests |
— |
— |
60,020 |
60,020 |
| Preferred Securities |
|
|
|
|
| Preferred Stocks |
— |
— |
3,501,508 |
3,501,508 |
| Rights |
— |
— |
42,669 |
42,669 |
| Warrants |
950 |
— |
33,440 |
34,390 |
| Short-Term Securities |
|
|
|
|
| Money Market Funds |
26,552,753 |
— |
— |
26,552,753 |
| |
$529,444,986 |
$16,510,220 |
$3,925,165 |
$549,880,371 |
| Derivative Financial Instruments(a)
|
|
|
|
|
| Liabilities |
|
|
|
|
| Equity Contracts |
$ (2,511,494 ) |
$ (310,607 ) |
$ — |
$ (2,822,101 ) |
| (a) |
Derivative financial instruments are options written. Options written are shown at
value. |
| Security |
|
Shares |
Value |
| Common Stocks | |||
| Aerospace & Defense — 5.7% |
| ||
| Axon Enterprise, Inc.(a)(b)(c)
|
|
117,375 |
$ 69,758,310
|
| HEICO Corp. |
|
136,452 |
32,440,098 |
| |
|
|
102,198,408 |
| Air Freight & Logistics — 0.4% |
| ||
| GXO Logistics, Inc.(c)(d) |
|
171,952 |
7,479,912 |
| Automobile Components — 0.5% |
| ||
| Fox Factory Holding Corp.(c)
|
|
313,368 |
9,485,649 |
| Biotechnology(c)
— 1.6% |
| ||
| Halozyme Therapeutics, Inc. |
|
146,673 |
7,012,436 |
| Natera, Inc. |
|
138,728 |
21,960,643 |
| |
|
|
28,973,079 |
| Building Products — 1.7% |
| ||
| AZEK Co., Inc., Class A(c) |
|
634,963 |
30,141,694 |
| Capital Markets — 4.9% |
| ||
| TPG, Inc., Class A |
|
666,226 |
41,865,642 |
| Tradeweb Markets, Inc., Class A(b) |
|
343,776 |
45,007,154 |
| |
|
|
86,872,796 |
| Construction & Engineering — 2.6% |
| ||
| Comfort Systems USA, Inc. |
|
110,064 |
46,673,740 |
| Diversified Consumer Services(c) —
2.1% |
| ||
| Duolingo, Inc., Class A |
|
63,181 |
20,485,176 |
| Grammarly, Inc., (Acquired 11/17/21, Cost:
$26,250,012)(e)(f) |
|
1,001,454 |
16,153,453 |
| |
|
|
36,638,629 |
| Electrical Equipment — 3.4% |
| ||
| Vertiv Holdings Co., Class
A(a)(b) |
|
537,870 |
61,107,411 |
| Electronic Equipment, Instruments & Components — 1.3% |
| ||
| Coherent Corp.(c) |
|
253,650 |
24,028,265 |
| Entertainment — 2.6% |
| ||
| Liberty Media Corp.-Liberty Formula One, Class
C(c) |
|
495,135 |
45,879,209 |
| Financial Services — 1.3% |
| ||
| Affirm Holdings, Inc., Class A(c)
|
|
390,474 |
23,779,867 |
| Food Products — 1.2% |
| ||
| Freshpet, Inc.(c) |
|
140,042 |
20,741,621 |
| Ground Transportation — 2.3% |
| ||
| Saia, Inc.(c) |
|
89,902 |
40,971,038 |
| Health Care Equipment & Supplies(c) —
3.7% |
| ||
| Align Technology, Inc. |
|
153,354 |
31,975,843 |
| Masimo Corp. |
|
202,454 |
33,465,646 |
| |
|
|
65,441,489 |
| Health Care Providers & Services — 0.5% |
| ||
| Surgery Partners, Inc.(c)(d)
|
|
438,226 |
9,277,244 |
| Hotels, Restaurants & Leisure(c) —
4.3% |
| ||
| DraftKings, Inc., Class A |
|
1,044,743 |
38,864,440 |
| Planet Fitness, Inc., Class A(b) |
|
377,719 |
37,345,077 |
| |
|
|
76,209,517 |
| Industrial REITs — 0.1% |
| ||
| Innovative Industrial Properties, Inc. |
|
11,558 |
770,225 |
| Rexford Industrial Realty, Inc. |
|
11,967 |
462,644 |
| |
|
|
1,232,869 |
| Security |
|
Shares |
Value |
| Interactive Media & Services(c) —
2.3% |
| ||
| Patreon, Inc., (Acquired 08/19/21, Cost:
$11,732,736)(e)(f) |
|
208,333 |
$ 5,754,157
|
| Pinterest, Inc., Class A |
|
123,002 |
3,567,058 |
| Reddit, Inc., Class A |
|
189,290 |
30,937,558 |
| |
|
|
40,258,773 |
| IT
Services(c) — 2.6% |
| ||
| Globant SA |
|
92,517 |
19,837,495 |
| MongoDB, Inc., Class A |
|
80,348 |
18,705,818 |
| Teya Services Ltd., Series C, (Acquired 11/16/21, Cost: $49,999,974)(e)(f) |
|
25,742 |
8,675,311 |
| |
|
|
47,218,624 |
| Life Sciences Tools & Services — 3.0% |
| ||
| Bio-Techne Corp. |
|
16,316 |
1,175,241 |
| Repligen Corp.(c) |
|
139,818 |
20,125,403 |
| West Pharmaceutical Services, Inc. |
|
97,993 |
32,098,587 |
| |
|
|
53,399,231 |
| Machinery — 0.5% |
| ||
| AutoStore Holdings Ltd.(c)(d)(g)
|
|
8,612,661 |
8,438,564 |
| Pharmaceuticals — 1.5% |
| ||
| Galderma Group AG(c) |
|
234,159 |
25,966,351 |
| Real Estate Management & Development — 2.2% |
| ||
| CoStar Group, Inc.(c) |
|
558,897 |
40,011,436 |
| Semiconductors & Semiconductor Equipment — 9.1% |
| ||
| ASM International NV |
|
55,544 |
32,114,714 |
| Astera Labs, Inc.(c) |
|
214,049 |
28,350,790 |
| BE Semiconductor Industries NV |
|
192,304 |
26,358,750 |
| Credo Technology Group Holding Ltd.(c) |
|
445,081 |
29,913,894 |
| Entegris, Inc.(b) |
|
353,478 |
35,015,531 |
| Monolithic Power Systems, Inc.(a) |
|
18,170 |
10,751,189 |
| |
|
|
162,504,868 |
| Software — 10.0% |
| ||
| Aspen Technology, Inc.(c) |
|
32,704 |
8,163,900 |
| Bentley Systems, Inc., Class B(d) |
|
521,406 |
24,349,660 |
| Confluent, Inc., Class A(c)
|
|
1,093,043 |
30,561,482 |
| CyberArk Software Ltd.(c) |
|
54,242 |
18,070,722 |
| Gitlab, Inc., Class A(c) |
|
319,546 |
18,006,417 |
| Guidewire Software, Inc.(c) |
|
105,741 |
17,825,818 |
| JFrog Ltd.(c) |
|
116,727 |
3,432,941 |
| Manhattan Associates, Inc.(c) |
|
58,476 |
15,802,554 |
| PTC, Inc.(c)(d) |
|
70,615 |
12,983,980 |
| SiteMinder Ltd.(c) |
|
3,228,034 |
12,053,475 |
| Snorkel AI, Inc., (Acquired 06/30/21, Cost: $2,999,997)(c)(e)(f) |
|
199,738 |
2,011,362 |
| Snyk Ltd., Ordinary Shares, (Acquired 09/02/21, Cost:
$25,961,537)(e)(f) |
|
1,809,860 |
15,691,486 |
| |
|
|
178,953,797 |
| Specialty Retail(c) —
2.1% |
| ||
| Carvana Co., Class A |
|
101,456 |
20,632,092 |
| Floor & Decor Holdings, Inc., Class A(d) |
|
164,932 |
16,443,721 |
| |
|
|
37,075,813 |
| Technology Hardware, Storage & Peripherals — 1.5% |
| ||
| Pure Storage, Inc., Class A(c)
|
|
434,364 |
26,682,981 |
| Security |
|
Shares |
Value |
| Textiles, Apparel & Luxury Goods — 2.6% |
| ||
| Brunello Cucinelli SpA |
|
237,493 |
$ 25,943,561
|
| On Holding AG, Class A(c) |
|
378,477 |
20,729,185 |
| |
|
|
46,672,746 |
| Trading Companies & Distributors — 0.7% |
| ||
| Core & Main, Inc., Class A(c) |
|
258,028 |
13,136,205 |
| Total Common Stocks — 78.3% (Cost: $1,214,338,592) |
1,397,451,826 | ||
| Preferred Securities | |||
| Preferred Stocks — 22.1%(e)(f) | |||
| Aerospace & Defense — 0.1% |
| ||
| SkySafe, Inc., Series B, (Acquired 12/02/21, Cost: $4,999,999)(c) |
|
909,438 |
1,136,797 |
| Automobile Components — 0.1% |
| ||
| Relativity Space, Inc., Series E, (Acquired 05/27/21, Cost: $50,000,009)(c) |
|
2,189,612 |
1,926,858 |
| Capital
Markets(c) — 2.6% |
| ||
| Anchor Labs, Inc., Series D, (Acquired 11/24/21, Cost: $9,999,995) |
|
428,785 |
3,554,628 |
| The Production Board LLC, Series A3, (Acquired
06/04/21, Cost: $50,000,001) |
|
16,666,667 |
25,833,334 |
| Varo Money, Inc., Series E, (Acquired 08/27/21, Cost: $40,000,001) |
|
4,316,904 |
16,447,404 |
| |
|
|
45,835,366 |
| Diversified Consumer Services — 0.3% |
| ||
| Grammarly, Inc., Series 3, (Acquired 11/17/21, Cost:
$8,750,004)(c) |
|
333,818 |
5,384,484 |
| Diversified Telecommunication Services — 0.5% |
| ||
| Discord, Inc., Series I, (Acquired 09/13/21, Cost:
$17,999,912)(c) |
|
32,690 |
8,287,569 |
| Entertainment — 0.4% |
| ||
| Under Canvas, Inc., Class A, (Acquired 08/19/21, Cost:
$49,999,983)(c) |
|
2,172,486 |
7,734,050 |
| Food Products — 0.3% |
| ||
| Motif Food Works, Inc., Series B, (Acquired 06/08/21,
Cost: $34,005,758)(c) |
|
1,972,240 |
5,212,039 |
| Hotels, Restaurants & Leisure(c) —
2.1% |
| ||
| Dapper Labs, Inc., Series 7, (Acquired 07/20/21, Cost:
$29,999,946) |
|
191,067 |
2,468,586 |
| Underdog Sports, Inc., Series B, (Acquired 01/11/22, Cost: $14,999,974) |
|
291,061 |
35,177,632 |
| |
|
|
37,646,218 |
| Security |
|
Shares |
Value |
| Interactive Media & Services — 0.6% |
| ||
| Patreon, Inc., Series D, (Acquired 07/14/21, Cost:
$23,333,352)(c) |
|
416,667 |
$ 11,508,342 |
| IT
Services(c) — 2.4% |
| ||
| Via Transportation, Inc., Series G, (Acquired 11/05/21,
Cost: $24,999,974) |
|
549,357 |
33,928,288 |
| Wagestream Holdings Ltd., Series C, (Acquired 02/11/22, Cost: $10,024,684) |
|
762,746 |
8,517,543 |
| |
|
|
42,445,831 |
| Semiconductors & Semiconductor Equipment(c) —
3.7% |
| ||
| PsiQuantum Corp., Series D, (Acquired 05/21/21, Cost:
$39,999,990) |
|
1,525,192 |
58,140,319 |
| Rivos, Inc., Series A1, (Acquired 12/03/21, Cost: $7,996,292) |
|
2,997,684 |
7,823,955 |
| |
|
|
65,964,274 |
| Software — 7.2% |
| ||
| AnyRoad, Inc., Series B, (Acquired 12/07/21, Cost:
$14,999,995)(c) |
|
2,745,894 |
8,567,189 |
| Bolt Financial, Inc., Series E, (Acquired 01/18/22, Cost: $44,999,983)(c) |
|
898,024 |
10,794,249 |
| Deepgram, Inc., Series B, (Acquired 10/22/21, Cost:
$11,999,997)(c) |
|
2,165,400 |
20,571,300 |
| Dragos, Inc., Series D, (Acquired 09/28/21, Cost: $39,999,959)(c) |
|
900,760 |
29,842,179 |
| Genesys Cloud Services, Inc., (Acquired 11/24/21,
Cost: $30,000,101) |
|
4,651,163 |
16,465,117 |
| Open Space Labs, Inc., Series D, (Acquired 01/31/22, Cost: $15,000,003)(c) |
|
1,687,916 |
12,794,403 |
| Snorkel AI, Inc., Series C, (Acquired 06/30/21, Cost:
$10,999,993)(c) |
|
732,373 |
7,374,996 |
| Snyk Ltd., Series F, (Acquired 09/02/21, Cost: $24,038,470)(c) |
|
1,685,092 |
14,609,748 |
| Validere Technologies, Inc., Series B, (Acquired
10/21/21, Cost: $10,000,000)(c) |
|
4,684,060 |
8,431,308 |
| |
|
|
129,450,489 |
| Specialty Retail — 0.1% |
| ||
| Super73, Inc., Series C-1, (Acquired 10/25/22, Cost: $12,000,000)(c) |
|
1,400,669 |
2,549,218 |
| Security |
|
Shares |
Value |
| Wireless Telecommunication Services — 1.7% |
| ||
| Loft Orbital Solutions, Inc., Series B, (Acquired
10/14/21, Cost: $24,999,992)(c) |
|
1,365,305 |
$ 29,681,731 |
| |
394,763,266 | ||
| Total Preferred Securities — 22.1% (Cost: $656,148,367) |
394,763,266 | ||
| Total Long-Term Investments — 100.4% (Cost: $1,870,486,959) |
1,792,215,092 | ||
| Short-Term Securities | |||
| Money Market Funds — 0.9% |
| ||
| BlackRock Cash Funds: Institutional, SL Agency
Shares, 4.63%(h)(i)(j) |
|
14,260,840 |
14,267,970 |
| BlackRock Liquidity Funds, T-Fund, Institutional Shares, 4.36%(h)(i) |
|
2,002,846 |
2,002,846 |
| Total Short-Term Securities — 0.9% (Cost: $16,270,379) |
16,270,816 | ||
| Total Investments Before Options Written — 101.3% (Cost: $1,886,757,338) |
1,808,485,908 | ||
| Options Written — (0.3)% (Premiums Received: $(10,409,882)) |
(6,220,791 ) | ||
| Total Investments, Net of Options Written — 101.0% (Cost: $1,876,347,456) |
1,802,265,117 | ||
| Liabilities in Excess of Other Assets — (1.0)% |
(17,303,702 ) | ||
| Net Assets — 100.0% |
$ 1,784,961,415 | ||
| (a) |
All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives. |
| (b) |
All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written. |
| (c) |
Non-income producing security. |
| (d) |
All or a portion of this security is on loan. |
| (e) |
Security is valued using significant unobservable inputs and is classified as Level 3 in the
fair value hierarchy. |
| (f) |
Restricted security as to resale, excluding 144A securities. The Trust held restricted
securities with a current value of $443,049,035, representing 24.8% of its net assets as
of period end, and an original cost of $773,092,623. |
| (g) |
Security exempt from registration pursuant to Rule 144A under the Securities Act of 1933,
as amended. These securities may be resold in transactions exempt from registration to
qualified institutional investors. |
| (h) |
Affiliate of the Trust. |
| (i) |
Annualized 7-day yield as of period end. |
| (j) |
All or a portion of this security was purchased with the cash collateral from loaned securities. |
| Affiliated Issuer |
Value at 12/31/23 |
Purchases at Cost |
Proceeds from Sales |
Net Realized Gain (Loss) |
Change in Unrealized Appreciation (Depreciation) |
Value at 12/31/24 |
Shares Held at 12/31/24 |
Income |
Capital Gain Distributions from Underlying Funds |
| BlackRock Cash Funds: Institutional, SL Agency Shares |
$ — |
$ 14,260,657 (a) |
$ — |
$ 6,876 |
$ 437 |
$ 14,267,970 |
14,260,840 |
$ 38,936 (b) |
$ — |
| BlackRock Liquidity Funds, T-Fund, Institutional Shares |
326,227 |
1,676,619 (a) |
— |
— |
— |
2,002,846 |
2,002,846 |
274,103 |
— |
| SL Liquidity Series, LLC, Money Market
Series(c) |
20,505,005 |
— |
(20,506,863
)(a) |
3,019 |
(1,161 ) |
— |
— |
14,373
(b) |
— |
| |
|
|
|
$ 9,895 |
$ (724 ) |
$ 16,270,816 |
|
$ 327,412 |
$ — |
| (a) |
Represents net amount purchased (sold). |
| (b) |
All or a portion represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of collateral investment fees, and
other payments to and from borrowers of securities. |
| (c) |
As of period end, the entity is no longer held. |
| Description |
Number of Contracts |
Expiration Date |
Exercise Price |
Notional Amount (000) |
Value | ||
| Call |
|
|
|
|
|
|
|
| Coherent Corp. |
45 |
01/03/25 |
USD |
108.00 |
USD |
426 |
$ (1,125
) |
| On Holding AG, Class A |
120 |
01/10/25 |
USD |
59.00 |
USD |
657 |
(3,120 ) |
| Description |
Number of Contracts |
Expiration Date |
Exercise Price |
Notional Amount (000) |
Value | ||
| Call (continued) |
|
|
|
|
|
|
|
| Vertiv Holdings Co., Class A |
657 |
01/10/25 |
USD |
150.00 |
USD |
7,464 |
$ (42,705
) |
| Affirm Holdings, Inc., Class A |
111 |
01/17/25 |
USD |
70.00 |
USD |
676 |
(9,491 ) |
| Align Technology, Inc. |
63 |
01/17/25 |
USD |
250.00 |
USD |
1,314 |
(1,260 ) |
| Align Technology, Inc. |
10 |
01/17/25 |
USD |
260.00 |
USD |
209 |
(350 ) |
| Aspen Technology, Inc. |
21 |
01/17/25 |
USD |
250.00 |
USD |
524 |
(9,398 ) |
| Astera Labs, Inc. |
189 |
01/17/25 |
USD |
125.00 |
USD |
2,503 |
(228,690 ) |
| Axon Enterprise, Inc. |
55 |
01/17/25 |
USD |
610.00 |
USD |
3,269 |
(67,650 ) |
| Axon Enterprise, Inc. |
150 |
01/17/25 |
USD |
640.00 |
USD |
8,915 |
(68,250 ) |
| AZEK Co., Inc., Class A |
505 |
01/17/25 |
USD |
60.00 |
USD |
2,397 |
(25,250 ) |
| AZEK Co., Inc., Class A |
528 |
01/17/25 |
USD |
55.00 |
USD |
2,506 |
(7,920 ) |
| Bentley Systems, Inc., Class B |
848 |
01/17/25 |
USD |
50.00 |
USD |
3,960 |
(19,080 ) |
| Carvana Co., Class A |
78 |
01/17/25 |
USD |
260.00 |
USD |
1,586 |
(6,903 ) |
| Comfort Systems USA, Inc. |
110 |
01/17/25 |
USD |
470.00 |
USD |
4,665 |
(29,150 ) |
| Confluent, Inc., Class A |
748 |
01/17/25 |
USD |
29.00 |
USD |
2,091 |
(44,880 ) |
| Core & Main, Inc., Class A |
420 |
01/17/25 |
USD |
52.50 |
USD |
2,138 |
(68,250 ) |
| CoStar Group, Inc. |
400 |
01/17/25 |
USD |
80.00 |
USD |
2,864 |
(6,000 ) |
| Credo Technology Group Holding Ltd. |
325 |
01/17/25 |
USD |
55.00 |
USD |
2,184 |
(414,375 ) |
| CyberArk Software Ltd. |
38 |
01/17/25 |
USD |
310.00 |
USD |
1,266 |
(100,700 ) |
| DraftKings, Inc., Class A |
400 |
01/17/25 |
USD |
42.00 |
USD |
1,488 |
(5,200 ) |
| Duolingo, Inc., Class A |
51 |
01/17/25 |
USD |
350.00 |
USD |
1,654 |
(20,145 ) |
| Entegris, Inc. |
170 |
01/17/25 |
USD |
115.00 |
USD |
1,684 |
(2,550 ) |
| Floor & Decor Holdings, Inc., Class A |
100 |
01/17/25 |
USD |
115.00 |
USD |
997 |
(2,750 ) |
| Fox Factory Holding Corp. |
235 |
01/17/25 |
USD |
35.50 |
USD |
711 |
(3,064 ) |
| Fox Factory Holding Corp. |
275 |
01/17/25 |
USD |
32.00 |
USD |
832 |
(17,505 ) |
| Freshpet, Inc. |
114 |
01/17/25 |
USD |
160.00 |
USD |
1,688 |
(12,540 ) |
| Gitlab, Inc., Class A |
170 |
01/17/25 |
USD |
64.00 |
USD |
958 |
(5,950 ) |
| Globant SA |
44 |
01/17/25 |
USD |
240.00 |
USD |
943 |
(5,940 ) |
| Guidewire Software, Inc. |
80 |
01/17/25 |
USD |
180.00 |
USD |
1,349 |
(8,600 ) |
| GXO Logistics, Inc. |
167 |
01/17/25 |
USD |
65.00 |
USD |
726 |
(1,670 ) |
| Halozyme Therapeutics, Inc. |
64 |
01/17/25 |
USD |
50.00 |
USD |
306 |
(5,440 ) |
| HEICO Corp. |
109 |
01/17/25 |
USD |
280.00 |
USD |
2,591 |
(1,090 ) |
| Innovative Industrial Properties, Inc. |
20 |
01/17/25 |
USD |
115.00 |
USD |
133 |
(100 ) |
| JFrog Ltd. |
198 |
01/17/25 |
USD |
35.00 |
USD |
582 |
(2,970 ) |
| Liberty Media Corp.-Liberty Formula One, Class C |
360 |
01/17/25 |
USD |
85.00 |
USD |
3,336 |
(293,400 ) |
| Manhattan Associates, Inc. |
136 |
01/17/25 |
USD |
290.00 |
USD |
3,675 |
(16,660 ) |
| Masimo Corp. |
127 |
01/17/25 |
USD |
190.00 |
USD |
2,099 |
(16,510 ) |
| MongoDB, Inc., Class A |
94 |
01/17/25 |
USD |
340.00 |
USD |
2,188 |
(11,750 ) |
| Monolithic Power Systems, Inc. |
18 |
01/17/25 |
USD |
702.00 |
USD |
1,065 |
(1,122 ) |
| Natera, Inc. |
50 |
01/17/25 |
USD |
175.00 |
USD |
792 |
(16,000 ) |
| On Holding AG, Class A |
341 |
01/17/25 |
USD |
55.00 |
USD |
1,868 |
(61,891 ) |
| Pinterest, Inc., Class A |
784 |
01/17/25 |
USD |
31.00 |
USD |
2,274 |
(19,600 ) |
| Planet Fitness, Inc., Class A |
310 |
01/17/25 |
USD |
97.50 |
USD |
3,065 |
(106,950 ) |
| PTC, Inc. |
122 |
01/17/25 |
USD |
190.00 |
USD |
2,243 |
(24,095 ) |
| Pure Storage, Inc., Class A |
40 |
01/17/25 |
USD |
55.00 |
USD |
246 |
(23,400 ) |
| Pure Storage, Inc., Class A |
40 |
01/17/25 |
USD |
60.00 |
USD |
246 |
(10,700 ) |
| Saia, Inc. |
56 |
01/17/25 |
USD |
570.00 |
USD |
2,552 |
(24,640 ) |
| Surgery Partners, Inc. |
410 |
01/17/25 |
USD |
22.50 |
USD |
868 |
(65,600 ) |
| TPG, Inc., Class A |
232 |
01/17/25 |
USD |
71.21 |
USD |
1,458 |
(13,929 ) |
| TPG, Inc., Class A |
463 |
01/17/25 |
USD |
65.00 |
USD |
2,909 |
(38,197 ) |
| Tradeweb Markets, Inc., Class A |
294 |
01/17/25 |
USD |
130.00 |
USD |
3,849 |
(99,960 ) |
| Vertiv Holdings Co., Class A |
117 |
01/17/25 |
USD |
160.00 |
USD |
1,329 |
(585 ) |
| West Pharmaceutical Services, Inc. |
58 |
01/17/25 |
USD |
340.00 |
USD |
1,900 |
(17,400 ) |
| Affirm Holdings, Inc., Class A |
290 |
01/24/25 |
USD |
75.00 |
USD |
1,766 |
(17,110 ) |
| Align Technology, Inc. |
176 |
01/24/25 |
USD |
235.00 |
USD |
3,670 |
(21,560 ) |
| Coherent Corp. |
150 |
01/24/25 |
USD |
113.00 |
USD |
1,421 |
(9,375 ) |
| Gitlab, Inc., Class A |
170 |
01/24/25 |
USD |
65.00 |
USD |
958 |
(5,525 ) |
| MongoDB, Inc., Class A |
36 |
01/24/25 |
USD |
320.00 |
USD |
838 |
(2,700 ) |
| On Holding AG, Class A |
87 |
01/24/25 |
USD |
61.00 |
USD |
476 |
(3,437 ) |
| Reddit, Inc., Class A |
65 |
01/24/25 |
USD |
185.00 |
USD |
1,062 |
(26,325 ) |
| Vertiv Holdings Co., Class A |
101 |
01/24/25 |
USD |
129.00 |
USD |
1,147 |
(12,120 ) |
| Affirm Holdings, Inc., Class A |
111 |
01/31/25 |
USD |
69.00 |
USD |
676 |
(23,199 ) |
| DraftKings, Inc., Class A |
431 |
01/31/25 |
USD |
42.00 |
USD |
1,603 |
(18,102 ) |
| Description |
Number of Contracts |
Expiration Date |
Exercise Price |
Notional Amount (000) |
Value | ||
| Call (continued) |
|
|
|
|
|
|
|
| On Holding AG, Class A |
120 |
01/31/25 |
USD |
59.00 |
USD |
657 |
$ (12,600
) |
| Reddit, Inc., Class A |
64 |
01/31/25 |
USD |
195.00 |
USD |
1,046 |
(24,736 ) |
| Comfort Systems USA, Inc. |
69 |
02/05/25 |
USD |
440.00 |
USD |
2,926 |
(99,822 ) |
| Halozyme Therapeutics, Inc. |
174 |
02/10/25 |
USD |
50.25 |
USD |
832 |
(29,956 ) |
| Astera Labs, Inc. |
159 |
02/21/25 |
USD |
152.58 |
USD |
2,106 |
(99,784 ) |
| Bio-Techne Corp. |
26 |
02/21/25 |
USD |
75.00 |
USD |
187 |
(8,580 ) |
| Carvana Co., Class A |
87 |
02/21/25 |
USD |
260.00 |
USD |
1,769 |
(68,295 ) |
| Coherent Corp. |
150 |
02/21/25 |
USD |
120.00 |
USD |
1,421 |
(28,500 ) |
| Confluent, Inc., Class A |
1,132 |
02/21/25 |
USD |
34.00 |
USD |
3,165 |
(110,370 ) |
| Credo Technology Group Holding Ltd. |
399 |
02/21/25 |
USD |
80.00 |
USD |
2,682 |
(105,735 ) |
| CyberArk Software Ltd. |
38 |
02/21/25 |
USD |
320.00 |
USD |
1,266 |
(109,250 ) |
| DraftKings, Inc., Class A |
370 |
02/21/25 |
USD |
45.00 |
USD |
1,376 |
(22,570 ) |
| Duolingo, Inc., Class A |
51 |
02/21/25 |
USD |
360.00 |
USD |
1,654 |
(52,275 ) |
| Entegris, Inc. |
405 |
02/21/25 |
USD |
115.00 |
USD |
4,012 |
(69,862 ) |
| Floor & Decor Holdings, Inc., Class A |
170 |
02/21/25 |
USD |
114.00 |
USD |
1,695 |
(35,007 ) |
| Freshpet, Inc. |
114 |
02/21/25 |
USD |
150.00 |
USD |
1,688 |
(66,690 ) |
| Gitlab, Inc., Class A |
171 |
02/21/25 |
USD |
67.50 |
USD |
964 |
(11,543 ) |
| Guidewire Software, Inc. |
80 |
02/21/25 |
USD |
185.00 |
USD |
1,349 |
(16,800 ) |
| GXO Logistics, Inc. |
115 |
02/21/25 |
USD |
50.00 |
USD |
500 |
(6,325 ) |
| HEICO Corp. |
113 |
02/21/25 |
USD |
260.00 |
USD |
2,686 |
(16,667 ) |
| Liberty Media Corp.-Liberty Formula One, Class C |
446 |
02/21/25 |
USD |
100.00 |
USD |
4,133 |
(111,500 ) |
| Monolithic Power Systems, Inc. |
50 |
02/21/25 |
USD |
670.00 |
USD |
2,959 |
(117,000 ) |
| Natera, Inc. |
171 |
02/21/25 |
USD |
185.00 |
USD |
2,707 |
(97,470 ) |
| Pinterest, Inc., Class A |
260 |
02/21/25 |
USD |
33.00 |
USD |
754 |
(26,780 ) |
| Planet Fitness, Inc., Class A |
304 |
02/21/25 |
USD |
110.00 |
USD |
3,006 |
(35,720 ) |
| Pure Storage, Inc., Class A |
173 |
02/21/25 |
USD |
70.00 |
USD |
1,063 |
(17,732 ) |
| Pure Storage, Inc., Class A |
268 |
02/21/25 |
USD |
75.00 |
USD |
1,646 |
(13,400 ) |
| Reddit, Inc., Class A |
179 |
02/21/25 |
USD |
170.00 |
USD |
2,926 |
(327,570 ) |
| Repligen Corp. |
223 |
02/21/25 |
USD |
165.00 |
USD |
3,210 |
(90,872 ) |
| Saia, Inc. |
90 |
02/21/25 |
USD |
590.00 |
USD |
4,102 |
(34,875 ) |
| TPG, Inc., Class A |
370 |
02/21/25 |
USD |
72.50 |
USD |
2,325 |
(48,100 ) |
| Tradeweb Markets, Inc., Class A |
257 |
02/21/25 |
USD |
140.00 |
USD |
3,365 |
(60,395 ) |
| West Pharmaceutical Services, Inc. |
101 |
02/21/25 |
USD |
350.00 |
USD |
3,308 |
(95,445 ) |
| Globant SA |
106 |
12/19/25 |
USD |
230.00 |
USD |
2,273 |
(292,560 ) |
| |
|
|
|
|
|
|
$ (4,616,689 ) |
| Description |
Counterparty |
Number of Contracts |
Expiration Date |
Exercise Price |
Notional Amount (000) |
Value | ||
| Call |
|
|
|
|
|
|
|
|
| SiteMinder Ltd. |
UBS AG |
115,400 |
01/07/25 |
AUD |
6.98 |
AUD |
696 |
$ (9
) |
| AutoStore Holdings Ltd. |
UBS AG |
321,500 |
01/09/25 |
NOK |
12.92 |
NOK |
3,586 |
(149 ) |
| SiteMinder Ltd. |
UBS AG |
185,500 |
01/09/25 |
AUD |
6.94 |
AUD |
1,119 |
(75 ) |
| Surgery Partners, Inc. |
Goldman Sachs International |
30,900 |
01/09/25 |
USD |
25.77 |
USD |
654 |
(711 ) |
| Masimo Corp. |
Citibank N.A. |
20,200 |
01/10/25 |
USD |
166.24 |
USD |
3,339 |
(80,096 ) |
| Rexford Industrial Realty, Inc. |
Citibank N.A. |
1,000 |
01/13/25 |
USD |
43.52 |
USD |
39 |
(3 ) |
| Rexford Industrial Realty, Inc. |
Goldman Sachs International |
900 |
01/13/25 |
USD |
41.30 |
USD |
35 |
(65 ) |
| ASM International NV |
Goldman Sachs International |
5,600 |
01/14/25 |
EUR |
554.95 |
EUR |
3,126 |
(103,360 ) |
| AutoStore Holdings Ltd. |
UBS AG |
237,900 |
01/14/25 |
NOK |
13.06 |
NOK |
2,653 |
(313 ) |
| AutoStore Holdings Ltd. |
Citibank N.A. |
280,000 |
01/15/25 |
NOK |
12.47 |
NOK |
3,123 |
(1,260 ) |
| ASM International NV |
Goldman Sachs International |
3,900 |
01/16/25 |
EUR |
524.74 |
EUR |
2,177 |
(160,510 ) |
| Brunello Cucinelli SpA |
Citibank N.A. |
30,000 |
01/16/25 |
EUR |
90.23 |
EUR |
3,164 |
(475,209 ) |
| BE Semiconductor Industries NV |
Goldman Sachs International |
31,400 |
01/24/25 |
EUR |
121.47 |
EUR |
4,155 |
(424,033 ) |
| Galderma Group AG |
Citibank N.A. |
15,000 |
01/24/25 |
CHF |
92.73 |
CHF |
1,510 |
(137,881 ) |
| SiteMinder Ltd. |
UBS AG |
29,200 |
01/24/25 |
AUD |
6.65 |
AUD |
176 |
(759 ) |
| AutoStore Holdings Ltd. |
Goldman Sachs International |
562,800 |
01/28/25 |
NOK |
12.54 |
NOK |
6,253 |
(6,604 ) |
| Brunello Cucinelli SpA |
Citibank N.A. |
8,600 |
01/28/25 |
EUR |
106.18 |
EUR |
906 |
(22,368 ) |
| Galderma Group AG |
Morgan Stanley & Co. International PLC |
9,400 |
01/28/25 |
CHF |
96.36 |
CHF |
946 |
(53,966 ) |
| SiteMinder Ltd. |
UBS AG |
89,000 |
01/28/25 |
AUD |
5.98 |
AUD |
538 |
(15,082 ) |
| CoStar Group, Inc. |
Barclays Bank PLC |
50,900 |
01/29/25 |
USD |
79.72 |
USD |
3,644 |
(22,560 ) |
| Description |
Counterparty |
Number of Contracts |
Expiration Date |
Exercise Price |
Notional Amount (000) |
Value | ||
| Call (continued) |
|
|
|
|
|
|
|
|
| Pure Storage, Inc., Class A |
UBS AG |
17,300 |
01/29/25 |
USD |
66.25 |
USD |
1,063 |
$ (17,452
) |
| Aspen Technology, Inc. |
Morgan Stanley & Co. International PLC |
3,200 |
02/04/25 |
USD |
252.93 |
USD |
799 |
(13,394 ) |
| Galderma Group AG |
Morgan Stanley & Co. International PLC |
13,800 |
02/06/25 |
CHF |
98.12 |
CHF |
1,389 |
(62,999 ) |
| SiteMinder Ltd. |
Goldman Sachs International |
106,500 |
02/06/25 |
AUD |
6.65 |
AUD |
643 |
(5,244 ) |
| |
|
|
|
|
|
|
|
$ (1,604,102 ) |
| Description |
Premiums Paid |
Premiums Received |
Unrealized Appreciation |
Unrealized Depreciation |
Value |
| Options Written |
$ N/A
|
$ (10,409,882
) |
$ 5,923,420
|
$ (1,734,329
) |
$ (6,220,791
) |
| |
Commodity Contracts |
Credit Contracts |
Equity Contracts |
Foreign Currency Exchange Contracts |
Interest Rate Contracts |
Other Contracts |
Total |
| Liabilities — Derivative Financial Instruments |
|
|
|
|
|
|
|
| Options written Options written at value |
$ — |
$ — |
$ 6,220,791 |
$ — |
$ — |
$ — |
$ 6,220,791 |
| |
Commodity Contracts |
Credit Contracts |
Equity Contracts |
Foreign Currency Exchange Contracts |
Interest Rate Contracts |
Other Contracts |
Total |
| Net Realized Gain (Loss) from: |
|
|
|
|
|
|
|
| Options purchased(a) |
$ —
|
$ —
|
$ (703
) |
$ —
|
$ —
|
$ —
|
$ (703
) |
| Options written |
— |
— |
(13,094,737 ) |
— |
— |
— |
(13,094,737 ) |
| |
$ — |
$ — |
$ (13,095,440 ) |
$ — |
$ — |
$ — |
$ (13,095,440 ) |
| Net Change in Unrealized Appreciation (Depreciation) on: |
|
|
|
|
|
|
|
| Options written |
$ — |
$ — |
$ 12,830,161 |
$ — |
$ — |
$ — |
$ 12,830,161 |
| (a) |
Options purchased are included in net realized gain (loss) from investments —
unaffiliated. |
| Options: |
|
| Average value of option contracts purchased |
$—
(a) |
| Average value of option contracts written |
9,265,650 |
| (a) |
Derivative financial instrument not held at any quarter-end. The risk exposure table serves as an
indicator of activity during the period. |
| |
Assets |
Liabilities |
| Derivative Financial Instruments |
|
|
| Options |
$ — |
$ 6,220,791 |
| Total derivative assets and liabilities in the Statements of Assets and Liabilities |
— |
6,220,791 |
| Derivatives not subject to a Master Netting Agreement or similar agreement (“MNA”) |
— |
(4,616,689 ) |
| Total derivative assets and liabilities subject to an MNA |
$ — |
$ 1,604,102 |
| Counterparty |
Derivative Liabilities Subject to an MNA by Counterparty |
Derivatives Available for Offset(a)
|
Non-Cash Collateral Pledged(b)
|
Cash Collateral Pledged(b)
|
Net Amount of Derivative Liabilities(c)
|
| Barclays Bank PLC |
$ 22,560
|
$ —
|
$ —
|
$ —
|
$ 22,560
|
| Citibank N.A. |
716,817 |
— |
(716,817 ) |
— |
— |
| Goldman Sachs International |
700,527 |
— |
(700,527 ) |
— |
— |
| Morgan Stanley & Co. International PLC |
130,359 |
— |
— |
— |
130,359 |
| UBS AG |
33,839 |
— |
(33,839 ) |
— |
— |
| |
$ 1,604,102 |
$ — |
$ (1,451,183 ) |
$ — |
$ 152,919 |
| (a) |
The amount of derivatives available for offset is limited to the amount of derivative assets and/or liabilities that are subject to an MNA. |
| (b) |
Excess of collateral received/pledged, if any, from the individual counterparty is not shown for financial reporting purposes. |
| (c) |
Net amount represents the net amount payable due to the counterparty in the event of default. Net amount may be offset further by the options written
receivable/payable on the Statements of Assets and Liabilities. |
| |
Level 1 |
Level 2 |
Level 3 |
Total |
| Assets |
|
|
|
|
| Investments |
|
|
|
|
| Long-Term Investments |
|
|
|
|
| Common Stocks |
|
|
|
|
| Aerospace & Defense |
$ 102,198,408
|
$ —
|
$ —
|
$ 102,198,408 |
| Air Freight & Logistics |
7,479,912 |
— |
— |
7,479,912 |
| Automobile Components |
9,485,649 |
— |
— |
9,485,649 |
| Biotechnology |
28,973,079 |
— |
— |
28,973,079 |
| Building Products |
30,141,694 |
— |
— |
30,141,694 |
| Capital Markets |
86,872,796 |
— |
— |
86,872,796 |
| Construction & Engineering |
46,673,740 |
— |
— |
46,673,740 |
| Diversified Consumer Services |
20,485,176 |
— |
16,153,453 |
36,638,629 |
| Electrical Equipment |
61,107,411 |
— |
— |
61,107,411 |
| Electronic Equipment, Instruments & Components |
24,028,265 |
— |
— |
24,028,265 |
| Entertainment |
45,879,209 |
— |
— |
45,879,209 |
| Financial Services |
23,779,867 |
— |
— |
23,779,867 |
| Food Products |
20,741,621 |
— |
— |
20,741,621 |
| Ground Transportation |
40,971,038 |
— |
— |
40,971,038 |
| Health Care Equipment & Supplies |
65,441,489 |
— |
— |
65,441,489 |
| Health Care Providers & Services |
9,277,244 |
— |
— |
9,277,244 |
| Hotels, Restaurants & Leisure |
76,209,517 |
— |
— |
76,209,517 |
| Industrial REITs |
1,232,869 |
— |
— |
1,232,869 |
| Interactive Media & Services |
34,504,616 |
— |
5,754,157 |
40,258,773 |
| IT Services |
38,543,313 |
— |
8,675,311 |
47,218,624 |
| |
Level 1 |
Level 2 |
Level 3 |
Total |
| Common Stocks (continued) |
|
|
|
|
| Life Sciences Tools & Services |
$ 53,399,231
|
$ —
|
$ —
|
$ 53,399,231
|
| Machinery |
— |
8,438,564 |
— |
8,438,564 |
| Pharmaceuticals |
25,966,351 |
— |
— |
25,966,351 |
| Real Estate Management & Development |
40,011,436 |
— |
— |
40,011,436 |
| Semiconductors & Semiconductor Equipment |
104,031,404 |
58,473,464 |
— |
162,504,868 |
| Software |
149,197,474 |
12,053,475 |
17,702,848 |
178,953,797 |
| Specialty Retail |
37,075,813 |
— |
— |
37,075,813 |
| Technology Hardware, Storage & Peripherals |
26,682,981 |
— |
— |
26,682,981 |
| Textiles, Apparel & Luxury Goods |
20,729,185 |
25,943,561 |
— |
46,672,746 |
| Trading Companies & Distributors |
13,136,205 |
— |
— |
13,136,205 |
| Preferred Securities |
|
|
|
|
| Preferred Stocks |
— |
— |
394,763,266 |
394,763,266 |
| Short-Term Securities |
|
|
|
|
| Money Market Funds |
16,270,816 |
— |
— |
16,270,816 |
| |
$1,260,527,809 |
$104,909,064 |
$443,049,035 |
$1,808,485,908 |
| Derivative Financial Instruments(a)
|
|
|
|
|
| Liabilities |
|
|
|
|
| Equity Contracts |
$ (4,316,500 ) |
$ (1,904,291 ) |
$ — |
$ (6,220,791 ) |
| (a) |
Derivative financial instruments are options written. Options written are shown at
value. |
| |
Common Stocks |
Preferred Stocks |
Total |
| Assets |
|
|
|
| Opening balance, as of December 31, 2023 |
$ 71,905,711
|
$ 441,207,138
|
$ 513,112,849
|
| Transfers into Level 3 |
— |
— |
— |
| Transfers out of Level 3 |
— |
— |
— |
| Accrued discounts/premiums |
— |
— |
— |
| Net realized gain (loss) |
(50,000,000 ) |
— |
(50,000,000 ) |
| Net change in unrealized appreciation (depreciation)(a)(b) |
26,380,058 |
(40,449,642
) |
(14,069,584 ) |
| Purchases |
— |
— |
— |
| Sales |
— |
(5,994,230 ) |
(5,994,230 ) |
| Closing balance, as of December 31, 2024 |
$ 48,285,769 |
$ 394,763,266 |
$ 443,049,035 |
| Net change in unrealized appreciation (depreciation) on investments still held at December 31, 2024(b) |
$ (7,380,687 ) |
$ (40,449,642 ) |
$ (47,830,329 ) |
| (a) |
Included in the related net change in unrealized appreciation (depreciation) in the Statements of Operations. |
| (b) |
Any difference between net change in unrealized appreciation (depreciation) and net change in unrealized appreciation (depreciation) on investments still held at
December 31, 2024 is generally due to investments no longer held or categorized as
Level 3 at period end. |
| |
Value |
Valuation Approach |
Unobservable Inputs |
Range of Unobservable Inputs Utilized(a) |
Weighted Average of Unobservable Inputs Based on Fair Value |
| Assets |
|
|
|
|
|
| Common Stocks |
$48,285,769
|
Market |
Revenue Multiple |
7.50x - 21.00x |
14.36x |
| |
|
|
Gross Profit Multiple |
10.00x |
— |
| |
|
|
|
|
|
| Preferred Stocks |
394,763,266 |
Market |
Revenue Multiple |
0.95x - 21.00x |
9.54x |
| |
|
|
Time to Exit |
0.5 - 5.0 years |
2.7 years |
| |
Value |
Valuation Approach |
Unobservable
Inputs |
Range of
Unobservable
Inputs
Utilized(a) |
Weighted
Average of
Unobservable
Inputs Based
on Fair Value |
| |
|
|
Volatility |
40% - 95% |
67% |
| |
|
|
Market Adjustment Multiple |
0.45x - 1.80x |
1.37x |
| |
$443,049,035 |
|
|
|
|
| (a) |
A
significant change in unobservable input could result in a correlated or inverse change in value. |
| Security |
|
Shares |
Value |
| Common Stocks | |||
| Chemicals — 10.0% |
| ||
| CF Industries Holdings,
Inc.(a)(b) |
|
228,992 |
$ 19,537,597
|
| Corteva, Inc. |
|
481,571 |
27,430,284 |
| Nutrien Ltd. |
|
662,393 |
29,642,087 |
| |
|
|
76,609,968 |
| Construction Materials — 1.8% |
| ||
| CRH PLC |
|
151,377 |
14,005,400 |
| Containers & Packaging — 12.1% |
| ||
| Avery Dennison Corp. |
|
81,741 |
15,296,193 |
| DS Smith PLC |
|
943,072 |
6,378,283 |
| Graphic Packaging Holding Co. |
|
461,697 |
12,539,691 |
| Packaging Corp. of America(b)
|
|
100,552 |
22,637,272 |
| Smurfit WestRock PLC |
|
670,121 |
36,092,717 |
| |
|
|
92,944,156 |
| Energy Equipment & Services — 1.4% |
| ||
| Saipem SpA(c) |
|
4,175,579 |
10,922,212 |
| Food Products — 2.0% |
| ||
| Bunge Global SA |
|
92,787 |
7,215,117 |
| Hofseth International, (Acquired 05/26/21, Cost:
$10,198,056)(c)(d)(e) |
|
18,993,283 |
8,642,867 |
| |
|
|
15,857,984 |
| Metals & Mining — 33.1% |
| ||
| Anglo American Platinum Ltd. |
|
116,507 |
3,514,288 |
| Anglo American PLC |
|
1,010,207 |
29,868,941 |
| ArcelorMittal SA, ADR(f) |
|
233,043 |
5,390,285 |
| Barrick Gold Corp. |
|
1,013,037 |
15,702,074 |
| BHP Group Ltd., ADR |
|
326,983 |
15,966,580 |
| Cleveland-Cliffs, Inc.(c) |
|
24,515 |
230,441 |
| First Quantum Minerals Ltd.(c)
|
|
468,464 |
6,038,915 |
| Freeport-McMoRan, Inc.(a) |
|
434,063 |
16,529,119 |
| Glencore PLC |
|
6,786,410 |
29,888,543 |
| Kinross Gold Corp. |
|
650,270 |
6,028,003 |
| Newmont Corp.(a) |
|
245,647 |
9,142,981 |
| Norsk Hydro ASA |
|
4,859,786 |
26,732,120 |
| Nucor Corp. |
|
32,671 |
3,813,032 |
| Polyus PJSC(c)(d) |
|
104,732 |
9 |
| Rio Tinto PLC |
|
417,639 |
24,653,238 |
| Teck Resources Ltd., Class B |
|
358,340 |
14,523,520 |
| U.S. Steel Corp. |
|
125,324 |
4,259,763 |
| Vale SA, ADR |
|
793,951 |
7,042,345 |
| Wheaton Precious Metals Corp. |
|
627,429 |
35,286,607 |
| |
|
|
254,610,804 |
| Oil, Gas & Consumable Fuels — 34.2% |
| ||
| Cameco Corp. |
|
272,234 |
13,997,576 |
| Canadian Natural Resources Ltd. |
|
536,262 |
16,556,616 |
| Cheniere Energy, Inc.(a) |
|
57,424 |
12,338,695 |
| ConocoPhillips(b) |
|
155,494 |
15,420,340 |
| Diamondback Energy, Inc. |
|
39,974 |
6,548,940 |
| Eni SpA |
|
1,139,481 |
15,586,205 |
| Exxon Mobil Corp.(b) |
|
531,109 |
57,131,395 |
| Gazprom PJSC(c)(d) |
|
5,430,000 |
478 |
| Hess Corp.(a) |
|
102,564 |
13,642,038 |
| Permian Resources Corp., Class A |
|
325,298 |
4,677,785 |
| Shell PLC, ADR(b) |
|
1,053,693 |
66,013,866 |
| TotalEnergies SE |
|
614,992 |
34,264,190 |
| Tourmaline Oil Corp. |
|
139,607 |
6,460,508 |
| |
|
|
262,638,632 |
| Security |
|
Shares |
Value |
| Paper & Forest Products — 1.1% |
| ||
| Mondi PLC |
|
553,396 |
$ 8,238,758
|
| Precious Woods Holding AG, Registered
Shares(c) |
|
20,000 |
110,187 |
| |
|
|
8,348,945 |
| Total Common Stocks — 95.7% (Cost: $686,390,037) |
735,938,101 | ||
| |
|
Par (000) |
|
| Corporate Bonds | |||
| Metals & Mining — 0.9% | |||
| Allied Gold Corp., 8.75%,
09/07/28(g)(h) |
$ |
7,200 |
6,624,000 |
| Total Corporate Bonds — 0.9% (Cost: $7,200,000) |
6,624,000 | ||
| Total Long-Term Investments — 96.6% (Cost: $693,590,037) |
742,562,101 | ||
| |
|
Shares |
|
| Short-Term Securities | |||
| Money Market Funds — 4.0% |
| ||
| BlackRock Cash Funds: Institutional, SL Agency Shares, 4.63%(i)(j)(k) |
|
1,846,362 |
1,847,286 |
| BlackRock Liquidity Funds, T-Fund, Institutional Shares,
4.36%(i)(j) |
|
28,918,529 |
28,918,529 |
| Total Short-Term Securities — 4.0% (Cost: $30,765,955) |
30,765,815 | ||
| Total Investments Before Options Written — 100.6% (Cost: $724,355,992) |
773,327,916 | ||
| Options Written — (0.4)% (Premiums Received: $(5,939,779)) |
(2,922,240 ) | ||
| Total Investments, Net of Options Written — 100.2% (Cost: $718,416,213) |
770,405,676 | ||
| Liabilities in Excess of Other Assets — (0.2)% |
(1,838,661 ) | ||
| Net Assets — 100.0% |
$ 768,567,015 | ||
| (a) |
All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives. |
| (b) |
All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written. |
| (c) |
Non-income producing security. |
| (d) |
Security is valued using significant unobservable inputs and is classified as Level 3 in the
fair value hierarchy. |
| (e) |
Restricted security as to resale, excluding 144A securities. The Trust held restricted
securities with a current value of $8,642,867, representing 1.1% of its net assets as of
period end, and an original cost of $10,198,056. |
| (f) |
All or a portion of this security is on loan. |
| (g) |
Convertible security. |
| (h) |
Security exempt from registration pursuant to Rule 144A under the Securities Act of 1933,
as amended. These securities may be resold in transactions exempt from registration to
qualified institutional investors. |
| (i) |
Affiliate of the Trust. |
| (j) |
Annualized 7-day yield as of period end. |
| (k) |
All or a portion of this security was purchased with the cash collateral from loaned securities. |
| Affiliated Issuer |
Value at 12/31/23 |
Purchases at Cost |
Proceeds from Sales |
Net Realized Gain (Loss) |
Change in Unrealized Appreciation (Depreciation) |
Value at 12/31/24 |
Shares Held at 12/31/24 |
Income |
Capital Gain Distributions from Underlying Funds |
| BlackRock Cash Funds: Institutional, SL Agency Shares |
$ — |
$ 1,846,881 (a) |
$ — |
$ 545 |
$ (140 ) |
$ 1,847,286 |
1,846,362 |
$ 6,907 (b) |
$ — |
| BlackRock Liquidity Funds, T-Fund, Institutional Shares |
14,160,077 |
14,758,452 (a) |
— |
— |
— |
28,918,529 |
28,918,529 |
997,798 |
— |
| SL Liquidity Series, LLC, Money Market
Series(c) |
6,150,469 |
— |
(6,150,168
)(a) |
(800 ) |
499 |
— |
— |
6,856
(b) |
— |
| |
|
|
|
$ (255 ) |
$ 359 |
$ 30,765,815 |
|
$ 1,011,561 |
$ — |
| (a) |
Represents net amount purchased (sold). |
| (b) |
All or a portion represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of collateral investment fees, and
other payments to and from borrowers of securities. |
| (c) |
As of period end, the entity is no longer held. |
| Description |
Number of Contracts |
Expiration Date |
Exercise Price |
Notional Amount (000) |
Value | ||
| Call |
|
|
|
|
|
|
|
| Nucor Corp. |
61 |
01/03/25 |
USD |
150.00 |
USD |
712 |
$ (305
) |
| Teck Resources Ltd., Class B |
309 |
01/03/25 |
USD |
48.00 |
USD |
1,252 |
(20,085 ) |
| ConocoPhillips |
166 |
01/10/25 |
USD |
109.00 |
USD |
1,646 |
(1,494 ) |
| Diamondback Energy, Inc. |
57 |
01/10/25 |
USD |
185.00 |
USD |
934 |
(855 ) |
| Exxon Mobil Corp. |
288 |
01/10/25 |
USD |
120.00 |
USD |
3,098 |
(576 ) |
| Freeport-McMoRan, Inc. |
930 |
01/10/25 |
USD |
47.00 |
USD |
3,541 |
(46,500 ) |
| Kinross Gold Corp. |
1,180 |
01/10/25 |
USD |
10.45 |
USD |
1,094 |
(1,054 ) |
| Shell PLC, ADR |
798 |
01/10/25 |
USD |
67.00 |
USD |
4,999 |
(3,990 ) |
| ArcelorMittal SA, ADR |
105 |
01/17/25 |
USD |
24.00 |
USD |
243 |
(2,100 ) |
| Avery Dennison Corp. |
180 |
01/17/25 |
USD |
210.00 |
USD |
3,368 |
(9,000 ) |
| Avery Dennison Corp. |
122 |
01/17/25 |
USD |
200.00 |
USD |
2,283 |
(8,845 ) |
| BHP Group Ltd., ADR |
1,012 |
01/17/25 |
USD |
57.50 |
USD |
4,942 |
(10,120 ) |
| Bunge Global SA |
175 |
01/17/25 |
USD |
92.50 |
USD |
1,361 |
(3,500 ) |
| Canadian Natural Resources Ltd. |
132 |
01/17/25 |
CAD |
49.00 |
CAD |
586 |
(551 ) |
| Cheniere Energy, Inc. |
54 |
01/17/25 |
USD |
200.00 |
USD |
1,160 |
(87,210 ) |
| Cheniere Energy, Inc. |
104 |
01/17/25 |
USD |
210.00 |
USD |
2,235 |
(82,160 ) |
| Corteva, Inc. |
890 |
01/17/25 |
USD |
60.00 |
USD |
5,069 |
(26,700 ) |
| CRH PLC |
205 |
01/17/25 |
USD |
105.00 |
USD |
1,897 |
(15,375 ) |
| Exxon Mobil Corp. |
483 |
01/17/25 |
USD |
125.00 |
USD |
5,196 |
(1,449 ) |
| First Quantum Minerals Ltd. |
725 |
01/17/25 |
CAD |
21.00 |
CAD |
1,343 |
(6,809 ) |
| Graphic Packaging Holding Co. |
648 |
01/17/25 |
USD |
30.00 |
USD |
1,760 |
(16,200 ) |
| Hess Corp. |
72 |
01/17/25 |
USD |
150.00 |
USD |
958 |
(1,800 ) |
| Nucor Corp. |
88 |
01/17/25 |
USD |
160.00 |
USD |
1,027 |
(440 ) |
| Packaging Corp. of America |
194 |
01/17/25 |
USD |
240.00 |
USD |
4,368 |
(36,860 ) |
| Permian Resources Corp., Class A |
433 |
01/17/25 |
USD |
15.20 |
USD |
623 |
(21,333 ) |
| Shell PLC, ADR |
511 |
01/17/25 |
USD |
70.00 |
USD |
3,201 |
(2,555 ) |
| Shell PLC, ADR |
338 |
01/17/25 |
USD |
67.50 |
USD |
2,118 |
(3,380 ) |
| Smurfit WestRock PLC |
700 |
01/17/25 |
USD |
55.00 |
USD |
3,770 |
(80,500 ) |
| Teck Resources Ltd., Class B |
609 |
01/17/25 |
USD |
49.00 |
USD |
2,468 |
(11,266 ) |
| Tourmaline Oil Corp. |
136 |
01/17/25 |
CAD |
65.50 |
CAD |
905 |
(18,828 ) |
| U.S. Steel Corp. |
230 |
01/17/25 |
USD |
40.00 |
USD |
782 |
(60,030 ) |
| Vale SA, ADR |
665 |
01/17/25 |
USD |
10.00 |
USD |
590 |
(1,663 ) |
| ArcelorMittal SA, ADR |
192 |
01/24/25 |
USD |
27.00 |
USD |
444 |
(1,920 ) |
| Canadian Natural Resources Ltd. |
926 |
01/24/25 |
CAD |
45.50 |
CAD |
4,110 |
(42,195 ) |
| ConocoPhillips |
212 |
01/24/25 |
USD |
108.00 |
USD |
2,102 |
(6,784 ) |
| Diamondback Energy, Inc. |
90 |
01/24/25 |
USD |
175.00 |
USD |
1,474 |
(11,250 ) |
| Exxon Mobil Corp. |
400 |
01/24/25 |
USD |
118.00 |
USD |
4,303 |
(5,200 ) |
| Description |
Number of Contracts |
Expiration Date |
Exercise Price |
Notional Amount (000) |
Value | ||
| Call (continued) |
|
|
|
|
|
|
|
| First Quantum Minerals Ltd. |
504 |
01/24/25 |
CAD |
19.50 |
CAD |
934 |
$ (19,109
) |
| Hess Corp. |
307 |
01/24/25 |
USD |
130.00 |
USD |
4,083 |
(135,080 ) |
| Shell PLC, ADR |
929 |
01/24/25 |
USD |
64.00 |
USD |
5,820 |
(69,675 ) |
| Tourmaline Oil Corp. |
244 |
01/24/25 |
CAD |
62.00 |
CAD |
1,623 |
(82,751 ) |
| U.S. Steel Corp. |
230 |
01/24/25 |
USD |
40.00 |
USD |
782 |
(64,170 ) |
| Canadian Natural Resources Ltd. |
926 |
01/31/25 |
CAD |
45.50 |
CAD |
4,110 |
(52,180 ) |
| ConocoPhillips |
197 |
01/31/25 |
USD |
101.00 |
USD |
1,954 |
(38,809 ) |
| CRH PLC |
355 |
01/31/25 |
USD |
101.00 |
USD |
3,284 |
(47,925 ) |
| Exxon Mobil Corp. |
442 |
01/31/25 |
USD |
112.00 |
USD |
4,755 |
(60,554 ) |
| First Quantum Minerals Ltd. |
504 |
01/31/25 |
CAD |
19.50 |
CAD |
934 |
(23,667 ) |
| Freeport-McMoRan, Inc. |
676 |
01/31/25 |
USD |
41.00 |
USD |
2,574 |
(43,264 ) |
| Kinross Gold Corp. |
1,225 |
01/31/25 |
USD |
10.10 |
USD |
1,136 |
(18,460 ) |
| Nucor Corp. |
70 |
01/31/25 |
USD |
135.00 |
USD |
817 |
(4,375 ) |
| Shell PLC, ADR |
528 |
01/31/25 |
USD |
66.00 |
USD |
3,308 |
(23,760 ) |
| Vale SA, ADR |
1,136 |
01/31/25 |
USD |
10.00 |
USD |
1,008 |
(6,248 ) |
| Shell PLC, ADR |
794 |
02/07/25 |
USD |
64.00 |
USD |
4,974 |
(132,995 ) |
| ArcelorMittal SA, ADR |
565 |
02/21/25 |
USD |
24.00 |
USD |
1,307 |
(39,550 ) |
| BHP Group Ltd., ADR |
197 |
02/21/25 |
USD |
55.00 |
USD |
962 |
(6,895 ) |
| Bunge Global SA |
168 |
02/21/25 |
USD |
85.25 |
USD |
1,306 |
(13,454 ) |
| Cheniere Energy, Inc. |
54 |
02/21/25 |
USD |
220.00 |
USD |
1,160 |
(32,130 ) |
| Corteva, Inc. |
891 |
02/21/25 |
USD |
60.00 |
USD |
5,075 |
(120,285 ) |
| Exxon Mobil Corp. |
352 |
02/21/25 |
USD |
120.00 |
USD |
3,786 |
(17,952 ) |
| Packaging Corp. of America |
178 |
02/21/25 |
USD |
239.81 |
USD |
4,007 |
(45,347 ) |
| Permian Resources Corp., Class A |
770 |
02/21/25 |
USD |
15.00 |
USD |
1,107 |
(38,500 ) |
| Teck Resources Ltd., Class B |
582 |
02/21/25 |
USD |
49.00 |
USD |
2,359 |
(25,317 ) |
| Tourmaline Oil Corp. |
136 |
02/21/25 |
CAD |
65.50 |
CAD |
905 |
(28,809 ) |
| Vale SA, ADR |
1,136 |
02/21/25 |
USD |
9.25 |
USD |
1,008 |
(30,984 ) |
| |
|
|
|
|
|
|
$ (1,873,127 ) |
| Description |
Counterparty |
Number of Contracts |
Expiration Date |
Exercise Price |
Notional Amount (000) |
Value | ||
| Call |
|
|
|
|
|
|
|
|
| Rio Tinto PLC |
Citibank N.A. |
128,000 |
01/07/25 |
GBP |
52.55 |
GBP |
6,036 |
$ (336
) |
| Anglo American PLC |
Bank of America N.A. |
228,600 |
01/09/25 |
GBP |
23.44 |
GBP |
5,399 |
(200,037 ) |
| DS Smith PLC |
Goldman Sachs International |
180,000 |
01/09/25 |
GBP |
5.82 |
GBP |
972 |
(394 ) |
| Eni SpA |
Goldman Sachs International |
217,500 |
01/09/25 |
EUR |
14.43 |
EUR |
2,872 |
(144 ) |
| Graphic Packaging Holding Co. |
Barclays Bank PLC |
106,000 |
01/09/25 |
USD |
29.75 |
USD |
2,879 |
(648 ) |
| Norsk Hydro ASA |
UBS AG |
458,800 |
01/09/25 |
NOK |
67.95 |
NOK |
28,728 |
(2,369 ) |
| Rio Tinto PLC |
Bank of America N.A. |
51,800 |
01/09/25 |
GBP |
48.53 |
GBP |
2,442 |
(12,125 ) |
| Glencore PLC |
BNP Paribas SA |
1,133,600 |
01/14/25 |
GBP |
3.93 |
GBP |
3,988 |
(3,562 ) |
| Saipem SpA |
Bank of America N.A. |
711,100 |
01/14/25 |
EUR |
2.43 |
EUR |
1,796 |
(81,393 ) |
| Mondi PLC |
Bank of America N.A. |
50,000 |
01/15/25 |
GBP |
12.31 |
GBP |
595 |
(4,869 ) |
| Saipem SpA |
UBS AG |
866,200 |
01/16/25 |
EUR |
2.46 |
EUR |
2,187 |
(87,706 ) |
| Smurfit WestRock PLC |
Citibank N.A. |
88,000 |
01/21/25 |
USD |
53.25 |
USD |
4,740 |
(179,088 ) |
| Glencore PLC |
Citibank N.A. |
817,400 |
01/22/25 |
GBP |
3.84 |
GBP |
2,876 |
(14,572 ) |
| TotalEnergies SE |
Goldman Sachs International |
151,500 |
01/22/25 |
EUR |
54.70 |
EUR |
8,149 |
(56,053 ) |
| Anglo American PLC |
Morgan Stanley & Co. International PLC |
145,000 |
01/24/25 |
GBP |
27.32 |
GBP |
3,425 |
(13,442 ) |
| DS Smith PLC |
Goldman Sachs International |
169,000 |
01/24/25 |
GBP |
6.03 |
GBP |
913 |
(1,126 ) |
| Eni SpA |
UBS AG |
204,300 |
01/24/25 |
EUR |
13.91 |
EUR |
2,698 |
(8,116 ) |
| Norsk Hydro ASA |
Morgan Stanley & Co. International PLC |
616,000 |
01/24/25 |
NOK |
71.75 |
NOK |
38,572 |
(16,161 ) |
| Glencore PLC |
Bank of America N.A. |
560,000 |
01/28/25 |
GBP |
3.68 |
GBP |
1,979 |
(39,189 ) |
| Mondi PLC |
Goldman Sachs International |
154,700 |
01/28/25 |
GBP |
12.14 |
GBP |
1,844 |
(38,040 ) |
| Norsk Hydro ASA |
Morgan Stanley & Co. International PLC |
723,300 |
01/28/25 |
NOK |
66.57 |
NOK |
45,235 |
(43,918 ) |
| TotalEnergies SE |
Goldman Sachs International |
76,000 |
01/28/25 |
EUR |
54.27 |
EUR |
4,056 |
(44,430 ) |
| Smurfit WestRock PLC |
Citibank N.A. |
90,000 |
02/14/25 |
USD |
54.10 |
USD |
4,847 |
(201,395 ) |
| |
|
|
|
|
|
|
|
$ (1,049,113 ) |
| Description |
Premiums Paid |
Premiums Received |
Unrealized Appreciation |
Unrealized Depreciation |
Value |
| Options Written |
$ N/A
|
$ (5,939,779
) |
$ 3,390,355
|
$ (372,816
) |
$ (2,922,240
) |
| |
Commodity Contracts |
Credit Contracts |
Equity Contracts |
Foreign Currency Exchange Contracts |
Interest Rate Contracts |
Other Contracts |
Total |
| Liabilities — Derivative Financial Instruments |
|
|
|
|
|
|
|
| Options written Options written at value |
$ — |
$ — |
$ 2,922,240 |
$ — |
$ — |
$ — |
$ 2,922,240 |
| |
Commodity Contracts |
Credit Contracts |
Equity Contracts |
Foreign Currency Exchange Contracts |
Interest Rate Contracts |
Other Contracts |
Total |
| Net Realized Gain (Loss) from: |
|
|
|
|
|
|
|
| Options purchased(a) |
$ —
|
$ —
|
$ (134,442
) |
$ —
|
$ —
|
$ —
|
$ (134,442
) |
| Options written |
— |
— |
2,811,864 |
— |
— |
— |
2,811,864 |
| |
$ — |
$ — |
$ 2,677,422 |
$ — |
$ — |
$ — |
$ 2,677,422 |
| Net Change in Unrealized Appreciation (Depreciation) on: |
|
|
|
|
|
|
|
| Options written |
$ — |
$ — |
$ 6,261,268 |
$ — |
$ — |
$ — |
$ 6,261,268 |
| (a) |
Options purchased are included in net realized gain (loss) from investments —
unaffiliated. |
| Options: |
|
| Average value of option contracts purchased |
$—
(a) |
| Average value of option contracts written |
8,357,934 |
| (a) |
Derivative financial instrument not held at any quarter-end. The risk exposure table serves as an
indicator of activity during the period. |
| |
Assets |
Liabilities |
| Derivative Financial Instruments |
|
|
| Options |
$ — |
$ 2,922,240 |
| Total derivative assets and liabilities in the Statements of Assets and Liabilities |
— |
2,922,240 |
| Derivatives not subject to a Master Netting Agreement or similar agreement (“MNA”) |
— |
(1,873,127 ) |
| Total derivative assets and liabilities subject to an MNA |
$ — |
$ 1,049,113 |
| Counterparty |
Derivative Liabilities Subject to an MNA by Counterparty |
Derivatives Available for Offset(a)
|
Non-Cash Collateral Pledged(b)
|
Cash Collateral Pledged(b)
|
Net Amount of Derivative Liabilities(c)
|
| Bank of America N.A. |
$ 337,613
|
$ —
|
$ (337,613
) |
$ —
|
$ —
|
| Counterparty |
Derivative Liabilities Subject to an MNA by Counterparty |
Derivatives Available for Offset(a) |
Non-Cash Collateral Pledged(b) |
Cash Collateral Pledged(b) |
Net Amount of Derivative Liabilities(c) |
| Barclays Bank PLC |
$ 648
|
$ —
|
$ (648
) |
$ —
|
$ —
|
| BNP Paribas SA |
3,562 |
— |
— |
— |
3,562 |
| Citibank N.A. |
395,391 |
— |
(395,391 ) |
— |
— |
| Goldman Sachs International |
140,187 |
— |
(140,187 ) |
— |
— |
| Morgan Stanley & Co. International PLC |
73,521 |
— |
(73,521 ) |
— |
— |
| UBS AG |
98,191 |
— |
— |
— |
98,191 |
| |
$ 1,049,113 |
$ — |
$ (947,360 ) |
$ — |
$ 101,753 |
| (a) |
The amount of derivatives available for offset is limited to the amount of derivative assets and/or liabilities that are subject to an MNA. |
| (b) |
Excess of collateral received/pledged, if any, from the individual counterparty is not shown for financial reporting purposes. |
| (c) |
Net amount represents the net amount payable due to the counterparty in the event of default. Net amount may be offset further by the options written
receivable/payable on the Statements of Assets and Liabilities. |
| |
Level 1 |
Level 2 |
Level 3 |
Total |
| Assets |
|
|
|
|
| Investments |
|
|
|
|
| Long-Term Investments |
|
|
|
|
| Common Stocks |
|
|
|
|
| Chemicals |
$ 76,609,968
|
$ —
|
$ —
|
$ 76,609,968 |
| Construction Materials |
14,005,400 |
— |
— |
14,005,400 |
| Containers & Packaging |
86,565,873 |
6,378,283 |
— |
92,944,156 |
| Energy Equipment & Services |
— |
10,922,212 |
— |
10,922,212 |
| Food Products |
7,215,117 |
— |
8,642,867 |
15,857,984 |
| Metals & Mining |
139,953,665 |
114,657,130 |
9 |
254,610,804 |
| Oil, Gas & Consumable Fuels |
212,787,759 |
49,850,395 |
478 |
262,638,632 |
| Paper & Forest Products |
— |
8,348,945 |
— |
8,348,945 |
| Corporate Bonds |
— |
6,624,000 |
— |
6,624,000 |
| Short-Term Securities |
|
|
|
|
| Money Market Funds |
30,765,815 |
— |
— |
30,765,815 |
| |
$567,903,597 |
$196,780,965 |
$8,643,354 |
$773,327,916 |
| Derivative Financial Instruments(a)
|
|
|
|
|
| Liabilities |
|
|
|
|
| Equity Contracts |
$ (1,742,495 ) |
$ (1,179,745 ) |
$ — |
$ (2,922,240 ) |
| (a) |
Derivative financial instruments are options written. Options written are shown at
value. |
| |
Common Stocks |
| Assets |
|
| Opening balance, as of December 31, 2023 |
$ 7,777,474
|
| Transfers into Level 3 |
— |
| Transfers out of Level 3 |
— |
| Accrued discounts/premiums |
— |
| Net realized gain (loss) |
— |
| Net change in unrealized appreciation (depreciation)(a)(b) |
865,880 |
| |
Common
Stocks |
| Purchases |
$ —
|
| Sales |
— |
| Closing balance, as of December 31, 2024 |
$ 8,643,354 |
| Net change in unrealized appreciation (depreciation) on investments still held at December 31, 2024(b) |
$ 865,880 |
| (a) |
Included in the related net change in unrealized appreciation (depreciation) in the Statements of Operations. |
| (b) |
Any difference between net change in unrealized appreciation (depreciation) and net change in unrealized appreciation (depreciation) on investments still held at
December 31, 2024 is generally due to investments no longer held or categorized as
Level 3 at period end. |
| |
Value |
Valuation Approach |
Unobservable Inputs |
Range of Unobservable Inputs Utilized(a) |
Weighted Average of Unobservable Inputs Based on Fair Value |
| Assets |
|
|
|
|
|
| Common Stocks |
$8,642,867
|
Market |
EBITDA Multiple |
11.50x |
— |
| |
|
|
|
|
|
| |
$8,642,867 |
|
|
|
|
| (a) |
A
significant change in unobservable input could result in a correlated or inverse change in value. |
| Security |
|
Shares |
Value |
| Common Stocks | |||
| Automobiles — 2.5% |
| ||
| Tesla, Inc.(a)(b) |
|
105,627 |
$ 42,656,408 |
| Broadline Retail — 1.1% |
| ||
| MercadoLibre, Inc.(b) |
|
10,574 |
17,980,452 |
| Communications Equipment — 0.9% |
| ||
| Accton Technology Corp. |
|
638,000 |
14,995,411 |
| Construction & Engineering — 0.4% |
| ||
| Quanta Services, Inc. |
|
22,780 |
7,199,619 |
| Consumer Finance — 0.9% |
| ||
| Kaspi.KZ JSC, ADR |
|
161,162 |
15,263,653 |
| Diversified Consumer Services — 0.0% |
| ||
| Think & Learn Private Ltd., Class J-B, (Acquired 09/30/20, Cost:
$7,113,729)(b)(c)(d) |
|
4,651 |
— |
| Electrical Equipment — 0.9% |
| ||
| Vertiv Holdings Co., Class A |
|
128,842 |
14,637,740 |
| Electronic Equipment, Instruments & Components — 4.4% |
| ||
| Celestica, Inc.(b) |
|
108,993 |
10,060,054 |
| Coherent Corp.(b) |
|
304,524 |
28,847,558 |
| E Ink Holdings, Inc. |
|
1,059,000 |
8,818,026 |
| Fabrinet(b)(e) |
|
64,395 |
14,159,172 |
| Lotes Co. Ltd. |
|
207,000 |
12,299,526 |
| |
|
|
74,184,336 |
| Entertainment — 4.0% |
| ||
| Nintendo Co. Ltd. |
|
204,000 |
11,881,320 |
| Spotify Technology SA(b) |
|
77,108 |
34,496,577 |
| Take-Two Interactive Software, Inc.(b) |
|
108,634 |
19,997,347 |
| |
|
|
66,375,244 |
| Financial Services — 0.8% |
| ||
| Adyen NV(b)(f) |
|
8,718 |
12,955,627 |
| Industrial Conglomerates — 1.2% |
| ||
| Hitachi Ltd. |
|
805,900 |
19,736,527 |
| Interactive Media & Services — 3.1% |
| ||
| Reddit, Inc., Class A(b)(e)
|
|
317,633 |
51,913,937 |
| IT Services — 5.7% |
| ||
| Automattic, Inc., Series E, (Acquired 02/03/21, Cost: $34,000,000)(b)(c)(d) |
|
400,000 |
15,004,000 |
| Cloudflare, Inc., Class A(b) |
|
122,629 |
13,204,691 |
| CNEX Labs, Inc., (Acquired 12/14/21, Cost: $5,699,998)(b)(c)(d) |
|
1,161,804 |
12 |
| Farmer’
s Business Network,
Inc.(b)(c) |
|
361,834 |
958,860 |
| Klarna Holdings AB, (Acquired 08/07/19, Cost: $23,354,996)(b)(c)(d) |
|
86,839 |
43,443,557 |
| MongoDB, Inc., Class A(b) |
|
61,778 |
14,382,536 |
| NEC Corp. |
|
103,100 |
8,822,995 |
| |
|
|
95,816,651 |
| Media — 0.8% |
| ||
| Informa PLC |
|
1,276,984 |
12,736,124 |
| Professional Services — 3.0% |
| ||
| Thomson Reuters Corp. |
|
86,670 |
13,900,135 |
| TransUnion |
|
103,833 |
9,626,357 |
| Wolters Kluwer NV, Class C |
|
160,019 |
26,586,247 |
| |
|
|
50,112,739 |
| Security |
|
Shares |
Value |
| Semiconductors & Semiconductor Equipment — 23.9% |
| ||
| ARM Holdings PLC, ADR(b) |
|
115,482 |
$ 14,245,860
|
| ASM International NV |
|
27,327 |
15,800,065 |
| Astera Labs, Inc.(b)(g) |
|
539,061 |
71,398,629 |
| Credo Technology Group Holding
Ltd.(b) |
|
806,482 |
54,203,655 |
| Disco Corp. |
|
44,200 |
11,725,262 |
| eMemory Technology, Inc. |
|
106,000 |
10,829,725 |
| Marvell Technology, Inc. |
|
279,976 |
30,923,349 |
| Monolithic Power Systems, Inc. |
|
18,081 |
10,698,528 |
| Mythic AI, Inc., Series C, (Acquired 01/26/21, Cost:
$7,000,000)(b)(c)(d) |
|
10,189 |
— |
| NVIDIA Corp.(a)(g) |
|
1,134,200 |
152,311,718 |
| SK Hynix, Inc. |
|
237,976 |
27,269,744 |
| |
|
|
399,406,535 |
| Software(b)
— 19.2% |
| ||
| AppLovin Corp., Class A |
|
42,513 |
13,766,985 |
| Atlassian Corp., Class A |
|
59,175 |
14,402,011 |
| Confluent, Inc., Class A |
|
501,639 |
14,025,826 |
| CyberArk Software Ltd. |
|
66,898 |
22,287,069 |
| Databricks, Inc., (Acquired 07/24/20, Cost: $5,501,686)(c)(d) |
|
343,659 |
31,541,023 |
| Datadog, Inc., Class A |
|
83,198 |
11,888,162 |
| DataRobot, Inc., (Acquired 03/01/21, Cost: $1,384,813)(c)(d) |
|
92,093 |
186,028 |
| Descartes Systems Group, Inc. |
|
105,869 |
12,026,718 |
| Elastic NV |
|
119,727 |
11,862,551 |
| Gitlab, Inc., Class A |
|
301,279 |
16,977,072 |
| Guidewire Software, Inc. |
|
75,799 |
12,778,195 |
| Manhattan Associates, Inc. |
|
45,258 |
12,230,522 |
| nCino, Inc.(e) |
|
306,178 |
10,281,457 |
| Palo Alto Networks, Inc. |
|
62,085 |
11,296,987 |
| Pony AI, Inc., ADR(e) |
|
560,508 |
8,043,290 |
| Q2 Holdings, Inc. |
|
133,346 |
13,421,275 |
| Samsara, Inc., Class A |
|
375,536 |
16,407,168 |
| SentinelOne, Inc., Class A |
|
593,231 |
13,169,728 |
| ServiceTitan, Inc. |
|
40,362 |
4,152,039 |
| Silvaco Group, Inc.(e) |
|
287,994 |
2,326,992 |
| SiteMinder Ltd. |
|
2,707,952 |
10,111,489 |
| Snorkel AI, Inc., (Acquired 10/13/20, Cost:
$2,017,593)(c)(d) |
|
500,250 |
5,037,518 |
| Snyk Ltd., Ordinary Shares, (Acquired 11/02/20, Cost: $9,287,400)(c)(d) |
|
1,267,643 |
10,990,465 |
| Synopsys, Inc.(a) |
|
50,159 |
24,345,172 |
| Xero Ltd. |
|
180,548 |
18,788,375 |
| |
|
|
322,344,117 |
| Technology Hardware, Storage & Peripherals — 3.0% |
| ||
| Asia Vital Components Co. Ltd. |
|
1,018,000 |
19,204,316 |
| Pure Storage, Inc., Class A(b)
|
|
510,733 |
31,374,328 |
| |
|
|
50,578,644 |
| Total Common Stocks — 75.8% (Cost: $726,242,008) |
1,268,893,764 | ||
| Preferred Securities | |||
| Preferred Stocks — 25.1%(b)(c) | |||
| Communications Equipment — 0.6% |
| ||
| Astranis Space Technologies Corp., Series C |
|
775,515 |
9,934,347 |
| Security |
|
Shares |
Value |
| Consumer Staples Distribution & Retail — 2.0% |
| ||
| GrubMarket, Inc., Series D, (Acquired 07/23/20, Cost:
$8,000,001)(d) |
|
1,762,969 |
$ 32,844,113 |
| Diversified Consumer Services — 0.0% |
| ||
| Think & Learn Private Ltd., Series F, (Acquired 09/30/20,
Cost: $14,251,080)(d) |
|
4,920 |
— |
| Entertainment — 0.3% |
| ||
| ResearchGate GmbH, Series D, (Acquired 09/24/20,
Cost: $6,999,988)(d) |
|
424,688 |
4,548,409 |
| Financial Services(d)(h)
— 1.7% |
| ||
| Trumid Holdings LLC |
|
|
|
| Class J-A, (Acquired 07/24/20, Cost: $9,999,857) |
|
20,154 |
14,589,884 |
| Class J-B, (Acquired 07/24/20, Cost: $5,999,914) |
|
20,154 |
14,589,883 |
| |
|
|
29,179,767 |
| Interactive Media & Services — 1.6% |
| ||
| ByteDance Ltd., Series E-1, (Acquired 11/11/20, Cost: $16,961,509)(d) |
|
150,113 |
27,125,419 |
| IT
Services(d) — 1.2% |
| ||
| Deep Instinct Ltd., Series D-2, (Acquired 03/19/21, Cost: $12,000,008) |
|
1,974,374 |
8,529,296 |
| TRAX Ltd. |
|
|
|
| (Acquired 09/12/19, Cost: $10,999,988) |
|
293,333 |
6,916,792 |
| (Acquired 02/18/21, Cost: $9,999,998) |
|
191,806 |
4,522,785 |
| |
|
|
19,968,873 |
| Professional Services — 0.5% |
| ||
| Rapyd Financial Network Ltd., Series E, (Acquired 03/31/21, Cost: $13,999,978)(d)
|
|
190,705 |
9,167,189 |
| Semiconductors & Semiconductor Equipment(d) —
8.2% |
| ||
| PsiQuantum Corp. |
|
|
|
| Series C, (Acquired 09/09/19, Cost: $9,101,310) |
|
1,962,335 |
67,739,804 |
| Series D, (Acquired 05/21/21, Cost: $19,999,969) |
|
762,595 |
29,070,122 |
| SambaNova Systems, Inc. |
|
|
|
| Series C, (Acquired 02/20/20, Cost: $33,904,162) |
|
636,800 |
35,501,600 |
| Series D, (Acquired 04/09/21, Cost: $6,999,979) |
|
73,670 |
4,712,670 |
| |
|
|
137,024,196 |
| Software(d)
— 9.0% |
| ||
| Databricks, Inc. |
|
|
|
| Series F, (Acquired 10/22/19, Cost: $13,200,019) |
|
922,038 |
84,624,648 |
| Series G, (Acquired 02/01/21, Cost: $18,500,004) |
|
312,909 |
28,718,788 |
| DataRobot, Inc., Series F, (Acquired 10/27/20, Cost:
$11,499,999) |
|
875,059 |
4,419,048 |
| Snorkel AI, Inc., Series B, (Acquired 10/13/20, Cost: $999,996) |
|
247,943 |
2,496,786 |
| Snyk Ltd., Seed Preferred, (Acquired 11/02/20, Cost:
$13,212,590) |
|
2,663,936 |
23,096,325 |
| Unqork, Inc. |
|
|
|
| Series B, (Acquired 09/19/19, Cost: $6,801,016) |
|
597,680 |
4,118,015 |
| Series C, (Acquired 09/18/20, Cost: $7,994,787) |
|
292,000 |
2,502,440 |
| |
|
|
149,976,050 |
| |
419,768,363 | ||
| Total Preferred Securities — 25.1% (Cost: $268,426,162) |
419,768,363 | ||
| Total Long-Term Investments — 100.9% (Cost: $994,668,170) |
1,688,662,127 | ||
| Security |
|
Shares |
Value |
| Short-Term Securities | |||
| Money Market Funds — 0.6% |
| ||
| BlackRock Cash Funds: Institutional, SL Agency Shares, 4.63%(i)(j)(k) |
|
7,487,405 |
$ 7,491,149
|
| BlackRock Liquidity Funds, T-Fund, Institutional Shares,
4.36%(i)(j) |
|
2,010,552 |
2,010,552 |
| Total Short-Term Securities — 0.6% (Cost: $9,500,263) |
9,501,701 | ||
| Total Investments Before Options Written — 101.5% (Cost: $1,004,168,433) |
1,698,163,828 | ||
| Options Written — (0.7)% (Premiums Received: $(14,389,743)) |
(11,477,631 ) | ||
| Total Investments, Net of Options Written — 100.8% (Cost: $989,778,690) |
1,686,686,197 | ||
| Liabilities in Excess of Other Assets — (0.8)% |
(13,094,747 ) | ||
| Net Assets — 100.0% |
$ 1,673,591,450 | ||
| (a) |
All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written. |
| (b) |
Non-income producing security. |
| (c) |
Security is valued using significant unobservable inputs and is classified as Level 3 in the
fair value hierarchy. |
| (d) |
Restricted security as to resale, excluding 144A securities. The Trust held restricted
securities with a current value of $516,036,619, representing 30.8% of its net assets as
of period end, and an original cost of $346,786,367. |
| (e) |
All or a portion of this security is on loan. |
| (f) |
Security exempt from registration pursuant to Rule 144A under the Securities Act of 1933,
as amended. These securities may be resold in transactions exempt from registration to
qualified institutional investors. |
| (g) |
All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives. |
| (h) |
All or a portion of the security is held by a wholly-owned subsidiary. See Note 1 of the
Notes to Financial Statements for details on the wholly-owned subsidiary. |
| (i) |
Affiliate of the Trust. |
| (j) |
Annualized 7-day yield as of period end. |
| (k) |
All or a portion of this security was purchased with the cash collateral from loaned securities. |
| Affiliated Issuer |
Value at 12/31/23 |
Purchases at Cost |
Proceeds from Sales |
Net Realized Gain (Loss) |
Change in Unrealized Appreciation (Depreciation) |
Value at 12/31/24 |
Shares Held at 12/31/24 |
Income |
Capital Gain Distributions from Underlying Funds |
| BlackRock Cash Funds: Institutional, SL Agency Shares |
$ — |
$ 7,485,829 (a) |
$ — |
$ 3,882 |
$ 1,438 |
$ 7,491,149 |
7,487,405 |
$ 188,515 (b) |
$ — |
| BlackRock Liquidity Funds, T-Fund, Institutional Shares |
1,471,804 |
538,748 (a) |
— |
— |
— |
2,010,552 |
2,010,552 |
681,264 |
— |
| SL Liquidity Series, LLC, Money Market
Series(c) |
2,878,719 |
— |
(2,879,043
)(a) |
886 |
(562 ) |
— |
— |
19,866
(b) |
— |
| |
|
|
|
$ 4,768 |
$ 876 |
$ 9,501,701 |
|
$ 889,645 |
$ — |
| (a) |
Represents net amount purchased (sold). |
| (b) |
All or a portion represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of collateral investment fees, and
other payments to and from borrowers of securities. |
| (c) |
As of period end, the entity is no longer held. |
| Description |
Number of Contracts |
Expiration Date |
Exercise Price |
Notional Amount (000) |
Value | ||
| Call |
|
|
|
|
|
|
|
| AppLovin Corp., Class A |
38 |
01/03/25 |
USD |
380.00 |
USD |
1,231 |
$ (665
) |
| ARM Holdings PLC, ADR |
195 |
01/03/25 |
USD |
139.00 |
USD |
2,406 |
(1,170 ) |
| Coherent Corp. |
234 |
01/03/25 |
USD |
108.00 |
USD |
2,217 |
(5,850 ) |
| Datadog, Inc., Class A |
17 |
01/03/25 |
USD |
165.00 |
USD |
243 |
(2,890 ) |
| MongoDB, Inc., Class A |
33 |
01/03/25 |
USD |
380.00 |
USD |
768 |
(6,501 ) |
| SentinelOne, Inc., Class A |
665 |
01/03/25 |
USD |
33.00 |
USD |
1,476 |
(33,250 ) |
| Datadog, Inc., Class A |
27 |
01/10/25 |
USD |
165.00 |
USD |
386 |
(540 ) |
| Marvell Technology, Inc. |
413 |
01/10/25 |
USD |
125.00 |
USD |
4,562 |
(6,402 ) |
| NVIDIA Corp. |
161 |
01/10/25 |
USD |
160.32 |
USD |
2,162 |
(399 ) |
| NVIDIA Corp. |
409 |
01/10/25 |
USD |
165.08 |
USD |
5,492 |
(335 ) |
| Palo Alto Networks, Inc. |
84 |
01/10/25 |
USD |
215.00 |
USD |
1,528 |
(1,008 ) |
| SentinelOne, Inc., Class A |
465 |
01/10/25 |
USD |
29.19 |
USD |
1,032 |
(1 ) |
| Take-Two Interactive Software, Inc. |
141 |
01/10/25 |
USD |
200.00 |
USD |
2,596 |
(1,551 ) |
| Tesla, Inc. |
23 |
01/10/25 |
USD |
420.00 |
USD |
929 |
(24,840 ) |
| Vertiv Holdings Co., Class A |
162 |
01/10/25 |
USD |
150.00 |
USD |
1,840 |
(10,530 ) |
| AppLovin Corp., Class A |
38 |
01/17/25 |
USD |
380.00 |
USD |
1,231 |
(8,740 ) |
| ARM Holdings PLC, ADR |
347 |
01/17/25 |
USD |
145.00 |
USD |
4,281 |
(14,574 ) |
| Astera Labs, Inc. |
775 |
01/17/25 |
USD |
95.00 |
USD |
10,265 |
(2,983,750 ) |
| Astera Labs, Inc. |
690 |
01/17/25 |
USD |
120.00 |
USD |
9,139 |
(1,076,400 ) |
| Atlassian Corp., Class A |
53 |
01/17/25 |
USD |
280.00 |
USD |
1,290 |
(2,120 ) |
| Celestica, Inc. |
147 |
01/17/25 |
USD |
95.00 |
USD |
1,357 |
(44,467 ) |
| Cloudflare, Inc., Class A |
156 |
01/17/25 |
USD |
105.00 |
USD |
1,680 |
(86,970 ) |
| Coherent Corp. |
23 |
01/17/25 |
USD |
120.00 |
USD |
218 |
(518 ) |
| Coherent Corp. |
36 |
01/17/25 |
USD |
115.00 |
USD |
341 |
(810 ) |
| Confluent, Inc., Class A |
916 |
01/17/25 |
USD |
29.00 |
USD |
2,561 |
(54,960 ) |
| Credo Technology Group Holding Ltd. |
473 |
01/17/25 |
USD |
50.00 |
USD |
3,179 |
(825,385 ) |
| CyberArk Software Ltd. |
93 |
01/17/25 |
USD |
310.00 |
USD |
3,098 |
(246,450 ) |
| Datadog, Inc., Class A |
180 |
01/17/25 |
USD |
150.00 |
USD |
2,572 |
(30,150 ) |
| Descartes Systems Group, Inc. |
112 |
01/17/25 |
USD |
115.00 |
USD |
1,272 |
(16,800 ) |
| Elastic NV |
150 |
01/17/25 |
USD |
105.00 |
USD |
1,486 |
(13,875 ) |
| Fabrinet |
122 |
01/17/25 |
USD |
260.00 |
USD |
2,683 |
(13,725 ) |
| Gitlab, Inc., Class A |
271 |
01/17/25 |
USD |
64.00 |
USD |
1,527 |
(9,485 ) |
| Guidewire Software, Inc. |
135 |
01/17/25 |
USD |
200.00 |
USD |
2,276 |
(1,350 ) |
| Guidewire Software, Inc. |
56 |
01/17/25 |
USD |
175.00 |
USD |
944 |
(9,100 ) |
| Kaspi.KZ JSC, ADR |
353 |
01/17/25 |
USD |
115.00 |
USD |
3,343 |
(35,300 ) |
| Manhattan Associates, Inc. |
125 |
01/17/25 |
USD |
290.00 |
USD |
3,378 |
(15,313 ) |
| Marvell Technology, Inc. |
86 |
01/17/25 |
USD |
92.50 |
USD |
950 |
(154,370 ) |
| MercadoLibre, Inc. |
21 |
01/17/25 |
USD |
1,960.00 |
USD |
3,571 |
(2,468 ) |
| MongoDB, Inc., Class A |
46 |
01/17/25 |
USD |
340.00 |
USD |
1,071 |
(5,750 ) |
| Description |
Number of Contracts |
Expiration Date |
Exercise Price |
Notional Amount (000) |
Value | ||
| Call (continued) |
|
|
|
|
|
|
|
| Monolithic Power Systems, Inc. |
69 |
01/17/25 |
USD |
702.00 |
USD |
4,083 |
$ (4,302
) |
| NVIDIA Corp. |
295 |
01/17/25 |
USD |
140.00 |
USD |
3,962 |
(83,927 ) |
| NVIDIA Corp. |
161 |
01/17/25 |
USD |
158.00 |
USD |
2,162 |
(4,267 ) |
| Palo Alto Networks, Inc. |
88 |
01/17/25 |
USD |
200.00 |
USD |
1,601 |
(4,224 ) |
| Pure Storage, Inc., Class A |
205 |
01/17/25 |
USD |
55.00 |
USD |
1,259 |
(119,925 ) |
| Pure Storage, Inc., Class A |
205 |
01/17/25 |
USD |
60.00 |
USD |
1,259 |
(54,837 ) |
| Q2 Holdings, Inc. |
166 |
01/17/25 |
USD |
110.00 |
USD |
1,671 |
(8,300 ) |
| Quanta Services, Inc. |
57 |
01/17/25 |
USD |
350.00 |
USD |
1,801 |
(7,553 ) |
| Reddit, Inc., Class A |
475 |
01/17/25 |
USD |
150.00 |
USD |
7,763 |
(839,562 ) |
| Spotify Technology SA |
97 |
01/17/25 |
USD |
470.00 |
USD |
4,340 |
(42,922 ) |
| Synopsys, Inc. |
153 |
01/17/25 |
USD |
550.00 |
USD |
7,426 |
(8,798 ) |
| Take-Two Interactive Software, Inc. |
237 |
01/17/25 |
USD |
175.00 |
USD |
4,363 |
(247,072 ) |
| Tesla, Inc. |
74 |
01/17/25 |
USD |
360.00 |
USD |
2,988 |
(374,070 ) |
| Tesla, Inc. |
18 |
01/17/25 |
USD |
405.00 |
USD |
727 |
(38,205 ) |
| Thomson Reuters Corp. |
113 |
01/17/25 |
USD |
170.00 |
USD |
1,812 |
(16,668 ) |
| TransUnion |
280 |
01/17/25 |
USD |
100.00 |
USD |
2,596 |
(13,300 ) |
| Vertiv Holdings Co., Class A |
117 |
01/17/25 |
USD |
160.00 |
USD |
1,329 |
(585 ) |
| Atlassian Corp., Class A |
82 |
01/24/25 |
USD |
275.00 |
USD |
1,996 |
(8,610 ) |
| Celestica, Inc. |
147 |
01/24/25 |
USD |
98.00 |
USD |
1,357 |
(44,100 ) |
| Cloudflare, Inc., Class A |
175 |
01/24/25 |
USD |
122.00 |
USD |
1,884 |
(10,150 ) |
| Coherent Corp. |
272 |
01/24/25 |
USD |
113.00 |
USD |
2,577 |
(17,000 ) |
| Coherent Corp. |
257 |
01/24/25 |
USD |
107.00 |
USD |
2,435 |
(30,197 ) |
| Gitlab, Inc., Class A |
271 |
01/24/25 |
USD |
65.00 |
USD |
1,527 |
(8,808 ) |
| MercadoLibre, Inc. |
8 |
01/24/25 |
USD |
1,900.00 |
USD |
1,360 |
(5,600 ) |
| MongoDB, Inc., Class A |
24 |
01/24/25 |
USD |
320.00 |
USD |
559 |
(1,800 ) |
| NVIDIA Corp. |
174 |
01/24/25 |
USD |
144.00 |
USD |
2,337 |
(42,543 ) |
| Reddit, Inc., Class A |
191 |
01/24/25 |
USD |
185.00 |
USD |
3,122 |
(77,355 ) |
| Samsara, Inc., Class A |
572 |
01/24/25 |
USD |
48.00 |
USD |
2,499 |
(30,030 ) |
| Spotify Technology SA |
111 |
01/24/25 |
USD |
485.00 |
USD |
4,966 |
(39,127 ) |
| Take-Two Interactive Software, Inc. |
132 |
01/24/25 |
USD |
190.00 |
USD |
2,430 |
(18,150 ) |
| Tesla, Inc. |
77 |
01/24/25 |
USD |
570.00 |
USD |
3,110 |
(12,859 ) |
| Vertiv Holdings Co., Class A |
68 |
01/24/25 |
USD |
129.00 |
USD |
773 |
(8,160 ) |
| Marvell Technology, Inc. |
146 |
01/31/25 |
USD |
123.00 |
USD |
1,613 |
(26,645 ) |
| NVIDIA Corp. |
194 |
01/31/25 |
USD |
131.00 |
USD |
2,605 |
(180,420 ) |
| NVIDIA Corp. |
241 |
01/31/25 |
USD |
152.50 |
USD |
3,236 |
(39,283 ) |
| Reddit, Inc., Class A |
191 |
01/31/25 |
USD |
195.00 |
USD |
3,122 |
(73,821 ) |
| SentinelOne, Inc., Class A |
471 |
01/31/25 |
USD |
25.50 |
USD |
1,046 |
(9,420 ) |
| Tesla, Inc. |
18 |
01/31/25 |
USD |
550.00 |
USD |
727 |
(8,235 ) |
| Atlassian Corp., Class A |
24 |
02/07/25 |
USD |
270.00 |
USD |
584 |
(21,960 ) |
| NVIDIA Corp. |
241 |
02/07/25 |
USD |
152.50 |
USD |
3,236 |
(53,984 ) |
| Tesla, Inc. |
75 |
02/07/25 |
USD |
515.00 |
USD |
3,029 |
(66,375 ) |
| NVIDIA Corp. |
241 |
02/14/25 |
USD |
152.51 |
USD |
3,236 |
(64,548 ) |
| Confluent, Inc., Class A |
348 |
02/21/25 |
USD |
34.00 |
USD |
973 |
(33,930 ) |
| Credo Technology Group Holding Ltd. |
1,704 |
02/21/25 |
USD |
80.00 |
USD |
11,453 |
(451,560 ) |
| CyberArk Software Ltd. |
92 |
02/21/25 |
USD |
320.00 |
USD |
3,065 |
(264,500 ) |
| Elastic NV |
173 |
02/21/25 |
USD |
110.00 |
USD |
1,714 |
(33,302 ) |
| Gitlab, Inc., Class A |
271 |
02/21/25 |
USD |
67.50 |
USD |
1,527 |
(18,293 ) |
| Kaspi.KZ JSC, ADR |
82 |
02/21/25 |
USD |
115.00 |
USD |
777 |
(8,610 ) |
| Marvell Technology, Inc. |
106 |
02/21/25 |
USD |
120.00 |
USD |
1,171 |
(41,870 ) |
| MongoDB, Inc., Class A |
63 |
02/21/25 |
USD |
300.00 |
USD |
1,467 |
(10,458 ) |
| nCino, Inc. |
233 |
02/21/25 |
USD |
40.00 |
USD |
782 |
(2,913 ) |
| NVIDIA Corp. |
741 |
02/21/25 |
USD |
148.00 |
USD |
9,951 |
(316,777 ) |
| Pure Storage, Inc., Class A |
596 |
02/21/25 |
USD |
70.00 |
USD |
3,661 |
(61,090 ) |
| Pure Storage, Inc., Class A |
798 |
02/21/25 |
USD |
75.00 |
USD |
4,902 |
(39,900 ) |
| Quanta Services, Inc. |
4 |
02/21/25 |
USD |
340.00 |
USD |
126 |
(3,060 ) |
| Thomson Reuters Corp. |
121 |
02/21/25 |
USD |
170.00 |
USD |
1,941 |
(58,080 ) |
| Descartes Systems Group, Inc. |
170 |
03/21/25 |
USD |
125.00 |
USD |
1,931 |
(27,200 ) |
| |
|
|
|
|
|
|
$ (9,888,002 ) |
| Description |
Counterparty |
Number of Contracts |
Expiration Date |
Exercise Price |
Notional Amount (000) |
Value | ||
| Call |
|
|
|
|
|
|
|
|
| E Ink Holdings, Inc. |
Morgan Stanley & Co. International PLC |
294,000 |
01/07/25 |
TWD |
329.28 |
TWD |
80,259 |
$ —
|
| NVIDIA Corp. |
Barclays Bank PLC |
20,400 |
01/08/25 |
USD |
149.60 |
USD |
2,740 |
(3,045 ) |
| SK Hynix, Inc. |
JPMorgan Chase Bank N.A. |
6,900 |
01/08/25 |
KRW |
208,000.80 |
KRW |
1,163,989 |
(37 ) |
| Informa PLC |
BNP Paribas SA |
194,600 |
01/09/25 |
GBP |
8.74 |
GBP |
1,550 |
(2 ) |
| Nintendo Co. Ltd. |
BNP Paribas SA |
53,900 |
01/09/25 |
JPY |
8,848.44 |
JPY |
493,942 |
(150,771 ) |
| SiteMinder Ltd. |
UBS AG |
130,300 |
01/09/25 |
AUD |
6.94 |
AUD |
786 |
(52 ) |
| Xero Ltd. |
UBS AG |
27,600 |
01/09/25 |
AUD |
167.59 |
AUD |
4,640 |
(51,872 ) |
| Q2 Holdings, Inc. |
Citibank N.A. |
19,400 |
01/10/25 |
USD |
107.87 |
USD |
1,953 |
(5,692 ) |
| ASM International NV |
Goldman Sachs International |
500 |
01/14/25 |
EUR |
554.95 |
EUR |
279 |
(9,229 ) |
| Wolters Kluwer NV, Class C |
BNP Paribas SA |
44,500 |
01/14/25 |
EUR |
163.67 |
EUR |
7,138 |
(48,208 ) |
| Disco Corp. |
JPMorgan Chase Bank N.A. |
4,900 |
01/15/25 |
JPY |
44,149.25 |
JPY |
204,526 |
(19,054 ) |
| Nintendo Co. Ltd. |
JPMorgan Chase Bank N.A. |
39,400 |
01/15/25 |
JPY |
8,555.04 |
JPY |
361,064 |
(185,902 ) |
| SiteMinder Ltd. |
UBS AG |
234,000 |
01/15/25 |
AUD |
6.91 |
AUD |
1,412 |
(742 ) |
| SK Hynix, Inc. |
Morgan Stanley & Co. International PLC |
29,200 |
01/15/25 |
KRW |
187,036.00 |
KRW |
4,925,869 |
(33,175 ) |
| Adyen NV |
Bank of America N.A. |
2,200 |
01/16/25 |
EUR |
1,488.24 |
EUR |
3,156 |
(39,802 ) |
| ASM International NV |
Goldman Sachs International |
8,300 |
01/16/25 |
EUR |
524.74 |
EUR |
4,633 |
(341,598 ) |
| Lotes Co. Ltd. |
JPMorgan Chase Bank N.A. |
17,000 |
01/16/25 |
TWD |
1,851.18 |
TWD |
33,116 |
(72,875 ) |
| Informa PLC |
Goldman Sachs International |
260,000 |
01/22/25 |
GBP |
8.55 |
GBP |
2,071 |
(2,578 ) |
| Lotes Co. Ltd. |
JPMorgan Chase Bank N.A. |
9,000 |
01/22/25 |
TWD |
2,084.50 |
TWD |
17,595 |
(12,406 ) |
| NEC Corp. |
Bank of America N.A. |
30,000 |
01/22/25 |
JPY |
13,340.64 |
JPY |
403,954 |
(134,655 ) |
| SiteMinder Ltd. |
JPMorgan Chase Bank N.A. |
95,000 |
01/22/25 |
AUD |
7.08 |
AUD |
573 |
(427 ) |
| Hitachi Ltd. |
Societe Generale |
112,900 |
01/23/25 |
JPY |
4,398.84 |
JPY |
444,487 |
(33,776 ) |
| SiteMinder Ltd. |
UBS AG |
42,100 |
01/24/25 |
AUD |
6.65 |
AUD |
254 |
(1,095 ) |
| Xero Ltd. |
Goldman Sachs International |
21,200 |
01/24/25 |
AUD |
184.27 |
AUD |
3,564 |
(3,279 ) |
| SiteMinder Ltd. |
UBS AG |
42,000 |
01/28/25 |
AUD |
5.98 |
AUD |
254 |
(7,117 ) |
| Pure Storage, Inc., Class A |
UBS AG |
59,600 |
01/29/25 |
USD |
66.25 |
USD |
3,661 |
(60,125 ) |
| Accton Technology Corp. |
JPMorgan Chase Bank N.A. |
172,000 |
02/04/25 |
TWD |
798.22 |
TWD |
132,956 |
(168,574 ) |
| Asia Vital Components Co. Ltd. |
Bank of America N.A. |
277,000 |
02/04/25 |
TWD |
748.19 |
TWD |
172,571 |
(25,933 ) |
| eMemory Technology, Inc. |
JPMorgan Chase Bank N.A. |
28,000 |
02/04/25 |
TWD |
3,604.64 |
TWD |
93,940 |
(113,877 ) |
| Lotes Co. Ltd. |
JPMorgan Chase Bank N.A. |
30,000 |
02/04/25 |
TWD |
2,123.00 |
TWD |
58,650 |
(52,001 ) |
| SiteMinder Ltd. |
JPMorgan Chase Bank N.A. |
104,600 |
02/05/25 |
AUD |
6.46 |
AUD |
632 |
(7,633 ) |
| SiteMinder Ltd. |
Goldman Sachs International |
83,200 |
02/06/25 |
AUD |
6.65 |
AUD |
503 |
(4,097 ) |
| |
|
|
|
|
|
|
|
$ (1,589,629 ) |
| Description |
Premiums Paid |
Premiums Received |
Unrealized Appreciation |
Unrealized Depreciation |
Value |
| Options Written |
$ N/A
|
$ (14,389,743
) |
$ 7,783,757
|
$ (4,871,645
) |
$ (11,477,631
) |
| |
Commodity Contracts |
Credit Contracts |
Equity Contracts |
Foreign Currency Exchange Contracts |
Interest Rate Contracts |
Other Contracts |
Total |
| Liabilities — Derivative Financial Instruments |
|
|
|
|
|
|
|
| Options written Options written at value |
$ — |
$ — |
$ 11,477,631 |
$ — |
$ — |
$ — |
$ 11,477,631 |
| |
Commodity Contracts |
Credit Contracts |
Equity Contracts |
Foreign Currency Exchange Contracts |
Interest Rate Contracts |
Other Contracts |
Total |
| Net Realized Gain (Loss) from: |
|
|
|
|
|
|
|
| Options purchased(a) |
$ —
|
$ —
|
$ (1,193
) |
$ —
|
$ —
|
$ —
|
$ (1,193
) |
| Options written |
— |
— |
(70,130,517 ) |
— |
— |
— |
(70,130,517 ) |
| |
$ — |
$ — |
$ (70,131,710 ) |
$ — |
$ — |
$ — |
$ (70,131,710 ) |
| Net Change in Unrealized Appreciation (Depreciation) on: |
|
|
|
|
|
|
|
| Options written |
$ — |
$ — |
$ 7,183,300 |
$ — |
$ — |
$ — |
$ 7,183,300 |
| (a) |
Options purchased are included in net realized gain (loss) from investments —
unaffiliated. |
| Options: |
|
| Average value of option contracts purchased |
$—
(a) |
| Average value of option contracts written |
16,436,858 |
| (a) |
Derivative financial instrument not held at any quarter-end. The risk exposure table serves as an
indicator of activity during the period. |
| |
Assets |
Liabilities |
| Derivative Financial Instruments |
|
|
| Options |
$ — |
$ 11,477,631 |
| Total derivative assets and liabilities in the Statements of Assets and Liabilities |
— |
11,477,631 |
| Derivatives not subject to a Master Netting Agreement or similar agreement (“MNA”) |
— |
(9,888,002 ) |
| Total derivative assets and liabilities subject to an MNA |
$ — |
$ 1,589,629 |
| Counterparty |
Derivative Liabilities Subject to an MNA by Counterparty |
Derivatives Available for Offset(a)
|
Non-Cash Collateral Pledged(b)
|
Cash Collateral Pledged(b)
|
Net Amount of Derivative Liabilities(c)
|
| Bank of America N.A. |
$ 200,390
|
$ —
|
$ —
|
$ (200,390
) |
$ —
|
| Barclays Bank PLC |
3,045 |
— |
— |
— |
3,045 |
| BNP Paribas SA |
198,981 |
— |
(198,981 ) |
— |
— |
| Citibank N.A. |
5,692 |
— |
— |
— |
5,692 |
| Goldman Sachs International |
360,781 |
— |
(360,781 ) |
— |
— |
| JPMorgan Chase Bank N.A. |
632,786 |
— |
(632,786 ) |
— |
— |
| Morgan Stanley & Co. International PLC |
33,175 |
— |
(33,175 ) |
— |
— |
| Societe Generale |
33,776 |
— |
— |
— |
33,776 |
| UBS AG |
121,003 |
— |
(121,003 ) |
— |
— |
| |
$ 1,589,629 |
$ — |
$ (1,346,726 ) |
$ (200,390 ) |
$ 42,513 |
| (a) |
The amount of derivatives available for offset is limited to the amount of derivative assets and/or liabilities that are subject to an MNA. |
| (b) |
Excess of collateral received/pledged, if any, from the individual counterparty is not shown for financial reporting purposes. |
| (c) |
Net amount represents the net amount payable due to the counterparty in the event of default. Net amount may be offset further by the options written
receivable/payable on the Statements of Assets and Liabilities. |
| |
Level 1 |
Level 2 |
Level 3 |
Total |
| Assets |
|
|
|
|
| Investments |
|
|
|
|
| Long-Term Investments |
|
|
|
|
| Common Stocks |
|
|
|
|
| Automobiles |
$ 42,656,408
|
$ —
|
$ —
|
$ 42,656,408 |
| Broadline Retail |
17,980,452 |
— |
— |
17,980,452 |
| Communications Equipment |
— |
14,995,411 |
— |
14,995,411 |
| Construction & Engineering |
7,199,619 |
— |
— |
7,199,619 |
| Consumer Finance |
15,263,653 |
— |
— |
15,263,653 |
| Diversified Consumer Services |
— |
— |
— |
— |
| Electrical Equipment |
14,637,740 |
— |
— |
14,637,740 |
| Electronic Equipment, Instruments & Components |
53,066,784 |
21,117,552 |
— |
74,184,336 |
| Entertainment |
54,493,924 |
11,881,320 |
— |
66,375,244 |
| Financial Services |
— |
12,955,627 |
— |
12,955,627 |
| Industrial Conglomerates |
— |
19,736,527 |
— |
19,736,527 |
| Interactive Media & Services |
51,913,937 |
— |
— |
51,913,937 |
| IT Services |
27,587,227 |
8,822,995 |
59,406,429 |
95,816,651 |
| Media |
— |
12,736,124 |
— |
12,736,124 |
| Professional Services |
23,526,492 |
26,586,247 |
— |
50,112,739 |
| Semiconductors & Semiconductor Equipment |
333,781,739 |
65,624,796 |
— |
399,406,535 |
| Software |
245,689,219 |
28,899,864 |
47,755,034 |
322,344,117 |
| Technology Hardware, Storage & Peripherals |
31,374,328 |
19,204,316 |
— |
50,578,644 |
| Preferred Securities |
|
|
|
|
| Preferred Stocks |
— |
— |
419,768,363 |
419,768,363 |
| Short-Term Securities |
|
|
|
|
| Money Market Funds |
9,501,701 |
— |
— |
9,501,701 |
| |
$928,673,223 |
$242,560,779 |
$526,929,826 |
$1,698,163,828 |
| Derivative Financial Instruments(a)
|
|
|
|
|
| Liabilities |
|
|
|
|
| Equity Contracts |
$ (9,818,417 ) |
$ (1,659,214 ) |
$ — |
$ (11,477,631 ) |
| (a) |
Derivative financial instruments are options written. Options written are shown at
value. |
| |
Common Stocks |
Preferred Stocks |
Total |
| Assets |
|
|
|
| Opening balance, as of December 31, 2023 |
$ 92,486,598
|
$ 448,979,134
|
$ 541,465,732
|
| Transfers into Level 3 |
— |
— |
— |
| Transfers out of Level 3 |
— |
— |
— |
| Accrued discounts/premiums |
— |
— |
— |
| Net realized gain (loss) |
— |
2,829,296 |
2,829,296 |
| Net change in unrealized appreciation (depreciation)(a)(b) |
14,674,865 |
4,552,310 |
19,227,175 |
| Purchases |
— |
513,000 |
513,000 |
| Sales |
— |
(37,105,377 ) |
(37,105,377 ) |
| Closing balance, as of December 31, 2024 |
$ 107,161,463 |
$ 419,768,363 |
$ 526,929,826 |
| Net change in unrealized appreciation (depreciation) on investments still held at December 31, 2024(b) |
$ 14,674,865 |
$ 13,018,596 |
$ 27,693,461 |
| (a) |
Included in the related net change in unrealized appreciation (depreciation) in the Statements of Operations. |
| (b) |
Any difference between net change in unrealized appreciation (depreciation) and net change in unrealized appreciation (depreciation) on investments still held at
December 31, 2024 is generally due to investments no longer held or categorized as
Level 3 at period end. |
| |
Value |
Valuation Approach |
Unobservable Inputs |
Range of Unobservable Inputs Utilized(a) |
Weighted Average of Unobservable Inputs Based on Fair Value |
| Assets |
|
|
|
|
|
| Common Stocks |
$107,161,451
|
Market |
Revenue Multiple |
2.10x - 24.00x |
13.53x |
| |
|
|
Volatility |
70% |
— |
| |
|
|
Time to Exit |
3.0 years |
— |
| |
|
|
|
|
|
| Preferred Stocks(b) |
419,768,363 |
Market |
Revenue Multiple |
1.26x - 24.00x |
17.42x |
| |
|
|
Time to Exit |
0.5 - 4.0 years |
3.5 years |
| |
|
|
Volatility |
35% - 90% |
63% |
| |
|
|
Market Adjustment Multiple |
1.80x |
— |
| |
|
|
Gross Profit Multiple |
8.00x |
— |
| |
$526,929,814 |
|
|
|
|
| (a) |
A significant change in unobservable input could result in a correlated or inverse change in value. |
| (b) |
The trust valued certain of its Level 3 Preferred Stocks using recent transactions as the best approximation of fair value. The value of Level 3 investments
obtained using recent prior transaction prices, for which inputs are unobservable,
is $27,125,419 as of December 31, 2024. |
| Security |
|
Shares |
Value |
| Common Stocks | |||
| Automobiles — 2.4% |
| ||
| Tesla, Inc.(a) |
|
80,979 |
$ 32,702,559 |
| Broadline Retail(a) —
3.6% |
| ||
| Amazon.com, Inc. |
|
171,202 |
37,560,007 |
| MercadoLibre, Inc. |
|
7,324 |
12,454,022 |
| |
|
|
50,014,029 |
| Capital Markets — 0.5% |
| ||
| S&P Global, Inc. |
|
12,819 |
6,384,247 |
| Communications Equipment — 0.9% |
| ||
| Arista Networks, Inc.(a) |
|
108,048 |
11,942,545 |
| Diversified Consumer Services(a)(b)(c)
— 0.8% |
| ||
| Grammarly, Inc., (Acquired 11/17/21, Cost: $18,749,975) |
|
715,323 |
11,538,160 |
| Think & Learn Private Ltd., Class J-B, (Acquired
09/30/20, Cost: $1,524,948) |
|
997 |
— |
| |
|
|
11,538,160 |
| Electrical Equipment — 0.7% |
| ||
| Vertiv Holdings Co., Class A |
|
82,102 |
9,327,608 |
| Electronic Equipment, Instruments & Components — 0.8% |
| ||
| Coherent Corp.(a) |
|
113,835 |
10,783,590 |
| Entertainment — 2.9% |
| ||
| Nintendo Co. Ltd. |
|
152,900 |
8,905,166 |
| Spotify Technology SA(a) |
|
48,098 |
21,518,083 |
| Take-Two Interactive Software,
Inc.(a) |
|
53,514 |
9,850,857 |
| |
|
|
40,274,106 |
| Financial Services — 1.3% |
| ||
| Mastercard, Inc., Class A |
|
33,698 |
17,744,356 |
| Industrial Conglomerates — 0.8% |
| ||
| Hitachi Ltd. |
|
443,100 |
10,851,539 |
| Interactive Media & Services — 4.6% |
| ||
| Alphabet, Inc., Class A |
|
92,635 |
17,535,805 |
| Meta Platforms, Inc., Class A |
|
75,331 |
44,107,054 |
| Patreon, Inc., (Acquired 08/19/21, Cost:
$3,352,226)(a)(b)(c) |
|
59,524 |
1,644,053 |
| |
|
|
63,286,912 |
| IT
Services(a) — 3.6% |
| ||
| Automattic, Inc., Series E, (Acquired 02/03/21, Cost: $7,999,945)(b)(c) |
|
94,117 |
3,530,328 |
| Farmer’
s Business Network,
Inc.(b) |
|
203,366 |
538,920 |
| Klarna Holdings AB, (Acquired 08/07/19, Cost: $7,971,978)(b)(c) |
|
26,430 |
13,222,322 |
| MongoDB, Inc., Class A |
|
40,976 |
9,539,622 |
| Shopify, Inc., Class A |
|
70,460 |
7,492,012 |
| Snowflake, Inc., Class A |
|
68,800 |
10,623,408 |
| Teya Services Ltd., Series C, (Acquired 12/17/21, Cost: $24,999,987)(b)(c) |
|
12,871 |
4,337,656 |
| |
|
|
49,284,268 |
| Professional Services — 1.0% |
| ||
| RELX PLC |
|
303,547 |
13,753,399 |
| Semiconductors & Semiconductor Equipment — 29.4% |
| ||
| ARM Holdings PLC, ADR(a)(d) |
|
90,562 |
11,171,728 |
| ASM International NV |
|
17,001 |
9,829,725 |
| ASML Holding NV |
|
22,835 |
15,994,415 |
| Broadcom, Inc. |
|
363,804 |
84,344,319 |
| Credo Technology Group Holding Ltd.(a) |
|
417,809 |
28,080,943 |
| Security |
|
Shares |
Value |
| Semiconductors & Semiconductor Equipment (continued) |
| ||
| Lam Research Corp. |
|
100,454 |
$ 7,255,793
|
| Marvell Technology, Inc. |
|
151,556 |
16,739,360 |
| Micron Technology, Inc. |
|
189,533 |
15,951,097 |
| Monolithic Power Systems, Inc. |
|
11,615 |
6,872,596 |
| NVIDIA Corp.(e)(f) |
|
1,368,128 |
183,725,909 |
| Taiwan Semiconductor Manufacturing Co. Ltd., ADR |
|
121,314 |
23,958,302 |
| |
|
|
403,924,187 |
| Software — 23.2% |
| ||
| AppLovin Corp., Class A(a) |
|
30,479 |
9,870,015 |
| Atlassian Corp., Class A(a)
|
|
39,816 |
9,690,418 |
| Autodesk, Inc.(a) |
|
31,261 |
9,239,814 |
| Cadence Design Systems, Inc.(a)
|
|
125,090 |
37,584,541 |
| Canva(a)(b) |
|
9,375 |
11,397,562 |
| Constellation Software, Inc./Canada |
|
4,113 |
12,718,296 |
| Crowdstrike Holdings, Inc., Class A(a) |
|
28,614 |
9,790,566 |
| CyberArk Software Ltd.(a) |
|
26,002 |
8,662,566 |
| Databricks, Inc., (Acquired 07/24/20, Cost:
$960,476)(a)(b)(c) |
|
59,997 |
5,506,525 |
| Datadog, Inc., Class A(a) |
|
58,545 |
8,365,495 |
| DataRobot, Inc., (Acquired 03/01/21, Cost:
$583,275)(a)(b)(c) |
|
38,789 |
78,354 |
| Guidewire Software, Inc.(a)
|
|
41,836 |
7,052,713 |
| Microsoft Corp.(f) |
|
279,041 |
117,615,781 |
| Oracle Corp. |
|
168,526 |
28,083,173 |
| Palo Alto Networks, Inc.(a) |
|
44,673 |
8,128,699 |
| ServiceNow, Inc.(a) |
|
21,589 |
22,886,931 |
| Snorkel AI, Inc., (Acquired 06/30/21, Cost:
$997,636)(a)(b)(c) |
|
66,422 |
668,870 |
| Snyk Ltd., Ordinary Shares, (Acquired 09/02/21, Cost: $5,192,307)(b)(c) |
|
361,972 |
3,138,297 |
| Xero Ltd.(a) |
|
80,625 |
8,390,083 |
| |
|
|
318,868,699 |
| Specialty Retail — 0.0% |
| ||
| AceVector Limited, Series I, (Acquired 08/31/18, Cost: $1,998,435)(a)(b)(c) |
|
168,640 |
64,668 |
| Technology Hardware, Storage & Peripherals — 8.2% |
| ||
| Apple, Inc.(f) |
|
452,078 |
113,209,373 |
| Total Common Stocks — 84.7% (Cost: $478,787,794) |
1,163,954,245 | ||
| |
|
Par (000) |
|
| Convertible Notes | |||
| Financial Services — 0.0% | |||
| Wyre, Inc., 0.00%, 12/08/24(b)
|
$ |
80 |
1 |
| IT Services — 0.1% | |||
| Voltron Capital, 0.00%(b) |
|
1,663 |
1,695,786 |
| Total Convertible Notes — 0.1% (Cost: $9,662,535) |
1,695,787 | ||
| Security |
|
Shares |
Value |
| Preferred Securities | |||
| Preferred Stocks — 16.0%(b) | |||
| Aerospace & Defense — 1.5% |
| ||
| Anduril Industries, Inc., Series F(a) |
|
920,107 |
$ 21,309,678 |
| Chemicals — 0.4% |
| ||
| Solugen, Inc., Series C, (Acquired 09/02/21, Cost:
$9,999,977)(a)(c) |
|
269,284 |
4,887,505 |
| Communications Equipment — 0.6% |
| ||
| Astranis, Series D(a) |
|
856,310 |
7,997,936 |
| Consumer Staples Distribution & Retail — 1.0% |
| ||
| Grubmarket, Inc., Series E, (Acquired 10/18/21, Cost:
$6,999,994)(a)(c) |
|
709,724 |
13,222,158 |
| Diversified Consumer Services(a)(c)
— 0.3% |
| ||
| Grammarly, Inc., Series 3, (Acquired 11/17/21, Cost:
$6,249,992) |
|
238,441 |
3,846,053 |
| Think & Learn Private Ltd., Series F, (Acquired 09/30/20, Cost: $3,052,975) |
|
1,054 |
— |
| |
|
|
3,846,053 |
| Diversified Telecommunication Services — 0.2% |
| ||
| Discord, Inc., Series I, (Acquired 09/13/21, Cost:
$7,000,088)(a)(c) |
|
12,713 |
3,223,000 |
| Financial Services(a)(c)(g)
— 1.1% |
| ||
| Trumid Holdings LLC |
|
|
|
| Class J-A, (Acquired 07/24/20, Cost: $2,499,716) |
|
5,038 |
3,647,109 |
| Class J-B, (Acquired 07/24/20, Cost: $1,499,830) |
|
5,038 |
3,647,109 |
| Class L, (Acquired 09/15/21, Cost: $9,999,695) |
|
11,420 |
8,267,166 |
| |
|
|
15,561,384 |
| Interactive Media & Services(a)(c)
— 0.6% |
| ||
| ByteDance Ltd., Series E-1, (Acquired 11/11/20, Cost:
$2,857,834) |
|
24,110 |
4,356,677 |
| Patreon, Inc., Series D, (Acquired 07/14/21, Cost: $6,666,632) |
|
119,047 |
3,288,078 |
| |
|
|
7,644,755 |
| IT
Services(a)(c) — 2.2% |
| ||
| Deep Instinct Ltd., Series D-2, (Acquired 03/19/21, Cost:
$2,999,391) |
|
493,493 |
2,131,890 |
| MNTN Digital, Inc., Series D, (Acquired 11/05/21, Cost: $24,999,980) |
|
1,088,598 |
17,319,594 |
| TRAX Ltd. |
|
|
|
| (Acquired 09/12/19, Cost: $4,000,013) |
|
106,667 |
2,515,208 |
| (Acquired 02/18/21, Cost: $1,999,989) |
|
38,361 |
904,552 |
| Voltron Data, Inc. |
|
|
|
| Series A, (Acquired 01/18/22, Cost: $10,000,000) |
|
6,201,935 |
4,713,471 |
| Series SEED, (Acquired 07/14/21, Cost: $5,000,000) |
|
9,090,909 |
2,363,636 |
| |
|
|
29,948,351 |
| Professional Services — 0.3% |
| ||
| ANT Group Co. Ltd., Series C |
|
1,703,548 |
4,599,580 |
| Semiconductors & Semiconductor Equipment(a) —
4.1% |
| ||
| PsiQuantum Corp.(c) |
|
|
|
| Series C, (Acquired 09/09/19, Cost: $3,200,234) |
|
690,003 |
23,818,904 |
| Series D, (Acquired 05/21/21, Cost: $5,000,025) |
|
190,650 |
7,267,578 |
| Rivos, Inc. |
|
|
|
| Series A1, (Acquired 12/03/21, Cost: $7,203,709)(c) |
|
2,700,558 |
7,048,456 |
| Series A2 |
|
2,464,862 |
5,891,020 |
| Security |
|
Shares |
Value |
| Semiconductors & Semiconductor Equipment (continued) |
| ||
| Rivos, Inc. (continued) |
|
|
|
| Series A3 |
|
1,027,026 |
$ 2,454,592
|
| SambaNova Systems, Inc., Series C, (Acquired
02/20/20, Cost: $9,972,125)(c) |
|
187,300 |
10,441,975 |
| |
|
|
56,922,525 |
| Software(a)(c)
— 3.7% |
| ||
| Bolt Financial, Inc., Series E, (Acquired 01/18/22, Cost: $29,999,955) |
|
598,682 |
7,196,157 |
| Databricks, Inc. |
|
|
|
| Series F, (Acquired 10/22/19, Cost: $3,999,999) |
|
279,405 |
25,643,791 |
| Series G, (Acquired 02/01/21, Cost: $4,500,001) |
|
76,113 |
6,985,651 |
| DataRobot, Inc., Series F, (Acquired 10/27/20, Cost: $2,999,996) |
|
228,276 |
1,152,794 |
| Prosimo, Inc., Series B, (Acquired 11/04/21, Cost:
$4,999,998) |
|
2,515,811 |
1,308,222 |
| Snorkel AI, Inc., Series C, (Acquired 06/30/21, Cost: $4,999,985) |
|
332,896 |
3,352,263 |
| Snyk Ltd., Series F, (Acquired 09/02/21, Cost:
$4,807,688) |
|
337,018 |
2,921,946 |
| Unqork, Inc. |
|
|
|
| Series B, (Acquired 09/19/19, Cost: $3,198,416) |
|
281,080 |
1,936,640 |
| Series C, (Acquired 09/18/20, Cost: $1,303,260) |
|
47,600 |
407,932 |
| |
|
|
50,905,396 |
| |
220,068,321 | ||
| Total Preferred Securities — 16.0% (Cost: $233,257,016) |
220,068,321 | ||
| Warrants | |||
| Software — 0.0% |
| ||
| Constellation Software, Inc., (Issued 08/29/23, 1 Share for 1 Warrant, Expires 03/31/40, Strike Price CAD 11.50)(a)(b) |
|
3,923 |
— |
| Total Warrants — 0.0% (Cost: $ — ) |
— | ||
| Total Long-Term Investments — 100.8% (Cost: $721,707,345) |
1,385,718,353 | ||
| Short-Term Securities | |||
| Money Market Funds — 0.2% |
| ||
| BlackRock Cash Funds: Institutional, SL Agency Shares,
4.63%(h)(i)(j) |
|
565,117 |
565,400 |
| BlackRock Liquidity Funds, T-Fund, Institutional Shares, 4.36%(h)(i) |
|
1,644,863 |
1,644,863 |
| Total Short-Term Securities — 0.2% (Cost: $2,210,263) |
2,210,263 | ||
| Total Investments Before Options Written — 101.0% (Cost: $723,917,608) |
1,387,928,616 | ||
| Options Written — (0.8)% (Premiums Received: $(15,302,365)) |
(10,929,305 ) | ||
| Total Investments, Net of Options Written — 100.2% (Cost: $708,615,243) |
1,376,999,311 | ||
| Liabilities in Excess of Other Assets — (0.2)% |
(2,122,951 ) | ||
| Net Assets — 100.0% |
$ 1,374,876,360 | ||
| (a) |
Non-income producing security. |
| (b) |
Security is valued using significant unobservable inputs and is classified as Level 3 in the
fair value hierarchy. |
| (c) |
Restricted security as to resale, excluding 144A securities. The Trust held restricted
securities with a current value of $221,544,748, representing 16.1% of its net assets as
of period end, and an original cost of $266,342,685. |
| (d) |
All or a portion of this security is on loan. |
| (e) |
All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives. |
| (f) |
All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written. |
| (g) |
All or a portion of the security is held by a wholly-owned subsidiary. See Note 1 of the
Notes to Financial Statements for details on the wholly-owned subsidiary. |
| (h) |
Affiliate of the Trust. |
| (i) |
Annualized 7-day yield as of period end. |
| (j) |
All or a portion of this security was purchased with the cash collateral from loaned securities. |
| Affiliated Issuer |
Value at 12/31/23 |
Purchases at Cost |
Proceeds from Sales |
Net Realized Gain (Loss) |
Change in Unrealized Appreciation (Depreciation) |
Value at 12/31/24 |
Shares Held at 12/31/24 |
Income |
Capital Gain Distributions from Underlying Funds |
| BlackRock Cash Funds: Institutional, SL Agency Shares |
$ — |
$ 565,119 (a) |
$ — |
$ 281 |
$ — |
$ 565,400 |
565,117 |
$ 31,077 (b) |
$ — |
| BlackRock Liquidity Funds, T-Fund, Institutional Shares |
365,499 |
1,279,364 (a) |
— |
— |
— |
1,644,863 |
1,644,863 |
323,911 |
— |
| SL Liquidity Series, LLC, Money Market
Series(c) |
5,860,878 |
— |
(5,861,604
)(a) |
231 |
495 |
— |
— |
10,431
(b) |
— |
| |
|
|
|
$ 512 |
$ 495 |
$ 2,210,263 |
|
$ 365,419 |
$ — |
| (a) |
Represents net amount purchased (sold). |
| (b) |
All or a portion represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of collateral investment fees, and
other payments to and from borrowers of securities. |
| (c) |
As of period end, the entity is no longer held. |
| Description |
Number of Contracts |
Expiration Date |
Exercise Price |
Notional Amount (000) |
Value | ||
| Call |
|
|
|
|
|
|
|
| AppLovin Corp., Class A |
47 |
01/03/25 |
USD |
380.00 |
USD |
1,522 |
$ (823
) |
| ARM Holdings PLC, ADR |
265 |
01/03/25 |
USD |
139.00 |
USD |
3,269 |
(1,590 ) |
| Coherent Corp. |
73 |
01/03/25 |
USD |
108.00 |
USD |
692 |
(1,825 ) |
| Datadog, Inc., Class A |
23 |
01/03/25 |
USD |
165.00 |
USD |
329 |
(3,910 ) |
| MongoDB, Inc., Class A |
35 |
01/03/25 |
USD |
380.00 |
USD |
815 |
(6,895 ) |
| Taiwan Semiconductor Manufacturing Co. Ltd., ADR |
190 |
01/03/25 |
USD |
200.00 |
USD |
3,752 |
(25,840 ) |
| Alphabet, Inc., Class A |
260 |
01/10/25 |
USD |
180.00 |
USD |
4,922 |
(265,850 ) |
| Amazon.com, Inc. |
147 |
01/10/25 |
USD |
230.00 |
USD |
3,225 |
(9,335 ) |
| Autodesk, Inc. |
48 |
01/10/25 |
USD |
315.00 |
USD |
1,419 |
(1,560 ) |
| Broadcom, Inc. |
221 |
01/10/25 |
USD |
178.30 |
USD |
5,124 |
(1,188,987 ) |
| Datadog, Inc., Class A |
187 |
01/10/25 |
USD |
165.00 |
USD |
2,672 |
(3,740 ) |
| Marvell Technology, Inc. |
182 |
01/10/25 |
USD |
125.00 |
USD |
2,010 |
(2,821 ) |
| Meta Platforms, Inc., Class A |
44 |
01/10/25 |
USD |
635.00 |
USD |
2,576 |
(2,508 ) |
| Micron Technology, Inc. |
46 |
01/10/25 |
USD |
107.00 |
USD |
387 |
(598 ) |
| NVIDIA Corp. |
633 |
01/10/25 |
USD |
160.32 |
USD |
8,501 |
(1,569 ) |
| NVIDIA Corp. |
571 |
01/10/25 |
USD |
165.08 |
USD |
7,668 |
(468 ) |
| Oracle Corp. |
247 |
01/10/25 |
USD |
185.00 |
USD |
4,116 |
(2,594 ) |
| Palo Alto Networks, Inc. |
62 |
01/10/25 |
USD |
215.00 |
USD |
1,128 |
(744 ) |
| ServiceNow, Inc. |
36 |
01/10/25 |
USD |
1,160.00 |
USD |
3,816 |
(2,700 ) |
| Take-Two Interactive Software, Inc. |
102 |
01/10/25 |
USD |
200.00 |
USD |
1,878 |
(1,122 ) |
| Tesla, Inc. |
93 |
01/10/25 |
USD |
420.00 |
USD |
3,756 |
(100,440 ) |
| Vertiv Holdings Co., Class A |
11 |
01/10/25 |
USD |
150.00 |
USD |
125 |
(715 ) |
| Amazon.com, Inc. |
105 |
01/17/25 |
USD |
215.00 |
USD |
2,304 |
(84,525 ) |
| Amazon.com, Inc. |
122 |
01/17/25 |
USD |
230.00 |
USD |
2,677 |
(17,568 ) |
| AppLovin Corp., Class A |
47 |
01/17/25 |
USD |
380.00 |
USD |
1,522 |
(10,810 ) |
| Description |
Number of Contracts |
Expiration Date |
Exercise Price |
Notional Amount (000) |
Value | ||
| Call (continued) |
|
|
|
|
|
|
|
| Arista Networks, Inc. |
184 |
01/17/25 |
USD |
100.00 |
USD |
2,034 |
$ (197,800
) |
| ARM Holdings PLC, ADR |
323 |
01/17/25 |
USD |
145.00 |
USD |
3,985 |
(13,566 ) |
| Atlassian Corp., Class A |
61 |
01/17/25 |
USD |
280.00 |
USD |
1,485 |
(2,440 ) |
| Cadence Design Systems, Inc. |
306 |
01/17/25 |
USD |
305.00 |
USD |
9,194 |
(200,430 ) |
| Coherent Corp. |
305 |
01/17/25 |
USD |
120.00 |
USD |
2,889 |
(6,863 ) |
| Coherent Corp. |
61 |
01/17/25 |
USD |
115.00 |
USD |
578 |
(1,373 ) |
| Credo Technology Group Holding Ltd. |
1,417 |
01/17/25 |
USD |
50.00 |
USD |
9,524 |
(2,472,664 ) |
| Crowdstrike Holdings, Inc., Class A |
79 |
01/17/25 |
USD |
350.00 |
USD |
2,703 |
(62,015 ) |
| CyberArk Software Ltd. |
56 |
01/17/25 |
USD |
310.00 |
USD |
1,866 |
(148,400 ) |
| CyberArk Software Ltd. |
4 |
01/17/25 |
USD |
340.00 |
USD |
133 |
(3,240 ) |
| Datadog, Inc., Class A |
53 |
01/17/25 |
USD |
150.00 |
USD |
757 |
(8,878 ) |
| Guidewire Software, Inc. |
92 |
01/17/25 |
USD |
200.00 |
USD |
1,551 |
(920 ) |
| Guidewire Software, Inc. |
85 |
01/17/25 |
USD |
175.00 |
USD |
1,433 |
(13,812 ) |
| Lam Research Corp. |
80 |
01/17/25 |
USD |
80.00 |
USD |
578 |
(2,760 ) |
| Lam Research Corp. |
191 |
01/17/25 |
USD |
78.00 |
USD |
1,380 |
(11,651 ) |
| Marvell Technology, Inc. |
194 |
01/17/25 |
USD |
92.50 |
USD |
2,143 |
(348,232 ) |
| Mastercard, Inc., Class A |
42 |
01/17/25 |
USD |
525.00 |
USD |
2,212 |
(38,745 ) |
| MercadoLibre, Inc. |
20 |
01/17/25 |
USD |
1,960.00 |
USD |
3,401 |
(2,350 ) |
| Meta Platforms, Inc., Class A |
87 |
01/17/25 |
USD |
600.00 |
USD |
5,094 |
(82,867 ) |
| Micron Technology, Inc. |
64 |
01/17/25 |
USD |
105.00 |
USD |
539 |
(416 ) |
| MongoDB, Inc., Class A |
69 |
01/17/25 |
USD |
340.00 |
USD |
1,606 |
(8,625 ) |
| Monolithic Power Systems, Inc. |
70 |
01/17/25 |
USD |
702.00 |
USD |
4,142 |
(4,365 ) |
| NVIDIA Corp. |
301 |
01/17/25 |
USD |
140.00 |
USD |
4,042 |
(85,635 ) |
| NVIDIA Corp. |
633 |
01/17/25 |
USD |
158.00 |
USD |
8,501 |
(16,774 ) |
| Oracle Corp. |
247 |
01/17/25 |
USD |
185.00 |
USD |
4,116 |
(2,717 ) |
| Palo Alto Networks, Inc. |
62 |
01/17/25 |
USD |
200.00 |
USD |
1,128 |
(2,976 ) |
| S&P Global, Inc. |
37 |
01/17/25 |
USD |
530.00 |
USD |
1,843 |
(2,220 ) |
| ServiceNow, Inc. |
33 |
01/17/25 |
USD |
1,080.00 |
USD |
3,498 |
(59,400 ) |
| Shopify, Inc., Class A |
136 |
01/17/25 |
USD |
120.00 |
USD |
1,446 |
(4,148 ) |
| Snowflake, Inc., Class A |
132 |
01/17/25 |
USD |
175.00 |
USD |
2,038 |
(6,006 ) |
| Spotify Technology SA |
114 |
01/17/25 |
USD |
470.00 |
USD |
5,100 |
(50,445 ) |
| Take-Two Interactive Software, Inc. |
104 |
01/17/25 |
USD |
175.00 |
USD |
1,914 |
(108,420 ) |
| Tesla, Inc. |
59 |
01/17/25 |
USD |
360.00 |
USD |
2,383 |
(298,245 ) |
| Tesla, Inc. |
30 |
01/17/25 |
USD |
405.00 |
USD |
1,212 |
(63,675 ) |
| Vertiv Holdings Co., Class A |
11 |
01/17/25 |
USD |
160.00 |
USD |
125 |
(55 ) |
| Alphabet, Inc., Class A |
155 |
01/24/25 |
USD |
205.00 |
USD |
2,934 |
(11,470 ) |
| Amazon.com, Inc. |
249 |
01/24/25 |
USD |
220.00 |
USD |
5,463 |
(146,910 ) |
| Arista Networks, Inc. |
302 |
01/24/25 |
USD |
110.00 |
USD |
3,338 |
(147,980 ) |
| Atlassian Corp., Class A |
72 |
01/24/25 |
USD |
275.00 |
USD |
1,752 |
(7,560 ) |
| Autodesk, Inc. |
90 |
01/24/25 |
USD |
320.00 |
USD |
2,660 |
(21,600 ) |
| Broadcom, Inc. |
227 |
01/24/25 |
USD |
235.00 |
USD |
5,263 |
(185,572 ) |
| Coherent Corp. |
73 |
01/24/25 |
USD |
107.00 |
USD |
692 |
(8,578 ) |
| Crowdstrike Holdings, Inc., Class A |
49 |
01/24/25 |
USD |
415.00 |
USD |
1,677 |
(5,415 ) |
| Mastercard, Inc., Class A |
80 |
01/24/25 |
USD |
540.00 |
USD |
4,213 |
(30,800 ) |
| MercadoLibre, Inc. |
5 |
01/24/25 |
USD |
1,900.00 |
USD |
850 |
(3,500 ) |
| MercadoLibre, Inc. |
8 |
01/24/25 |
USD |
1,790.00 |
USD |
1,360 |
(16,080 ) |
| Meta Platforms, Inc., Class A |
129 |
01/24/25 |
USD |
680.00 |
USD |
7,553 |
(8,643 ) |
| Micron Technology, Inc. |
237 |
01/24/25 |
USD |
112.00 |
USD |
1,995 |
(1,778 ) |
| MongoDB, Inc., Class A |
61 |
01/24/25 |
USD |
320.00 |
USD |
1,420 |
(4,575 ) |
| NVIDIA Corp. |
754 |
01/24/25 |
USD |
144.00 |
USD |
10,125 |
(184,353 ) |
| NVIDIA Corp. |
96 |
01/24/25 |
USD |
135.00 |
USD |
1,289 |
(55,440 ) |
| Palo Alto Networks, Inc. |
77 |
01/24/25 |
USD |
217.50 |
USD |
1,401 |
(3,812 ) |
| Spotify Technology SA |
102 |
01/24/25 |
USD |
485.00 |
USD |
4,563 |
(35,955 ) |
| Taiwan Semiconductor Manufacturing Co. Ltd., ADR |
40 |
01/24/25 |
USD |
210.00 |
USD |
790 |
(16,700 ) |
| Take-Two Interactive Software, Inc. |
141 |
01/24/25 |
USD |
190.00 |
USD |
2,596 |
(19,387 ) |
| Tesla, Inc. |
58 |
01/24/25 |
USD |
570.00 |
USD |
2,342 |
(9,686 ) |
| Vertiv Holdings Co., Class A |
347 |
01/24/25 |
USD |
129.00 |
USD |
3,942 |
(41,640 ) |
| Broadcom, Inc. |
175 |
01/31/25 |
USD |
240.00 |
USD |
4,057 |
(134,750 ) |
| Broadcom, Inc. |
55 |
01/31/25 |
USD |
230.00 |
USD |
1,275 |
(70,812 ) |
| Lam Research Corp. |
181 |
01/31/25 |
USD |
78.00 |
USD |
1,307 |
(31,675 ) |
| Marvell Technology, Inc. |
106 |
01/31/25 |
USD |
123.00 |
USD |
1,171 |
(19,345 ) |
| Meta Platforms, Inc., Class A |
78 |
01/31/25 |
USD |
660.00 |
USD |
4,567 |
(49,725 ) |
| Description |
Number of Contracts |
Expiration Date |
Exercise Price |
Notional Amount (000) |
Value | ||
| Call (continued) |
|
|
|
|
|
|
|
| NVIDIA Corp. |
669 |
01/31/25 |
USD |
131.00 |
USD |
8,984 |
$ (622,170
) |
| NVIDIA Corp. |
331 |
01/31/25 |
USD |
152.50 |
USD |
4,445 |
(53,953 ) |
| Oracle Corp. |
256 |
01/31/25 |
USD |
180.00 |
USD |
4,266 |
(21,888 ) |
| ServiceNow, Inc. |
29 |
01/31/25 |
USD |
1,120.00 |
USD |
3,074 |
(66,555 ) |
| Tesla, Inc. |
30 |
01/31/25 |
USD |
550.00 |
USD |
1,212 |
(13,725 ) |
| Alphabet, Inc., Class A |
1 |
02/07/25 |
USD |
205.00 |
USD |
19 |
(287 ) |
| Atlassian Corp., Class A |
46 |
02/07/25 |
USD |
270.00 |
USD |
1,120 |
(42,090 ) |
| Marvell Technology, Inc. |
56 |
02/07/25 |
USD |
125.00 |
USD |
619 |
(10,668 ) |
| NVIDIA Corp. |
331 |
02/07/25 |
USD |
152.50 |
USD |
4,445 |
(74,144 ) |
| Shopify, Inc., Class A |
181 |
02/07/25 |
USD |
111.00 |
USD |
1,925 |
(59,911 ) |
| Tesla, Inc. |
94 |
02/07/25 |
USD |
515.00 |
USD |
3,796 |
(83,190 ) |
| NVIDIA Corp. |
331 |
02/14/25 |
USD |
152.51 |
USD |
4,445 |
(88,652 ) |
| Amazon.com, Inc. |
147 |
02/21/25 |
USD |
230.00 |
USD |
3,225 |
(103,635 ) |
| Broadcom, Inc. |
175 |
02/21/25 |
USD |
240.00 |
USD |
4,057 |
(207,375 ) |
| Broadcom, Inc. |
55 |
02/21/25 |
USD |
230.00 |
USD |
1,275 |
(84,287 ) |
| Credo Technology Group Holding Ltd. |
1,298 |
02/21/25 |
USD |
80.00 |
USD |
8,724 |
(343,970 ) |
| CyberArk Software Ltd. |
57 |
02/21/25 |
USD |
320.00 |
USD |
1,899 |
(163,875 ) |
| Marvell Technology, Inc. |
144 |
02/21/25 |
USD |
120.00 |
USD |
1,590 |
(56,880 ) |
| Mastercard, Inc., Class A |
29 |
02/21/25 |
USD |
530.00 |
USD |
1,527 |
(46,472 ) |
| Micron Technology, Inc. |
128 |
02/21/25 |
USD |
95.00 |
USD |
1,077 |
(21,504 ) |
| MongoDB, Inc., Class A |
19 |
02/21/25 |
USD |
300.00 |
USD |
442 |
(3,154 ) |
| NVIDIA Corp. |
920 |
02/21/25 |
USD |
148.00 |
USD |
12,355 |
(393,300 ) |
| S&P Global, Inc. |
20 |
02/21/25 |
USD |
510.00 |
USD |
996 |
(23,500 ) |
| Snowflake, Inc., Class A |
177 |
02/21/25 |
USD |
175.00 |
USD |
2,733 |
(51,949 ) |
| Taiwan Semiconductor Manufacturing Co. Ltd., ADR |
73 |
02/21/25 |
USD |
220.00 |
USD |
1,442 |
(33,945 ) |
| |
|
|
|
|
|
|
$ (10,017,485 ) |
| Description |
Counterparty |
Number of Contracts |
Expiration Date |
Exercise Price |
Notional Amount (000) |
Value | ||
| Call |
|
|
|
|
|
|
|
|
| ASML Holding NV |
Goldman Sachs International |
3,300 |
01/07/25 |
EUR |
691.14 |
EUR |
2,231 |
$ (24,555
) |
| NVIDIA Corp. |
Barclays Bank PLC |
58,600 |
01/08/25 |
USD |
149.60 |
USD |
7,869 |
(8,748 ) |
| Nintendo Co. Ltd. |
BNP Paribas SA |
53,700 |
01/09/25 |
JPY |
8,848.44 |
JPY |
492,110 |
(150,211 ) |
| Xero Ltd. |
UBS AG |
14,600 |
01/09/25 |
AUD |
167.59 |
AUD |
2,455 |
(27,439 ) |
| ASM International NV |
Goldman Sachs International |
4,100 |
01/14/25 |
EUR |
554.95 |
EUR |
2,289 |
(75,675 ) |
| Hitachi Ltd. |
JPMorgan Chase Bank N.A. |
98,700 |
01/15/25 |
JPY |
4,005.08 |
JPY |
380,329 |
(58,397 ) |
| Nintendo Co. Ltd. |
JPMorgan Chase Bank N.A. |
27,600 |
01/15/25 |
JPY |
8,555.04 |
JPY |
252,928 |
(130,225 ) |
| ASM International NV |
Goldman Sachs International |
3,900 |
01/16/25 |
EUR |
524.74 |
EUR |
2,177 |
(160,510 ) |
| RELX PLC |
Goldman Sachs International |
136,500 |
01/22/25 |
GBP |
38.22 |
GBP |
4,940 |
(16,031 ) |
| Xero Ltd. |
Goldman Sachs International |
20,500 |
01/24/25 |
AUD |
184.27 |
AUD |
3,447 |
(3,169 ) |
| Nintendo Co. Ltd. |
JPMorgan Chase Bank N.A. |
13,500 |
02/04/25 |
JPY |
9,397.72 |
JPY |
125,064 |
(24,377 ) |
| Cadence Design Systems, Inc. |
Morgan Stanley & Co. International PLC |
25,600 |
02/05/25 |
USD |
307.02 |
USD |
7,692 |
(232,483 ) |
| |
|
|
|
|
|
|
|
$ (911,820 ) |
| Description |
Premiums Paid |
Premiums Received |
Unrealized Appreciation |
Unrealized Depreciation |
Value |
| Options Written |
$ N/A
|
$ (15,302,365
) |
$ 8,565,901
|
$ (4,192,841
) |
$ (10,929,305
) |
| |
Commodity Contracts |
Credit Contracts |
Equity Contracts |
Foreign Currency Exchange Contracts |
Interest Rate Contracts |
Other Contracts |
Total |
| Liabilities — Derivative Financial Instruments |
|
|
|
|
|
|
|
| Options written Options written at value |
$ — |
$ — |
$ 10,929,305 |
$ — |
$ — |
$ — |
$ 10,929,305 |
| |
Commodity Contracts |
Credit Contracts |
Equity Contracts |
Foreign Currency Exchange Contracts |
Interest Rate Contracts |
Other Contracts |
Total |
| Net Realized Gain (Loss) from: |
|
|
|
|
|
|
|
| Options purchased(a) |
$ —
|
$ —
|
$ (54
) |
$ —
|
$ —
|
$ —
|
$ (54
) |
| Options written |
— |
— |
(68,799,557 ) |
— |
— |
— |
(68,799,557 ) |
| |
$ — |
$ — |
$ (68,799,611 ) |
$ — |
$ — |
$ — |
$ (68,799,611 ) |
| Net Change in Unrealized Appreciation (Depreciation) on: |
|
|
|
|
|
|
|
| Options written |
$ — |
$ — |
$ 9,341,761 |
$ — |
$ — |
$ — |
$ 9,341,761 |
| (a) |
Options purchased are included in net realized gain (loss) from investments —
unaffiliated. |
| Options: |
|
| Average value of option contracts purchased |
$—
(a) |
| Average value of option contracts written |
14,433,904 |
| (a) |
Derivative financial instrument not held at any quarter-end. The risk exposure table serves as an
indicator of activity during the period. |
| |
Assets |
Liabilities |
| Derivative Financial Instruments |
|
|
| Options |
$ — |
$ 10,929,305 |
| Total derivative assets and liabilities in the Statements of Assets and Liabilities |
— |
10,929,305 |
| Derivatives not subject to a Master Netting Agreement or similar agreement (“MNA”) |
— |
(10,017,485 ) |
| Total derivative assets and liabilities subject to an MNA |
$ — |
$ 911,820 |
| Counterparty |
Derivative Liabilities Subject to an MNA by Counterparty |
Derivatives Available for Offset(a)
|
Non-Cash Collateral Pledged(b)
|
Cash Collateral Pledged(b)
|
Net Amount of Derivative Liabilities(c)
|
| Barclays Bank PLC |
$ 8,748
|
$ —
|
$ —
|
$ —
|
$ 8,748
|
| BNP Paribas SA |
150,211 |
— |
— |
— |
150,211 |
| Goldman Sachs International |
279,940 |
— |
(279,940 ) |
— |
— |
| JPMorgan Chase Bank N.A. |
212,999 |
— |
(212,999 ) |
— |
— |
| Counterparty |
Derivative Liabilities Subject to an MNA by Counterparty |
Derivatives Available for Offset(a) |
Non-Cash Collateral Pledged(b) |
Cash Collateral Pledged(b) |
Net Amount of Derivative Liabilities(c) |
| Morgan Stanley & Co. International PLC |
$ 232,483
|
$ —
|
$ —
|
$ —
|
$ 232,483
|
| UBS AG |
27,439 |
— |
— |
— |
27,439 |
| |
$ 911,820 |
$ — |
$ (492,939 ) |
$ — |
$ 418,881 |
| (a) |
The amount of derivatives available for offset is limited to the amount of derivative assets and/or liabilities that are subject to an MNA. |
| (b) |
Excess of collateral received/pledged, if any, from the individual counterparty is not shown for financial reporting purposes. |
| (c) |
Net amount represents the net amount payable due to the counterparty in the event of default. Net amount may be offset further by the options written
receivable/payable on the Statements of Assets and Liabilities. |
| |
Level 1 |
Level 2 |
Level 3 |
Total |
| Assets |
|
|
|
|
| Investments |
|
|
|
|
| Long-Term Investments |
|
|
|
|
| Common Stocks |
|
|
|
|
| Automobiles |
$ 32,702,559
|
$ —
|
$ —
|
$ 32,702,559 |
| Broadline Retail |
50,014,029 |
— |
— |
50,014,029 |
| Capital Markets |
6,384,247 |
— |
— |
6,384,247 |
| Communications Equipment |
11,942,545 |
— |
— |
11,942,545 |
| Diversified Consumer Services |
— |
— |
11,538,160 |
11,538,160 |
| Electrical Equipment |
9,327,608 |
— |
— |
9,327,608 |
| Electronic Equipment, Instruments & Components |
10,783,590 |
— |
— |
10,783,590 |
| Entertainment |
31,368,940 |
8,905,166 |
— |
40,274,106 |
| Financial Services |
17,744,356 |
— |
— |
17,744,356 |
| Industrial Conglomerates |
— |
10,851,539 |
— |
10,851,539 |
| Interactive Media & Services |
61,642,859 |
— |
1,644,053 |
63,286,912 |
| IT Services |
27,655,042 |
— |
21,629,226 |
49,284,268 |
| Professional Services |
— |
13,753,399 |
— |
13,753,399 |
| Semiconductors & Semiconductor Equipment |
378,100,047 |
25,824,140 |
— |
403,924,187 |
| Software |
289,689,008 |
8,390,083 |
20,789,608 |
318,868,699 |
| Specialty Retail |
— |
— |
64,668 |
64,668 |
| Technology Hardware, Storage & Peripherals |
113,209,373 |
— |
— |
113,209,373 |
| Convertible Notes |
— |
— |
1,695,787 |
1,695,787 |
| Preferred Securities |
|
|
|
|
| Preferred Stocks |
— |
— |
220,068,321 |
220,068,321 |
| Warrants |
— |
— |
— |
— |
| Short-Term Securities |
|
|
|
|
| Money Market Funds |
2,210,263 |
— |
— |
2,210,263 |
| |
$1,042,774,466 |
$67,724,327 |
$277,429,823 |
$1,387,928,616 |
| Derivative Financial Instruments(a)
|
|
|
|
|
| Liabilities |
|
|
|
|
| Equity Contracts |
$ (8,733,444 ) |
$ (2,195,861 ) |
$ — |
$ (10,929,305 ) |
| (a) |
Derivative financial instruments are options written. Options written are shown at
value. |
| |
Common Stocks |
Convertible Notes |
Preferred Stocks |
Warrants |
Total |
| Assets |
|
|
|
|
|
| Opening balance, as of December 31, 2023 |
$ 46,135,347
|
$ 1
|
$ 212,114,583
|
$ —
(a) |
$ 258,249,931
|
| Transfers into Level 3 |
— |
— |
— |
— |
— |
| Transfers out of Level 3 |
— |
— |
— |
— |
— |
| Other(b) |
(4,480,331 ) |
— |
4,480,331 |
— |
— |
| Accrued discounts/premiums |
— |
— |
— |
— |
— |
| Net realized gain (loss) |
— |
— |
1,155,081 |
— |
1,155,081 |
| Net change in unrealized appreciation (depreciation)(c)(d) |
4,010,750 |
33,251 |
(12,203,406 ) |
— |
(8,159,405 ) |
| Purchases |
9,999,949 |
1,662,535 |
28,215,988 |
— |
39,878,472 |
| Sales |
— |
— |
(13,694,256 ) |
— |
(13,694,256
) |
| Closing balance, as of December 31, 2024 |
$ 55,665,715 |
$ 1,695,787 |
$ 220,068,321 |
$ —
(a) |
$ 277,429,823 |
| Net change in unrealized appreciation (depreciation) on investments still held at December 31, 2024(d) |
$ 4,010,750 |
$ 33,251 |
$ (9,464,315 ) |
$ — (a) |
$ (5,420,314 ) |
| (a) |
Rounds to less than $1. |
| (b) |
Certain Level 3 investments were re-classified between Common Stocks and Preferred Stocks. |
| (c) |
Included in the related net change in unrealized appreciation (depreciation) in the Statements of Operations. |
| (d) |
Any difference between net change in unrealized appreciation (depreciation) and net change in unrealized appreciation (depreciation) on investments still held at
December 31, 2024 is generally due to investments no longer held or categorized as
Level 3 at period end. |
| |
Value |
Valuation Approach |
Unobservable Inputs |
Range of Unobservable Inputs Utilized(a) |
Weighted Average of Unobservable Inputs Based on Fair Value |
| Assets |
|
|
|
|
|
| Common Stocks |
$55,665,715
|
Market |
Revenue Multiple |
2.10x - 24.00x |
11.03x |
| |
|
|
Volatility |
70% |
— |
| |
|
|
Time to Exit |
3.0 years |
— |
| |
|
|
Gross Profit Multiple |
10.00x |
— |
| |
|
|
|
|
|
| Preferred Stocks(b) |
220,068,321 |
Market |
Revenue Multiple |
1.26x - 24.00x |
13.85x |
| |
|
|
Volatility |
50% - 90% |
68% |
| |
|
|
Time to Exit |
0.5 - 5.0 years |
3.3 years |
| |
|
|
Market Adjustment Multiple |
1.25x-1.80x |
1.62x |
| |
|
|
Terminal Growth Rate |
5% |
— |
| |
|
|
Gross Profit Multiple |
8.00x |
— |
| |
|
Income |
Discount Rate |
12% |
— |
| |
|
|
|
|
|
| Convertible Notes |
1,695,787 |
Market |
Revenue Multiple |
27.54x |
— |
| |
|
|
Volatility |
75% |
— |
| |
|
|
Time to Exit |
4.0 years |
— |
| |
|
|
|
|
|
| |
$277,429,823 |
|
|
|
|
| (a) |
A significant change in unobservable input could result in a correlated or inverse change in value. |
| (b) |
The trust valued certain of its Level 3 Preferred Stocks using recent transactions as the best approximation of fair value. The value of Level 3 investments obtained
using recent prior transaction prices, for which inputs are unobservable, is
$4,356,677 as of December 31, 2024. |
| Security |
|
Shares |
Value |
| Common Stocks | |||
| Building Products — 9.0% |
| ||
| Cie de Saint-Gobain SA |
|
156,650 |
$ 13,920,174
|
| Kingspan Group PLC |
|
106,465 |
7,739,739 |
| Owens Corning |
|
45,600 |
7,766,592 |
| Trane Technologies PLC |
|
45,500 |
16,805,425 |
| |
|
|
46,231,930 |
| Chemicals — 2.7% |
| ||
| Air Liquide SA |
|
39,589 |
6,435,575 |
| Linde PLC |
|
17,928 |
7,505,916 |
| |
|
|
13,941,491 |
| Commercial Services & Supplies — 4.4% |
| ||
| Republic Services, Inc. |
|
60,300 |
12,131,154 |
| Waste Management, Inc. |
|
51,550 |
10,402,274 |
| |
|
|
22,533,428 |
| Construction & Engineering — 5.5% |
| ||
| Quanta Services, Inc.(a) |
|
43,310 |
13,688,126 |
| Vinci SA |
|
139,750 |
14,388,174 |
| |
|
|
28,076,300 |
| Electric Utilities — 26.0% |
| ||
| American Electric Power Co.,
Inc.(a) |
|
109,550 |
10,103,796 |
| Constellation Energy Corp. |
|
58,100 |
12,997,551 |
| Duke Energy Corp.(a) |
|
99,168 |
10,684,360 |
| EDP SA |
|
3,229,150 |
10,330,102 |
| Enel SpA |
|
2,181,575 |
15,568,092 |
| Entergy Corp. |
|
106,100 |
8,044,502 |
| NextEra Energy, Inc.(a)(b) |
|
387,030 |
27,746,181 |
| PG&E Corp. |
|
642,650 |
12,968,677 |
| Southern Co. |
|
140,400 |
11,557,728 |
| SSE PLC |
|
641,700 |
12,862,547 |
| |
|
|
132,863,536 |
| Electrical Equipment — 14.4% |
| ||
| Eaton Corp. PLC |
|
14,990 |
4,974,731 |
| GE Vernova, Inc.(a) |
|
64,050 |
21,067,966 |
| Hubbell, Inc. |
|
21,100 |
8,838,579 |
| NEXTracker, Inc., Class A(c) |
|
107,500 |
3,926,975 |
| nVent Electric PLC |
|
109,650 |
7,473,744 |
| Prysmian SpA |
|
144,950 |
9,276,266 |
| Regal Rexnord Corp. |
|
38,900 |
6,034,557 |
| Schneider Electric SE |
|
26,460 |
6,587,370 |
| Vestas Wind Systems A/S(c) |
|
410,821 |
5,635,189 |
| |
|
|
73,815,377 |
| Ground Transportation — 2.6% |
| ||
| Canadian Pacific Kansas City Ltd. |
|
109,000 |
7,892,254 |
| Union Pacific Corp. |
|
22,900 |
5,222,116 |
| |
|
|
13,114,370 |
| Independent Power and Renewable Electricity Producers — 5.0% |
| ||
| Orron Energy AB(c) |
|
3,401,100 |
2,186,275 |
| RWE AG |
|
319,545 |
9,542,747 |
| Vistra Corp. |
|
99,550 |
13,724,959 |
| |
|
|
25,453,981 |
| Security |
|
Shares |
Value |
| Machinery — 1.9% |
| ||
| Ingersoll Rand, Inc. |
|
104,500 |
$ 9,453,070 |
| Multi-Utilities — 13.2% |
| ||
| CenterPoint Energy, Inc. |
|
211,850 |
6,722,001 |
| CMS Energy Corp.(a) |
|
115,110 |
7,672,081 |
| National Grid PLC |
|
1,487,988 |
17,677,671 |
| NiSource, Inc. |
|
240,500 |
8,840,780 |
| Public Service Enterprise Group, Inc.(b) |
|
124,192 |
10,492,982 |
| Sempra(a)(b) |
|
182,900 |
16,043,988 |
| |
|
|
67,449,503 |
| Oil, Gas & Consumable Fuels — 11.5% |
| ||
| Cheniere Energy, Inc. |
|
66,950 |
14,385,546 |
| Hess Midstream LP, Class A |
|
103,250 |
3,823,348 |
| Pembina Pipeline Corp. |
|
171,100 |
6,321,695 |
| Targa Resources Corp. |
|
67,400 |
12,030,900 |
| TC Energy Corp. |
|
133,000 |
6,198,247 |
| Williams Cos., Inc.(a)(b) |
|
295,805 |
16,008,967 |
| |
|
|
58,768,703 |
| Semiconductors & Semiconductor Equipment(c) —
1.5% |
| ||
| First Solar, Inc. |
|
20,584 |
3,627,724 |
| ON Semiconductor Corp. |
|
60,550 |
3,817,678 |
| |
|
|
7,445,402 |
| Total Long-Term Investments — 97.7% (Cost: $346,826,799) |
499,147,091 | ||
| Short-Term Securities | |||
| Money Market Funds — 2.6% |
| ||
| BlackRock Liquidity Funds, T-Fund, Institutional Shares,
4.36%(d)(e) |
|
13,062,505 |
13,062,505 |
| Total Short-Term Securities — 2.6% (Cost: $13,062,505) |
13,062,505 | ||
| Total Investments Before Options Written — 100.3% (Cost: $359,889,304) |
512,209,596 | ||
| Options Written — (0.5)% (Premiums Received: $(4,545,706)) |
(2,376,764 ) | ||
| Total Investments, Net of Options Written — 99.8% (Cost: $355,343,598) |
509,832,832 | ||
| Other Assets Less Liabilities — 0.2% |
1,021,142 | ||
| Net Assets — 100.0% |
$ 510,853,974 | ||
| (a) |
All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written. |
| (b) |
All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives. |
| (c) |
Non-income producing security. |
| (d) |
Affiliate of the Trust. |
| (e) |
Annualized 7-day yield as of period end. |
| Affiliated Issuer |
Value at 12/31/23 |
Purchases at Cost |
Proceeds from Sales |
Net Realized Gain (Loss) |
Change in Unrealized Appreciation (Depreciation) |
Value at 12/31/24 |
Shares Held at 12/31/24 |
Income |
Capital Gain Distributions from Underlying Funds |
| BlackRock Cash Funds: Institutional, SL Agency Shares(a) |
$ — |
$ — |
$ (707 )(b) |
$ 707 |
$ — |
$ — |
— |
$ 1,208 (c) |
$ — |
| BlackRock Liquidity Funds, T-Fund, Institutional Shares |
5,318,307 |
7,744,198 (b) |
— |
— |
— |
13,062,505 |
13,062,505 |
377,953 |
— |
| SL Liquidity Series, LLC, Money Market
Series(a) |
1,297,977 |
— |
(1,298,025
)(b) |
52 |
(4 ) |
— |
— |
3,797
(c) |
— |
| |
|
|
|
$ 759 |
$ (4 ) |
$ 13,062,505 |
|
$ 382,958 |
$ — |
| (a) |
As of period end, the entity is no longer held. |
| (b) |
Represents net amount purchased (sold). |
| (c) |
All or a portion represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of collateral investment fees, and
other payments to and from borrowers of securities. |
| Description |
Number of Contracts |
Expiration Date |
Exercise Price |
Notional Amount (000) |
Value | ||
| Call |
|
|
|
|
|
|
|
| PG&E Corp. |
435 |
01/03/25 |
USD |
21.50 |
USD |
878 |
$ (6,525
) |
| Constellation Energy Corp. |
72 |
01/10/25 |
USD |
265.00 |
USD |
1,611 |
(2,520 ) |
| NextEra Energy, Inc. |
357 |
01/10/25 |
USD |
79.89 |
USD |
2,559 |
(374 ) |
| PG&E Corp. |
166 |
01/10/25 |
USD |
21.32 |
USD |
335 |
(324 ) |
| Union Pacific Corp. |
24 |
01/10/25 |
USD |
240.00 |
USD |
547 |
(840 ) |
| American Electric Power Co., Inc. |
124 |
01/17/25 |
USD |
97.50 |
USD |
1,144 |
(1,550 ) |
| Canadian Pacific Kansas City Ltd. |
381 |
01/17/25 |
CAD |
110.00 |
CAD |
3,965 |
(7,952 ) |
| CenterPoint Energy, Inc. |
446 |
01/17/25 |
USD |
30.20 |
USD |
1,415 |
(73,462 ) |
| Cheniere Energy, Inc. |
82 |
01/17/25 |
USD |
200.00 |
USD |
1,762 |
(132,430 ) |
| Cheniere Energy, Inc. |
70 |
01/17/25 |
USD |
210.00 |
USD |
1,504 |
(55,300 ) |
| CMS Energy Corp. |
284 |
01/17/25 |
USD |
70.00 |
USD |
1,893 |
(38,340 ) |
| Duke Energy Corp. |
175 |
01/17/25 |
USD |
115.00 |
USD |
1,885 |
(2,188 ) |
| Eaton Corp. PLC |
35 |
01/17/25 |
USD |
370.00 |
USD |
1,162 |
(1,400 ) |
| First Solar, Inc. |
22 |
01/17/25 |
USD |
220.00 |
USD |
388 |
(506 ) |
| GE Vernova, Inc. |
74 |
01/17/25 |
USD |
350.00 |
USD |
2,434 |
(34,040 ) |
| Hess Midstream LP, Class A |
180 |
01/17/25 |
USD |
36.04 |
USD |
667 |
(23,836 ) |
| Hubbell, Inc. |
42 |
01/17/25 |
USD |
450.00 |
USD |
1,759 |
(11,970 ) |
| Ingersoll Rand, Inc. |
270 |
01/17/25 |
USD |
105.00 |
USD |
2,442 |
(36,450 ) |
| Linde PLC |
31 |
01/17/25 |
USD |
475.00 |
USD |
1,298 |
(7,750 ) |
| NextEra Energy, Inc. |
387 |
01/17/25 |
USD |
77.50 |
USD |
2,774 |
(5,225 ) |
| NEXTracker, Inc., Class A |
188 |
01/17/25 |
USD |
40.00 |
USD |
687 |
(9,400 ) |
| NiSource, Inc. |
387 |
01/17/25 |
USD |
36.68 |
USD |
1,423 |
(29,248 ) |
| nVent Electric PLC |
181 |
01/17/25 |
USD |
80.00 |
USD |
1,234 |
(38,915 ) |
| ON Semiconductor Corp. |
120 |
01/17/25 |
USD |
75.00 |
USD |
757 |
(1,440 ) |
| Owens Corning |
80 |
01/17/25 |
USD |
210.00 |
USD |
1,363 |
(6,000 ) |
| PG&E Corp. |
846 |
01/17/25 |
USD |
22.00 |
USD |
1,707 |
(3,384 ) |
| Public Service Enterprise Group, Inc. |
207 |
01/17/25 |
USD |
88.10 |
USD |
1,749 |
(9,368 ) |
| Quanta Services, Inc. |
82 |
01/17/25 |
USD |
350.00 |
USD |
2,592 |
(10,865 ) |
| Regal Rexnord Corp. |
115 |
01/17/25 |
USD |
180.00 |
USD |
1,784 |
(8,625 ) |
| Republic Services, Inc. |
116 |
01/17/25 |
USD |
220.00 |
USD |
2,334 |
(1,450 ) |
| Sempra |
325 |
01/17/25 |
USD |
91.25 |
USD |
2,851 |
(9,266 ) |
| Targa Resources Corp. |
136 |
01/17/25 |
USD |
195.00 |
USD |
2,428 |
(8,500 ) |
| TC Energy Corp. |
278 |
01/17/25 |
CAD |
68.00 |
CAD |
1,862 |
(9,960 ) |
| Trane Technologies PLC |
91 |
01/17/25 |
USD |
420.00 |
USD |
3,361 |
(11,830 ) |
| Trane Technologies PLC |
68 |
01/17/25 |
USD |
410.00 |
USD |
2,512 |
(8,500 ) |
| Union Pacific Corp. |
34 |
01/17/25 |
USD |
250.00 |
USD |
775 |
(1,020 ) |
| Waste Management, Inc. |
180 |
01/17/25 |
USD |
220.00 |
USD |
3,632 |
(2,250 ) |
| Williams Cos., Inc. |
432 |
01/17/25 |
USD |
60.00 |
USD |
2,338 |
(3,240 ) |
| Description |
Number of Contracts |
Expiration Date |
Exercise Price |
Notional Amount (000) |
Value | ||
| Call (continued) |
|
|
|
|
|
|
|
| Constellation Energy Corp. |
131 |
01/24/25 |
USD |
265.00 |
USD |
2,931 |
$ (9,498
) |
| GE Vernova, Inc. |
150 |
01/24/25 |
USD |
345.00 |
USD |
4,934 |
(156,750 ) |
| Southern Co. |
255 |
01/24/25 |
USD |
85.00 |
USD |
2,099 |
(14,025 ) |
| Vistra Corp. |
166 |
01/24/25 |
USD |
162.50 |
USD |
2,289 |
(23,655 ) |
| Williams Cos., Inc. |
603 |
01/24/25 |
USD |
54.00 |
USD |
3,263 |
(183,915 ) |
| NextEra Energy, Inc. |
248 |
01/31/25 |
USD |
76.00 |
USD |
1,778 |
(21,576 ) |
| ON Semiconductor Corp. |
91 |
01/31/25 |
USD |
69.00 |
USD |
574 |
(11,875 ) |
| PG&E Corp. |
802 |
01/31/25 |
USD |
20.50 |
USD |
1,618 |
(28,471 ) |
| NextEra Energy, Inc. |
362 |
02/07/25 |
USD |
74.00 |
USD |
2,595 |
(72,400 ) |
| Vistra Corp. |
182 |
02/07/25 |
USD |
150.00 |
USD |
2,509 |
(111,020 ) |
| American Electric Power Co., Inc. |
259 |
02/21/25 |
USD |
95.00 |
USD |
2,389 |
(33,022 ) |
| CenterPoint Energy, Inc. |
295 |
02/21/25 |
USD |
33.00 |
USD |
936 |
(14,750 ) |
| Cheniere Energy, Inc. |
82 |
02/21/25 |
USD |
220.00 |
USD |
1,762 |
(48,790 ) |
| Duke Energy Corp. |
172 |
02/21/25 |
USD |
110.00 |
USD |
1,853 |
(47,300 ) |
| Eaton Corp. PLC |
17 |
02/21/25 |
USD |
350.00 |
USD |
564 |
(14,110 ) |
| Hess Midstream LP, Class A |
181 |
02/21/25 |
USD |
38.00 |
USD |
670 |
(9,502 ) |
| Hubbell, Inc. |
31 |
02/21/25 |
USD |
460.00 |
USD |
1,299 |
(20,227 ) |
| Ingersoll Rand, Inc. |
95 |
02/21/25 |
USD |
97.00 |
USD |
859 |
(13,072 ) |
| Linde PLC |
31 |
02/21/25 |
USD |
465.00 |
USD |
1,298 |
(2,558 ) |
| NiSource, Inc. |
454 |
02/21/25 |
USD |
36.47 |
USD |
1,669 |
(61,928 ) |
| nVent Electric PLC |
202 |
02/21/25 |
USD |
75.00 |
USD |
1,377 |
(30,300 ) |
| Owens Corning |
80 |
02/21/25 |
USD |
190.00 |
USD |
1,363 |
(15,200 ) |
| Public Service Enterprise Group, Inc. |
227 |
02/21/25 |
USD |
86.01 |
USD |
1,918 |
(50,833 ) |
| Quanta Services, Inc. |
69 |
02/21/25 |
USD |
340.00 |
USD |
2,181 |
(52,785 ) |
| Republic Services, Inc. |
96 |
02/21/25 |
USD |
210.00 |
USD |
1,931 |
(24,000 ) |
| Sempra |
316 |
02/21/25 |
USD |
86.50 |
USD |
2,772 |
(114,941 ) |
| Southern Co. |
236 |
02/21/25 |
USD |
85.00 |
USD |
1,943 |
(29,500 ) |
| Union Pacific Corp. |
22 |
02/21/25 |
USD |
245.00 |
USD |
502 |
(3,630 ) |
| |
|
|
|
|
|
|
$ (1,835,876 ) |
| Description |
Counterparty |
Number of Contracts |
Expiration Date |
Exercise Price |
Notional Amount (000) |
Value | ||
| Call |
|
|
|
|
|
|
|
|
| Air Liquide SA |
Bank of America N.A. |
5,100 |
01/07/25 |
EUR |
170.59 |
EUR |
800 |
$ (22
) |
| Cie de Saint-Gobain SA |
Bank of America N.A. |
23,700 |
01/07/25 |
EUR |
87.65 |
EUR |
2,033 |
(11,892 ) |
| EDP SA |
Goldman Sachs International |
269,700 |
01/07/25 |
EUR |
3.70 |
EUR |
833 |
— |
| Kingspan Group PLC |
Bank of America N.A. |
17,000 |
01/07/25 |
EUR |
83.22 |
EUR |
1,193 |
(1 ) |
| Prysmian SpA |
Citibank N.A. |
18,000 |
01/07/25 |
EUR |
68.63 |
EUR |
1,112 |
— |
| Vinci SA |
Bank of America N.A. |
48,000 |
01/07/25 |
EUR |
105.00 |
EUR |
4,771 |
(471 ) |
| Cie de Saint-Gobain SA |
BNP Paribas SA |
28,300 |
01/09/25 |
EUR |
88.56 |
EUR |
2,428 |
(11,913 ) |
| EDP SA |
Morgan Stanley & Co. International PLC |
46,200 |
01/09/25 |
EUR |
3.48 |
EUR |
143 |
(4 ) |
| Prysmian SpA |
Bank of America N.A. |
22,700 |
01/09/25 |
EUR |
63.45 |
EUR |
1,402 |
(4,205 ) |
| Air Liquide SA |
Goldman Sachs International |
7,300 |
01/14/25 |
EUR |
166.18 |
EUR |
1,146 |
(1,567 ) |
| EDP SA |
Morgan Stanley & Co. International PLC |
84,200 |
01/14/25 |
EUR |
3.52 |
EUR |
260 |
(27 ) |
| Enel SpA |
UBS AG |
559,500 |
01/14/25 |
EUR |
6.97 |
EUR |
3,855 |
(28,955 ) |
| National Grid PLC |
Goldman Sachs International |
235,800 |
01/14/25 |
GBP |
9.88 |
GBP |
2,238 |
(14,355 ) |
| Schneider Electric SE |
BNP Paribas SA |
5,300 |
01/14/25 |
EUR |
256.79 |
EUR |
1,274 |
(1,481 ) |
| National Grid PLC |
Goldman Sachs International |
69,100 |
01/15/25 |
GBP |
10.03 |
GBP |
656 |
(3,318 ) |
| Enel SpA |
Goldman Sachs International |
204,100 |
01/16/25 |
EUR |
7.09 |
EUR |
1,406 |
(6,114 ) |
| RWE AG |
UBS AG |
139,700 |
01/16/25 |
EUR |
33.03 |
EUR |
4,028 |
(1,858 ) |
| SSE PLC |
UBS AG |
36,800 |
01/16/25 |
GBP |
17.28 |
GBP |
589 |
(2,079 ) |
| EDP SA |
Goldman Sachs International |
537,100 |
01/22/25 |
EUR |
3.33 |
EUR |
1,659 |
(5,068 ) |
| Schneider Electric SE |
Barclays Bank PLC |
3,900 |
01/22/25 |
EUR |
252.38 |
EUR |
937 |
(5,790 ) |
| SSE PLC |
UBS AG |
187,800 |
01/23/25 |
GBP |
16.40 |
GBP |
3,012 |
(65,480 ) |
| Vestas Wind Systems A/S |
Goldman Sachs International |
61,700 |
01/24/25 |
DKK |
113.43 |
DKK |
6,093 |
(6,265 ) |
| EDP SA |
Bank of America N.A. |
96,500 |
01/28/25 |
EUR |
3.22 |
EUR |
298 |
(2,751 ) |
| Kingspan Group PLC |
Bank of America N.A. |
20,200 |
01/28/25 |
EUR |
70.67 |
EUR |
1,423 |
(45,194 ) |
| National Grid PLC |
Goldman Sachs International |
215,900 |
01/28/25 |
GBP |
9.51 |
GBP |
2,051 |
(49,078 ) |
| Vestas Wind Systems A/S |
Morgan Stanley & Co. International PLC |
82,100 |
01/28/25 |
DKK |
100.05 |
DKK |
8,052 |
(48,291 ) |
| Description |
Counterparty |
Number of Contracts |
Expiration Date |
Exercise Price |
Notional Amount (000) |
Value | ||
| Call (continued) |
|
|
|
|
|
|
|
|
| EDP SA |
Bank of America N.A. |
96,500 |
02/06/25 |
EUR |
3.17 |
EUR |
298 |
$ (4,833
) |
| Targa Resources Corp. |
Morgan Stanley & Co. International PLC |
9,900 |
02/07/25 |
USD |
184.62 |
USD |
1,767 |
(49,152 ) |
| TC Energy Corp. |
Morgan Stanley & Co. International PLC |
18,800 |
02/10/25 |
CAD |
68.76 |
CAD |
1,259 |
(14,849 ) |
| Entergy Corp. |
Citibank N.A. |
37,100 |
02/19/25 |
USD |
76.41 |
USD |
2,813 |
(82,768 ) |
| CMS Energy Corp. |
Barclays Bank PLC |
26,100 |
02/24/25 |
USD |
67.99 |
USD |
1,740 |
(36,004 ) |
| Pembina Pipeline Corp. |
Royal Bank of Canada |
59,800 |
02/27/25 |
CAD |
54.25 |
CAD |
3,176 |
(37,103 ) |
| |
|
|
|
|
|
|
|
$ (540,888 ) |
| Description |
Premiums Paid |
Premiums Received |
Unrealized Appreciation |
Unrealized Depreciation |
Value |
| Options Written |
$ N/A
|
$ (4,545,706
) |
$ 2,494,490
|
$ (325,548
) |
$ (2,376,764
) |
| |
Commodity Contracts |
Credit Contracts |
Equity Contracts |
Foreign Currency Exchange Contracts |
Interest Rate Contracts |
Other Contracts |
Total |
| Liabilities — Derivative Financial Instruments |
|
|
|
|
|
|
|
| Options written Options written at value |
$ — |
$ — |
$ 2,376,764 |
$ — |
$ — |
$ — |
$ 2,376,764 |
| |
Commodity Contracts |
Credit Contracts |
Equity Contracts |
Foreign Currency Exchange Contracts |
Interest Rate Contracts |
Other Contracts |
Total |
| Net Realized Gain (Loss) from: |
|
|
|
|
|
|
|
| Options written |
$ — |
$ — |
$ (14,328,396 ) |
$ — |
$ — |
$ — |
$ (14,328,396 ) |
| Net Change in Unrealized Appreciation (Depreciation) on: |
|
|
|
|
|
|
|
| Options written |
$ — |
$ — |
$ 5,965,132 |
$ — |
$ — |
$ — |
$ 5,965,132 |
| Options: |
|
| Average value of option contracts written |
$4,798,363
|
| |
Assets |
Liabilities |
| Derivative Financial Instruments |
|
|
| Options |
$ — |
$ 2,376,764 |
| Total derivative assets and liabilities in the Statements of Assets and Liabilities |
— |
2,376,764 |
| Derivatives not subject to a Master Netting Agreement or similar agreement (“MNA”) |
— |
(1,835,876 ) |
| Total derivative assets and liabilities subject to an MNA |
$ — |
$ 540,888 |
| Counterparty |
Derivative Liabilities Subject to an MNA by Counterparty |
Derivatives Available for Offset(a)
|
Non-Cash Collateral Pledged(b)
|
Cash Collateral Pledged(b)
|
Net Amount of Derivative Liabilities(c)
|
| Bank of America N.A. |
$ 69,369
|
$ —
|
$ (69,369
) |
$ —
|
$ —
|
| Barclays Bank PLC |
41,794 |
— |
(41,794 ) |
— |
— |
| BNP Paribas SA |
13,394 |
— |
— |
— |
13,394 |
| Citibank N.A. |
82,768 |
— |
(45,523 ) |
— |
37,245 |
| Goldman Sachs International |
85,765 |
— |
(85,765 ) |
— |
— |
| Morgan Stanley & Co. International PLC |
112,323 |
— |
(112,323 ) |
— |
— |
| Royal Bank of Canada |
37,103 |
— |
— |
— |
37,103 |
| UBS AG |
98,372 |
— |
(40,702 ) |
— |
57,670 |
| |
$ 540,888 |
$ — |
$ (395,476 ) |
$ — |
$ 145,412 |
| (a) |
The amount of derivatives available for offset is limited to the amount of derivative assets and/or liabilities that are subject to an MNA. |
| (b) |
Excess of collateral received/pledged, if any, from the individual counterparty is not shown for financial reporting purposes. |
| (c) |
Net amount represents the net amount payable due to the counterparty in the event of default. Net amount may be offset further by the options written
receivable/payable on the Statements of Assets and Liabilities. |
| |
Level 1 |
Level 2 |
Level 3 |
Total |
| Assets |
|
|
|
|
| Investments |
|
|
|
|
| Long-Term Investments |
|
|
|
|
| Common Stocks |
|
|
|
|
| Building Products |
$ 24,572,017
|
$ 21,659,913
|
$ —
|
$ 46,231,930 |
| Chemicals |
7,505,916 |
6,435,575 |
— |
13,941,491 |
| Commercial Services & Supplies |
22,533,428 |
— |
— |
22,533,428 |
| Construction & Engineering |
13,688,126 |
14,388,174 |
— |
28,076,300 |
| Electric Utilities |
94,102,795 |
38,760,741 |
— |
132,863,536 |
| Electrical Equipment |
52,316,552 |
21,498,825 |
— |
73,815,377 |
| Ground Transportation |
13,114,370 |
— |
— |
13,114,370 |
| Independent Power and Renewable Electricity Producers |
25,453,981 |
— |
— |
25,453,981 |
| Machinery |
9,453,070 |
— |
— |
9,453,070 |
| Multi-Utilities |
49,771,832 |
17,677,671 |
— |
67,449,503 |
| Oil, Gas & Consumable Fuels |
58,768,703 |
— |
— |
58,768,703 |
| Semiconductors & Semiconductor Equipment |
7,445,402 |
— |
— |
7,445,402 |
| Short-Term Securities |
|
|
|
|
| Money Market Funds |
13,062,505 |
— |
— |
13,062,505 |
| |
$391,788,697 |
$120,420,899 |
$— |
$512,209,596 |
| Derivative Financial Instruments(a)
|
|
|
|
|
| Liabilities |
|
|
|
|
| Equity Contracts |
$ (1,449,224 ) |
$ (927,540 ) |
$ — |
$ (2,376,764 ) |
| (a) |
Derivative financial instruments are options written. Options written are shown at
value. |
| |
BGR |
BDJ(a) |
BOE |
BGY |
| ASSETS |
|
|
|
|
| Investments, at value —
unaffiliated(b) |
$ 353,822,195 |
$ 1,563,922,401 |
$ 701,429,725 |
$ 564,976,361 |
| Investments, at value —
affiliated(c) |
7,583,996 |
46,597,729 |
7,033,278 |
3,742,337 |
| Cash |
— |
15,980 |
— |
— |
| Foreign currency, at value(d)
|
228,832 |
31,968 |
262,325 |
90,323 |
| Receivables: |
|
|
|
|
| Dividends — unaffiliated |
325,935 |
1,899,848 |
1,406,936 |
1,376,170 |
| Dividends — affiliated |
30,929 |
108,656 |
23,254 |
17,106 |
| Deferred offering costs |
— |
210,889 |
— |
— |
| Prepaid expenses |
— |
7,440 |
— |
— |
| Total assets |
361,991,887 |
1,612,794,911 |
710,155,518 |
570,202,297 |
| LIABILITIES |
|
|
|
|
| Options written, at value(e)
|
1,632,661 |
10,489,212 |
4,114,542 |
4,331,111 |
| Payables: |
|
|
|
|
| Investments purchased |
— |
3,452,040 |
— |
— |
| Accounting services fees |
18,334 |
39,168 |
24,604 |
20,420 |
| Custodian fees |
8,458 |
33,867 |
31,709 |
50,454 |
| Deferred capital gain tax |
— |
— |
— |
9,770 |
| Investment advisory fees |
308,781 |
1,108,223 |
504,661 |
489,031 |
| IRS compliance fee for foreign withholding tax claims |
— |
— |
— |
1,650,132 |
| Trustees’ and Officer’s fees |
358,035 |
942,751 |
617,771 |
515,644 |
| Other accrued expenses |
15,134 |
29,592 |
15,593 |
18,108 |
| Professional fees |
68,254 |
56,711 |
120,176 |
143,702 |
| Transfer agent fees |
12,455 |
34,902 |
17,263 |
14,894 |
| Total liabilities |
2,422,112 |
16,186,466 |
5,446,319 |
7,243,266 |
| Commitments and contingent liabilities |
|
|
|
|
| NET ASSETS |
$ 359,569,775
|
$ 1,596,608,445
|
$ 704,709,199
|
$ 562,959,031 |
| NET ASSETS CONSIST OF |
|
|
|
|
| Paid-in capital(f)(g)(h) |
$ 473,802,245 |
$ 1,226,341,998 |
$ 577,667,232 |
$ 509,795,862 |
| Accumulated earnings (loss) |
(114,232,470) |
370,266,447 |
127,041,967 |
53,163,169 |
| NET ASSETS |
$ 359,569,775 |
$ 1,596,608,445 |
$ 704,709,199 |
$ 562,959,031 |
| Net asset value |
$ 13.77 |
$ 9.02 |
$ 12.05 |
$ 5.91 |
| (a) Consolidated Statements of Assets and
Liabilities. | ||||
| (b) Investments, at cost—unaffiliated |
$241,326,966 |
$1,276,112,714 |
$550,585,379 |
$494,250,581 |
| (c) Investments, at cost—affiliated |
$7,583,996 |
$46,597,729 |
$7,033,278 |
$3,742,337 |
| (d) Foreign currency, at cost
|
$229,183 |
$32,119 |
$262,916 |
$90,262 |
| (e) Premiums received |
$2,551,928 |
$20,123,825 |
$7,687,194 |
$5,915,885 |
| (f) Shares outstanding |
26,108,893 |
176,944,689 |
58,487,968 |
95,320,925 |
| (g) Shares authorized |
Unlimited |
Unlimited |
Unlimited |
Unlimited |
| (h) Par value |
$0.001 |
$0.001 |
$0.001 |
$0.001 |
| |
CII |
BMEZ |
BME |
BIGZ |
| ASSETS |
|
|
|
|
| Investments, at value —
unaffiliated(a)(b) |
$ 905,684,805 |
$ 1,624,787,940 |
$ 523,327,618 |
$ 1,792,215,092 |
| Investments, at value —
affiliated(c) |
6,755,922 |
61,349,683 |
26,552,753 |
16,270,816 |
| Cash |
— |
127,446 |
5,813 |
— |
| Foreign currency, at value(d)
|
617 |
701 |
235 |
— |
| Receivables: |
|
|
|
|
| Investments sold |
— |
17,105 |
1,713 |
— |
| Securities lending income — affiliated |
456 |
7,807 |
158 |
2,842 |
| Dividends — unaffiliated |
214,914 |
773,117 |
299,577 |
49,669 |
| Dividends — affiliated |
39,432 |
226,282 |
100,806 |
14,178 |
| Interest — unaffiliated |
— |
22,060 |
2,168 |
— |
| Deferred offering costs |
— |
— |
84,599 |
— |
| Prepaid expenses |
703 |
8,652 |
— |
8,742 |
| Total assets |
912,696,849 |
1,687,320,793 |
550,375,440 |
1,808,561,339 |
| LIABILITIES |
|
|
|
|
| Bank overdraft |
181,324 |
— |
— |
— |
| Collateral on securities loaned |
435,165 |
10,228,332 |
278,058 |
14,260,657 |
| Options written, at value(e)
|
11,480,390 |
10,440,970 |
2,822,101 |
6,220,791 |
| Payables: |
|
|
|
|
| Investments purchased |
— |
— |
493,107 |
— |
| Accounting services fees |
20,419 |
84,331 |
12,106 |
84,484 |
| Custodian fees |
12,280 |
98,311 |
21,115 |
34,068 |
| Investment advisory fees |
659,437 |
1,826,937 |
473,572 |
1,973,979 |
| Trustees’ and Officer’s fees |
265,082 |
265,414 |
25,730 |
237,229 |
| Other accrued expenses |
7,284 |
121,644 |
15,739 |
555,658 |
| Professional fees |
67,014 |
143,488 |
83,654 |
182,353 |
| Proxy fees |
— |
167,274 |
— |
— |
| Transfer agent fees |
17,146 |
61,837 |
14,994 |
50,705 |
| Total liabilities |
13,145,541 |
23,438,538 |
4,240,176 |
23,599,924 |
| Commitments and contingent liabilities |
|
|
|
|
| NET ASSETS |
$ 899,551,308
|
$ 1,663,882,255
|
$ 546,135,264
|
$ 1,784,961,415 |
| NET ASSETS CONSIST OF |
|
|
|
|
| Paid-in capital(f)(g)(h) |
$ 516,182,985 |
$ 1,685,240,974 |
$ 381,133,280 |
$ 3,723,540,676 |
| Accumulated earnings (loss) |
383,368,323 |
(21,358,719) |
165,001,984 |
(1,938,579,261) |
| NET ASSETS |
$ 899,551,308 |
$ 1,663,882,255 |
$ 546,135,264 |
$ 1,784,961,415 |
| Net asset value |
$ 21.43 |
$ 16.43 |
$ 41.20 |
$ 8.37 |
| (a) Investments, at cost—unaffiliated |
$599,221,066 |
$1,598,524,737 |
$353,885,548 |
$1,870,486,959 |
| (b) Securities loaned, at value
|
$425,316 |
$9,958,080 |
$276,299 |
$13,912,671 |
| (c) Investments, at cost—affiliated |
$6,755,963 |
$61,350,462 |
$26,552,737 |
$16,270,379 |
| (d) Foreign currency, at cost
|
$620 |
$732 |
$239 |
$— |
| (e) Premiums received |
$14,633,458 |
$15,891,589 |
$5,345,930 |
$10,409,882 |
| (f) Shares outstanding |
41,967,166 |
101,255,117 |
13,255,490 |
213,338,148 |
| (g) Shares authorized |
200 million |
Unlimited |
Unlimited |
Unlimited |
| (h) Par value |
$0.10 |
$0.001 |
$0.001 |
$0.001 |
| |
BCX |
BSTZ(a) |
BST(a) |
BUI |
| ASSETS |
|
|
|
|
| Investments, at value —
unaffiliated(b)(c) |
$ 742,562,101 |
$ 1,688,662,127 |
$ 1,385,718,353 |
$ 499,147,091 |
| Investments, at value —
affiliated(d) |
30,765,815 |
9,501,701 |
2,210,263 |
13,062,505 |
| Cash |
— |
11,578 |
134,293 |
155,364 |
| Cash pledged as collateral for OTC derivatives |
— |
380,000 |
— |
— |
| Foreign currency, at value(e)
|
71,339 |
1,164 |
2,100 |
69,811 |
| Receivables: |
|
|
|
|
| Investments sold |
— |
— |
456 |
707 |
| Securities lending income — affiliated |
505 |
15,132 |
773 |
397 |
| Capital shares sold |
— |
— |
— |
574,300 |
| Dividends — unaffiliated |
961,398 |
74,883 |
142,252 |
681,135 |
| Dividends — affiliated |
74,327 |
43,476 |
14,475 |
35,211 |
| Interest — unaffiliated |
159,250 |
— |
— |
— |
| Deferred offering costs |
— |
— |
71,340 |
106,065 |
| Prepaid expenses |
— |
6,466 |
4,122 |
— |
| Total assets |
774,594,735 |
1,698,696,527 |
1,388,298,427 |
513,832,586 |
| LIABILITIES |
|
|
|
|
| Bank overdraft |
152,061 |
— |
— |
— |
| Collateral on securities loaned |
1,847,500 |
7,485,830 |
565,400 |
— |
| Options written, at value(f)
|
2,922,240 |
11,477,631 |
10,929,305 |
2,376,764 |
| Payables: |
|
|
|
|
| Accounting services fees |
24,582 |
79,933 |
20,425 |
20,425 |
| Custodian fees |
22,956 |
67,069 |
17,543 |
18,735 |
| Deferred capital gain tax |
— |
3,558,599 |
421,779 |
— |
| Investment advisory fees |
670,918 |
1,814,551 |
1,183,708 |
444,445 |
| Trustees’ and Officer’s fees |
241,888 |
246,792 |
36,003 |
246 |
| Other accrued expenses |
36,065 |
107,336 |
84,358 |
36,829 |
| Professional fees |
86,029 |
173,377 |
133,508 |
67,054 |
| Transfer agent fees |
23,481 |
93,959 |
30,038 |
14,114 |
| Total liabilities |
6,027,720 |
25,105,077 |
13,422,067 |
2,978,612 |
| Commitments and contingent liabilities |
|
|
|
|
| NET ASSETS |
$ 768,567,015 |
$ 1,673,591,450 |
$ 1,374,876,360 |
$ 510,853,974 |
| NET ASSETS CONSIST OF |
|
|
|
|
| Paid-in capital(g)(h)(i) |
$ 942,097,295 |
$ 1,029,251,385 |
$ 729,562,726 |
$ 370,865,705 |
| Accumulated earnings (loss) |
(173,530,280) |
644,340,065 |
645,313,634 |
139,988,269 |
| NET ASSETS |
$ 768,567,015 |
$ 1,673,591,450 |
$ 1,374,876,360 |
$ 510,853,974 |
| Net asset value |
$ 9.58 |
$ 23.14 |
$ 39.60 |
$ 22.65 |
| (a) Consolidated Statements of Assets and
Liabilities. | ||||
| (b) Investments, at cost—unaffiliated |
$693,590,037 |
$994,668,170 |
$721,707,345 |
$346,826,799 |
| (c) Securities loaned, at value
|
$1,818,411 |
$7,194,950 |
$542,784 |
$— |
| (d) Investments, at cost—affiliated |
$30,765,955 |
$9,500,263 |
$2,210,263 |
$13,062,505 |
| (e) Foreign currency, at cost
|
$71,616 |
$1,188 |
$2,313 |
$69,918 |
| (f) Premiums received |
$5,939,779 |
$14,389,743 |
$15,302,365 |
$4,545,706 |
| (g) Shares outstanding |
80,197,858 |
72,314,687 |
34,720,019 |
22,551,850 |
| (h) Shares authorized |
Unlimited |
Unlimited |
Unlimited |
Unlimited |
| (i) Par value |
$0.001 |
$0.001 |
$0.001 |
$0.001 |
| |
BGR |
BDJ(a) |
BOE |
BGY |
| INVESTMENT INCOME |
|
|
|
|
| Dividends — unaffiliated |
$13,636,673
|
$45,639,398
|
$18,323,631
|
$16,618,755
|
| Dividends — affiliated |
368,659 |
1,687,407 |
348,611 |
352,353 |
| Securities lending income — affiliated — net |
— |
464 |
23 |
— |
| Other income — unaffiliated |
— |
— |
60,158 |
— |
| Foreign taxes withheld |
(660,284 ) |
(521,780 ) |
(1,015,017 ) |
(1,524,537 ) |
| Foreign withholding tax claims |
— |
— |
206,782 |
2,442,978 |
| IRS compliance fee for foreign withholding tax claims |
— |
— |
— |
(1,650,133 ) |
| Total investment income |
13,345,048 |
46,805,489 |
17,924,188 |
16,239,416 |
| EXPENSES |
|
|
|
|
| Investment advisory |
4,360,775 |
13,517,101 |
7,420,543 |
6,196,036 |
| Transfer agent |
196,674 |
582,621 |
286,448 |
239,086 |
| Professional |
108,815 |
87,308 |
138,602 |
441,749 |
| Trustees and Officer |
66,404 |
191,850 |
110,146 |
94,132 |
| Accounting services |
44,039 |
94,542 |
59,537 |
49,500 |
| Printing and postage |
26,082 |
68,199 |
27,099 |
28,331 |
| Custodian |
21,255 |
79,329 |
75,259 |
122,535 |
| Registration |
9,555 |
64,758 |
21,405 |
34,885 |
| Miscellaneous |
53,763 |
176,326 |
88,686 |
122,466 |
| Total expenses excluding interest expense |
4,887,362 |
14,862,034 |
8,227,725 |
7,328,720 |
| Interest expense — unaffiliated |
680 |
4,073 |
4,783 |
23,113 |
| Total expenses |
4,888,042 |
14,866,107 |
8,232,508 |
7,351,833 |
| Less: |
|
|
|
|
| Fees waived and/or reimbursed by the Manager |
(445,644 ) |
(25,016 ) |
(1,303,769 ) |
(5,220 ) |
| Total expenses after fees waived and/or reimbursed |
4,442,398 |
14,841,091 |
6,928,739 |
7,346,613 |
| Net investment income |
8,902,650 |
31,964,398 |
10,995,449 |
8,892,803 |
| REALIZED AND UNREALIZED GAIN (LOSS) |
|
|
|
|
| Net realized gain (loss) from: |
|
|
|
|
| Investments — unaffiliated |
19,721,209 |
124,738,978 |
36,871,450 |
40,623,999 |
| Investments — affiliated |
— |
(896 ) |
98 |
— |
| Foreign currency transactions |
31,675 |
36,494 |
(3,347 ) |
(136,984 ) |
| Options written |
(2,739,126 ) |
(53,221,661 ) |
(15,973,502 ) |
(6,055,084 ) |
| Payment by affiliate |
4,285 |
3,800 |
— |
— |
| |
17,018,043 |
71,556,715 |
20,894,699 |
34,431,931 |
| Net change in unrealized appreciation (depreciation) on: |
|
|
|
|
| Investments — unaffiliated |
(11,982,519 ) |
35,744,378 |
22,824,628 |
(37,527,918 )(b) |
| Foreign currency translations |
(1,304 ) |
(4,483 ) |
(57,001 ) |
(49,368 ) |
| Options written |
206,038 |
25,508,715 |
7,740,032 |
6,032,978 |
| |
(11,777,785 ) |
61,248,610 |
30,507,659 |
(31,544,308 ) |
| Net realized and unrealized gain |
5,240,258 |
132,805,325 |
51,402,358 |
2,887,623 |
| NET INCREASE IN NET ASSETS RESULTING FROM OPERATIONS |
$14,142,908 |
$164,769,723 |
$62,397,807 |
$11,780,426 |
| (a) Consolidated Statements of
Operations. | ||||
| (b) Net of increase in deferred capital gain tax
of |
$—
|
$—
|
$—
|
$(5,295
) |
| |
CII |
BMEZ |
BME |
BIGZ |
| INVESTMENT INCOME |
|
|
|
|
| Dividends — unaffiliated |
$9,956,254
|
$28,192,494
|
$6,529,959
|
$5,228,417
|
| Dividends — affiliated |
550,353 |
2,809,760 |
1,061,011 |
274,104 |
| Securities lending income — affiliated — net |
2,875 |
89,537 |
3,625 |
53,308 |
| Foreign taxes withheld |
(197,142 ) |
(183,293 ) |
(27,568 ) |
(62,600 ) |
| Total investment income |
10,312,340 |
30,908,498 |
7,567,027 |
5,493,229 |
| EXPENSES |
|
|
|
|
| Investment advisory |
7,793,092 |
23,420,085 |
6,050,327 |
24,065,312 |
| Transfer agent |
309,522 |
394,121 |
249,680 |
517,805 |
| Professional |
103,418 |
178,014 |
128,947 |
120,754 |
| Trustees and Officer |
80,516 |
132,355 |
41,486 |
132,620 |
| Printing and postage |
63,964 |
32,738 |
27,440 |
34,101 |
| Accounting services |
49,500 |
193,581 |
29,507 |
192,505 |
| Custodian |
41,975 |
202,461 |
46,494 |
80,865 |
| Registration |
15,373 |
37,332 |
8,486 |
78,352 |
| Proxy |
— |
1,973,287 |
— |
2,696,205 |
| Miscellaneous |
58,314 |
502,628 |
73,166 |
1,074,124 |
| Total expenses excluding interest expense |
8,515,674 |
27,066,602 |
6,655,533 |
28,992,643 |
| Interest expense — unaffiliated |
72 |
1,713 |
78 |
15,435 |
| Total expenses |
8,515,746 |
27,068,315 |
6,655,611 |
29,008,078 |
| Less: |
|
|
|
|
| Fees waived and/or reimbursed by the Manager |
(8,174 ) |
(42,160 ) |
(15,682 ) |
(4,111 ) |
| Total expenses after fees waived and/or reimbursed |
8,507,572 |
27,026,155 |
6,639,929 |
29,003,967 |
| Net investment income (loss) |
1,804,768 |
3,882,343 |
927,098 |
(23,510,738 ) |
| REALIZED AND UNREALIZED GAIN (LOSS) |
|
|
|
|
| Net realized gain (loss) from: |
|
|
|
|
| Investments — unaffiliated |
166,095,625 |
25,274,742 |
36,669,600 |
63,941,483 |
| Investments — affiliated |
7 |
984 |
(735 ) |
9,895 |
| Forward foreign currency exchange contracts |
— |
(3,753,243 ) |
— |
— |
| Foreign currency transactions |
39,231 |
(78,838 ) |
2,524 |
23,765 |
| Options written |
(35,047,640 ) |
(4,293,260 ) |
(7,907,613 ) |
(13,094,737 ) |
| |
131,087,223 |
17,150,385 |
28,763,776 |
50,880,406 |
| Net change in unrealized appreciation (depreciation) on: |
|
|
|
|
| Investments — unaffiliated |
(19,670,041 ) |
(17,966,664 ) |
(11,233,566 ) |
(4,493,880 ) |
| Investments — affiliated |
(1 ) |
(199 ) |
16 |
(724 ) |
| Forward foreign currency exchange contracts |
— |
(1,429,095 ) |
— |
— |
| Foreign currency translations |
(3 ) |
(42,997 ) |
(5,773 ) |
(2 ) |
| Options written |
11,435,274 |
22,155,749 |
5,003,236 |
12,830,161 |
| |
(8,234,771 ) |
2,716,794 |
(6,236,087 ) |
8,335,555 |
| Net realized and unrealized gain |
122,852,452 |
19,867,179 |
22,527,689 |
59,215,961 |
| NET INCREASE IN NET ASSETS RESULTING FROM OPERATIONS |
$124,657,220 |
$23,749,522 |
$23,454,787 |
$35,705,223 |
| |
BCX |
BSTZ(a) |
BST(a) |
BUI |
| INVESTMENT INCOME |
|
|
|
|
| Dividends — unaffiliated |
$28,083,269
|
$5,760,807
|
$4,836,227
|
$11,435,023
|
| Dividends — affiliated |
997,798 |
681,264 |
323,911 |
377,953 |
| Securities lending income — affiliated — net |
13,763 |
208,381 |
41,508 |
5,005 |
| Non-cash dividends — unaffiliated |
— |
— |
— |
605,556 |
| Foreign taxes withheld |
(1,182,907 ) |
(2,674,798 ) |
(1,005,839 ) |
(505,472 ) |
| Foreign withholding tax claims |
— |
— |
— |
100,738 |
| Total investment income |
27,911,923 |
3,975,654 |
4,195,807 |
12,018,803 |
| EXPENSES |
|
|
|
|
| Investment advisory |
8,660,001 |
20,704,192 |
12,950,170 |
5,139,069 |
| Transfer agent |
388,892 |
482,845 |
145,372 |
68,569 |
| Professional |
106,982 |
176,069 |
169,035 |
110,430 |
| Trustees and Officer |
73,736 |
117,773 |
72,757 |
32,990 |
| Accounting services |
59,061 |
180,165 |
49,074 |
49,074 |
| Custodian |
56,098 |
139,701 |
40,495 |
43,795 |
| Registration |
29,351 |
26,466 |
13,813 |
4,202 |
| Printing and postage |
29,340 |
33,436 |
14,495 |
11,337 |
| Proxy |
— |
2,335,932 |
— |
— |
| Miscellaneous |
103,212 |
374,032 |
389,236 |
86,099 |
| Total expenses excluding interest expense |
9,506,673 |
24,570,611 |
13,844,447 |
5,545,565 |
| Interest expense — unaffiliated |
2,071 |
16,198 |
3,501 |
957 |
| Total expenses |
9,508,744 |
24,586,809 |
13,847,948 |
5,546,522 |
| Less: |
|
|
|
|
| Fees waived and/or reimbursed by the Manager |
(14,944 ) |
(10,202 ) |
(4,806 ) |
(5,615 ) |
| Total expenses after fees waived and/or reimbursed |
9,493,800 |
24,576,607 |
13,843,142 |
5,540,907 |
| Net investment income (loss) |
18,418,123 |
(20,600,953 ) |
(9,647,335 ) |
6,477,896 |
| REALIZED AND UNREALIZED GAIN (LOSS) |
|
|
|
|
| Net realized gain (loss) from: |
|
|
|
|
| Investments — unaffiliated |
19,396,946 |
197,832,704 |
117,923,679 |
39,576,285 |
| Investments — affiliated |
(255 ) |
4,768 |
512 |
759 |
| Foreign currency transactions |
193,297 |
(254,867 ) |
(39,933 ) |
(40,162 ) |
| Options written |
2,811,864 |
(70,130,517 ) |
(68,799,557 ) |
(14,328,396 ) |
| Payment by affiliate |
2,350 |
— |
— |
— |
| |
22,404,202 |
127,452,088 |
49,084,701 |
25,208,486 |
| Net change in unrealized appreciation (depreciation) on: |
|
|
|
|
| Investments — unaffiliated |
(73,943,037 ) |
163,506,985 (b) |
223,500,563 (b) |
(2,032,720 ) |
| Investments — affiliated |
359 |
876 |
495 |
(4 ) |
| Foreign currency translations |
2,135 |
(2,374 ) |
(730 ) |
(3,584 ) |
| Options written |
6,261,268 |
7,183,300 |
9,341,761 |
5,965,132 |
| |
(67,679,275 ) |
170,688,787 |
232,842,089 |
3,928,824 |
| Net realized and unrealized gain (loss) |
(45,275,073 ) |
298,140,875 |
281,926,790 |
29,137,310 |
| NET INCREASE (DECREASE) IN NET ASSETS RESULTING FROM OPERATIONS |
$(26,856,950 ) |
$277,539,922 |
$272,279,455 |
$35,615,206 |
| (a) Consolidated Statements of
Operations. | ||||
| (b) Net of increase in deferred capital gain tax
of |
$—
|
$(2,056,047
) |
$(421,779
) |
$—
|
| |
BGR |
BDJ(a)
| ||
| |
Year Ended
12/31/24 |
Year Ended
12/31/23 |
Year Ended
12/31/24 |
Year Ended 12/31/23
|
| | ||||
| INCREASE (DECREASE) IN NET ASSETS |
|
|
|
|
| OPERATIONS |
|
|
|
|
| Net investment income |
$8,902,650
|
$10,408,652
|
$31,964,398
|
$34,246,184
|
| Net realized gain |
17,018,043 |
23,169,588 |
71,556,715 |
102,886,094 |
| Net change in unrealized appreciation (depreciation) |
(11,777,785 ) |
(15,169,570 ) |
61,248,610 |
12,843,150 |
| Net increase in net assets resulting from operations |
14,142,908 |
18,408,670 |
164,769,723 |
149,975,428 |
| DISTRIBUTIONS TO SHAREHOLDERS(b) |
|
|
|
|
| From net investment income and net realized gain |
(8,876,987 ) |
(10,396,825 ) |
(125,237,041 ) |
(135,982,780 ) |
| Return of capital |
(13,896,512 ) |
(11,108,880 ) |
— |
— |
| Decrease in net assets resulting from distributions to shareholders |
(22,773,499 ) |
(21,505,705 ) |
(125,237,041 ) |
(135,982,780 ) |
| CAPITAL SHARE TRANSACTIONS |
|
|
|
|
| Reinvestment of distributions |
— |
— |
— |
702,786 |
| Redemption of shares resulting from share repurchase program (including transaction costs) |
(19,781,491 ) |
(7,413,692 ) |
(84,525,360 ) |
(2,735,878 ) |
| Net decrease in net assets derived from capital share transactions |
(19,781,491 ) |
(7,413,692 ) |
(84,525,360 ) |
(2,033,092 ) |
| NET ASSETS |
|
|
|
|
| Total increase (decrease) in net assets |
(28,412,082 ) |
(10,510,727 ) |
(44,992,678 ) |
11,959,556 |
| Beginning of year |
387,981,857 |
398,492,584 |
1,641,601,123 |
1,629,641,567 |
| End of year |
$359,569,775 |
$387,981,857 |
$1,596,608,445 |
$1,641,601,123 |
| (a) |
Consolidated Statements of Changes in Net Assets. |
| (b) |
Distributions for annual periods determined in accordance with U.S. federal income tax regulations. |
| |
BOE |
BGY | ||
| |
Year Ended
12/31/24 |
Year Ended
12/31/23 |
Year Ended
12/31/24 |
Year Ended 12/31/23
|
| | ||||
| INCREASE (DECREASE) IN NET ASSETS |
|
|
|
|
| OPERATIONS |
|
|
|
|
| Net investment income |
$10,995,449
|
$13,670,798
|
$8,892,803
|
$8,622,266
|
| Net realized gain (loss) |
20,894,699 |
(3,531,179 ) |
34,431,931 |
25,103,078 |
| Net change in unrealized appreciation (depreciation) |
30,507,659 |
86,840,574 |
(31,544,308 ) |
49,586,269 |
| Net increase in net assets resulting from operations |
62,397,807 |
96,980,193 |
11,780,426 |
83,311,613 |
| DISTRIBUTIONS TO SHAREHOLDERS(a) |
|
|
|
|
| From net investment income and net realized gain |
(10,955,631 ) |
(13,739,848 ) |
(41,087,555 ) |
(17,300,662 ) |
| Return of capital |
(36,227,997 ) |
(33,325,380 ) |
— |
(23,857,237 ) |
| Decrease in net assets resulting from distributions to shareholders |
(47,183,628 ) |
(47,065,228 ) |
(41,087,555 ) |
(41,157,899 ) |
| CAPITAL SHARE TRANSACTIONS |
|
|
|
|
| Redemption of shares resulting from share repurchase program (including transaction costs) |
(36,994,167 ) |
(11,889,663 ) |
(30,215,690 ) |
(13,143,239 ) |
| NET ASSETS |
|
|
|
|
| Total increase (decrease) in net assets |
(21,779,988 ) |
38,025,302 |
(59,522,819 ) |
29,010,475 |
| Beginning of year |
726,489,187 |
688,463,885 |
622,481,850 |
593,471,375 |
| End of year |
$704,709,199 |
$726,489,187 |
$562,959,031 |
$622,481,850 |
| (a) |
Distributions for annual periods determined in accordance with U.S. federal income tax
regulations. |
| |
CII |
BMEZ | ||
| |
Year Ended
12/31/24 |
Year Ended
12/31/23 |
Year Ended
12/31/24 |
Year Ended 12/31/23
|
| | ||||
| INCREASE (DECREASE) IN NET ASSETS |
|
|
|
|
| OPERATIONS |
|
|
|
|
| Net investment income (loss) |
$1,804,768
|
$2,873,748
|
$3,882,343
|
$(12,827,913
) |
| Net realized gain (loss) |
131,087,223 |
27,313,271 |
17,150,385 |
(125,606 ) |
| Net change in unrealized appreciation (depreciation) |
(8,234,771 ) |
122,020,412 |
2,716,794 |
82,812,081 |
| Net increase in net assets resulting from operations |
124,657,220 |
152,207,431 |
23,749,522 |
69,858,562 |
| DISTRIBUTIONS TO SHAREHOLDERS(a) |
|
|
|
|
| From net investment income and net realized gain |
(53,906,727 ) |
(52,698,168 ) |
— |
— |
| Return of capital |
— |
— |
(177,775,924 ) |
(170,987,587 ) |
| Decrease in net assets resulting from distributions to shareholders |
(53,906,727 ) |
(52,698,168 ) |
(177,775,924 ) |
(170,987,587 ) |
| CAPITAL SHARE TRANSACTIONS |
|
|
|
|
| Reinvestment of distributions |
— |
274,446 |
— |
— |
| Redemption of shares resulting from share repurchase program (including transaction costs) |
(45,649,966 ) |
— |
(89,462,275 ) |
(47,918,763 ) |
| Net increase (decrease) in net assets derived from capital share transactions |
(45,649,966 ) |
274,446 |
(89,462,275 ) |
(47,918,763 ) |
| NET ASSETS |
|
|
|
|
| Total increase (decrease) in net assets |
25,100,527 |
99,783,709 |
(243,488,677 ) |
(149,047,788 ) |
| Beginning of year |
874,450,781 |
774,667,072 |
1,907,370,932 |
2,056,418,720 |
| End of year |
$899,551,308 |
$874,450,781 |
$1,663,882,255 |
$1,907,370,932 |
| (a) |
Distributions for annual periods determined in accordance with U.S. federal income tax
regulations. |
| |
BME |
BIGZ | ||
| |
Year Ended
12/31/24 |
Year Ended
12/31/23 |
Year Ended
12/31/24 |
Year Ended 12/31/23
|
| | ||||
| INCREASE (DECREASE) IN NET ASSETS |
|
|
|
|
| OPERATIONS |
|
|
|
|
| Net investment income (loss) |
$927,098
|
$2,005,523
|
$(23,510,738
) |
$(24,835,889
) |
| Net realized gain (loss) |
28,763,776 |
26,685,806 |
50,880,406 |
(395,036,508 ) |
| Net change in unrealized appreciation (depreciation) |
(6,236,087 ) |
(8,674,311 ) |
8,335,555 |
631,441,416 |
| Net increase in net assets resulting from operations |
23,454,787 |
20,017,018 |
35,705,223 |
211,569,019 |
| DISTRIBUTIONS TO SHAREHOLDERS(a) |
|
|
|
|
| From net investment income and net realized gain |
(28,577,659 ) |
(25,396,234 ) |
— |
— |
| Return of capital |
(7,344,579 ) |
(10,214,453 ) |
(184,726,032 ) |
(173,714,456 ) |
| Decrease in net assets resulting from distributions to shareholders |
(35,922,238 ) |
(35,610,687 ) |
(184,726,032 ) |
(173,714,456 ) |
| CAPITAL SHARE TRANSACTIONS |
|
|
|
|
| Net proceeds from the issuance of shares |
— |
3,020,683 |
— |
— |
| Reinvestment of distributions |
— |
511,503 |
— |
— |
| Redemption of shares resulting from share repurchase program (including transaction costs) |
(29,532,715 ) |
— |
(92,487,614 ) |
(37,872,639 ) |
| Net increase (decrease) in net assets derived from capital share transactions |
(29,532,715 ) |
3,532,186 |
(92,487,614 ) |
(37,872,639 ) |
| NET ASSETS |
|
|
|
|
| Total decrease in net assets |
(42,000,166 ) |
(12,061,483 ) |
(241,508,423 ) |
(18,076 ) |
| Beginning of year |
588,135,430 |
600,196,913 |
2,026,469,838 |
2,026,487,914 |
| End of year |
$546,135,264 |
$588,135,430 |
$1,784,961,415 |
$2,026,469,838 |
| (a) |
Distributions for annual periods determined in accordance with U.S. federal income tax
regulations. |
| |
BCX |
BSTZ(a)
| ||
| |
Year Ended
12/31/24 |
Year Ended
12/31/23 |
Year Ended
12/31/24 |
Year Ended 12/31/23
|
| | ||||
| INCREASE (DECREASE) IN NET ASSETS |
|
|
|
|
| OPERATIONS |
|
|
|
|
| Net investment income (loss) |
$18,418,123
|
$24,403,314
|
$(20,600,953
) |
$(15,155,748
) |
| Net realized gain (loss) |
22,404,202 |
33,949,389 |
127,452,088 |
(40,897,514 ) |
| Net change in unrealized appreciation (depreciation) |
(67,679,275 ) |
(66,990,639 ) |
170,688,787 |
336,014,543 |
| Net increase (decrease) in net assets resulting from operations |
(26,856,950 ) |
(8,637,936 ) |
277,539,922 |
279,961,281 |
| DISTRIBUTIONS TO SHAREHOLDERS(b) |
|
|
|
|
| From net investment income and net realized gain |
(20,754,349 ) |
(24,357,046 ) |
(76,763,205 ) |
— |
| Return of capital |
(32,577,896 ) |
(29,035,558 ) |
(74,781,695 ) |
(140,469,092 ) |
| Decrease in net assets resulting from distributions to shareholders |
(53,332,245 ) |
(53,392,604 ) |
(151,544,900 ) |
(140,469,092 ) |
| CAPITAL SHARE TRANSACTIONS |
|
|
|
|
| Redemption of shares resulting from share repurchase program (including transaction costs) |
(42,582,282 ) |
(29,812,008 ) |
(82,227,801 ) |
(34,325,597 ) |
| NET ASSETS |
|
|
|
|
| Total increase (decrease) in net assets |
(122,771,477 ) |
(91,842,548 ) |
43,767,221 |
105,166,592 |
| Beginning of year |
891,338,492 |
983,181,040 |
1,629,824,229 |
1,524,657,637 |
| End of year |
$768,567,015 |
$891,338,492 |
$1,673,591,450 |
$1,629,824,229 |
| (a) |
Consolidated Statements of Changes in Net Assets. |
| (b) |
Distributions for annual periods determined in accordance with U.S. federal income tax regulations. |
| |
BST(a)
|
BUI | ||
| |
Year Ended
12/31/24 |
Year Ended
12/31/23 |
Year Ended
12/31/24 |
Year Ended 12/31/23
|
| | ||||
| INCREASE (DECREASE) IN NET ASSETS |
|
|
|
|
| OPERATIONS |
|
|
|
|
| Net investment income (loss) |
$(9,647,335
) |
$(7,655,006
) |
$6,477,896
|
$7,841,668
|
| Net realized gain |
49,084,701 |
50,365,846 |
25,208,486 |
19,192,335 |
| Net change in unrealized appreciation (depreciation) |
232,842,089 |
247,434,391 |
3,928,824 |
9,049,746 |
| Net increase in net assets resulting from operations |
272,279,455 |
290,145,231 |
35,615,206 |
36,083,749 |
| DISTRIBUTIONS TO SHAREHOLDERS(b) |
|
|
|
|
| From net investment income and net realized gain |
(54,438,359 ) |
(50,091,649 ) |
(25,151,530 ) |
(21,447,319 ) |
| Return of capital |
(49,592,586 ) |
(51,595,440 ) |
(7,834,340 ) |
(11,077,670 ) |
| Decrease in net assets resulting from distributions to shareholders |
(104,030,945 ) |
(101,687,089 ) |
(32,985,870 ) |
(32,524,989 ) |
| CAPITAL SHARE TRANSACTIONS |
|
|
|
|
| Net proceeds from the issuance of shares |
8,635,484 |
41,619,188 |
1,263,628 |
3,779,817 |
| Reinvestment of distributions |
1,567,740 |
5,644,095 |
499,080 |
730,387 |
| Net increase in net assets derived from capital share transactions |
10,203,224 |
47,263,283 |
1,762,708 |
4,510,204 |
| NET ASSETS |
|
|
|
|
| Total increase in net assets |
178,451,734 |
235,721,425 |
4,392,044 |
8,068,964 |
| Beginning of year |
1,196,424,626 |
960,703,201 |
506,461,930 |
498,392,966 |
| End of year |
$1,374,876,360 |
$1,196,424,626 |
$510,853,974 |
$506,461,930 |
| (a) |
Consolidated Statements of Changes in Net Assets. |
| (b) |
Distributions for annual periods determined in accordance with U.S. federal income tax regulations. |
| |
BGR |
BDJ(a) |
BOE |
BGY |
| CASH PROVIDED BY (USED FOR) OPERATING ACTIVITIES |
|
|
|
|
| Net increase in net assets resulting from operations |
$14,142,908
|
$164,769,723
|
$62,397,807
|
$11,780,426
|
| Adjustments to reconcile net increase in net assets resulting from operations to net cash provided by operating
activities: |
|
|
|
|
| Proceeds from sales of long-term investments |
203,256,591 |
1,115,371,847 |
469,806,899 |
347,730,427 |
| Purchases of long-term investments |
(163,748,127 ) |
(843,739,396 ) |
(377,488,003 ) |
(284,754,516 ) |
| Net proceeds from sales (purchases) of short-term securities |
(3,971,676 ) |
(41,394,091 ) |
(4,364,957 ) |
4,517,766 |
| Premiums paid on closing options written |
(26,335,898 ) |
(217,449,684 ) |
(73,375,425 ) |
(50,868,012 ) |
| Premiums received from options written |
23,858,154 |
163,928,358 |
58,486,887 |
44,680,839 |
| Net realized gain on investments and options written |
(16,586,800 ) |
(70,748,137 ) |
(20,855,218 ) |
(34,572,070 ) |
| Net unrealized (appreciation) depreciation on investments, options written and foreign currency translations |
11,776,031 |
(61,253,075 ) |
(30,564,075 ) |
31,489,380 |
| (Increase) Decrease in Assets |
|
|
|
|
| Receivables |
|
|
|
|
| Dividends — affiliated |
(9,256 ) |
(19,572 ) |
(6,847 ) |
15,072 |
| Dividends — unaffiliated |
275,108 |
160,407 |
419,807 |
(369,814 ) |
| Prepaid expenses |
3,815 |
7,191 |
6,414 |
5,495 |
| Deferred offering costs. |
— |
(2,000 ) |
— |
— |
| Increase (Decrease) in Liabilities |
|
|
|
|
| Due to broker |
— |
— |
(530,000 ) |
— |
| Payables |
|
|
|
|
| Accounting services fees |
7,351 |
16,189 |
10,349 |
8,646 |
| Custodian fees |
23 |
1,622 |
5,117 |
20,270 |
| Deferred capital gain tax |
— |
— |
— |
5,295 |
| Investment advisory fees |
(12,656 ) |
8,262 |
3,931 |
(26,877 ) |
| IRS compliance fee for foreign withholding tax claims |
— |
— |
— |
1,650,132 |
| Trustees’ and Officer’s fees |
(63,008 ) |
(76,774 ) |
(58,419 ) |
(51,329 ) |
| Other accrued expenses |
6,051 |
21,224 |
1,381 |
2,427 |
| Professional fees |
21,585 |
(63,118 ) |
15,762 |
60,724 |
| Transfer agent fees |
(491 ) |
(1,868 ) |
(728 ) |
(2,808 ) |
| Net cash provided by operating activities |
42,619,705 |
209,537,108 |
83,910,682 |
71,321,473 |
| CASH PROVIDED BY (USED FOR) FINANCING ACTIVITIES |
|
|
|
|
| Cash dividends paid to shareholders |
(22,773,499 ) |
(125,237,041 ) |
(47,183,628 ) |
(41,087,555 ) |
| Net payments on redemption of capital shares |
(19,781,491 ) |
(84,525,360 ) |
(36,994,167 ) |
(30,215,690 ) |
| Net cash used for financing activities |
(42,554,990 ) |
(209,762,401 ) |
(84,177,795 ) |
(71,303,245 ) |
| CASH IMPACT FROM FOREIGN EXCHANGE FLUCTUATIONS |
|
|
|
|
| Cash impact from foreign exchange fluctuations |
450 |
(18 ) |
(586 ) |
265 |
| CASH AND FOREIGN CURRENCY |
|
|
|
|
| Net increase (decrease) in restricted and unrestricted cash and foreign currency |
65,165 |
(225,311 ) |
(267,699 ) |
18,493 |
| Restricted and unrestricted cash and foreign currency at beginning of year |
163,667 |
273,259 |
530,024 |
71,830 |
| Restricted and unrestricted cash and foreign currency at end of year |
$228,832 |
$47,948 |
$262,325 |
$90,323 |
| SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION |
|
|
|
|
| Cash paid during the year for interest expense |
$680 |
$4,073 |
$4,783 |
$23,113 |
| RECONCILIATION OF RESTRICTED AND UNRESTRICTED CASH AND FOREIGN CURRENCY
AT THE END OF YEAR TO THE
STATEMENTS OF ASSETS AND LIABILITIES |
|
|
|
|
| Cash |
$—
|
$15,980
|
$—
|
$—
|
| Foreign currency at value |
228,832 |
31,968 |
262,325 |
90,323 |
| |
$228,832 |
$47,948 |
$262,325 |
$90,323 |
| (a) |
Consolidated Statements of Cash Flows. |
| |
CII |
BMEZ |
BME |
BIGZ |
| CASH PROVIDED BY (USED FOR) OPERATING ACTIVITIES |
|
|
|
|
| Net increase in net assets resulting from operations |
$124,657,220
|
$23,749,522
|
$23,454,787
|
$35,705,223
|
| Adjustments to reconcile net increase in net assets resulting from operations to net cash provided by operating
activities: |
|
|
|
|
| Proceeds from sales of long-term investments |
700,914,329 |
1,066,705,136 |
236,385,392 |
1,071,283,597 |
| Purchases of long-term investments |
(580,344,779 ) |
(786,866,228 ) |
(169,972,875 ) |
(758,164,326 ) |
| Net proceeds from sales (purchases) of short-term securities |
6,574,549 |
(8,566,839 ) |
4,843,505 |
4,569,587 |
| Premiums paid on closing options written |
(142,820,784 ) |
(125,536,961 ) |
(54,577,918 ) |
(78,332,496 ) |
| Premiums received from options written |
112,228,696 |
122,748,096 |
47,273,379 |
67,420,574 |
| Net realized gain on investments and options written |
(130,474,013 ) |
(20,624,389 ) |
(28,624,695 ) |
(50,870,709 ) |
| Net unrealized (appreciation) depreciation on investments, options written and foreign currency translations |
8,234,771 |
(2,759,744 ) |
6,230,321 |
(8,335,555 ) |
| (Increase) Decrease in Assets |
|
|
|
|
| Receivables |
|
|
|
|
| Dividends — affiliated |
340 |
83,936 |
44,608 |
(7,093 ) |
| Dividends — unaffiliated |
298,713 |
259,776 |
173,479 |
271,755 |
| Interest — unaffiliated |
— |
(22,060 ) |
(2,168 ) |
— |
| Securities lending income — affiliated |
(141 ) |
2,990 |
(12 ) |
1,525 |
| Prepaid expenses |
5,339 |
7,508 |
5,292 |
7,878 |
| Deferred offering costs. |
— |
— |
(1,999 ) |
— |
| Increase (Decrease) in Liabilities |
|
|
|
|
| Collateral on securities loaned |
37,580 |
(2,072,335 ) |
278,058 |
(6,243,802 ) |
| Payables |
|
|
|
|
| Accounting services fees |
8,645 |
10,611 |
5,320 |
7,312 |
| Custodian fees |
4,394 |
27,329 |
6,120 |
8,750 |
| Investment advisory fees |
40,930 |
(127,787 ) |
(15,535 ) |
(127,668 ) |
| Trustees’ and Officer’s fees |
10,276 |
45,047 |
(10,245 ) |
46,792 |
| Other accrued expenses |
4,238 |
52,534 |
2,044 |
330,204 |
| Professional fees |
(4,859 ) |
(27,074 ) |
23,387 |
(59,331 ) |
| Proxy fees |
— |
78,541 |
— |
(309,518 ) |
| Transfer agent fees |
545 |
33,497 |
915 |
10,582 |
| Net cash provided by operating activities |
99,375,989 |
267,201,106 |
65,521,160 |
277,213,281 |
| CASH PROVIDED BY (USED FOR) FINANCING ACTIVITIES |
|
|
|
|
| Cash dividends paid to shareholders |
(53,906,727 ) |
(177,775,924 ) |
(35,922,238 ) |
(184,726,032 ) |
| Net payments on redemption of capital shares |
(45,649,966 ) |
(89,462,275 ) |
(29,532,715 ) |
(92,487,614 ) |
| Increase (decrease) in bank overdraft |
181,324 |
(291,881 ) |
(60,686 ) |
— |
| Net cash used for financing activities |
(99,375,369 ) |
(267,530,080 ) |
(65,515,639 ) |
(277,213,646 ) |
| CASH IMPACT FROM FOREIGN EXCHANGE FLUCTUATIONS |
|
|
|
|
| Cash impact from foreign exchange fluctuations |
(3 ) |
(47 ) |
(7 ) |
(2 ) |
| CASH AND FOREIGN CURRENCY |
|
|
|
|
| Net increase (decrease) in restricted and unrestricted cash and foreign currency |
617 |
(329,021 ) |
5,514 |
(367 ) |
| Restricted and unrestricted cash and foreign currency at beginning of year |
— |
457,168 |
534 |
367 |
| Restricted and unrestricted cash and foreign currency at end of year |
$617 |
$128,147 |
$6,048 |
$— |
| SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION |
|
|
|
|
| Cash paid during the year for interest expense |
$72 |
$1,713 |
$78 |
$15,435 |
| RECONCILIATION OF RESTRICTED AND UNRESTRICTED CASH AND FOREIGN CURRENCY
AT THE END OF YEAR TO THE
STATEMENTS OF ASSETS AND LIABILITIES |
|
|
|
|
| Cash |
$—
|
$127,446
|
$5,813
|
$—
|
| Foreign currency at value |
617 |
701 |
235 |
— |
| |
$617 |
$128,147 |
$6,048 |
$— |
| |
BCX |
BSTZ(a) |
BST(a) |
BUI |
| CASH PROVIDED BY (USED FOR) OPERATING ACTIVITIES |
|
|
|
|
| Net increase (decrease) in net assets resulting from operations |
$(26,856,950
) |
$277,539,922
|
$272,279,455
|
$35,615,206
|
| Adjustments to reconcile net increase (decrease) in net assets resulting from operations to net cash provided by
operating activities: |
|
|
|
|
| Proceeds from sales of long-term investments |
660,629,481 |
937,664,056 |
421,072,421 |
228,640,108 |
| Purchases of long-term investments |
(571,105,925 ) |
(614,120,813 ) |
(252,275,442 ) |
(183,065,954 ) |
| Net proceeds from sales (purchases) of short-term securities |
(10,455,165 ) |
(5,145,534 ) |
4,017,121 |
(6,445,466 ) |
| Premiums paid on closing options written |
(50,215,675 ) |
(195,731,851 ) |
(188,574,880 ) |
(46,650,211 ) |
| Premiums received from options written |
52,334,610 |
125,489,655 |
124,649,063 |
32,881,901 |
| Net realized gain on investments and options written |
(22,124,734 ) |
(127,390,592 ) |
(49,205,583 ) |
(24,302,832 ) |
| Net unrealized (appreciation) depreciation on investments, options written and foreign currency translations |
67,681,688 |
(172,747,184 ) |
(233,264,478 ) |
(3,932,116 ) |
| (Increase) Decrease in Assets |
|
|
|
|
| Receivables |
|
|
|
|
| Dividends — affiliated |
(15,186 ) |
(27,307 ) |
(8,613 ) |
4,014 |
| Dividends — unaffiliated |
342,318 |
174,359 |
22,973 |
85,367 |
| Securities lending income — affiliated |
640 |
(12,583 ) |
2,502 |
(7 ) |
| Prepaid expenses |
— |
6,125 |
5,991 |
— |
| Deferred offering costs. |
— |
— |
118,886 |
(1,639 ) |
| Increase (Decrease) in Liabilities |
|
|
|
|
| Due to broker |
— |
(680,000 ) |
— |
— |
| Collateral on securities loaned |
(4,300,290 ) |
4,620,303 |
(5,295,789 ) |
(1,296,550 ) |
| Payables |
|
|
|
|
| Accounting services fees |
9,874 |
16,021 |
8,220 |
8,220 |
| Custodian fees |
6,035 |
(2,903 ) |
(5,416 ) |
2,001 |
| Deferred capital gain tax |
— |
2,056,047 |
421,779 |
— |
| Investment advisory fees |
(73,211 ) |
108,527 |
182,892 |
22,605 |
| Trustees’ and Officer’s fees |
(28,645 ) |
39,267 |
17,500 |
(7,995 ) |
| Other accrued expenses |
4,605 |
(7,956 ) |
2,560 |
8,321 |
| Professional fees |
(9,408 ) |
(208,619 ) |
(62,683 ) |
27,338 |
| Transfer agent fees |
(1,223 ) |
63,888 |
1,593 |
250 |
| Net cash provided by operating activities |
95,822,839 |
231,702,828 |
94,110,072 |
31,592,561 |
| CASH PROVIDED BY (USED FOR) FINANCING ACTIVITIES |
|
|
|
|
| Cash dividends paid to shareholders |
(53,332,245 ) |
(151,544,900 ) |
(102,463,205 ) |
(32,486,790 ) |
| Payments for offering costs |
— |
— |
(122,160 ) |
— |
| Net payments on redemption of capital shares |
(42,582,282 ) |
(82,227,801 ) |
— |
— |
| Increase (decrease) in bank overdraft |
152,061 |
(347,361 ) |
(506,784 ) |
— |
| Proceeds from issuance of capital shares |
— |
— |
8,635,484 |
689,328 |
| Net cash used for financing activities |
(95,762,466 ) |
(234,120,062 ) |
(94,456,665 ) |
(31,797,462 ) |
| CASH IMPACT FROM FOREIGN EXCHANGE FLUCTUATIONS |
|
|
|
|
| Cash impact from foreign exchange fluctuations |
(278 ) |
(24 ) |
(120 ) |
(292 ) |
| CASH AND FOREIGN CURRENCY |
|
|
|
|
| Net increase (decrease) in restricted and unrestricted cash and foreign currency |
60,095 |
(2,417,258 ) |
(346,713 ) |
(205,193 ) |
| Restricted and unrestricted cash and foreign currency at beginning of year |
11,244 |
2,810,000 |
483,106 |
430,368 |
| Restricted and unrestricted cash and foreign currency at end of year |
$71,339 |
$392,742 |
$136,393 |
$225,175 |
| SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION |
|
|
|
|
| Cash paid during the year for interest expense |
$2,071 |
$16,198 |
$3,501 |
$957 |
| NON-CASH FINANCING ACTIVITIES |
|
|
|
|
| Reinvestment of distributions |
$— |
$— |
$1,567,740 |
$499,080 |
| |
BCX |
BSTZ(a) |
BST(a) |
BUI |
| RECONCILIATION OF RESTRICTED AND UNRESTRICTED CASH AND FOREIGN CURRENCY
AT THE END OF YEAR TO THE
STATEMENTS OF ASSETS AND LIABILITIES |
|
|
|
|
| Cash |
$—
|
$11,578
|
$134,293
|
$155,364
|
| Cash pledged |
|
|
|
|
| Collateral — OTC derivatives |
— |
380,000 |
— |
— |
| Foreign currency at value |
71,339 |
1,164 |
2,100 |
69,811 |
| |
$71,339 |
$392,742 |
$136,393 |
$225,175 |
| (a) |
Consolidated Statements of Cash Flows. |
| |
BGR | ||||
| |
Year Ended
12/31/24 |
Year Ended
12/31/23 |
Year Ended
12/31/22 |
Year Ended
12/31/21 |
Year Ended
12/31/20 |
| | |||||
| Net asset value, beginning of year |
$14.13 |
$14.21 |
$10.77 |
$8.17 |
$12.57 |
| Net investment income(a) |
0.33 |
0.37 |
0.42 |
0.28 |
0.32 |
| Net realized and unrealized gain (loss) |
0.15 |
0.32 |
3.60 |
2.77 |
(4.06 ) |
| Net increase (decrease) from investment operations |
0.48 |
0.69 |
4.02 |
3.05 |
(3.74 ) |
| Distributions(b)
|
|
|
|
|
|
| From net investment income |
(0.33 ) |
(0.37 ) |
(0.42 ) |
(0.28 ) |
(0.32 ) |
| Return of capital |
(0.51 ) |
(0.40 ) |
(0.16 ) |
(0.17 ) |
(0.34 ) |
| Total distributions |
(0.84 ) |
(0.77 ) |
(0.58 ) |
(0.45 ) |
(0.66 ) |
| Net asset value, end of year |
$13.77 |
$14.13 |
$14.21 |
$10.77 |
$8.17 |
| Market price, end of year |
$12.61 |
$12.45 |
$12.53 |
$9.48 |
$7.10 |
| Total
Return(c) |
|
|
|
|
|
| Based on net asset value |
3.93
%(d)
|
5.75 % |
38.51 % |
38.36
%(d)
|
(29.03 )% |
| Based on market price |
8.02 % |
5.66 % |
38.76 % |
40.14 % |
(34.74 )% |
| Ratios to Average Net
Assets(e) |
|
|
|
|
|
| Total expenses |
1.23 % |
1.29 % |
1.26 % |
1.33 % |
1.37 % |
| Total expenses after fees waived and/or reimbursed |
1.12 % |
1.07 % |
1.04 % |
1.11 % |
1.15 % |
| Net investment income |
2.25 % |
2.66 % |
3.21 % |
2.88 % |
3.77 % |
| Supplemental Data |
|
|
|
|
|
| Net assets, end of year (000) |
$359,570 |
$387,982 |
$398,493 |
$313,503 |
$237,868 |
| Portfolio turnover rate |
42 % |
38 % |
76 % |
61 % |
62 % |
| (a) |
Based on average shares outstanding. |
| (b) |
Distributions for annual periods determined in accordance with U.S. federal income tax regulations. |
| (c) |
Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where
applicable, excludes the effects of any sales charges and assumes the reinvestment
of distributions at actual reinvestment prices. |
| (d) |
Includes payment from an affiliate, which had no impact on the
Trust’s total return. |
| (e) |
Excludes fees and expenses incurred indirectly as a result of investments in underlying funds. |
| |
BDJ | ||||
| |
Year Ended
12/31/24(a) |
Year Ended
12/31/23(a) |
Year Ended
12/31/22(a) |
Year Ended
12/31/21 |
Year Ended
12/31/20 |
| | |||||
| Net asset value, beginning of year |
$8.82 |
$8.74 |
$10.23 |
$9.35 |
$10.03 |
| Net investment income(b) |
0.17 |
0.18 |
0.16 |
0.15 |
0.18 |
| Net realized and unrealized gain (loss) |
0.71 |
0.63 |
(0.56 ) |
1.60 |
(0.26 ) |
| Net increase (decrease) from investment operations |
0.88 |
0.81 |
(0.40 ) |
1.75 |
(0.08 ) |
| Distributions(c)
|
|
|
|
|
|
| From net investment income |
(0.20 ) |
(0.13 ) |
(0.04 ) |
(0.28 ) |
(0.15 ) |
| From net realized gain |
(0.48 ) |
(0.60 ) |
(1.05 ) |
(0.59 ) |
(0.45 ) |
| Total distributions |
(0.68 ) |
(0.73 ) |
(1.09 ) |
(0.87 ) |
(0.60 ) |
| Net asset value, end of year |
$9.02 |
$8.82 |
$8.74 |
$10.23 |
$9.35 |
| Market price, end of year |
$8.28 |
$7.69 |
$9.01 |
$10.08 |
$8.47 |
| Total
Return(d) |
|
|
|
|
|
| Based on net asset value |
10.89
%(e)
|
10.37 % |
(3.71
)%(e)
|
19.33 % |
0.77 % |
| Based on market price |
16.76 % |
(6.65 )% |
0.74 % |
29.80 % |
(7.70 )% |
| Ratios to Average Net
Assets(f) |
|
|
|
|
|
| Total expenses |
0.88 % |
0.86 % |
0.84 % |
0.85 % |
0.86 % |
| Total expenses after fees waived and/or reimbursed |
0.88 % |
0.86 % |
0.84 % |
0.85 % |
0.86 % |
| Net investment income |
1.89 % |
2.12 % |
1.69 % |
1.44 % |
2.15 % |
| Supplemental Data |
|
|
|
|
|
| Net assets, end of year (000) |
$1,596,608 |
$1,641,601 |
$1,629,642 |
$1,902,838 |
$1,739,122 |
| Portfolio turnover rate |
50 % |
43 % |
81 % |
40 % |
48 % |
| (a) |
Consolidated Financial Highlights. |
| (b) |
Based on average shares outstanding. |
| (c) |
Distributions for annual periods determined in accordance with U.S. federal income tax regulations. |
| (d) |
Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where
applicable, excludes the effects of any sales charges and assumes the reinvestment
of distributions at actual reinvestment prices. |
| (e) |
Includes payment from an affiliate, which had no impact on the
Trust’s total return. |
| (f) |
Excludes fees and expenses incurred indirectly as a result of investments in underlying funds. |
| |
BOE | ||||
| |
Year Ended
12/31/24 |
Year Ended
12/31/23 |
Year Ended
12/31/22 |
Year Ended
12/31/21 |
Year Ended
12/31/20 |
| | |||||
| Net asset value, beginning of year |
$11.81 |
$10.97 |
$13.40 |
$12.28 |
$12.32 |
| Net investment income(a) |
0.18 |
0.22 |
0.20 |
0.19 |
0.26 |
| Net realized and unrealized gain (loss) |
0.84 |
1.38 |
(1.87 ) |
1.69 |
0.46 |
| Net increase (decrease) from investment operations |
1.02 |
1.60 |
(1.67 ) |
1.88 |
0.72 |
| Distributions(b)
|
|
|
|
|
|
| From net investment income |
(0.18 ) |
(0.22 ) |
(0.19 ) |
(0.19 ) |
(0.26 ) |
| From net realized gain |
— |
— |
(0.41 ) |
(0.57 ) |
— |
| Return of capital |
(0.60 ) |
(0.54 ) |
(0.16 ) |
— |
(0.50 ) |
| Total distributions |
(0.78 ) |
(0.76 ) |
(0.76 ) |
(0.76 ) |
(0.76 ) |
| Net asset value, end of year |
$12.05 |
$11.81 |
$10.97 |
$13.40 |
$12.28 |
| Market price, end of year |
$10.77 |
$9.92 |
$9.56 |
$12.18 |
$10.91 |
| Total
Return(c) |
|
|
|
|
|
| Based on net asset value |
9.67 % |
16.16 % |
(11.87 )% |
16.21 % |
7.65 % |
| Based on market price |
16.70 % |
11.95 % |
(15.51 )% |
18.89 % |
7.22 % |
| Ratios to Average Net
Assets(d) |
|
|
|
|
|
| Total expenses |
1.11 % |
1.09 % |
1.06 % |
1.07 % |
1.09 % |
| Total expenses after fees waived and/or reimbursed |
0.93 % |
0.91 % |
0.89 % |
0.90 % |
0.92 % |
| Total expenses after fees waived and/or reimbursed and excluding professional fees for foreign withholding
taxes |
0.93 % |
0.91 % |
0.88 % |
0.90 % |
0.92 % |
| Net investment income |
1.48 % |
1.93 % |
1.72 % |
1.46 % |
2.33 % |
| Supplemental Data |
|
|
|
|
|
| Net assets, end of year (000) |
$704,709 |
$726,489 |
$688,464 |
$857,721 |
$786,230 |
| Portfolio turnover rate |
51 % |
46 % |
44 % |
65 % |
61 % |
| (a) |
Based on average shares outstanding. |
| (b) |
Distributions for annual periods determined in accordance with U.S. federal income tax regulations. |
| (c) |
Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where
applicable, excludes the effects of any sales charges and assumes the reinvestment
of distributions at actual reinvestment prices. |
| (d) |
Excludes fees and expenses incurred indirectly as a result of investments in underlying funds. |
| |
BGY | ||||
| |
Year Ended
12/31/24 |
Year Ended
12/31/23 |
Year Ended
12/31/22 |
Year Ended
12/31/21 |
Year Ended
12/31/20 |
| | |||||
| Net asset value, beginning of year |
$6.21 |
$5.78 |
$6.81 |
$6.49 |
$6.47 |
| Net investment income(a) |
0.09 |
0.09 |
0.10 |
0.09 |
0.12 |
| Net realized and unrealized gain (loss) |
0.02 |
0.75 |
(0.72 ) |
0.64 |
0.31 |
| Net increase (decrease) from investment operations |
0.11 |
0.84 |
(0.62 ) |
0.73 |
0.43 |
| Distributions(b)
|
|
|
|
|
|
| From net investment income |
(0.08 ) |
(0.08 ) |
(0.10 ) |
(0.14 ) |
(0.13 ) |
| From net realized gain |
(0.33 ) |
(0.09 ) |
(0.10 ) |
(0.15 ) |
— |
| Return of capital |
— |
(0.24 ) |
(0.21 ) |
(0.12 ) |
(0.28 ) |
| Total distributions |
(0.41 ) |
(0.41 ) |
(0.41 ) |
(0.41 ) |
(0.41 ) |
| Net asset value, end of year |
$5.91 |
$6.21 |
$5.78 |
$6.81 |
$6.49 |
| Market price, end of year |
$5.31 |
$5.27 |
$5.02 |
$6.28 |
$5.87 |
| Total
Return(c) |
|
|
|
|
|
| Based on net asset value |
2.55 % |
15.94 % |
(8.33 )% |
11.92 % |
8.18 % |
| Based on market price |
8.58 % |
13.29 % |
(13.67 )% |
14.11 % |
7.49 % |
| Ratios to Average Net
Assets(d) |
|
|
|
|
|
| Total expenses |
1.19 % |
1.10 % |
1.08 % |
1.09 % |
1.10 % |
| Total expenses after fees waived and/or reimbursed |
1.19 % |
1.10 % |
1.03 % |
0.99 % |
1.00 % |
| Total expenses after fees waived and/or reimbursed and excluding professional fees for foreign withholding
taxes |
1.13 % |
1.10 % |
1.02 % |
0.99 % |
1.00 % |
| Net investment income |
1.44 % |
1.40 % |
1.71 % |
1.34 % |
1.99 % |
| Supplemental Data |
|
|
|
|
|
| Net assets, end of year (000) |
$562,959 |
$622,482 |
$593,471 |
$709,510 |
$676,949 |
| Portfolio turnover rate |
46 % |
55 % |
41 % |
71 % |
60 % |
| (a) |
Based on average shares outstanding. |
| (b) |
Distributions for annual periods determined in accordance with U.S. federal income tax regulations. |
| (c) |
Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where
applicable, excludes the effects of any sales charges and assumes the reinvestment
of distributions at actual reinvestment prices. |
| (d) |
Excludes fees and expenses incurred indirectly as a result of investments in underlying funds. |
| |
CII | ||||
| |
Year Ended
12/31/24 |
Year Ended
12/31/23 |
Year Ended
12/31/22 |
Year Ended
12/31/21 |
Year Ended
12/31/20 |
| | |||||
| Net asset value, beginning of year |
$19.81 |
$17.55 |
$22.10 |
$19.12 |
$17.96 |
| Net investment income(a) |
0.04 |
0.07 |
0.06 |
0.04 |
0.13 |
| Net realized and unrealized gain (loss) |
2.82 |
3.38 |
(2.51 ) |
4.04 |
2.08 |
| Net increase (decrease) from investment operations |
2.86 |
3.45 |
(2.45 ) |
4.08 |
2.21 |
| Distributions(b)
|
|
|
|
|
|
| From net investment income |
(0.03 ) |
(0.07 ) |
(0.04 ) |
(0.04 ) |
(0.13 ) |
| From net realized gain |
(1.21 ) |
(1.12 ) |
(2.06 ) |
(1.06 ) |
(0.92 ) |
| Total distributions |
(1.24 ) |
(1.19 ) |
(2.10 ) |
(1.10 ) |
(1.05 ) |
| Net asset value, end of year |
$21.43 |
$19.81 |
$17.55 |
$22.10 |
$19.12 |
| Market price, end of year |
$20.10 |
$19.00 |
$17.12 |
$22.12 |
$17.40 |
| Total
Return(c) |
|
|
|
|
|
| Based on net asset value |
15.21 % |
20.45 % |
(10.95 )% |
21.97 % |
13.94 % |
| Based on market price |
12.66 % |
18.43 % |
(13.21 )% |
34.15 % |
7.97 % |
| Ratios to Average Net
Assets(d) |
|
|
|
|
|
| Total expenses |
0.93 % |
0.89 % |
0.89 % |
0.90 % |
0.91 % |
| Total expenses after fees waived and/or reimbursed |
0.93 % |
0.89 % |
0.89 % |
0.90 % |
0.91 % |
| Net investment income |
0.20 % |
0.35 % |
0.31 % |
0.21 % |
0.78 % |
| Supplemental Data |
|
|
|
|
|
| Net assets, end of year (000) |
$899,551 |
$874,451 |
$774,667 |
$975,479 |
$843,673 |
| Portfolio turnover rate |
63 % |
28 % |
32 % |
27 % |
46 % |
| (a) |
Based on average shares outstanding. |
| (b) |
Distributions for annual periods determined in accordance with U.S. federal income tax regulations. |
| (c) |
Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where
applicable, excludes the effects of any sales charges and assumes the reinvestment
of distributions at actual reinvestment prices. |
| (d) |
Excludes fees and expenses incurred indirectly as a result of investments in underlying funds. |
| |
BMEZ | ||||
| |
Year Ended
12/31/24 |
Year Ended
12/31/23 |
Year Ended
12/31/22 |
Year Ended
12/31/21 |
Period from
01/30/20(a) to 12/31/20 |
| | |||||
| Net asset value, beginning of period |
$17.91 |
$18.76 |
$26.47 |
$30.73 |
$20.00 |
| Net investment income (loss)(b)
|
0.04 |
(0.12 ) |
(0.18 ) |
(0.32 ) |
(0.22 ) |
| Net realized and unrealized gain (loss) |
0.17 |
0.85 |
(5.79 ) |
(2.23 ) |
11.85 |
| Net increase (decrease) from investment operations |
0.21 |
0.73 |
(5.97 ) |
(2.55 ) |
11.63 |
| Distributions(c)
|
|
|
|
|
|
| From net realized gain |
— |
— |
(1.63 ) |
(1.71 ) |
(0.90 ) |
| Return of capital |
(1.69 ) |
(1.58 ) |
(0.11 ) |
— |
— |
| Total distributions |
(1.69 ) |
(1.58 ) |
(1.74 ) |
(1.71 ) |
(0.90 ) |
| Net asset value, end of period |
$16.43 |
$17.91 |
$18.76 |
$26.47 |
$30.73 |
| Market price, end of period |
$14.40 |
$14.65 |
$15.43 |
$25.36 |
$28.65 |
| Total
Return(d) |
|
|
|
|
|
| Based on net asset value |
2.11 % |
5.60 % |
(21.66 )% |
(8.31 )% |
59.62
%(e)(f)
|
| Based on market price |
9.40 % |
5.02 % |
(32.75 )% |
(5.76 )% |
48.82
%(f)
|
| Ratios to Average Net
Assets(g) |
|
|
|
|
|
| Total expenses |
1.44
%(h)
|
1.33
%(i)
|
1.32 % |
1.30 % |
1.29
%(j)
|
| Total expenses after fees waived and/or reimbursed |
1.44
%(h)
|
1.32
%(i)
|
1.32 % |
1.30 % |
1.28
%(j)
|
| Net investment income (loss) |
0.21 % |
(0.65 )% |
(0.91 )% |
(1.10 )% |
(1.00
)%(j)
|
| Supplemental Data |
|
|
|
|
|
| Net assets, end of period (000) |
$1,663,882 |
$1,907,371 |
$2,056,419 |
$2,981,886 |
$3,462,638 |
| Portfolio turnover rate |
43 % |
63 % |
63 % |
44 % |
43 % |
| (a) |
Commencement of operations. |
| (b) |
Based on average shares outstanding. |
| (c) |
Distributions for annual periods determined in accordance with U.S. federal income tax regulations. |
| (d) |
Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where
applicable, excludes the effects of any sales charges and assumes the reinvestment
of distributions at actual reinvestment prices. |
| (e) |
Includes payment from an affiliate, which had no impact on the
Trust’s total return. |
| (f) |
Not annualized. |
| (g) |
Excludes fees and expenses incurred indirectly as a result of investments in underlying funds. |
| (h) |
Includes non-recurring expenses of proxy costs. Without these costs, total expenses, total expenses after fees waived and/or reimbursed would have been 1.34% and 1.34%,
respectively. |
| (i) |
Includes non-recurring expenses of proxy costs. Without these costs, total expenses, total expenses after fees waived and/or reimbursed would have been 1.31% and 1.30%,
respectively. |
| (j) |
Annualized. |
| |
BME | ||||
| |
Year Ended
12/31/24 |
Year Ended
12/31/23 |
Year Ended
12/31/22 |
Year Ended
12/31/21 |
Year Ended
12/31/20 |
| | |||||
| Net asset value, beginning of year |
$42.18 |
$43.30 |
$47.96 |
$45.66 |
$41.19 |
| Net investment income(a) |
0.07 |
0.14 |
0.11 |
— |
0.01 |
| Net realized and unrealized gain (loss) |
1.56 |
1.30 |
(2.21 ) |
4.74 |
6.86 |
| Net increase (decrease) from investment operations |
1.63 |
1.44 |
(2.10 ) |
4.74 |
6.87 |
| Distributions(b)
|
|
|
|
|
|
| From net investment income |
(0.07 ) |
(0.17 ) |
(0.12 ) |
(0.00 )(c) |
(0.05 ) |
| From net realized gain |
(2.01 ) |
(1.66 ) |
(2.34 ) |
(2.44 ) |
(2.35 ) |
| Return of capital |
(0.53 ) |
(0.73 ) |
(0.10 ) |
— |
— |
| Total distributions |
(2.61 ) |
(2.56 ) |
(2.56 ) |
(2.44 ) |
(2.40 ) |
| Net asset value, end of year |
$41.20 |
$42.18 |
$43.30 |
$47.96 |
$45.66 |
| Market price, end of year |
$37.93 |
$40.46 |
$43.58 |
$48.50 |
$47.59 |
| Total
Return(d) |
|
|
|
|
|
| Based on net asset value |
4.09 % |
3.80 % |
(4.19 )% |
10.66
%(e)
|
17.50 % |
| Based on market price |
(0.09 )% |
(1.08 )% |
(4.64 )% |
7.37 % |
18.69 % |
| Ratios to Average Net
Assets(f) |
|
|
|
|
|
| Total expenses |
1.10 % |
1.06 % |
1.08 % |
1.08 % |
1.10 % |
| Total expenses after fees waived and/or reimbursed |
1.10 % |
1.06 % |
1.07 % |
1.08 % |
1.10 % |
| Net investment income |
0.15 % |
0.34 % |
0.27 % |
0.01 % |
0.01 % |
| Supplemental Data |
|
|
|
|
|
| Net assets, end of year (000) |
$546,135 |
$588,135 |
$600,197 |
$625,775 |
$545,936 |
| Portfolio turnover rate |
29 % |
43 % |
41 % |
49 % |
28 % |
| (a) |
Based on average shares outstanding. |
| (b) |
Distributions for annual periods determined in accordance with U.S. federal income tax regulations. |
| (c) |
Amount is greater than $(0.005) per share. |
| (d) |
Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where
applicable, excludes the effects of any sales charges and assumes the reinvestment
of distributions at actual reinvestment prices. |
| (e) |
Includes payment from an affiliate, which had no impact on the
Trust’s total return. |
| (f) |
Excludes fees and expenses incurred indirectly as a result of investments in underlying funds. |
| |
BIGZ | |||
| |
Year Ended
12/31/24 |
Year Ended
12/31/23 |
Year Ended
12/31/22 |
Period from
03/29/21(a) to 12/31/21 |
| | ||||
| Net asset value, beginning of period |
$9.03 |
$8.82 |
$16.72 |
$20.00 |
| Net investment loss(b) |
(0.11 ) |
(0.11 ) |
(0.13 ) |
(0.15 ) |
| Net realized and unrealized gain (loss) |
0.28 |
1.09 |
(6.78 ) |
(2.43 ) |
| Net increase (decrease) from investment operations |
0.17 |
0.98 |
(6.91 ) |
(2.58 ) |
| Distribution from return of
capital(c) |
(0.83 ) |
(0.77 ) |
(0.99 ) |
(0.70 ) |
| Net asset value, end of period |
$8.37 |
$9.03 |
$8.82 |
$16.72 |
| Market price, end of period |
$7.44 |
$7.33 |
$6.81 |
$14.54 |
| Total
Return(d) |
|
|
|
|
| Based on net asset value |
3.39 % |
13.28 % |
(41.14
)%(e)
|
(13.03
)%(f)
|
| Based on market price |
13.22 % |
19.09 % |
(47.74 )% |
(24.37
)%(f)
|
| Ratios to Average Net
Assets(g) |
|
|
|
|
| Total expenses |
1.51
%(h)
|
1.44
%(i)
|
1.36 % |
1.29
%(j)
|
| Total expenses after fees waived and/or reimbursed |
1.51
%(h)
|
1.44
%(i)
|
1.36 % |
1.28
%(j)
|
| Net investment loss |
(1.22 )% |
(1.22 )% |
(1.22 )% |
(1.02
)%(j)
|
| Supplemental Data |
|
|
|
|
| Net assets, end of period (000) |
$1,784,961 |
$2,026,470 |
$2,026,488 |
$3,981,653 |
| Portfolio turnover rate |
39 % |
37 % |
41 % |
55 % |
| (a) |
Commencement of operations. |
| (b) |
Based on average shares outstanding. |
| (c) |
Distributions for annual periods determined in accordance with U.S. federal income tax regulations. |
| (d) |
Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where
applicable, excludes the effects of any sales charges and assumes the reinvestment
of distributions at actual reinvestment prices. |
| (e) |
Includes payment from an affiliate, which had no impact on the
Trust’s total return. |
| (f) |
Not annualized. |
| (g) |
Excludes fees and expenses incurred indirectly as a result of investments in underlying funds. |
| (h) |
Includes non-recurring expenses of proxy costs. Without these costs, total expenses, total expenses after fees waived and/or reimbursed would have been 1.37% and 1.37%,
respectively. |
| (i) |
Includes non-recurring expenses of proxy costs. Without these costs, total expenses, total expenses after fees waived and/or reimbursed would have been 1.33% and 1.33%,
respectively. |
| (j) |
Annualized. |
| |
BCX | ||||
| |
Year Ended
12/31/24 |
Year Ended
12/31/23 |
Year Ended
12/31/22 |
Year Ended
12/31/21 |
Year Ended
12/31/20 |
| | |||||
| Net asset value, beginning of year |
$10.57 |
$11.23 |
$10.21 |
$8.45 |
$9.04 |
| Net investment income(a) |
0.22 |
0.29 |
0.30 |
0.29 |
0.20 |
| Net realized and unrealized gain (loss) |
(0.57 ) |
(0.33 ) |
1.27 |
1.95 |
(0.26 ) |
| Net increase (decrease) from investment operations |
(0.35 ) |
(0.04 ) |
1.57 |
2.24 |
(0.06 ) |
| Distributions(b)
|
|
|
|
|
|
| From net investment income |
(0.25 ) |
(0.28 ) |
(0.29 ) |
(0.38 ) |
(0.23 ) |
| Return of capital |
(0.39 ) |
(0.34 ) |
(0.26 ) |
(0.10 ) |
(0.30 ) |
| Total distributions |
(0.64 ) |
(0.62 ) |
(0.55 ) |
(0.48 ) |
(0.53 ) |
| Net asset value, end of year |
$9.58 |
$10.57 |
$11.23 |
$10.21 |
$8.45 |
| Market price, end of year |
$8.54 |
$8.88 |
$9.97 |
$9.35 |
$7.41 |
| Total
Return(c) |
|
|
|
|
|
| Based on net asset value |
(2.80
)%(d)
|
0.56 % |
16.31 % |
27.20 % |
1.56 % |
| Based on market price |
3.14 % |
(4.84 )% |
12.76 % |
32.83 % |
(0.23 )% |
| Ratios to Average Net
Assets(e) |
|
|
|
|
|
| Total expenses |
1.10 % |
1.06 % |
1.05 % |
1.07 % |
1.09 % |
| Total expenses after fees waived and/or reimbursed |
1.10 % |
1.06 % |
1.05 % |
1.07 % |
1.09 % |
| Total expenses after fees waived and/or reimbursed and excluding professional fees for foreign withholding
taxes |
1.10 % |
1.06 % |
1.05 % |
1.07 % |
1.09 % |
| Net investment income |
2.13 % |
2.63 % |
2.73 % |
3.05 % |
2.62 % |
| Supplemental Data |
|
|
|
|
|
| Net assets, end of year (000) |
$768,567 |
$891,338 |
$983,181 |
$901,782 |
$746,615 |
| Portfolio turnover rate |
67 % |
46 % |
92 % |
66 % |
78 % |
| (a) |
Based on average shares outstanding. |
| (b) |
Distributions for annual periods determined in accordance with U.S. federal income tax regulations. |
| (c) |
Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where
applicable, excludes the effects of any sales charges and assumes the reinvestment
of distributions at actual reinvestment prices. |
| (d) |
Includes payment from an affiliate, which had no impact on the
Trust’s total return. |
| (e) |
Excludes fees and expenses incurred indirectly as a result of investments in underlying funds. |
| |
BSTZ | ||||
| |
Year Ended
12/31/24(a) |
Year Ended
12/31/23(a) |
Year Ended
12/31/22(a) |
Year Ended
12/31/21(a) |
Year Ended
12/31/20(a) |
| | |||||
| Net asset value, beginning of year |
$21.43 |
$19.53 |
$38.82 |
$38.72 |
$20.95 |
| Net investment loss(b) |
(0.27 ) |
(0.20 ) |
(0.30 ) |
(0.51 ) |
(0.30 ) |
| Net realized and unrealized gain (loss) |
4.00 |
3.92 |
(16.69 ) |
3.69 |
19.32 |
| Net increase (decrease) from investment operations |
3.73 |
3.72 |
(16.99 ) |
3.18 |
19.02 |
| Distributions(c)
|
|
|
|
|
|
| From net realized gain |
(1.02 ) |
— |
(0.89 ) |
(3.08 ) |
(1.10 ) |
| Return of capital |
(1.00 ) |
(1.82 ) |
(1.41 ) |
— |
(0.15 ) |
| Total distributions |
(2.02 ) |
(1.82 ) |
(2.30 ) |
(3.08 ) |
(1.25 ) |
| Net asset value, end of year |
$23.14 |
$21.43 |
$19.53 |
$38.82 |
$38.72 |
| Market price, end of year |
$20.71 |
$16.71 |
$15.64 |
$38.94 |
$36.38 |
| Total
Return(d) |
|
|
|
|
|
| Based on net asset value |
19.60 % |
21.74
%(e)
|
(43.98 )% |
8.41 % |
94.60
%(f)
|
| Based on market price |
37.27 % |
18.54 % |
(55.27 )% |
15.75 % |
86.85 % |
| Ratios to Average Net
Assets(g) |
|
|
|
|
|
| Total expenses |
1.48
%(h)
|
1.35 % |
1.33 % |
1.31 % |
1.33 % |
| Total expenses after fees waived and/or reimbursed |
1.48
%(h)
|
1.34 % |
1.33 % |
1.31 % |
1.33 % |
| Net investment loss |
(1.24 )% |
(0.96 )% |
(1.16 )% |
(1.25 )% |
(1.16 )% |
| Supplemental Data |
|
|
|
|
|
| Net assets, end of year (000) |
$1,673,591 |
$1,629,824 |
$1,524,658 |
$3,048,962 |
$3,023,744 |
| Portfolio turnover rate |
37 % |
38 % |
47 % |
18 % |
45 % |
| (a) |
Consolidated Financial Highlights. |
| (b) |
Based on average shares outstanding. |
| (c) |
Distributions for annual periods determined in accordance with U.S. federal income tax regulations. |
| (d) |
Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where
applicable, excludes the effects of any sales charges and assumes the reinvestment
of distributions at actual reinvestment prices. |
| (e) |
Includes payment from an affiliate, which impacted the Fund’s total return. Excluding the payment from an affiliate, the Fund’s total return would have been
21.68%. |
| (f) |
Includes payment from an affiliate, which had no impact on the Trust’s total return. |
| (g) |
Excludes fees and expenses incurred indirectly as a result of investments in underlying funds. |
| (h) |
Includes non-recurring expenses of proxy costs. Without these costs, total expenses, total expenses after fees waived and/or reimbursed would have been 1.34% and 1.34%,
respectively. |
| |
BST | ||||
| |
Year Ended
12/31/24(a) |
Year Ended
12/31/23(a) |
Year Ended
12/31/22(a) |
Year Ended
12/31/21(a) |
Year Ended
12/31/20(a) |
| | |||||
| Net asset value, beginning of year |
$34.74 |
$29.11 |
$52.40 |
$51.94 |
$32.45 |
| Net investment loss(b) |
(0.28 ) |
(0.23 ) |
(0.29 ) |
(0.43 ) |
(0.28 ) |
| Net realized and unrealized gain (loss) |
8.14 |
8.86 |
(20.00 ) |
5.84 |
21.82 |
| Net increase (decrease) from investment operations |
7.86 |
8.63 |
(20.29 ) |
5.41 |
21.54 |
| Distributions(c)
|
|
|
|
|
|
| From net realized gain |
(1.57 ) |
(1.48 ) |
(2.16 ) |
(4.27 ) |
(2.05 ) |
| Return of capital |
(1.43 ) |
(1.52 ) |
(0.84 ) |
— |
— |
| Total distributions |
(3.00 ) |
(3.00 ) |
(3.00 ) |
(4.27 ) |
(2.05 ) |
| Dilutive effect of rights offer (Note 10) |
— |
— |
— |
(0.68 ) |
— |
| Net asset value, end of year |
$39.60 |
$34.74 |
$29.11 |
$52.40 |
$51.94 |
| Market price, end of year |
$36.56 |
$33.66 |
$28.37 |
$49.97 |
$53.30 |
| Total
Return(d) |
|
|
|
|
|
| Based on net asset value |
23.84 % |
30.78 % |
(39.56
)%(e)
|
9.44 % |
68.76
%(f)
|
| Based on market price |
18.01 % |
30.03 % |
(38.23 )% |
1.70 % |
68.92 % |
| Ratios to Average Net
Assets(g) |
|
|
|
|
|
| Total expenses |
1.07 % |
1.09 % |
1.11 % |
1.05 % |
1.09 % |
| Total expenses after fees waived and/or reimbursed |
1.07 % |
1.09 % |
1.11 % |
1.00 % |
0.99 % |
| Total expenses after fees waived and/or reimbursed and excluding dividend expense |
1.07 % |
1.09 % |
1.10 % |
1.00 % |
0.99 % |
| Net investment loss |
(0.75 )% |
(0.70 )% |
(0.77 )% |
(0.78 )% |
(0.73 )% |
| Supplemental Data |
|
|
|
|
|
| Net assets, end of year (000) |
$1,374,876 |
$1,196,425 |
$960,703 |
$1,681,166 |
$1,297,344 |
| Portfolio turnover rate |
19 % |
32 % |
38 % |
31 % |
20 % |
| (a) |
Consolidated Financial Highlights. |
| (b) |
Based on average shares outstanding. |
| (c) |
Distributions for annual periods determined in accordance with U.S. federal income tax regulations. |
| (d) |
Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where
applicable, excludes the effects of any sales charges and assumes the reinvestment
of distributions at actual reinvestment prices. |
| (e) |
Includes payment from an affiliate, which had no impact on the
Trust’s total return. |
| (f) |
For financial reporting purposes, the market value of a certain investment was adjusted as of the report date. Accordingly, the net asset value (NAV) per share and total
return performance based on NAV presented herein are different than the
information previously published as of December 31, 2020. |
| (g) |
Excludes fees and expenses incurred indirectly as a result of investments in underlying funds. |
| |
BUI | ||||
| |
Year Ended
12/31/24 |
Year Ended
12/31/23 |
Year Ended
12/31/22 |
Year Ended
12/31/21 |
Year Ended
12/31/20 |
| | |||||
| Net asset value, beginning of year |
$22.53 |
$22.37 |
$25.86 |
$23.80 |
$22.02 |
| Net investment income(a) |
0.29 |
0.35 |
0.33 |
0.24 |
0.33 |
| Net realized and unrealized gain (loss) |
1.30 |
1.26 |
(2.37 ) |
3.27 |
2.90 |
| Net increase (decrease) from investment operations |
1.59 |
1.61 |
(2.04 ) |
3.51 |
3.23 |
| Distributions(b)
|
|
|
|
|
|
| From net investment income |
(0.25 ) |
(0.37 ) |
(0.30 ) |
(0.24 ) |
(0.20 ) |
| From net realized gain |
(0.87 ) |
(0.59 ) |
(0.56 ) |
(0.76 ) |
(1.08 ) |
| Return of capital |
(0.35 ) |
(0.49 ) |
(0.59 ) |
(0.45 ) |
(0.17 ) |
| Total distributions |
(1.47 ) |
(1.45 ) |
(1.45 ) |
(1.45 ) |
(1.45 ) |
| Net asset value, end of year |
$22.65 |
$22.53 |
$22.37 |
$25.86 |
$23.80 |
| Market price, end of year |
$23.43 |
$21.82 |
$20.77 |
$26.62 |
$25.04 |
| Total
Return(c) |
|
|
|
|
|
| Based on net asset value |
7.28 % |
7.66 % |
(7.73 )% |
15.13 % |
15.87 % |
| Based on market price |
14.58 % |
12.30 % |
(16.78 )% |
12.65 % |
20.32 % |
| Ratios to Average Net
Assets(d) |
|
|
|
|
|
| Total expenses |
1.08 % |
1.08 % |
1.08 % |
1.08 % |
1.13 % |
| Total expenses after fees waived and/or reimbursed |
1.08 % |
1.08 % |
1.08 % |
1.07 % |
1.10 % |
| Net investment income |
1.26 % |
1.58 % |
1.44 % |
0.97 % |
1.58 % |
| Supplemental Data |
|
|
|
|
|
| Net assets, end of year (000) |
$510,854 |
$506,462 |
$498,393 |
$559,805 |
$444,526 |
| Portfolio turnover rate |
36 % |
31 % |
36 % |
20 % |
39 % |
| (a) |
Based on average shares outstanding. |
| (b) |
Distributions for annual periods determined in accordance with U.S. federal income tax regulations. |
| (c) |
Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where
applicable, excludes the effects of any sales charges and assumes the reinvestment
of distributions at actual reinvestment prices. |
| (d) |
Excludes fees and expenses incurred indirectly as a result of investments in underlying funds. |
| Trust Name |
Herein Referred To As |
Organized |
Diversification Classification |
| BlackRock Energy and Resources Trust |
BGR |
Delaware |
Non-diversified |
| BlackRock Enhanced Equity Dividend Trust |
BDJ |
Delaware |
Diversified |
| BlackRock Enhanced Global Dividend Trust |
BOE |
Delaware |
Diversified |
| BlackRock Enhanced International Dividend Trust |
BGY |
Delaware |
Diversified |
| BlackRock Enhanced Large Cap Core Fund, Inc. |
CII |
Maryland |
Diversified |
| BlackRock Health Sciences Term Trust |
BMEZ |
Maryland |
Diversified* |
| BlackRock Health Sciences Trust |
BME |
Delaware |
Diversified |
| BlackRock Innovation and Growth Term Trust |
BIGZ |
Maryland |
Diversified* |
| BlackRock Resources & Commodities Strategy Trust |
BCX |
Delaware |
Non-diversified |
| BlackRock Science and Technology Term Trust |
BSTZ |
Delaware |
Diversified |
| BlackRock Science and Technology Trust |
BST |
Delaware |
Diversified |
| BlackRock Utilities, Infrastructure & Power Opportunities Trust |
BUI |
Delaware |
Diversified |
| * |
The
Trust’s classification changed from non-diversified to
diversified during the reporting period. |
| Trust Name/Counterparty |
Securities Loaned at Value |
Cash Collateral Received(a) |
Non-Cash Collateral Received, at Fair Value(a)
|
Net Amount |
| CII |
|
|
|
|
| Citigroup Global Markets, Inc. |
$ 425,316 |
$ (425,316 ) |
$ — |
$ — |
| BMEZ |
|
|
|
|
| Barclays Capital, Inc. |
$ 18,471
|
$ (18,471
) |
$ —
|
$ —
|
| Citigroup Global Markets, Inc. |
6,780,092 |
(6,780,092 ) |
— |
— |
| Goldman Sachs & Co. LLC |
1,105,584 |
(1,105,584 ) |
— |
— |
| Jefferies LLC |
620,303 |
(620,303 ) |
— |
— |
| Morgan Stanley |
745,404 |
(745,404 ) |
— |
— |
| National Financial Services LLC |
688,226 |
(688,226 ) |
— |
— |
| |
$ 9,958,080 |
$ (9,958,080 ) |
$ — |
$ — |
| BME |
|
|
|
|
| Morgan Stanley |
$ 162,584
|
$ (162,584
) |
$ —
|
$ —
|
| Toronto-Dominion Bank |
113,715 |
(113,715 ) |
— |
— |
| |
$ 276,299 |
$ (276,299 ) |
$ — |
$ — |
| BIGZ |
|
|
|
|
| J.P. Morgan Securities LLC |
$ 7,862,045
|
$ (7,862,045
) |
$ —
|
$ —
|
| Morgan Stanley |
6,050,626 |
(6,050,626 ) |
— |
— |
| |
$ 13,912,671 |
$ (13,912,671 ) |
$ — |
$ — |
| BCX |
|
|
|
|
| J.P. Morgan Securities LLC |
$ 1,758,273
|
$ (1,758,273
) |
$ —
|
$ —
|
| Morgan Stanley |
60,138 |
(60,138 ) |
— |
— |
| |
$ 1,818,411 |
$ (1,818,411 ) |
$ — |
$ — |
| BSTZ |
|
|
|
|
| Barclays Capital, Inc. |
$ 1,076,250
|
$ (1,076,250
) |
$ —
|
$ —
|
| BofA Securities, Inc. |
66,256 |
(66,256 ) |
— |
— |
| Goldman Sachs & Co. LLC |
1,984,578 |
(1,984,578 ) |
— |
— |
| J.P. Morgan Securities LLC |
649,390 |
(649,390 ) |
— |
— |
| Jefferies LLC |
1,297,292 |
(1,297,292 ) |
— |
— |
| Trust Name/Counterparty |
Securities Loaned at Value |
Cash Collateral Received(a) |
Non-Cash Collateral Received, at Fair Value(a) |
Net
Amount |
| BSTZ (continued) |
|
|
|
|
| Morgan Stanley |
$ 808
|
$ (808
) |
$ —
|
$ —
|
| Toronto-Dominion Bank |
2,120,376 |
(2,120,376 ) |
— |
— |
| |
$ 7,194,950 |
$ (7,194,950 ) |
$ — |
$ — |
| BST |
|
|
|
|
| J.P. Morgan Securities LLC |
$ 542,784 |
$ (542,784 ) |
$ — |
$ — |
| (a) |
Collateral received, if any, in excess of the market value of securities on loan is not
presented in this table. The total cash collateral received by each Trust is disclosed in the Trust’s Statements of Assets and Liabilities. |
| |
BGR |
BDJ |
BOE |
BME |
| Investment advisory fees |
1.00 % |
0.80
% |
1.00
% |
1.00 % |
| |
CII |
| Investment advisory fees |
0.85 % |
| |
BGY |
BUI |
| Investment advisory fees |
1.00 % |
1.00 % |
| |
BMEZ |
BIGZ |
BSTZ |
BST |
| Investment advisory fees |
1.25 % |
1.25
% |
1.25
% |
1.00 % |
| |
BGR |
BOE |
| |
0.220
% |
0.175
% |
| Trust Name |
Fees Waived and/or Reimbursed by the Manager |
| BGR |
$ 440,153
|
| BOE |
1,298,595 |
| Trust Name |
Fees Waived and/or Reimbursed by the Manager |
| BGR |
$ 5,491
|
| BDJ |
25,016 |
| BOE |
5,174 |
| BGY |
5,220 |
| CII |
8,174 |
| BMEZ |
42,160 |
| BME |
15,682 |
| BIGZ |
4,111 |
| BCX |
14,944 |
| BSTZ |
10,202 |
| BST |
4,806 |
| BUI |
5,615 |
| Trust Name |
Amounts |
| BDJ |
$ 109
|
| BOE |
5 |
| CII |
589 |
| BMEZ |
19,878 |
| BME |
714 |
| BIGZ |
11,532 |
| BSTZ |
44,038 |
| BST |
9,111 |
| BUI |
971 |
| Trust Name |
Purchases |
Sales |
| BGR |
$ 163,427,180
|
$ 202,555,797
|
| BDJ |
847,191,436 |
1,111,523,109 |
| BOE |
377,480,352 |
469,500,006 |
| BGY |
284,754,516 |
347,615,872 |
| CII |
580,344,779 |
700,914,329 |
| BMEZ |
786,861,504 |
1,066,653,242 |
| BME |
170,459,756 |
235,402,650 |
| BIGZ |
758,164,326 |
1,065,289,369 |
| BCX |
570,713,687 |
660,371,685 |
| BSTZ |
612,621,706 |
932,655,460 |
| BST |
250,714,635 |
419,580,255 |
| BUI |
183,065,954 |
228,632,632 |
| Trust Name |
Paid-in Capital |
Accumulated Earnings (Loss) |
| BDJ |
$ (6,180
) |
$ 6,180
|
| BMEZ |
1,418,313 |
(1,418,313 ) |
| BME |
392,774 |
(392,774 ) |
| BIGZ |
(21,453,458 ) |
21,453,458 |
| BSTZ |
(18,257,604 ) |
18,257,604 |
| BST |
(9,633,236 ) |
9,633,236 |
| BUI |
(993 ) |
993 |
| Trust Name |
Year Ended 12/31/24 |
Year Ended 12/31/23 |
| BGR |
|
|
| Ordinary income |
$ 8,876,987 |
$ 10,396,825 |
| Return of capital |
13,896,512 |
11,108,880 |
| |
$ 22,773,499 |
$ 21,505,705 |
| BDJ |
|
|
| Ordinary income |
$ 53,926,860 |
$ 33,363,489 |
| Long-term capital gains |
71,310,181 |
102,619,291 |
| |
$ 125,237,041 |
$ 135,982,780 |
| BOE |
|
|
| Ordinary income |
$ 10,955,631 |
$ 13,739,848 |
| Return of capital |
36,227,997 |
33,325,380 |
| |
$ 47,183,628 |
$ 47,065,228 |
| BGY |
|
|
| Ordinary income |
$ 26,539,165 |
$ 9,930,219 |
| Long-term capital gains |
14,548,390 |
7,370,443 |
| Return of capital |
— |
23,857,237 |
| |
$ 41,087,555 |
$ 41,157,899 |
| CII |
|
|
| Ordinary income |
$ 1,420,313 |
$ 11,634,813 |
| Long-term capital gains |
52,486,414 |
41,063,355 |
| |
$ 53,906,727 |
$ 52,698,168 |
| BMEZ |
|
|
| Return of capital |
$ 177,775,924 |
$ 170,987,587 |
| BME |
|
|
| Ordinary income |
$ 932,858 |
$ 2,244,293 |
| Long-term capital gains |
27,644,801 |
23,151,941 |
| Return of capital |
7,344,579 |
10,214,453 |
| |
$ 35,922,238 |
$ 35,610,687 |
| BIGZ |
|
|
| Return of capital |
$ 184,726,032 |
$ 173,714,456 |
| BCX |
|
|
| Ordinary income |
$ 20,754,349 |
$ 24,357,046 |
| Return of capital |
32,577,896 |
29,035,558 |
| |
$ 53,332,245 |
$ 53,392,604 |
| Trust Name |
Year Ended 12/31/24 |
Year Ended 12/31/23 |
| BSTZ |
|
|
| Long-term capital gains |
$ 76,763,205 |
$ — |
| Return of capital |
74,781,695 |
140,469,092 |
| |
$ 151,544,900 |
$ 140,469,092 |
| BST |
|
|
| Long-term capital gains |
$ 54,438,359 |
$ 50,091,649 |
| Return of capital |
49,592,586 |
51,595,440 |
| |
$ 104,030,945 |
$ 101,687,089 |
| BUI |
|
|
| Ordinary income |
$ 5,606,511 |
$ 19,423,039 |
| Long-term capital gains |
19,545,019 |
2,024,280 |
| Return of capital |
7,834,340 |
11,077,670 |
| |
$ 32,985,870 |
$ 32,524,989 |
| Trust Name |
Undistributed Ordinary Income |
Undistributed Long-Term Capital Gains |
Non-Expiring Capital Loss Carryforwards(a)
|
Net Unrealized Gains (Losses)(b)
|
Qualified Late-Year Ordinary Losses(c)
|
Total |
| BGR |
$ — |
$ — |
$ (203,787,893 ) |
$ 89,555,423 |
$ — |
$ (114,232,470
) |
| BDJ |
30,908,455 |
62,402,387 |
— |
276,955,605 |
— |
370,266,447 |
| BOE |
— |
— |
(5,383,743
) |
132,448,997 |
(23,287
) |
127,041,967 |
| BGY |
1,331,198 |
729,744 |
— |
51,102,227 |
— |
53,163,169 |
| CII |
1,202,600 |
83,236,805 |
— |
298,928,918 |
— |
383,368,323 |
| BMEZ |
— |
— |
(26,094,837 ) |
4,736,118 |
— |
(21,358,719 ) |
| BME |
— |
— |
— |
165,011,194 |
(9,210
) |
165,001,984 |
| BIGZ |
— |
— |
(1,849,884,782 ) |
(88,694,479 ) |
— |
(1,938,579,261 ) |
| BCX |
— |
— |
(210,243,025
) |
36,712,745 |
— |
(173,530,280 ) |
| BSTZ |
— |
— |
— |
644,340,065 |
— |
644,340,065 |
| BST |
— |
— |
— |
645,319,822 |
(6,188
) |
645,313,634 |
| BUI |
— |
— |
— |
140,031,936 |
(43,667 ) |
139,988,269 |
| (a) |
Amounts available to offset future realized capital gains. |
| (b) |
The difference between book-basis and tax-basis net unrealized gains (losses) was attributable primarily to the tax deferral of losses on wash sales and straddles, the
realization for tax purposes of unrealized gains (losses) on certain futures
and foreign currency contracts, the realization for tax purposes of unrealized gains on investments in passive foreign investment companies, the timing and recognition of partnership income, the characterization of corporate actions and the deferral of compensation to Trustees. |
| (c) |
The Trust has elected to defer these qualified late-year losses and recognize such losses in the next taxable year. |
| Trust Name |
Utilized |
| BGR |
$ 13,144,882
|
| BOE |
19,996,421 |
| BMEZ |
16,685,568 |
| BIGZ |
50,852,083 |
| BCX |
15,861,436 |
| BSTZ |
42,767,288 |
| Trust Name |
Tax Cost |
Gross Unrealized Appreciation |
Gross Unrealized Depreciation |
Net Unrealized Appreciation (Depreciation) |
| BGR |
$ 264,036,299
|
$ 106,677,003
|
$ (8,387,844
) |
$ 98,289,159
|
| BDJ |
1,321,911,186 |
369,940,178 |
(71,805,382 ) |
298,134,796 |
| BOE |
558,141,555 |
167,758,668 |
(13,864,568 ) |
153,894,100 |
| BGY |
497,992,918 |
100,960,858 |
(28,650,284 ) |
72,310,574 |
| CII |
608,169,798 |
324,217,320 |
(16,793,323 ) |
307,423,997 |
| BMEZ |
1,682,044,422 |
285,256,958 |
(275,713,138 ) |
9,543,820 |
| BME |
382,089,953 |
191,404,688 |
(21,090,441 ) |
170,314,247 |
| BIGZ |
1,898,004,755 |
378,726,881 |
(464,056,637 ) |
(85,329,756 ) |
| BCX |
734,793,135 |
114,588,132 |
(73,036,031 ) |
41,552,101 |
| BSTZ |
1,031,508,484 |
796,312,045 |
(126,744,589 ) |
669,567,456 |
| Trust Name |
Tax Cost |
Gross Unrealized Appreciation |
Gross Unrealized Depreciation |
Net Unrealized Appreciation (Depreciation) |
| BST |
$ 725,704,368
|
$ 804,079,132
|
$ (137,481,824
) |
$ 666,597,308
|
| BUI |
356,282,824 |
171,435,831 |
(13,340,117 ) |
158,095,714 |
| Sectors |
Trust Name |
| Energy |
BGR, BCX |
| Financials |
BDJ
|
| Health Care |
BMEZ, BME |
| Information Technology |
CII, BSTZ,
BST |
| Materials |
BCX |
| Utilities |
BUI
|
| |
Year Ended | |
| Trust Name |
12/31/24 |
12/31/23 |
| BME |
— |
71,333 |
| BST |
236,917 |
1,266,090 |
| BUI |
55,243 |
167,658 |
| |
Year Ended | |
| Trust Name |
12/31/24 |
12/31/23 |
| BDJ |
— |
78,103 |
| CII |
— |
14,818 |
| BME |
— |
12,112 |
| BST |
43,442 |
173,563 |
| BUI |
21,581 |
31,913 |
| |
BGR | |
| |
Shares |
Amounts |
| Year Ended December 31, 2024 |
1,356,082 |
$ 19,781,491
|
| Year Ended December 31, 2023 |
587,768 |
7,413,692 |
| |
BDJ | |
| |
Shares |
Amounts |
| Year Ended December 31, 2024 |
9,190,420 |
$ 84,525,360
|
| Year Ended December 31, 2023 |
359,086 |
2,735,878 |
| |
BOE | |
| |
Shares |
Amounts |
| Year Ended December 31, 2024 |
3,037,836 |
$ 36,994,167
|
| Year Ended December 31, 2023 |
1,214,010 |
11,889,663 |
| |
BGY | |
| |
Shares |
Amounts |
| Year Ended December 31, 2024 |
4,950,922 |
$ 30,215,690
|
| Year Ended December 31, 2023 |
2,473,793 |
13,143,239 |
| |
CII | |
| |
Shares |
Amounts |
| Year Ended December 31, 2024 |
2,179,753 |
$ 45,649,966
|
| |
BMEZ | |
| |
Shares |
Amounts |
| Year Ended December 31, 2024 |
5,259,141 |
$ 89,462,275
|
| Year Ended December 31, 2023 |
3,082,831 |
47,918,763 |
| |
BME | |
| |
Shares |
Amounts |
| Year Ended December 31, 2024 |
688,483 |
$ 29,532,715
|
| |
BIGZ | |
| |
Shares |
Amounts |
| Year Ended December 31, 2024 |
11,080,678 |
$ 92,487,614
|
| Year Ended December 31, 2023 |
5,247,265 |
37,872,639 |
| |
BCX | |
| |
Shares |
Amounts |
| Year Ended December 31, 2024 |
4,165,437 |
$ 42,582,282
|
| Year Ended December 31, 2023 |
3,155,189 |
29,812,008 |
| |
BSTZ | |
| |
Shares |
Amounts |
| Year Ended December 31, 2024 |
3,755,988 |
$ 82,227,801
|
| Year Ended December 31, 2023 |
2,006,073 |
34,325,597 |
| Commencement Date of Tender Offer
Period(a) |
Valuation Date |
Number of Shares Tendered |
Tendered Shares as a Percentage of Outstanding Shares |
Number of Tendered Shares Purchased |
Tendered Shares Purchased as a Percentage of Outstanding Shares |
Purchase Price |
Total Amount of Purchases |
| 07/17/24 |
08/19/24 |
7,466,508 |
27.2 % |
686,624 |
2.5 % |
$14.5824 |
$10,012,626 |
| 10/15/24 |
11/18/24 |
6,002,507 |
22.4 |
669,458 |
2.5 |
14.5922 |
9,768,865 |
| Commencement Date of Tender Offer
Period(a) |
Valuation Date |
Number of Shares Tendered |
Tendered Shares as a Percentage of Outstanding Shares |
Number of Tendered Shares Purchased |
Tendered Shares Purchased as a Percentage of Outstanding Shares |
Purchase Price |
Total Amount of Purchases |
| 07/17/24 |
08/19/24 |
22,908,137 |
12.3 % |
4,653,377 |
2.5 % |
$9.1826 |
$42,730,100 |
| 10/15/24 |
11/18/24 |
18,268,902 |
10.1 |
4,537,043 |
2.5 |
9.2120 |
41,795,240 |
| Commencement Date of Tender Offer
Period(a) |
Valuation Date |
Number of Shares Tendered |
Tendered Shares as a Percentage of Outstanding Shares |
Number of Tendered Shares Purchased |
Tendered Shares Purchased as a Percentage of Outstanding Shares |
Purchase Price |
Total Amount of Purchases |
| 07/19/24 |
08/21/24 |
14,942,512 |
24.3 % |
1,538,145 |
2.5 % |
$12.2794 |
$18,887,498 |
| 10/17/24 |
11/20/24 |
14,941,364 |
24.9 |
1,499,691 |
2.5 |
12.0736 |
18,106,669 |
| Commencement Date of Tender Offer
Period(a) |
Valuation Date |
Number of Shares Tendered |
Tendered Shares as a Percentage of Outstanding Shares |
Number of Tendered Shares Purchased |
Tendered Shares Purchased as a Percentage of Outstanding Shares |
Purchase Price |
Total Amount of Purchases |
| 07/18/24 |
08/20/24 |
33,752,225 |
33.7 % |
2,506,796 |
2.5 % |
$6.3014 |
$15,796,324 |
| Commencement Date of Tender Offer
Period(a) |
Valuation Date |
Number of Shares Tendered |
Tendered Shares as a Percentage of Outstanding Shares |
Number of Tendered Shares Purchased |
Tendered Shares Purchased as a Percentage of Outstanding Shares |
Purchase Price |
Total Amount of Purchases |
| 10/16/24 |
11/19/24 |
33,315,326 |
34.1 % |
2,444,126 |
2.5 % |
5.8996 |
14,419,366 |
| Commencement Date of Tender Offer
Period(a) |
Valuation Date |
Number of Shares Tendered |
Tendered Shares as a Percentage of Outstanding Shares |
Number of Tendered Shares Purchased |
Tendered Shares Purchased as a Percentage of Outstanding Shares |
Purchase Price |
Total Amount of Purchases |
| 07/17/24 |
08/19/24 |
5,850,437 |
13.3 % |
1,103,672 |
2.5 % |
$20.9524 |
$23,124,577 |
| 10/15/24 |
11/18/24 |
5,713,692 |
13.3 |
1,076,081 |
2.5 |
20.9328 |
22,525,388 |
| Commencement Date of Tender Offer
Period(a) |
Valuation Date |
Number of Shares Tendered |
Tendered Shares as a Percentage of Outstanding Shares |
Number of Tendered Shares Purchased |
Tendered Shares Purchased as a Percentage of Outstanding Shares |
Purchase Price |
Total Amount of Purchases |
| 07/18/24 |
08/20/24 |
24,040,558 |
22.6 % |
2,662,856 |
2.5 % |
$17.6204 |
$46,920,588 |
| 10/16/24 |
11/19/24 |
21,043,412 |
20.3 |
2,596,285 |
2.5 |
16.3856 |
42,541,687 |
| Commencement Date of Tender Offer
Period(a) |
Valuation Date |
Number of Shares Tendered |
Tendered Shares as a Percentage of Outstanding Shares |
Number of Tendered Shares Purchased |
Tendered Shares Purchased as a Percentage of Outstanding Shares |
Purchase Price |
Total Amount of Purchases |
| 07/18/24 |
08/20/24 |
1,279,599 |
9.2 % |
348,599 |
2.5 % |
$44.4822 |
$15,506,450 |
| 10/16/24 |
11/19/24 |
1,360,222 |
10.0 |
339,884 |
2.5 |
41.2678 |
14,026,265 |
| Commencement Date of Tender Offer
Period(a) |
Valuation Date |
Number of Shares Tendered |
Tendered Shares as a Percentage of Outstanding Shares |
Number of Tendered Shares Purchased |
Tendered Shares Purchased as a Percentage of Outstanding Shares |
Purchase Price |
Total Amount of Purchases |
| 07/22/24 |
08/22/24 |
42,424,300 |
18.9 % |
5,610,470 |
2.5 % |
$8.1242 |
$45,580,580 |
| 10/18/24 |
11/21/24 |
35,904,019 |
16.4 |
5,470,208 |
2.5 |
8.5750 |
46,907,034 |
| Commencement Date of Tender Offer
Period(a) |
Valuation Date |
Number of Shares Tendered |
Tendered Shares as a Percentage of Outstanding Shares |
Number of Tendered Shares Purchased |
Tendered Shares Purchased as a Percentage of Outstanding Shares |
Purchase Price |
Total Amount of Purchases |
| 07/19/24 |
08/21/24 |
22,521,822 |
26.7 % |
2,109,082 |
2.5 % |
$10.3292 |
$21,785,130 |
| 10/17/24 |
11/20/24 |
20,587,371 |
25.0 |
2,056,355 |
2.5 |
10.1136 |
20,797,152 |
| Commencement Date of Tender Offer
Period(a) |
Valuation Date |
Number of Shares Tendered |
Tendered Shares as a Percentage of Outstanding Shares |
Number of Tendered Shares Purchased |
Tendered Shares Purchased as a Percentage of Outstanding Shares |
Purchase Price |
Total Amount of Purchases |
| 07/19/24 |
08/21/24 |
23,251,771 |
30.6 % |
1,901,766 |
2.5 % |
$21.4522 |
$40,797,065 |
| 10/17/24 |
11/20/24 |
19,714,994 |
26.6 |
1,854,222 |
2.5 |
22.3440 |
41,430,736 |
| (a) |
Date
the tender offer period began. |
| Trust Name |
Declaration Date |
Record Date |
Payable/ Paid Date |
|
Dividend Per Common Share |
| BGR |
01/02/25 |
01/15/25 |
01/31/25 |
|
$ 0.097300
|
| |
02/03/25 |
02/14/25 |
02/28/25 |
|
0.097300 |
| BDJ |
01/02/25 |
01/15/25 |
01/31/25 |
|
0.061900 |
| |
02/03/25 |
02/14/25 |
02/28/25 |
|
0.061900 |
| BOE |
01/02/25 |
01/15/25 |
01/31/25 |
|
0.082700 |
| |
02/03/25 |
02/14/25 |
02/28/25 |
|
0.082700 |
| BGY |
01/02/25 |
01/15/25 |
01/31/25 |
|
0.042600 |
| |
02/03/25 |
02/14/25 |
02/28/25 |
|
0.042600 |
| CII |
01/02/25 |
01/15/25 |
01/31/25 |
|
0.141000 |
| |
02/03/25 |
02/14/25 |
02/28/25 |
|
0.141000 |
| BMEZ |
01/02/25 |
01/15/25 |
01/31/25 |
|
0.178190 |
| |
02/03/25 |
02/14/25 |
02/28/25 |
|
0.177300 |
| BME |
01/02/25 |
01/15/25 |
01/31/25 |
|
0.262100 |
| |
02/03/25 |
02/14/25 |
02/28/25 |
|
0.262100 |
| BIGZ |
01/02/25 |
01/15/25 |
01/31/25 |
|
0.086810 |
| |
02/03/25 |
02/14/25 |
02/28/25 |
|
0.086570 |
| BCX |
01/02/25 |
01/15/25 |
01/31/25 |
|
0.069700 |
| |
02/03/25 |
02/14/25 |
02/28/25 |
|
0.069700 |
| BSTZ |
01/02/25 |
01/15/25 |
01/31/25 |
|
0.219880 |
| |
02/03/25 |
02/14/25 |
02/28/25 |
|
0.221780 |
| BST |
01/02/25 |
01/15/25 |
01/31/25 |
|
0.250000 |
| |
02/03/25 |
02/14/25 |
02/28/25 |
|
0.250000 |
| BUI |
01/02/25 |
01/15/25 |
01/31/25 |
|
0.136000 |
| |
02/03/25 |
02/14/25 |
02/28/25 |
|
0.136000 |
| Commencement Date of Tender Offer
Period(a) |
Valuation Date |
Number of Shares Tendered |
Tendered Shares as a Percentage of Outstanding Shares |
Number of Tendered Shares to be Purchased |
Tendered Shares to be Purchased as a Percentage of Outstanding Shares |
Purchase Price |
Total Amount of Purchases |
| 01/22/25 |
02/24/25 |
3,894,759 |
14.9 % |
652,722 |
2.5 % |
$13.8376 |
$9,032,106 |
| Commencement Date of Tender Offer
Period(a) |
Valuation Date |
Number of Shares Tendered |
Tendered Shares as a Percentage of Outstanding Shares |
Number of Tendered Shares to be Purchased |
Tendered Shares to be Purchased as a Percentage of Outstanding Shares |
Purchase Price |
Total Amount of Purchases |
| 01/22/25 |
02/24/25 |
4,275,883 |
10.2 % |
1,049,179 |
2.5 % |
$21.1974 |
$22,239,867 |
| Commencement Date of Tender Offer
Period(a) |
Valuation Date |
Number of Shares Tendered |
Tendered Shares as a Percentage of Outstanding Shares |
Number of Tendered Shares to be Purchased |
Tendered Shares to be Purchased as a Percentage of Outstanding Shares |
Purchase Price |
Total Amount of Purchases |
| 01/22/25 |
02/24/25 |
1,188,063 |
9.0 % |
331,387 |
2.5 % |
$42.1792 |
$13,977,639 |
| (a) |
Date
the tender offer period began. |
| Fund |
Financial Highlights |
| BlackRock Energy and Resources Trust, BlackRock Enhanced Equity Dividend Trust, BlackRock Enhanced Global Dividend Trust, BlackRock Enhanced International Dividend Trust, BlackRock Enhanced Large Cap Core Fund, Inc., BlackRock Health Sciences Trust, BlackRock Resources & Commodities Strategy Trust, BlackRock Science and Technology Term Trust, BlackRock Science and Technology Trust and BlackRock Utilities, Infrastructure
& Power Opportunities Trust |
For each of the five years in the period ended December 31, 2024. |
| BlackRock Health Sciences Term Trust |
For each of the four years in the period ended December 31, 2024, and for the period from January 30, 2020 (commencement of operations) through December 31, 2020. |
| BlackRock Innovation and Growth Term Trust |
For each of the three years in the period ended December 31, 2024, and for the period from
March 29, 2021 (commencement of operations) through December 31, 2021. |
| Trust Name |
Qualified Dividend Income |
| BGR |
$ 8,876,987
|
| BDJ |
37,667,714 |
| BOE |
10,955,631 |
| BGY |
9,933,846 |
| CII |
8,711,972 |
| BME |
932,858 |
| BCX |
21,906,083 |
| BUI |
5,606,513 |
| Trust Name |
20% Rate Long-Term Capital Gain Dividends |
| BDJ |
$ 71,310,181
|
| BGY |
14,548,390 |
| CII |
52,486,414 |
| BME |
27,644,801 |
| BSTZ |
76,763,205 |
| BST |
54,438,359 |
| BUI |
19,545,019 |
| Trust Name |
Foreign Source Income Earned |
Foreign Taxes Paid |
| BOE |
$ —
|
$ —
|
| BGY |
7,090,627 |
— |
| BCX |
14,328,277 |
1,151,734 |
| BUI |
— |
— |
| Trust Name |
Federal Obligation Interest |
| BGR |
$ 116,131
|
| BDJ |
599,318 |
| BOE |
106,006 |
| BGY |
85,754 |
| CII |
48,115 |
| BME |
64,832 |
| BCX |
345,272 |
| BUI |
90,213 |
| Trust Name |
Dividends-Received Deduction |
| BGR |
78.51 % |
| BDJ |
48.72 |
| BOE |
72.75 |
| BGY |
4.76 |
| CII |
100.00 |
| BME |
100.00 |
| BCX |
30.80 |
| BUI |
100.00 |
| Trust Name |
Interest Dividends |
| BGR |
$ 236,542
|
| BDJ |
1,208,058 |
| BOE |
213,721 |
| BGY |
172,891 |
| CII |
97,845 |
| BME |
130,983 |
| BCX |
696,112 |
| BUI |
181,858 |
| Trust Name |
Interest- Related Dividends |
Qualified Short-Term Capital Gains |
| BGR |
$ 236,542
|
$ —
|
| BDJ |
1,208,058 |
17,993,020 |
| BOE |
213,721 |
— |
| BGY |
172,891 |
18,293,621 |
| CII |
97,815 |
— |
| BME |
130,977 |
— |
| BCX |
696,112 |
— |
| BUI |
181,858 |
— |
| |
BDJ |
| Shareholder Transaction Expenses |
|
| Maximum sales load (as a percentage of offering price)(a) |
1.00% |
| Offering expenses borne by the Trust (as a percentage of offering price)(a) |
0.01% |
| Dividend reinvestment plan fees |
$0.02 per share for open market purchases of common shares(b) |
| Estimated Annual Expenses (as a percentage of net assets
attributable to common shares) |
|
| Investment advisory fees(c)(d)
|
0.80% |
| Other expenses |
0.08 |
| Total annual expenses |
0.88 |
| Fee waivers(d) |
— |
| Total annual Trust operating expenses after fee waivers(d) |
0.88 |
| |
1 Year |
3 Years |
5 Years |
10 Years |
|
|
| Total expenses incurred |
$ 19
|
$ 38
|
$ 58
|
$ 117
|
|
|
| |
BME |
| Shareholder Transaction Expenses |
|
| Maximum sales load (as a percentage of offering price)(a) |
1.00% |
| Offering expenses borne by the Trust (as a percentage of offering price)(a) |
0.02% |
| Dividend reinvestment plan fees |
$0.02 per share for open market purchases of common shares(b) |
| Estimated Annual Expenses (as a percentage of net assets
attributable to common shares) |
|
| Investment advisory fees(c)(d)
|
1.00% |
| Other expenses |
0.10 |
| Acquired fund fees and
expenses(e) |
0.01 |
| Total annual expenses(e) |
1.11 |
| Fee waivers(d) |
— |
| Total annual Trust operating expenses after fee waivers(d) |
1.11 |
| |
1 Year |
3 Years |
5 Years |
10 Years |
|
|
| Total expenses incurred |
$ 21
|
$ 45
|
$ 71
|
$ 144
|
|
|
| |
BST |
| Shareholder Transaction Expenses |
|
| Maximum sales load (as a percentage of offering price)(a) |
1.00% |
| Offering expenses borne by the Trust (as a percentage of offering price)(a) |
0.01% |
| Dividend reinvestment plan fees |
$0.02 per share for open market purchases of common shares(b) |
| Dividend reinvestment plan sale transaction fee |
$2.50(b)
|
| Estimated Annual Expenses (as a percentage of net assets
attributable to common shares) |
|
| Investment advisory fees(c)(d)
|
1.00% |
| Other expenses |
0.07 |
| Total annual expenses |
1.07 |
| Fee waivers(d) |
— |
| Total annual Trust operating expenses after fee waivers(d) |
1.07 |
| |
1 Year |
3 Years |
5 Years |
10 Years |
|
|
| Total expenses incurred |
$ 21
|
$ 44
|
$ 68
|
$ 139
|
|
|
| |
BUI |
| Shareholder Transaction Expenses |
|
| Maximum sales load (as a percentage of offering price)(a) |
1.00% |
| Offering expenses borne by the Trust (as a percentage of offering price)(a) |
0.02% |
| Dividend reinvestment plan fees |
$0.02 per share for open market purchases of common shares(b) |
| Estimated Annual Expenses (as a percentage of net assets
attributable to common shares) |
|
| Investment advisory fees(c)(d)
|
1.00% |
| Other expenses |
0.08 |
| Total annual expenses |
1.08 |
| Fee waivers(d) |
— |
| Total annual Trust operating expenses after fee waivers(d) |
1.08 |
| |
1 Year |
3 Years |
5 Years |
10 Years |
|
|
| Total expenses incurred |
$ 21
|
$ 44
|
$ 69
|
$ 141
|
|
|
| |
NYSE Market Price Per Common Share |
NAV per Common Share on Date of
Market Price |
Premium/ (Discount) on
Date of Market Price |
| |||
| BDJ — During Quarter Ended |
High |
Low |
High |
Low |
High |
Low |
Trading Volume |
| December 31, 2024 |
$ 9.04
|
$ 8.10
|
$ 9.40
|
$ 8.91
|
(3.83 )% |
(9.09 )% |
30,703,948 |
| September 30, 2024 |
8.65 |
8.04 |
9.44 |
8.97 |
(8.37 ) |
(10.37 ) |
33,016,032 |
| June 30, 2024 |
8.32 |
7.81 |
9.32 |
8.92 |
(10.73 ) |
(12.44 ) |
25,713,056 |
| March 31, 2024 |
8.27 |
7.73 |
9.18 |
8.73 |
(9.91 ) |
(11.45 ) |
34,122,416 |
| December 31, 2023 |
7.91 |
6.92 |
8.68 |
8.17 |
(8.87 ) |
(15.30 ) |
38,503,054 |
| September 30, 2023 |
8.39 |
7.47 |
8.96 |
8.38 |
(6.36 ) |
(10.86 ) |
35,094,623 |
| June 30, 2023 |
8.60 |
8.03 |
8.76 |
8.56 |
(1.83 ) |
(6.19 ) |
24,527,314 |
| March 31, 2023 |
9.36 |
8.26 |
9.15 |
8.23 |
2.30 |
0.36 |
25,059,984 |
| |
NYSE Market Price Per Common Share |
NAV per Common Share on Date of
Market Price |
Premium/ (Discount) on
Date of Market Price |
| |||
| BME — During Quarter Ended |
High |
Low |
High |
Low |
High |
Low |
Trading Volume |
| December 31, 2024 |
$ 42.26
|
$ 36.92
|
$ 45.47
|
$ 40.83
|
(7.06 )% |
(9.58 )% |
3,271,504 |
| September 30, 2024 |
42.41 |
39.94 |
46.00 |
43.63 |
(7.80 ) |
(8.46 ) |
1,882,708 |
| June 30, 2024 |
40.88 |
38.45 |
44.28 |
42.28 |
(7.68 ) |
(9.06 ) |
2,131,401 |
| March 31, 2024 |
42.71 |
40.60 |
43.06 |
42.62 |
(0.81 ) |
(4.74 ) |
2,003,876 |
| December 31, 2023 |
40.46 |
35.53 |
42.18 |
39.01 |
(4.08 ) |
(8.92 ) |
2,698,691 |
| September 30, 2023 |
40.90 |
38.98 |
43.13 |
41.02 |
(5.17 ) |
(4.97 ) |
2,017,234 |
| June 30, 2023 |
42.93 |
39.55 |
42.91 |
41.26 |
0.05 |
(4.14 ) |
1,769,337 |
| March 31, 2023 |
43.68 |
39.34 |
43.03 |
40.48 |
1.51 |
(2.82 ) |
1,728,269 |
| |
NYSE Market Price Per Common Share |
NAV per Common Share on Date of
Market Price |
Premium/ (Discount) on
Date of Market Price |
| |||
| BST — During Quarter Ended |
High |
Low |
High |
Low |
High |
Low |
Trading Volume |
| December 31, 2024 |
$ 38.04
|
$ 34.86
|
$ 40.69
|
$ 37.17
|
(6.51 )% |
(6.21 )% |
7,229,183 |
| September 30, 2024 |
38.95 |
33.05 |
40.40 |
34.58 |
(3.59 ) |
(4.42 ) |
9,154,401 |
| June 30, 2024 |
37.95 |
32.97 |
39.28 |
33.96 |
(3.39 ) |
(2.92 ) |
5,952,304 |
| March 31, 2024 |
37.77 |
32.92 |
36.86 |
33.83 |
2.47 |
(2.69 ) |
6,442,036 |
| December 31, 2023 |
34.48 |
29.72 |
34.21 |
30.15 |
0.79 |
(1.43 ) |
6,323,509 |
| September 30, 2023 |
35.25 |
30.61 |
34.81 |
31.31 |
1.26 |
(2.24 ) |
5,818,231 |
| June 30, 2023 |
34.44 |
30.25 |
34.14 |
30.31 |
0.88 |
(0.20 ) |
5,884,379 |
| March 31, 2023 |
34.12 |
28.52 |
32.41 |
28.95 |
5.28 |
(1.49 ) |
8,051,284 |
| |
NYSE Market Price Per Common Share |
NAV per Common Share on Date of
Market Price |
Premium/ (Discount) on
Date of Market Price |
| |||
| BUI — During Quarter Ended |
High |
Low |
High |
Low |
High |
Low |
Trading Volume |
| December 31, 2024 |
$ 24.37
|
$ 22.12
|
$ 24.41
|
$ 22.44
|
(0.16 )% |
(1.43 )% |
3,031,403 |
| September 30, 2024 |
24.83 |
22.14 |
24.43 |
22.30 |
1.64 |
(0.72 ) |
2,940,462 |
| June 30, 2024 |
23.03 |
20.20 |
22.97 |
21.24 |
0.26 |
(4.90 ) |
3,430,077 |
| March 31, 2024 |
22.24 |
20.57 |
22.28 |
21.47 |
(0.18 ) |
(4.19 ) |
3,733,789 |
| December 31, 2023 |
21.82 |
18.75 |
22.54 |
19.79 |
(3.19 ) |
(5.26 ) |
4,511,140 |
| September 30, 2023 |
23.34 |
19.64 |
23.05 |
20.42 |
1.26 |
(3.82 ) |
3,117,194 |
| June 30, 2023 |
23.73 |
21.56 |
22.95 |
22.18 |
3.40 |
(2.80 ) |
2,819,113 |
| |
NYSE Market Price Per Common Share |
NAV per Common Share on Date of
Market Price |
Premium/ (Discount) on Date
of Market Price |
| |||
| BUI — During Quarter Ended |
High |
Low |
High |
Low |
High |
Low |
Trading Volume |
| March 31, 2023 |
$ 23.98
|
$ 20.99
|
$ 22.97
|
$ 22.33
|
4.40 % |
(6.00 )% |
3,092,154 |
| |
BDJ | ||||
| |
Year Ended |
Year Ended |
Year Ended |
Year Ended |
Year Ended |
| |
12/31/19 |
12/31/18 |
12/31/17 |
12/31/16 |
12/31/15 |
| Net asset value, beginning of year |
$8.74 |
$9.96 |
$9.22 |
$8.70 |
$9.24 |
| Net investment income(a) |
0.18 |
0.18 (b) |
0.16 |
0.17 |
0.17 |
| Net realized and unrealized gain (loss) |
1.86 |
(0.84 ) |
1.14 |
0.91 |
(0.15 ) |
| Net increase (decrease) from investment operations |
2.04 |
(0.66 ) |
1.30 |
1.08 |
0.02 |
| Distributions(c)
|
|
|
|
|
|
| From net investment income |
(0.08 ) |
(0.18 )(d) |
(0.17 ) |
(0.17 ) |
(0.17 ) |
| From net realized gain |
(0.67 ) |
(0.38 )(d) |
(0.39 ) |
— |
— |
| Return of capital |
— |
— |
— |
(0.39 ) |
(0.39 ) |
| Total distributions |
(0.75 ) |
(0.56 ) |
(0.56 ) |
(0.56 ) |
(0.56 ) |
| Net asset value, end of year |
$10.03 |
$8.74 |
$9.96 |
$9.22 |
$8.70 |
| Market price, end of period year |
$9.92 |
$7.77 |
$9.23 |
$8.15 |
$7.61 |
| Total
Return(e) |
|
|
|
|
|
| Based on net asset value |
24.52 % |
(6.59 )% |
15.06 % |
13.90 % |
1.10 % |
| Based on market price |
38.53 % |
(10.39 )% |
20.63 % |
15.11 % |
0.63 % |
| Ratios to Average Net Assets |
|
|
|
|
|
| Total expenses |
0.87 % |
0.85 % |
0.86 % |
0.87 % |
0.86 % |
| Total expenses after fees waived and/or reimbursed |
0.87 % |
0.85 % |
0.86 % |
0.85 % |
0.85 % |
| Net investment income |
1.99 % |
1.85
%(b)
|
1.73 % |
1.91 % |
1.85 % |
| Supplemental Data |
|
|
|
|
|
| Net assets, end of year (000) |
$1,881,675 |
$1,638,237 |
$1,868,457 |
$1,741,649 |
$1,643,508 |
| Portfolio turnover rate |
40 % |
34 % |
42 % |
33 % |
26 % |
| (a) |
Based on average shares outstanding. |
| (b) |
Net investment income per share and the ratio of net investment income to average net assets includes $0.01 per share and 0.14%, respectively, resulting from a special
dividend. |
| (c) |
Distributions for annual periods determined in accordance with U.S. federal income tax regulations. |
| (d) |
Amount previously presented incorrectly as solely distributions from net investment income has been revised to reflect the proper classification of distributions between
net realized gain and net investment income. |
| (e) |
Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where
applicable, excludes the effects of any sales charges and assumes the reinvestment
of distributions at actual reinvestment prices. |
| |
BME | ||||
| |
Year Ended |
Year Ended |
Year Ended |
Year Ended |
Year Ended |
| |
12/31/19 |
12/31/18 |
12/31/17 |
12/31/16 |
12/31/15 |
| Net asset value, beginning of year |
$35.87 |
$35.69 |
$31.30 |
$36.19 |
$38.61 |
| Net investment income (loss)(a)
|
0.06 |
0.07 |
0.02 |
0.02 |
(0.06 ) |
| Net realized and unrealized gain (loss) |
7.66 |
2.51 |
6.77 |
(1.91 ) |
4.34 |
| Net increase (decrease) from investment operations |
7.72 |
2.58 |
6.79 |
(1.89 ) |
4.28 |
| Distributions(b)
|
|
|
|
|
|
| From net investment income |
(0.12 ) |
(0.07 )(c) |
(0.04 ) |
(0.03 ) |
(0.63 ) |
| From net realized gain |
(2.28 ) |
(2.33 )(c) |
(2.11 ) |
(2.97 ) |
(6.07 ) |
| Return of capital |
— |
— |
(0.25 ) |
— |
— |
| Total distributions |
(2.40 ) |
(2.40 ) |
(2.40 ) |
(3.00 ) |
(6.70 ) |
| Net asset value, end of year |
$41.19 |
$35.87 |
$35.69 |
$31.30 |
$36.19 |
| Market price, end of period year |
$42.50 |
$36.45 |
$36.50 |
$31.75 |
$39.35 |
| Total
Return(d) |
|
|
|
|
|
| Based on net asset value |
22.26 % |
7.26 % |
22.17 % |
(5.36 )% |
10.70 % |
| Based on market price |
24.15 % |
6.57 % |
23.17 % |
(11.71 )% |
8.87 % |
| Ratios to Average Net Assets(e) |
|
|
|
|
|
| Total expenses |
1.09 % |
1.11 % |
1.12 % |
1.15
%(f)
|
1.13 % |
| Total expenses after fees waived and/or reimbursed |
1.09 % |
1.11 % |
1.12 % |
1.14 % |
1.12 % |
| Net investment income (loss) |
0.16 % |
0.19 % |
0.06 % |
0.07 % |
(0.14 )% |
| Supplemental Data |
|
|
|
|
|
| Net assets, end of year (000) |
$446,773 |
$352,675 |
$331,858 |
$270,693 |
$297,530 |
| Portfolio turnover rate |
47 % |
37 % |
38 % |
59 % |
68 % |
| (a) |
Based on average shares outstanding. |
| (b) |
Distributions for annual periods determined in accordance with U.S. federal income tax regulations. |
| (c) |
Amount previously presented incorrectly as solely distributions from net investment income has been revised to reflect the proper classification of distributions between
net realized gain and net investment income. |
| (d) |
Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where
applicable, excludes the effects of any sales charges and assumes the
reinvestment of distributions at actual reinvestment prices. |
| (e) |
Excludes expenses incurred indirectly as a result of investments in underlying funds as follows: |
| |
|
Year Ended |
Year Ended |
Year Ended |
Year Ended |
Year Ended |
| |
|
12/31/19 |
12/31/18 |
12/31/17 |
12/31/16 |
12/31/15 |
| Investments in underlying funds |
|
0.01 % |
0.01 % |
0.01 % |
— % |
— % |
| (f) |
Offering costs were not annualized in the calculation of the expense ratios. If these expenses
were annualized, the total expenses would have been 1.16%. |
| |
BST | ||||
| |
Year Ended |
Year Ended |
Year Ended |
Year Ended |
Year Ended |
| |
12/31/19 |
12/31/18 |
12/31/17 |
12/31/16 |
12/31/15 |
| Net asset value, beginning of year |
$26.21 |
$27.73 |
$20.10 |
$19.70 |
$19.43 |
| Net investment income (loss)(a)
|
(0.17 ) |
(0.13 ) |
(0.05 ) |
0.00 (b) |
0.03 |
| Net realized and unrealized gain |
9.92 |
0.37 |
8.96 |
1.60 |
1.44 |
| Net increase from investment operations |
9.75 |
0.24 |
8.91 |
1.60 |
1.47 |
| Distributions(c)
|
|
|
|
|
|
| From net investment income |
— |
— (d) |
(0.05 ) |
— |
(0.03 ) |
| From net realized gain |
(3.51 ) |
(1.76 )(d) |
(0.22 ) |
— |
(0.01 ) |
| Return of capital |
— |
— |
(1.01 ) |
(1.20 ) |
(1.16 ) |
| Total distributions |
(3.51 ) |
(1.76 ) |
(1.28 ) |
(1.20 ) |
(1.20 ) |
| Net asset value, end of year |
$32.45 |
$26.21 |
$27.73 |
$20.10 |
$19.70 |
| Market price, end of period year |
$33.27 |
$27.48 |
$26.69 |
$17.94 |
$17.31 |
| Total
Return(e) |
|
|
|
|
|
| Based on net asset value |
37.82 % |
0.24 % |
45.73 % |
9.36 % |
8.61 % |
| Based on market price |
34.77 % |
9.18 % |
57.15 % |
11.08 % |
5.36 % |
| Ratios to Average Net Assets |
|
|
|
|
|
| Total expenses |
1.08 % |
1.09 % |
1.09 % |
1.10 % |
1.12 % |
| Total expenses after fees waived and/or reimbursed |
0.92 % |
0.89 % |
0.89 % |
0.90 % |
0.92 % |
| Net investment income (loss) |
(0.52 )% |
(0.43 )% |
(0.19 )% |
0.02 % |
0.15 % |
| Supplemental Data |
|
|
|
|
|
| Net assets, end of year (000) |
$742,672 |
$587,908 |
$620,300 |
$452,443 |
$443,477 |
| Portfolio turnover rate |
32 % |
53 % |
41 % |
74 % |
91 % |
| (a) |
Based on average shares outstanding. |
| (b) |
Amount is less than $0.005 per share. |
| (c) |
Distributions for annual periods determined in accordance with U.S. federal income tax regulations. |
| (d) |
Amount previously presented incorrectly as solely distributions from net investment income has been revised to reflect the proper classification of distributions between
net realized gain and net investment income. |
| (e) |
Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where
applicable, excludes the effects of any sales charges and assumes the
reinvestment of distributions at actual reinvestment prices. |
| |
BUI | ||||
| |
Year Ended |
Year Ended |
Year Ended |
Year Ended |
Year Ended |
| |
12/31/19 |
12/31/18 |
12/31/17 |
12/31/16 |
12/31/15 |
| Net asset value, beginning of year |
$18.77 |
$21.12 |
$19.42 |
$19.50 |
$22.47 |
| Net investment income(a) |
0.37 |
0.49 |
0.56 |
0.56 |
0.47 |
| Net realized and unrealized gain (loss) |
4.33 |
(1.39 ) |
2.59 |
0.81 |
(1.99 ) |
| Net increase (decrease) from investment operations |
4.70 |
(0.90 ) |
3.15 |
1.37 |
(1.52 ) |
| Distributions(b)
|
|
|
|
|
|
| From net investment income |
(0.24 ) |
(0.63 )(c) |
(0.47 ) |
(0.49 ) |
(0.42 ) |
| From net realized gain |
(1.06 ) |
(0.81 )(c) |
(0.98 ) |
(0.53 ) |
(0.54 ) |
| Return of capital |
(0.15 ) |
(0.01 ) |
— |
(0.43 ) |
(0.49 ) |
| Total distributions |
(1.45 ) |
(1.45 ) |
(1.45 ) |
(1.45 ) |
(1.45 ) |
| Net asset value, end of year |
$22.02 |
$18.77 |
$21.12 |
$19.42 |
$19.50 |
| Market price, end of period year |
$22.31 |
$19.76 |
$21.62 |
$18.41 |
$16.78 |
| Total
Return(d) |
|
|
|
|
|
| Based on net asset value |
25.63 % |
(4.40 )% |
16.62 % |
7.57 % |
(6.09 )% |
| Based on market price |
20.91 % |
(1.68 )% |
25.93 % |
18.50 % |
(12.45 )% |
| Ratios to Average Net Assets |
|
|
|
|
|
| Total expenses |
1.12 % |
1.12 % |
1.11 % |
1.13 % |
1.11 % |
| Total expenses after fees waived and/or reimbursed |
1.10 % |
1.09 % |
1.09 % |
1.13 % |
1.11 % |
| Net investment income |
1.78 % |
2.46 % |
2.70 % |
2.83 % |
2.24 % |
| Supplemental Data |
|
|
|
|
|
| Net assets, end of year (000) |
$383,337 |
$318,933 |
$357,776 |
$328,297 |
$329,747 |
| Portfolio turnover rate |
39 % |
28 % |
31 % |
8 % |
20 % |
| (a) |
Based on average shares outstanding. |
| (b) |
Distributions for annual periods determined in accordance with U.S. federal income tax regulations. |
| (c) |
Amount previously presented incorrectly as solely distributions from net investment income has been revised to reflect the proper classification of distributions between
net realized gain and net investment income. |
| (d) |
Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where
applicable, excludes the effects of any sales charges and assumes the
reinvestment of distributions at actual reinvestment prices. |
| Independent Trustees(a) | ||||
| Name Year of Birth(b)
|
Position(s) Held
(Length of Service)(c) |
Principal Occupation(s) During Past 5 Years |
Number of BlackRock-Advised
Registered Investment Companies
(“RICs”) Consisting of Investment
Portfolios (“Portfolios”) Overseen |
Public Company and Other Investment Company Directorships Held During Past 5 Years |
| R. Glenn Hubbard 1958 |
Chair of the Board (Since
2022)
Trustee
(Since 2007) |
Dean, Columbia Business School from 2004 to 2019;
Faculty member, Columbia Business School since 1988. |
67 RICs consisting of 102 Portfolios |
ADP (data and information services) from 2004 to 2020; Metropolitan Life Insurance Company (insurance); TotalEnergies SE (multi-energy) |
| W. Carl
Kester(d)
1951 |
Vice Chair of the Board
(Since 2022)
Trustee
(Since 2007) |
Baker Foundation Professor and George Fisher Baker Jr.
Professor of Business Administration, Emeritus, Harvard
Business School since 2022; George Fisher Baker Jr.
Professor of Business Administration, Harvard Business
School from 2008 to 2022; Deputy Dean for Academic
Affairs from 2006 to 2010; Chairman of the Finance Unit,
from 2005 to 2006; Senior Associate Dean and Chairman
of the MBA Program from 1999 to 2005; Member of the
faculty of Harvard Business School since 1981. |
69 RICs consisting of 104 Portfolios |
None |
| Cynthia L.
Egan(d)
1955 |
Trustee
(Since 2016) |
Advisor, U.S. Department of the Treasury from 2014 to
2015; President, Retirement Plan Services, for T. Rowe
Price Group, Inc. from 2007 to 2012; executive positions
within Fidelity Investments from 1989 to 2007. |
69 RICs consisting of 104 Portfolios |
Unum (insurance); The Hanover Insurance Group (Board Chair); Huntsman Corporation (Lead Independent Director and non-Executive Vice Chair of the Board) (chemical products) |
| Lorenzo A. Flores 1964 |
Trustee
(Since 2021) |
Chief Financial Officer, Intel Foundry since 2024; Vice
Chairman, Kioxia, Inc. from 2019 to 2024; Chief Financial
Officer, Xilinx, Inc. from 2016 to 2019; Corporate
Controller, Xilinx, Inc. from 2008 to 2016. |
67 RICs consisting of 102 Portfolios |
None |
| Stayce D. Harris 1959 |
Trustee
(Since 2021) |
Lieutenant General, Inspector General of the United States
Air Force from 2017 to 2019; Lieutenant General, Assistant
Vice Chief of Staff and Director, Air Staff, United States Air
Force from 2016 to 2017; Major General, Commander,
22nd Air Force, AFRC, Dobbins Air Reserve Base, Georgia
from 2014 to 2016; Pilot, United Airlines from 1990 to
2020. |
67 RICs consisting of 102 Portfolios |
KULR Technology Group, Inc. in 2021; The Boeing Company (airplane manufacturer) |
| J. Phillip Holloman 1955 |
Trustee
(Since 2021) |
President and Chief Operating Officer, Cintas Corporation
from 2008 to 2018. |
67 RICs consisting of 102 Portfolios |
PulteGroup, Inc. (home construction); Vestis Corporation (uniforms and facilities services) |
| Catherine A. Lynch(d)
1961 |
Trustee
(Since 2016) |
Chief Executive Officer, Chief Investment Officer and
various other positions, National Railroad Retirement
Investment Trust from 2003 to 2016; Associate Vice
President for Treasury Management, The George
Washington University from 1999 to 2003; Assistant
Treasurer, Episcopal Church of America from 1995 to
1999. |
69 RICs consisting of 104 Portfolios |
PennyMac Mortgage Investment Trust |
| Independent Trustees(a) (continued) | ||||
| Name
Year of Birth(b) |
Position(s) Held
(Length of Service)(c) |
Principal Occupation(s) During Past 5 Years |
Number of BlackRock-Advised
Registered Investment Companies
(“RICs”) Consisting of Investment
Portfolios (“Portfolios”) Overseen |
Public Company and Other Investment Company
Directorships Held
During Past 5 Years |
| Arthur P. Steinmetz(d)
1958 |
Trustee
(Since 2023) |
Trustee of Denison University since 2020; Consultant,
Posit PBC (enterprise data science) since 2020; Director,
ScotiaBank (U.S.) from 2020 to 2023; Chairman, Chief
Executive Officer and President of OppenheimerFunds,
Inc. from 2015, 2014 and 2013, respectively to 2019;
Trustee, President and Principal Executive Officer of
104 OppenheimerFunds funds from 2014 to 2019;
Portfolio manager of various OppenheimerFunds fixed
income mutual funds from 1986 to 2014. |
69 RICs consisting of 104 Portfolios |
Trustee of 104 OppenheimerFunds funds from 2014 to 2019 |
| Interested Trustees(a)(e) | ||||
| Name Year of Birth(b)
|
Position(s) Held
(Length of Service)(c) |
Principal Occupation(s) During Past 5 Years |
Number of BlackRock-Advised
Registered Investment Companies
(“RICs”) Consisting of Investment
Portfolios (“Portfolios”) Overseen |
Public Company and Other Investment Company Directorships Held During Past 5 Years |
| Robert Fairbairn 1965 |
Trustee
(Since 2018) |
Vice Chairman of BlackRock, Inc. since 2019; Member of
BlackRock’s Global Executive and Global Operating
Committees; Co-Chair of BlackRock’s Human Capital
Committee; Senior Managing Director of BlackRock, Inc.
from 2010 to 2019; oversaw BlackRock’s Strategic Partner
Program and Strategic Product Management Group from
2012 to 2019; Member of the Board of Managers of
BlackRock Investments, LLC from 2011 to 2018; Global
Head of BlackRock’s Retail and iShares® businesses from
2012 to 2016. |
95 RICs consisting of 268 Portfolios |
None |
| John M. Perlowski(d)
1964 |
Trustee
(Since 2015)
President and Chief
Executive Officer
(Since 2010) |
Managing Director of BlackRock, Inc. since 2009; Head of
BlackRock Global Accounting and Product Services since
2009; Advisory Director of Family Resource Network
(charitable foundation) since 2009. |
97 RICs consisting of 270 Portfolios |
None |
| (a) |
The address of each Trustee is c/o BlackRock, Inc., 50 Hudson Yards, New York, New York 10001. |
| (b) |
Each Independent Trustee holds office until his or her successor is duly elected and qualifies or until his or her earlier death, resignation, retirement or removal as
provided by the Trust’s by-laws or charter or statute, or until
December 31 of the year in which he or she turns 75. Trustees who are “interested persons,” as defined in the Investment Company Act serve until their successor
is duly elected and qualifies or until their earlier death, resignation, retirement or
removal as provided by the Trust’s by-laws or statute, or until December 31 of the year in which they turn 72. The Board may determine to extend the terms of Independent Trustees on a case-by-case basis, as appropriate. |
| (c) |
Following the combination of Merrill Lynch Investment Managers, L.P. (“MLIM”) and BlackRock, Inc. in September 2006, the various legacy MLIM and legacy
BlackRock fund boards were realigned and consolidated into three new fund
boards in 2007. Certain Independent Trustees first became members of the boards of other legacy MLIM or legacy BlackRock funds as follows: R. Glenn Hubbard, 2004 and W. Carl Kester, 1995. |
| (d) |
Ms. Egan, Dr. Kester, Ms. Lynch, Mr. Steinmetz and Mr. Perlowski are also trustees of the BlackRock Credit Strategies Fund and BlackRock Private Investments
Fund. |
| (e) |
Mr. Fairbairn and Mr. Perlowski are both “interested persons,” as defined in the 1940 Act, of the Trust based on their positions with BlackRock, Inc. and its
affiliates. Mr. Fairbairn and Mr. Perlowski are also board members of the BlackRock
Multi-Asset Complex. |
| Officers Who Are Not Trustees(a) | ||
| Name Year of Birth(b)
|
Position(s) Held
(Length of Service) |
Principal Occupation(s) During Past 5 Years |
| Jonathan Diorio 1980 |
Vice President
(Since 2015) |
Member of BlackRock’s Global Operating Committee since 2023; Managing Director of BlackRock, Inc. since 2015. |
| Trent Walker 1974 |
Chief Financial Officer
(Since 2021) |
Managing Director of BlackRock, Inc. since 2019; Executive Vice President of PIMCO from 2016 to 2019. |
| Jay M. Fife 1970 |
Treasurer
(Since 2007) |
Managing Director of BlackRock, Inc. since 2007. |
| Aaron Wasserman 1974 |
Chief Compliance Officer
(Since 2023) |
Managing Director of BlackRock, Inc. since 2018; Chief Compliance Officer of the BlackRock-advised funds in the
BlackRock Multi-Asset Complex, the BlackRock Fixed-Income Complex and the iShares Complex since
2023; Deputy Chief Compliance Officer for the BlackRock-advised funds in the
BlackRock Multi-Asset Complex, the BlackRock Fixed- Income Complex and the iShares
Complex from 2014 to 2023. |
| Janey Ahn 1975 |
Secretary
(Since 2012) |
Managing Director of BlackRock, Inc. since 2018. |
| (a) |
The address of each Officer is c/o BlackRock, Inc., 50 Hudson Yards, New York, New York 10001. |
| (b) |
Officers of the Trust serve at the pleasure of the Board. |
| Effective April 11, 2024, Rosie Edwards is no longer a portfolio manager of BGY. |
| Effective March 14, 2024, Joseph Wolfe is no longer a portfolio manager of CII. Effective March 14, 2024, Ibrahim Kanan became a portfolio manager of CII. Mr. Kanan has
been employed by BlackRock since 2014. Effective November 7, 2024,
Todd Burnside is no longer a portfolio manager of CII. Effective November 7, 2024, Sam Console and Sally Du became portfolio managers of CII. Mr. Console and Ms. Du have been employed by BlackRock since 2014 and 2007, respectively. |
| Effective February 20, 2025, Christopher Accettella, Kyle McClements, and Phil Ruvinsky are no longer portfolio managers of BIGZ. Effective February 20, 2025, Reid Menge
and Tony Kim became portfolio managers of BIGZ. Mr. Menge and Mr.
Kim have been employed by BlackRock since 2014 and 2013, respectively. |
| |
J. Phillip Holloman |
Arthur P. Steinmetz |
Catherine A. Lynch | |||
| Trust Name |
Votes For |
Votes Withheld |
Votes For |
Votes Withheld |
Votes For |
Votes Withheld |
| BDJ |
143,488,755 |
6,376,865 |
144,450,054 |
5,415,566 |
143,597,909 |
6,267,711 |
| BGR |
20,216,743 |
2,400,282 |
20,238,967 |
2,378,058 |
20,219,466 |
2,397,559 |
| BOE |
50,282,224 |
3,716,839 |
51,175,698 |
2,823,365 |
50,329,810 |
3,669,253 |
| BME |
10,554,546 |
336,544 |
10,597,301 |
293,789 |
10,544,663 |
346,427 |
| BGY |
83,031,565 |
5,599,409 |
83,096,420 |
5,534,554 |
83,126,553 |
5,504,421 |
| BCX |
63,445,771 |
5,524,627 |
63,856,742 |
5,113,656 |
63,504,741 |
5,465,657 |
| BUI |
15,989,739 |
618,921 |
16,016,922 |
591,738 |
16,017,830 |
590,830 |
| BST |
25,894,043 |
707,028 |
25,918,124 |
682,947 |
25,986,036 |
615,035 |
| |
R. Glenn Hubbard |
W. Carl Kester |
John M. Perlowski | |||
| Trust Name |
Votes For |
Votes Withheld |
Votes For |
Votes Withheld |
Votes For |
Votes Withheld |
| CII |
34,708,775 |
1,436,951 |
34,769,341 |
1,376,385 |
34,810,704 |
1,335,022 |
| Currency Abbreviation | |
| AUD |
Australian Dollar |
| CAD |
Canadian Dollar |
| CHF |
Swiss Franc |
| DKK |
Danish Krone |
| EUR |
Euro |
| GBP |
British Pound |
| HKD |
Hong Kong Dollar |
| JPY |
Japanese Yen |
| KRW |
South Korean Won |
| NOK |
Norwegian Krone |
| SEK |
Swedish Krona |
| SGD |
Singapore Dollar |
| TWD |
New Taiwan Dollar |
| USD |
United States Dollar |
| Portfolio Abbreviation | |
| ADR |
American Depositary Receipt |
| CVR |
Contingent Value Right |
| GDR |
Global Depositary Receipt |
| JSC |
Joint Stock Company |
| LP |
Limited Partnership |
| PIPE |
Private Investment in Public Equity
|
| PJSC |
Public Joint Stock Company |
| REIT |
Real Estate Investment Trust |
| S&P |
Standard & Poor’s |
| SAP |
Subject to Appropriations |
(b) Not Applicable
| Item 3 – | Audit Committee Financial Expert – The registrant’s board of trustees (the “board of trustees”) has determined that (i) the registrant has the following audit committee financial experts serving on its audit committee and (ii) each audit committee financial expert is independent: |
Lorenzo A. Flores
Catherine A. Lynch
Arthur P. Steinmetz
Under applicable securities laws, a person determined to be an audit committee financial expert will not be deemed an “expert” for any purpose, including without limitation for the purposes of Section 11 of the Securities Act of 1933, as a result of being designated or identified as an audit committee financial expert. The designation or identification of a person as an audit committee financial expert does not impose on such person any duties, obligations, or liabilities greater than the duties, obligations, and liabilities imposed on such person as a member of the audit committee and board of trustees in the absence of such designation or identification. The designation or identification of a person as an audit committee financial expert does not affect the duties, obligations, or liability of any other member of the audit committee or board of trustees.
| Item 4 – | Principal Accountant Fees and Services – |
The following table presents fees billed by Deloitte & Touche LLP (“D&T”) in each of the last two fiscal years for the services rendered to the Fund:
| (a) Audit Fees |
(b) Audit-Related Fees1 |
(c) Tax Fees2 | (d) All Other Fees | |||||||||||||
| Entity Name |
Current Year End |
Previous Fiscal Year End |
Current Fiscal Year End |
Previous Year End |
Current Year End |
Previous Year End |
Current Year End |
Previous Year End | ||||||||
| BlackRock Energy and Resources Trust | $37,944 | $37,944 | $0 | $0 | $16,800 | $17,648 | $0 | $407 | ||||||||
The following table presents fees billed by D&T that were required to be approved by the registrant’s audit committee (the “Committee”) for services that relate directly to the operations or financial reporting of the Fund and that are rendered on behalf of BlackRock Advisors, LLC (the “Investment Adviser” or “BlackRock”) and entities controlling, controlled by, or under common control with BlackRock (not including any sub-adviser whose role is primarily
1
portfolio management and is subcontracted with or overseen by another investment adviser) that provide ongoing services to the Fund (“Affiliated Service Providers”):
| Current Fiscal Year End | Previous Fiscal Year End | |||
| (b) Audit-Related Fees1 |
$0 | $0 | ||
| (c) Tax Fees2 |
$0 | $0 | ||
| (d) All Other Fees3 |
$2,149,000 | $2,154,000 |
1 The nature of the services includes assurance and related services reasonably related to the performance of the audit or review of financial statements not included in Audit Fees, including accounting consultations, agreed-upon procedure reports, attestation reports, comfort letters, out-of-pocket expenses and internal control reviews not required by regulators.
2 The nature of the services includes tax compliance and/or tax preparation, including services relating to the filing or amendment of federal, state or local income tax returns, regulated investment company qualification reviews, taxable income and tax distribution calculations.
3 Non-audit fees of $2,149,000 and $2,154,000 for the current fiscal year and previous fiscal year, respectively, were paid to the Fund’s principal accountant in their entirety by BlackRock, in connection with services provided to the Affiliated Service Providers of the Fund and of certain other funds sponsored and advised by BlackRock or its affiliates for a service organization review and an accounting research tool subscription. These amounts represent aggregate fees paid by BlackRock and were not allocated on a per fund basis.
(e)(1) Audit Committee Pre-Approval Policies and Procedures:
The Committee has adopted policies and procedures with regard to the pre-approval of services. Audit, audit-related and tax compliance services provided to the registrant on an annual basis require specific pre-approval by the Committee. The Committee also must approve other non-audit services provided to the registrant and those non-audit services provided to the Investment Adviser and Affiliated Service Providers that relate directly to the operations and the financial reporting of the registrant. Certain of these non-audit services that the Committee believes are (a) consistent with the SEC’s auditor independence rules and (b) routine and recurring services that will not impair the independence of the independent accountants may be approved by the Committee without consideration on a specific case-by-case basis (“general pre-approval”). The term of any general pre-approval is 12 months from the date of the pre-approval, unless the Committee provides for a different period. Tax or other non-audit services provided to the registrant which have a direct impact on the operations or financial reporting of the registrant will only be deemed pre-approved provided that any individual project does not exceed $10,000 attributable to the registrant or $50,000 per project. For this purpose, multiple projects will be aggregated to determine if they exceed the previously mentioned cost levels.
Any proposed services exceeding the pre-approved cost levels will require specific pre-approval by the Committee, as will any other services not subject to general pre-approval (e.g., unanticipated but permissible services). The Committee is informed of each service approved subject to general pre-approval at the next regularly scheduled in-person board meeting. At this meeting, an analysis of such services is presented to the Committee for ratification. The Committee may delegate to the Committee Chairman the authority to approve the provision of and fees for any specific engagement of permitted non-audit services, including services exceeding pre-approved cost levels.
(e)(2) None of the services described in each of Items 4(b) through (d) were approved by the Committee pursuant to the de minimis exception in paragraph (c)(7)(i)(C) of Rule 2-01 of Regulation S-X.
2
(f) Not Applicable
(g) The aggregate non-audit fees, defined as the sum of the fees shown under “Audit-Related Fees,” “Tax Fees” and “All Other Fees,” paid to the accountant for services rendered by the accountant to the registrant, the Investment Adviser and the Affiliated Service Providers were:
| Entity Name |
Current Fiscal Year End |
Previous Fiscal Year End | ||
| BlackRock Energy and Resources Trust | $16,800 | $18,055 |
Additionally, the amounts billed by D&T in connection with services provided to the Affiliated Service Providers of the Fund and of other funds sponsored or advised by BlackRock or its affiliates during the current and previous fiscal years for a service organization review and an accounting research tool subscription were:
|
Current Fiscal Year End |
Previous Fiscal Year End | |
|
$2,149,000 |
$2,154,000 |
These amounts represent aggregate fees paid by BlackRock and were not allocated on a per fund basis.
(h) The Committee has considered and determined that the provision of non-audit services that were rendered to the Investment Adviser and the Affiliated Service Providers that were not pre-approved pursuant to paragraph (c)(7)(ii) of Rule 2-01 of Regulation S-X is compatible with maintaining the principal accountant’s independence.
(i) Not Applicable
(j) Not Applicable
| Item 5 – | Audit Committee of Listed Registrant |
(a) The following individuals are members of the registrant’s separately designated standing audit committee established in accordance with Section 3(a)(58)(A) of the Securities Exchange Act of 1934 (15 U.S.C. 78c(a)(58)(A)):
Lorenzo A. Flores
J. Phillip Holloman
Catherine A. Lynch
Arthur P. Steinmetz
(b) Not Applicable
| Item 6 – | Investments |
(a) The registrant’s Schedule of Investments is included as part of the Report to Stockholders filed under Item 1(a) of this Form.
(b) Not Applicable due to no such divestments during the semi-annual period covered since the previous Form N-CSR filing.
3
| Item 7 – | Financial Statements and Financial Highlights for Open-End Management Investment Companies – Not Applicable |
| Item 8 – | Changes in and Disagreements with Accountants for Open-End Management Investment Companies – Not Applicable |
| Item 9 – | Proxy Disclosures for Open-End Management Investment Companies – Not Applicable |
| Item 10 – | Remuneration Paid to Directors, Officers, and Others of Open-End Management Investment Companies – Not Applicable |
| Item 11 – | Statement Regarding Basis for Approval of Investment Advisory Contract – Not Applicable |
| Item 12 – | Disclosure of Proxy Voting Policies and Procedures for Closed-End Management Investment Companies – The board of trustees has delegated the voting of proxies for the Fund’s portfolio securities to the Investment Adviser pursuant to the Closed-End Fund Proxy Voting Policy. The Investment Adviser has adopted the BlackRock Active Investment Stewardship - Global Engagement and Voting Guidelines (the “BAIS Guidelines”) with respect to certain funds, including the Fund. Copies of the Closed-End Fund Proxy Voting Policy and the BAIS Guidelines are attached as Exhibit 99.PROXYPOL. Information on how the Fund voted proxies relating to portfolio securities during the most recent 12-month period ended June 30 is available (i) without charge, upon request, by calling (800) 882-0052, (ii) at www.blackrock.com and (iii) on the SEC’s website at http://www.sec.gov. |
| Item 13 – | Portfolio Managers of Closed-End Management Investment Companies |
(a)(1) As of the date of filing this Report:
The registrant is managed by a team of investment professionals comprised of Kyle G. McClements, CFA, Managing Director at BlackRock, Christopher Accettella, Director at BlackRock, Alastair Bishop, Managing Director at BlackRock and Mark Hume, Managing Director at BlackRock. Messrs. McClements, Accettella, Bishop and Hume are the Fund’s portfolio managers and are jointly responsible for the day-to-day management of the Fund’s portfolio and the selection of its investments. Messrs. McClements and Accettella have been members of the Fund’s portfolio management team since 2012. Messrs. Bishop and Hume have been members of the Fund’s portfolio management team since 2015 and 2018, respectively.
| Portfolio Manager | Biography | |
| Kyle G. McClements, CFA |
Managing Director of BlackRock since 2009; Director of BlackRock from 2006 to 2008; Vice President of BlackRock in 2005; Vice President of State Street Research & Management from 2004 to 2005. | |
| Christopher Accettella |
Director of BlackRock since 2008; Vice President of BlackRock, Inc. from 2005 to 2008. | |
| Alastair Bishop |
Managing Director of BlackRock since 2019; Director of BlackRock from 2010 to 2018. | |
| Mark Hume |
Managing Director of BlackRock since2023; Director of BlackRock from 2017 to 2022; Portfolio Manager at Colonial First State Global Asset Management from 2010 to 2017; Senior Director of Bank of America Merrill Lynch from 2008 to 2010. |
4
(a)(2) As of December 31, 2024:
|
(ii) Number of Other Accounts Managed and Assets by Account Type |
(iii) Number of Other Accounts and Assets for Which Advisory Fee is Performance-Based | |||||||||||
| (i) Name of Portfolio Manager | Other Registered Investment Companies |
Other Pooled Vehicles |
Other Accounts |
Other Registered Investment Companies |
Other Pooled Vehicles |
Other Accounts | ||||||
| Kyle G. McClements, CFA |
16 | 18 | 0 | 0 | 0 | 0 | ||||||
| $15.35 Billion | $3.50 Billion | $0 | $0 | $0 | $0 | |||||||
| Christopher Accettella |
16 | 15 | 0 | 0 | 0 | 0 | ||||||
| $15.5 Billion | $2.09 Billion | $0 | $0 | $0 | $0 | |||||||
| Alastair Bishop |
6 | 14 | 2 | 0 | 1 | 0 | ||||||
| $3.05 Billion | $7.52 Billion | $160.0 Million | $0 | $0.03 Million | $0 | |||||||
| Mark Hume |
1 | 3 | 0 | 0 | 0 | 0 | ||||||
| $300.0 Million | $2.26 Billion | $0 | $0 | $0 | $0 | |||||||
(iv) Portfolio Manager Potential Material Conflicts of Interest
BlackRock has built a professional working environment, firm-wide compliance culture and compliance procedures and systems designed to protect against potential incentives that may favor one account over another. BlackRock has adopted policies and procedures that address the allocation of investment opportunities, execution of portfolio transactions, personal trading by employees and other potential conflicts of interest that are designed to ensure that all client accounts are treated equitably over time. Nevertheless, BlackRock furnishes investment management and advisory services to numerous clients in addition to the Fund, and BlackRock may, consistent with applicable law, make investment recommendations to other clients or accounts (including accounts which are hedge funds or have performance or higher fees paid to BlackRock, or in which portfolio managers have a personal interest in the receipt of such fees), which may be the same as or different from those made to the Fund. In addition, BlackRock, Inc., its affiliates and significant shareholders and any officer, director, shareholder or employee may or may not have an interest in the securities whose purchase and sale BlackRock recommends to the Fund. BlackRock, Inc. or any of its affiliates or significant shareholders, or any officer, director, shareholder, employee or any member of their families may take different actions than those recommended to the Fund by BlackRock with respect to the same securities. Moreover, BlackRock may refrain from rendering any advice or services concerning securities of companies of which any of BlackRock, Inc.’s (or its affiliates’ or significant shareholders’) officers, directors or employees are directors or officers, or companies as to which BlackRock, Inc. or any of its affiliates or significant shareholders or the officers, directors and employees of any of them has any substantial economic interest or possesses material non-public information. Certain portfolio managers also may manage accounts whose investment strategies may at times be opposed to the strategy utilized for a fund. It should also be noted that Messrs. Bishop and Hume may be managing hedge fund and/or long only accounts, or may be part of a team managing hedge fund and/or long only accounts, subject to incentive fees. Messrs. Bishop and Hume may therefore be entitled to receive a portion of any incentive fees earned on such accounts.
As a fiduciary, BlackRock owes a duty of loyalty to its clients and must treat each client fairly. When BlackRock purchases or sells securities for more than one account, the trades must be allocated in a manner consistent with its fiduciary duties. BlackRock attempts to allocate investments in a fair and equitable manner among client accounts, with no account receiving preferential treatment. To this end, BlackRock, Inc. has adopted policies that are intended to
5
ensure reasonable efficiency in client transactions and provide BlackRock with sufficient flexibility to allocate investments in a manner that is consistent with the particular investment discipline and client base, as appropriate.
(a)(3) As of December 31, 2024:
Portfolio Manager Compensation Overview
The discussion below describes the portfolio managers’ compensation as of December 31, 2024.
BlackRock’s financial arrangements with its portfolio managers, its competitive compensation and its career path emphasis at all levels reflect the value senior management places on key resources. Compensation may include a variety of components and may vary from year to year based on a number of factors. The principal components of compensation include a base salary, a performance-based discretionary bonus, participation in various benefits programs and one or more of the incentive compensation programs established by BlackRock.
Base Compensation. Generally, portfolio managers receive base compensation based on their position with the firm.
Discretionary Incentive Compensation – Messrs. Bishop and Hume. Generally, discretionary incentive compensation for Fundamental Equities portfolio managers is based on a formulaic compensation program. BlackRock’s formulaic portfolio manager compensation program is based on team revenue and pre-tax investment performance relative to appropriate competitors or benchmarks over 1-, 3- and 5-year performance periods, as applicable. In most cases, these benchmarks are the same as the benchmark or benchmarks against which the performance of the funds or other accounts managed by the portfolio managers are measured. BlackRock’s Chief Investment Officers determine the benchmarks or rankings against which the performance of funds and other accounts managed by each portfolio management team is compared and the period of time over which performance is evaluated. With respect to these portfolio managers, such benchmarks for the Fund and other accounts are: Bloomberg Commodity Index Total Return; FTSE Gold Mines Index (Gross Total Return); FTSE Gold Mining Index - expressed in JPY; FTSE Gold Mining Index - GBP Price; LIBOR 3 Month Index; MSCI 10/40 DW Energy (Net); MSCI ACWI Metals & Mining 30% Buffer 10/40 (1994) GBP Net TR; MSCI ACWI Metals & Mining 30% Buffer 10/40 (1994) USD Net TR; MSCI World Energy Net Daily TR Index; NYSE Arca Gold Miners Index EUR Net Total Return; S&P Global Natural Resources Index; S&P Global Natural Resources Index - In GBP; S&P Global Natural Resources Net Return.
A smaller element of portfolio manager discretionary compensation may include consideration of: financial results, expense control, profit margins, strategic planning and implementation, quality of client service, market share, corporate reputation, capital allocation, compliance and risk control, leadership, technology and innovation. These factors are considered collectively by BlackRock management and the relevant Chief Investment Officers.
Discretionary Incentive Compensation - Messrs. Accettella and McClements. Discretionary incentive compensation is a function of several components: the performance of BlackRock, Inc., the performance of the portfolio manager’s group within BlackRock, the investment performance, including risk-adjusted returns, of the firm’s assets or strategies under management or supervision by that portfolio manager, and/or the individual’s performance and
6
contribution to the overall performance of these portfolios and BlackRock. Among other things, BlackRock’s Chief Investment Officers make a subjective determination with respect to each portfolio manager’s compensation based on the performance of the funds, other accounts or strategies managed by each portfolio manager. Performance is generally measured on a pre-tax basis over various time periods including 1-, 3- and 5- year periods, as applicable. The performance of some funds, other accounts or strategies may not be measured against a specific benchmark. The performance of Messrs. Accettella and McClements is not measured against a specific benchmark.
Distribution of Discretionary Incentive Compensation. Discretionary incentive compensation is distributed to portfolio managers in a combination of cash, deferred BlackRock, Inc. stock awards, and/or deferred cash awards that notionally track the return of certain BlackRock investment products.
Portfolio managers receive their annual discretionary incentive compensation in the form of cash. Portfolio managers whose total compensation is above a specified threshold also receive deferred BlackRock, Inc. stock awards annually as part of their discretionary incentive compensation. Paying a portion of discretionary incentive compensation in the form of deferred BlackRock, Inc. stock puts compensation earned by a portfolio manager for a given year “at risk” based on BlackRock’s ability to sustain and improve its performance over future periods. In some cases, additional deferred BlackRock, Inc. stock may be granted to certain key employees as part of a long-term incentive award to aid in retention, align interests with long-term shareholders and motivate performance. Deferred BlackRock, Inc. stock awards are generally granted in the form of BlackRock, Inc. restricted stock units that vest pursuant to the terms of the applicable plan and, once vested, settle in BlackRock, Inc. common stock. The portfolio managers of this Fund have deferred BlackRock, Inc. stock awards.
For certain portfolio managers, a portion of the discretionary incentive compensation is also distributed in the form of deferred cash awards that notionally track the returns of select BlackRock investment products they manage, which provides direct alignment of portfolio manager discretionary incentive compensation with investment product results. Deferred cash awards vest ratably over a number of years and, once vested, settle in the form of cash. Only portfolio managers who manage specified products and whose total compensation is above a specified threshold are eligible to participate in the deferred cash award program.
Other Compensation Benefits. In addition to base salary and discretionary incentive compensation, portfolio managers may be eligible to receive or participate in one or more of the following:
Incentive Savings Plans — BlackRock, Inc. has created a variety of incentive savings plans in which BlackRock, Inc. employees are eligible to participate, including a 401(k) plan, the BlackRock Retirement Savings Plan (RSP), and the BlackRock Employee Stock Purchase Plan (ESPP). The employer contribution components of the RSP include a company match equal to 50% of the first 8% of eligible pay contributed to the plan capped at $5,000 per year, and a company retirement contribution equal to 3-5% of eligible compensation up to the Internal Revenue Service limit ($345,000 for 2024). The RSP offers a range of investment options, including registered investment companies and collective investment funds managed by the firm. BlackRock, Inc. contributions follow the investment direction set by participants for their own contributions or, absent participant investment direction, are invested into a target date fund that corresponds to, or is closest to, the year in which the participant attains age 65. The ESPP allows for investment in BlackRock, Inc. common stock at a 5% discount on the fair
7
market value of the stock on the purchase date. Annual participation in the ESPP is limited to the purchase of 1,000 shares of common stock or a dollar value of $25,000 based on its fair market value on the purchase date. Messrs. Accettella and McClements are eligible to participate in these plans.
United Kingdom-based portfolio managers are also eligible to participate in broad-based plans offered generally to BlackRock employees, including broad-based retirement, health and other employee benefit plans. For example, BlackRock has created a variety of incentive savings plans in which BlackRock employees are eligible to participate, including the BlackRock Retirement Savings Plan (RSP) and the BlackRock Employee Stock Purchase Plan (ESPP). The employer contribution to the RSP is between 10% and 15% of eligible pay capped at £160,000 per annum. The RSP offers a range of investment options, including several collective investment funds managed by the firm. BlackRock contributions follow the investment direction set by participants for their own contributions or, in the absence of an investment election being made, are invested into a target date fund that corresponds to, or is closest to, the year in which the participant attains age 65. The ESPP allows for investment in BlackRock common stock at a 5% discount on the fair market value of the stock on the purchase date. Annual participation in the ESPP is limited to the purchase of 1,000 shares of common stock or a US dollar value of $25,000 based on its fair market value on the purchase date. Messrs. Bishop and Hume are eligible to participate in these plans.
(a)(4) Beneficial Ownership of Securities – As of December 31, 2024.
| Portfolio Manager |
Dollar Range of Equity Securities of the Fund Beneficially Owned |
| ||
| Kyle G. McClements, CFA |
$50,001 - $100,000 | |||
| Christopher Accettella |
$10,001 - $50,000 | |||
| Alastair Bishop |
$100,001 - $500,000 | |||
| Mark Hume |
$10,001 - $50,000 |
(b) Not Applicable
| Item 14 – | Purchases of Equity Securities by Closed-End Management Investment Company and Affiliated Purchasers – Not Applicable due to no such purchases during the period covered by this report. |
| Item 15 – | Submission of Matters to a Vote of Security Holders – There have been no material changes to these procedures. |
| Item 16 – | Controls and Procedures |
(a) The registrant’s principal executive and principal financial officers, or persons performing similar functions, have concluded that the registrant’s disclosure controls and procedures (as defined in Rule 30a-3(c) under the Investment Company Act of 1940, as amended (the “1940 Act”)) are effective as of a date within 90 days of the filing date of this report based on the evaluation of these controls and procedures required by Rule 30a-3(b) under the 1940 Act and Rule 13a-15(b) or 15d-15(b) under the Securities Exchange Act of 1934, as amended.
(b) There were no changes in the registrant’s internal control over financial reporting (as defined in Rule 30a-3(d) under the 1940 Act) that occurred during the period covered by this
8
report that have materially affected, or are reasonably likely to materially affect, the registrant’s internal control over financial reporting.
| Item 17 – | Disclosure of Securities Lending Activities for Closed-End Management Investment Companies – Not Applicable |
| Item 18 – | Recovery of Erroneously Awarded Compensation – Not Applicable |
| Item 19 – | Exhibits attached hereto |
(a)(1) Code of Ethics – See Item 2
(a)(2) Any policy required by the listing standards adopted pursuant to Rule 10D-1 under the Exchange Act (17 CFR 240.10D-1) by the registered national securities exchange or registered national securities association upon which the registrant’s securities are listed – Not Applicable
(a)(3) Section 302 Certifications are attached
(a)(4) Any written solicitation to purchase securities under Rule 23c-1 – Not Applicable
(a)(5) Change in Registrant’s independent public accountant – Not Applicable
(b) Section 906 Certifications are attached
1 The Fund has received exemptive relief from the Securities and Exchange Commission permitting it to make periodic distributions of long-term capital gains with respect to its outstanding common stock as frequently as twelve times each year, and as frequently as distributions are specified by or in accordance with the terms of its outstanding preferred stock. This relief is conditioned, in part, on an undertaking by the Fund to make the disclosures to the holders of the Fund’s common shares, in addition to the information required by Section 19(a) of the 1940 Act and Rule 19a-1 thereunder. The Fund is likewise obligated to file with the SEC the information contained in any such notice to shareholders and, in that regard, has attached hereto copies of each such notice made during the period.
9
Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
BlackRock Energy and Resources Trust
| By: |
/s/ John M. Perlowski | |||
| John M. Perlowski | ||||
| Chief Executive Officer (principal executive officer) of | ||||
| BlackRock Energy and Resources Trust |
Date: February 26, 2025
Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| By: |
/s/ John M. Perlowski | |||
| John M. Perlowski | ||||
| Chief Executive Officer (principal executive officer) of | ||||
| BlackRock Energy and Resources Trust |
Date: February 26, 2025
| By: |
/s/ Trent Walker | |||
| Trent Walker | ||||
| Chief Financial Officer (principal financial officer) of | ||||
| BlackRock Energy and Resources Trust |
Date: February 26, 2025
10
EX-99. CERT
CERTIFICATION PURSUANT TO RULE 30a-2(a) UNDER THE 1940 ACT AND SECTION 302 OF THE
SARBANES-OXLEY ACT OF 2002
I, John M. Perlowski, Chief Executive Officer (principal executive officer) of BlackRock Energy and Resources Trust, certify that:
1. I have reviewed this report on Form N-CSR of BlackRock Energy and Resources Trust;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, changes in net assets, and cash flows (if the financial statements are required to include a statement of cash flows) of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Rule 30a-3(c) under the Investment Company Act of 1940) and internal control over financial reporting (as defined in Rule 30a-3(d) under the Investment Company Act of 1940) for the registrant and have:
a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of a date within 90 days prior to the filing date of this report based on such evaluation; and
d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer(s) and I have disclosed to the registrant’s auditors and the audit committee of the registrant’s board of trustees (or persons performing the equivalent functions):
a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize, and report financial information; and
b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: February 26, 2025
/s/ John M. Perlowski
John M. Perlowski
Chief Executive Officer (principal executive officer) of
BlackRock Energy and Resources Trust
EX-99. CERT
CERTIFICATION PURSUANT TO RULE 30a-2(a) UNDER THE 1940 ACT AND SECTION 302 OF THE
SARBANES-OXLEY ACT OF 2002
I, Trent Walker, Chief Financial Officer (principal financial officer) of BlackRock Energy and Resources Trust, certify that:
1. I have reviewed this report on Form N-CSR of BlackRock Energy and Resources Trust;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, changes in net assets, and cash flows (if the financial statements are required to include a statement of cash flows) of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Rule 30a-3(c) under the Investment Company Act of 1940) and internal control over financial reporting (as defined in Rule 30a-3(d) under the Investment Company Act of 1940) for the registrant and have:
a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of a date within 90 days prior to the filing date of this report based on such evaluation; and
d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer(s) and I have disclosed to the registrant’s auditors and the audit committee of the registrant’s board of trustees (or persons performing the equivalent functions):
a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize, and report financial information; and
b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: February 26, 2025
/s/ Trent Walker
Trent Walker
Chief Financial Officer (principal financial officer) of
BlackRock Energy and Resources Trust
Exhibit 99.906CERT
Certification Pursuant to Rule 30a-2(b) under the 1940 Act and
Section 906 of the Sarbanes-Oxley Act of 2002
Pursuant to 18 U.S.C. § 1350, the undersigned officer of BlackRock Energy and Resources Trust(the “Registrant”), hereby certifies, to the best of his knowledge, that the Registrant’s Report on Form N-CSR for the period ended December 31, 2024 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.
Date: February 26, 2025
/s/ John M. Perlowski
John M. Perlowski
Chief Executive Officer (principal executive officer) of
BlackRock Energy and Resources Trust
Pursuant to 18 U.S.C. § 1350, the undersigned officer of BlackRock Energy and Resources Trust (the “Registrant”), hereby certifies, to the best of his knowledge, that the Registrant’s Report on Form N-CSR for the period ended December 31, 2024 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.
Date: February 26, 2025
/s/ Trent Walker
Trent Walker
Chief Financial Officer (principal financial officer) of
BlackRock Energy and Resources Trust
This certification is being furnished pursuant to Rule 30a-2(b) under the Investment Company Act of 1940, as amended, and 18 U.S.C. § 1350 and is not being filed as part of the Form N-CSR with the Securities and Exchange Commission.
Closed-End Fund Proxy Voting Policy
August 1, 2021
|
Closed-End Fund Proxy Voting Policy
Procedures Governing Delegation of Proxy Voting to Fund Adviser
|
| Effective Date: August 1, 2021 Last Review Date: September 1, 2024 |
| Applies to the following types of Funds registered under the 1940 Act: ☐ Open-End Mutual Funds (including money market funds) ☐ Money Market Funds ☐ Exchange-Traded Funds ☒ Closed-End Funds ☐ Other |
||
Objective and Scope
Set forth below is the Closed-End Fund Proxy Voting Policy.
Policy / Document Requirements and Statements
The Boards of Trustees/Directors (the “Directors”) of the closed-end funds advised by BlackRock Advisors, LLC (“BlackRock”), (the “Funds”) have the responsibility for the oversight of voting proxies relating to portfolio securities of the Funds, and have determined that it is in the best interests of the Funds and their shareholders to delegate that responsibility to BlackRock as part of BlackRock’s authority to manage, acquire and dispose of account assets, all as contemplated by the Funds’ respective investment management agreements.
BlackRock has adopted guidelines and procedures (together and as from time to time amended, the “BlackRock proxy voting guidelines”) governing proxy voting by accounts managed by BlackRock. BlackRock will cast votes on behalf of each of the Funds on specific proxy issues in respect of securities held by each such Fund in accordance with the BlackRock Proxy voting guidelines; provided, however, that in the case of underlying closed-end funds (including business development companies and other similarly-situated asset pools) held by the Funds that have, or are proposing to adopt, a classified board structure, BlackRock will typically (a) vote in favor of proposals to adopt classification and against proposals to eliminate classification, and (b) not vote against directors as a result of their adoption of a classified board structure.
BlackRock will report on an annual basis to the Directors on (1) a summary of the proxy voting process as applicable to the Funds in the preceding year together with a representation that all votes were in accordance with the BlackRock proxy voting guidelines (as modified pursuant to the immediately preceding paragraph), and (2) any changes to the BlackRock proxy voting guidelines that have not previously been reported.
|
Public | Page 1 of 1 |
BlackRock
Active
Investment
Stewardship
Global Engagement and Voting Guidelines
Effective as of January 2025
| 3 | ||||
| 4 | ||||
| 4 | ||||
| 5 | ||||
| 5 | ||||
| 6 | ||||
| 9 | ||||
| 10 | ||||
| 10 | ||||
| 11 | ||||
| 12 | ||||
| 14 | ||||
| 15 | ||||
| 15 | ||||
| 16 | ||||
| 16 | ||||
| 17 | ||||
| Appendix 1: How we fulfil and oversee our active investment stewardship responsibilities |
18 | |||
| BlackRock Active Investment Stewardship | Global Engagement and Voting Guidelines | 2 |
This document provides high level guidance on how BlackRock Active Investment Stewardship (BAIS) views corporate governance matters that are commonly put to a shareholder vote, or on which investors engage with issuers. BAIS works in partnership with BlackRock’s investment teams, excluding index equity, providing expertise on investment stewardship, engaging with companies on behalf of those teams when appropriate, and assisting in recommending, operationalizing and reporting on voting decisions. The guidance informs BAIS’ voting recommendations to BlackRock’s active portfolio managers. It applies to active equity holdings in BlackRock’s fundamental equity, systematic equity and multi-asset solutions strategies. It also may apply to holdings in BlackRock’s index and active fixed income strategies, to the extent those strategies hold voting securities or conduct issuer engagements. The guidelines are not prescriptive as active portfolio managers have discretion as to how they integrate these guidelines within their investment processes in light of their clients’ or funds’ investment objectives. There are separate, independently developed principles and voting policies that are applied to BlackRock’s index equity investments by a distinct and independent function, BlackRock Investment Stewardship.
| BlackRock Active Investment Stewardship | Global Engagement and Voting Guidelines | 3 |
BlackRock’s purpose is to help more and more people experience financial well-being. We manage assets on behalf of institutional and individual clients, across a full spectrum of investment strategies, asset classes, and regions. Our client base includes pension plans, endowments, foundations, charities, official institutions, insurers, and other financial institutions, as well as individuals around the world.
About BlackRock Active Investment Stewardship
BlackRock Active Investment Stewardship (BAIS) is a specialist team within the Portfolio Management Group and manages BlackRock’s stewardship engagement and voting on behalf of clients invested in active strategies globally. BAIS is also responsible for engagement with issuers in index fixed income strategies, where appropriate. Our activities are informed by these Global Engagement and Voting Guidelines (“the Guidelines”) and insights from active investment analysts and portfolio managers, with whom we work closely in engaging companies and voting at shareholder meetings.
Engagement with public companies is the foundation of our approach to stewardship within fundamental active investing. Through direct dialogue with company leadership, we seek to understand their businesses and how they manage risks and opportunities to deliver durable, risk adjusted financial returns. Generally, portfolio managers and stewardship specialists engage jointly on substantive matters. Our discussions focus on topics relevant to a company’s success over time including governance and leadership, corporate strategy, capital structure and financial performance, operations and sustainability-related risks, as well as macro-economic, geopolitical and sector dynamics. We aim to be constructive investors and are generally supportive of management teams that have a track record of financial value creation. We aim to build and maintain strong relationships with company leadership based on open dialogue and mutual respect.
Different active equity strategies may implement these voting guidelines differently, as a result of the latitude the portfolio manager has to make independent voting decisions aligned with their portfolio objectives and investment strategy. For example, BAIS will generally vote the holdings in Systematic Active Equity portfolios in accordance with these guidelines. We provide voting recommendations to fundamental equity portfolio managers, who may determine to vote differently based on their portfolio investment objectives and strategy.
These guidelines discuss corporate governance topics on which we may engage with management teams and board directors1 and matters that routinely come to a shareholder vote. We recognize that accepted corporate governance norms can differ across markets, and believe these guidelines represent globally applicable elements of governance that support a company’s ability to manage material risks and opportunities and deliver financial returns to investors. Generally, we believe companies should observe accepted corporate governance norms within their local markets or, particularly in markets without well-established norms, aspire to widely recognized international best practices. As one of many minority shareholders, BlackRock cannot – and does not try to – direct a company’s strategy or its implementation. We look to companies to provide disclosures that explain how their approach to corporate governance best aligns with the financial interests of their investors.
1 References to the board, board directors or non-executive directors should be understood to include supervisory boards and their members, where relevant.
| BlackRock Active Investment Stewardship | Global Engagement and Voting Guidelines | 4 |
Our approach to stewardship within active equities
As shareholders of public companies, BlackRock’s clients have certain fundamental rights, including the right to vote on proposals put forth by a company’s management or its shareholders. The voting rights attached to these clients’ holdings are an important mechanism for investors to express support for, or concern about, a company’s performance. As a fiduciary, BlackRock is legally required to make proxy voting determinations, on behalf of clients who have delegated voting authority to us, in a manner that is consistent with their investment objectives.
In general, we tend to support the recommendations of the board of directors and management. As indicated below, we may vote against management recommendations when we have concerns about how companies are serving the financial interests of our clients as their shareholders. We take a globally consistent approach to voting but consider the different corporate governance regulations and norms in various markets. Votes are determined on a case-by-case basis, in the context of a company’s situation and the investment mandate we have from clients. Please see page 16 for more information about how we fulfil and oversee BlackRock’s non-index equity investment stewardship responsibilities.
Our approach to stewardship within fixed income
Although fixed income investors do not have the right to vote at shareholder meetings, issuer engagement is a component of fixed income investment strategies at BlackRock, particularly those with sustainability objectives in addition to financial objectives. Most corporate governance-related fixed income engagements are undertaken in conjunction with the active investment stewardship team, and often active equity investors. In addition to the topics listed below, engagement with fixed income investment teams can help inform an issuer’s approach to structuring specialist issuances, such as green bonds, and the standard terms and information in bond documentation.
| BlackRock Active Investment Stewardship | Global Engagement and Voting Guidelines | 5 |
Roles and responsibilities
There is widespread consensus that the foundation of good corporate governance is an effective board of directors that is able to advise and supervise management in an independent and objective manner.2
We look to the board of directors (hereafter ‘the board’) to have an oversight role in the establishment and realization of a company’s strategy, purpose and culture. These constructs are interdependent and, when aligned, can better position a company to be resilient in the face of a changing business environment, help reduce the risks of corporate or employee misconduct, and attract and retain the caliber of workers necessary to deliver financial performance over time.
In promoting the success of the company, the board ensures the necessary resources, policies and procedures are in place to help management meet its strategic objectives within an agreed risk tolerance.
One of the most important responsibilities of the board is to appoint, and remove as necessary, the chief executive officer (CEO). In addition, the board plays a meaningful role in monitoring the performance of the CEO and other key executives, determining executive compensation, ensuring a rigorous audit, overseeing strategy execution and risk management and engaging with shareholders, and other stakeholders, as necessary.
Composition and effectiveness
Appointment process
A formal and transparent process for identifying and appointing director candidates is critical to ensuring the board is composed of directors with the appropriate mix of skills and experience. The board or a sub-committee should determine the general criteria given the company’s circumstances (e.g., sector, maturity, geographic footprint) and any additional criteria for a specific role being filled (e.g., financial expertise, industry track record). To inform the process, we encourage companies to review the skills and experience of incumbent directors to identify any gaps and whether a director candidate’s characteristics would be additive. We welcome disclosures that explain how the board considered different skills, backgrounds and experience to ensure the directors collectively can be effective in fulfilling their responsibilities. We assess a company’s board composition against that of its peer group and local market requirements.
Shareholders periodically vote to elect, remove and nominate directors to serve on the board. We may vote against the election of the most senior independent director, or the chair of the relevant committee, where a company has not demonstrated it has an appointment process that results in a high functioning board with the appropriate complement of skills, backgrounds and experience amongst the directors to support strong financial performance over time. We may vote against newly nominated directors who do not seem to have the appropriate skills or experience to contribute to the board’s effectiveness.
Independence
Director independence from management, significant shareholders or other stakeholders (e.g., government or employees) is of paramount importance to the protection of the interests of minority shareholders such as BlackRock’s clients. At least half of the directors should be independent and free
2 See the Corporate Governance Codes of Germany, Japan, and the UK, as well as the corporate governance principles of the US Business Roundtable as examples.
| BlackRock Active Investment Stewardship | Global Engagement and Voting Guidelines | 6 |
from conflicts of interest or undue influence.3 This ensures sufficient independent directors to have appropriately independent board committees. Companies domiciled in markets with a higher threshold for board independence should meet those requirements.
We may vote against the election of non-independent directors if the board does not have a sufficient balance of independence. We may also vote against the election of the chair of the committee responsible for board composition if this is a perennial issue.
Independent board leadership
Practices across markets differ, as do board structures, but we observe two main approaches to independent board leadership. One is a non-executive, independent chair of the board who is responsible for leading the board in the effective exercise of its duties. The other is a lead or senior independent director, who is responsible for coordinating with the other non-executive directors and working closely with the executive chair on the board agenda and other board procedures. In this case, the executive chair and the lead independent director work together to ensure the board is effectively fulfilling its responsibilities. In our view, the independent leader of the board, and/or the chair of a relevant committee, should be available to investors to discuss board governance matters such as CEO succession, executive pay, and board performance. We look to boards to explain their independent board leadership model and how it serves the interests of shareholders.
We may vote against the election of the chair of the committee responsible for board composition if there is not an identified independent leader of the board with clear responsibilities for board performance. We may vote against the most senior independent director if the board has a policy of not engaging with shareholders.
Tenure and succession
Boards should establish the length of time a director would normally be expected to serve, in line with market norms where those exist. In such markets, we find it helpful when companies disclose their approach to director tenure particularly around the contributions of directors who have served for longer periods than provided for in local practices. In our experience, long-serving directors could become less independent given their relationship with management and involvement in past board decisions.
Succession planning for board roles helps achieve the appropriate cadence of turnover that balances renewal through the regular introduction of directors with fresh perspectives and expertise with continuity through the retention of directors with long-term knowledge of the board and company.
In markets where there is not specific director tenure guidance, we may vote against the election of the chair of the committee responsible for board composition if there is not a clearly disclosed approach to director tenure and board renewal. We may vote against the election of directors who have served for longer duration than typical in markets with specific guidance, where the case for their continued service is not evident.
3 Common impediments to independence may include but are not limited to: current or recent employment at the company or a subsidiary; being, or representing, a shareholder with a substantial shareholding in the company; interlocking directorships; lengthy tenure, and having any other interest, business, or other relationship which could, or could reasonably be perceived to, materially interfere with a director’s ability to act in the best interests of the company and shareholders.
| BlackRock Active Investment Stewardship | Global Engagement and Voting Guidelines | 7 |
Capacity
To be effective and engaged, directors must commit appropriate time and energy to the role. A board should assess the ability of its members to maintain an appropriate focus on board matters and the company taking into consideration competing responsibilities. We recognize that board leadership roles vary across markets in responsibilities and required time commitment but note that they are generally more intensive than a standard directorship. We will take local norms and practices into consideration when making our voting determinations across markets.
We may vote against the election of directors who do not seem to have sufficient capacity to effectively fulfil their duties to the board and company.
Director elections
In support of director accountability to shareholders, directors should stand for election on a regular basis, ideally annually. A classified board structure may be justified by a company when it needs consistency and stability during a time of transition, or on the basis of its business model, e.g., a non-operating company such as closed-end funds.
Shareholders should have the opportunity to evaluate nominated directors individually rather than in bundled slates. We look to companies to provide sufficient information on each director standing for election so that shareholders can assess their capabilities and suitability. We will not support the election of directors whose names and biographical details have not been disclosed sufficiently in advance of the shareholder meeting.
Each director’s appointment should be dependent on receiving a simple majority of the votes cast at the shareholder meeting. Where a company’s practices differ, we look to the board to provide a detailed explanation as to how its approach best serves investors’ interests.
We may vote for shareholder or management proposals seeking to establish annual election of directors and/or a simple majority vote standard for director elections. We may vote against all the directors standing for election as part of a single slate if we have concerns about the profile or performance of an individual director.
Committees
Many boards establish committees to focus on specific responsibilities of the board such as audit and risk, governance and human capital, and executive compensation, amongst other matters. We do not prescribe to companies what committees they should establish but we seek to understand the board’s rationale for the committee structure it determines is appropriate. We note that, in some markets, regulation requires such committees. The responsibilities of each committee should be clear, and the board should ensure that all critical matters are assigned either to the full board or to one of the committees. The board should disclose to shareholders the structure, membership, proportion of independent directors, and responsibilities of each committee. The responsibilities we typically see assigned to the three most common committees include:
| ● | Audit and risk – oversight responsibilities for the integrity of financial reporting, risk management and compliance with legal and regulatory requirements; may also play an oversight role in relation to the internal audit function and whistleblowing mechanisms. |
| BlackRock Active Investment Stewardship | Global Engagement and Voting Guidelines | 8 |
| ● | Nominating, governance and human capital – ensures appropriate corporate governance principles and practices including the periodic review of board performance; responsible for succession planning for CEO and key board roles, as well as the director appointment process; may also have oversight responsibilities for human capital management strategies including corporate culture and purpose. |
| ● | Executive compensation – determines the compensation policies and programs for the CEO and other executive officers, approves annual awards and payments under the policies; may also have oversight responsibilities for firm-wide compensation policies. |
We may vote against the election of the chair of the committee or other directors serving as committee members to convey our concerns and provide feedback on how a committee has undertaken its responsibilities. We may vote against the election of the most senior non-executive director if there is not a clearly disclosed approach to board committees.
Board and director evaluation
We consider it best practice for companies to conduct an annual review of the performance of the board, the committees, the chair and individual directors. Periodically, this review could be undertaken by an independent third party able to bring objective perspectives to the board on governance and performance. We encourage companies to disclose their approach to and objectives of evaluations, including any changes made to the board’s approach as a result.
Access to independent advice
To support the directors in effectively fulfilling their duties to the company and shareholders, they should have access to independent advice. When circumstances warrant, boards should be able to retain independent third parties to advise on critical matters. These might include new industry developments such as emergent and disruptive technology, operating events with material consequences for the company’s reputation and/or performance, or significant transactions. Board committees may similarly retain third parties to advise them on specialist matters such as audit, compensation and succession planning.
Boards should establish compensation arrangements that enable the company to recruit, retain and reward the caliber of executive management necessary to lead and operate the company to deliver superior financial returns over time. We focus on alignment between variable pay and a company’s financial performance.
Generally, executive compensation arrangements have four components: base salary, annual bonus that rewards performance against short-term metrics, share-based incentives that reward performance against long-term metrics, and pensions and benefits. In our observation, base salary, pensions and benefits are largely set relative to market norms and benchmarks. The annual bonus and share-based incentive, or variable pay plans, tend to be tailored to the company, its sector and long-term strategy, as well as the individuals the board is seeking to recruit and motivate.
Recognizing the unique circumstances of each company, we determine whether to support a company’s approach to executive compensation on a case-by-case basis. We rely on companies providing sufficient quantitative and qualitative information in their disclosures to enable shareholders to understand the
| BlackRock Active Investment Stewardship | Global Engagement and Voting Guidelines | 9 |
compensation arrangements and assess the alignment with investors’ interests. Features we look for in compensation arrangements include:
| ● | Fixed pay components, including base salary, benefits and prerequisites that are appropriate in the context of the company’s size, sector and market. |
| ● | Variable pay subject to performance metrics that are closely linked to the company’s short- and long-term strategic objectives. |
| ● | Long-term incentives that motivate sustained performance across a multi-year period. |
| ● | A balance between fixed and variable pay, short- and long-term incentives, and specific instruments (cash and equity awards) that promotes pay program durability and seldom necessitates one-off, discretionary payments. |
| ● | Outcomes that are consistent with the returns to investors over the relevant time period. |
| ● | Board discretion, if allowed within the variable pay arrangements, to be used sparingly, responsibly and transparently. |
| ● | A requirement, that participants in long-term share-based incentive plans build a meaningful shareholding in the company within a defined time period, as determined by the board. |
| ● | Change of control provisions that appropriately balance the interests of executives and shareholders. |
| ● | Clawback or malus provisions that allow the company to recoup or hold back variable compensation from individuals whose awards were based on fraudulent activities, misstated financial reports, or executive misconduct. |
| ● | Severance arrangements that protect the company’s interests but do not cost more than is contractual. |
We may vote against proposals to introduce new share-based incentives, approve existing policies or plans, or approve the compensation report where we do not see alignment between executive compensation arrangements and our clients’ financial interests. When there is not an alternative, or where there have been multi-year issues with compensation misaligned with performance, we may vote against the election of the chair of the responsible committee, or the most senior independent director.
Non-executive director compensation
Companies generally pay non-executive directors an annual retainer or fee in cash, shares or a combination of the two. Some companies also pay additional fees for service on board committees or in board leadership roles. We do not support non-executive directors participating in performance-based incentive plans as doing so may create a conflict of interest and undermine their independence from management, whom they oversee.
Boards are responsible for ensuring senior executive leadership has established a capital strategy that achieves appropriate capital allocation and management in support of long-term financial resilience.
| BlackRock Active Investment Stewardship | Global Engagement and Voting Guidelines | 10 |
Where company practices diverge from those set out below, we look for companies to disclose why they view these practices to be aligned with shareholders’ interests. We may vote against management proposals seeking capital-related authorities or the election of the most senior independent director if we have concerns about a company’s approach. We may also support a shareholder proposal seeking conversion of shares with differentiated voting rights to a one-share, one-vote standard.
Share issuance
We assess requests for share issuance for particular transactions on a case-by-case basis. We will generally support authorities to issue shares when subject to pre-emptive rights, and up to 20% absent pre-emptive rights. Companies should seek regular approval of these authorities to allow shareholders to take into consideration how prior authorities were used, as well as the current circumstances of the company and the market environment.
Share buybacks
We assess share buyback proposals in the context of the company’s disclosed capital management strategy and management’s determination of the appropriate balance between investment that supports the long-term growth of the company and returning cash to investors. We also take into consideration the effect of a buyback program on the company’s balance sheet and executive compensation arrangements and the price at which shares are repurchased relative to market price. Companies should seek regular approval of these authorities to allow shareholders to take into consideration how prior authorities were used, as well as the current circumstances of the company and the market environment.
We would normally expect companies to cancel repurchased shares. If a company plans to retain them as treasury shares, management should provide a detailed rationale in the context of the disclosed capital management strategy.
Dividends
We generally defer to management and the board on dividend policy but may engage to seek further clarification where a proposed dividend appears out of line with the company’s financial position.
Differentiated voting rights
We prefer companies to adopt a one-share, one-vote structure for share classes with the same economic exposure. Certain companies, particularly those new to public markets, could make the case to adopt a differentiated voting rights structure, or dual class stock. In those situations, we encourage companies to evaluate and seek approval for their capital structure on a periodic basis.
Transactions and special situations
We monitor developments in transactions and special situations closely and undertake our own detailed analyses of proposals.
Mergers and acquisitions
We evaluate proposed mergers or acquisitions by assessing the financial outcome for our clients as minority shareholders. Management should provide an assessment of the proposed transaction’s strategic and financial rationale, along with its execution and operational risks. We review each transaction independently based on these factors and the degree to which the transaction enhances
| BlackRock Active Investment Stewardship | Global Engagement and Voting Guidelines | 11 |
shareholder value. The board should consider establishing an ad hoc transaction committee to undertake an independent assessment of a significant merger or acquisition, in advance of making its recommendation to shareholders.
We will vote against transactions that, in our assessment, do not advance our clients’ financial interests.
Anti-takeover defenses
In principle, we do not support companies using anti-takeover defenses, also known as poison pills or shareholder rights plans, as they can entrench management and boards which have not delivered long-term shareholder value. By exception, a poison pill may be supported if its purpose is to delay a takeover that is considered sub-optimal and enable management to seek an improved offer. Similarly, management could make the case to use a poison pill to block a shareholder activism campaign that may be counter to the interests of other investors. Defense mechanisms introduced in these circumstances should be limited in term and threshold, and also be closely monitored by the independent members of the board. We look for a shareholder vote for any mechanisms expected to be in place for more than 12 months.
Shareholder activism
When companies are the focus of an activism campaign, we may engage with the activist to understand their analysis and objectives, once they have gone public. We will also engage with company management and possibly board members, especially those the activist may be seeking to replace. In our assessment, we evaluate various factors, including the concerns raised by the activist and the case for change; the quality of both the activist’s and management’s plans; and the qualifications of each party’s candidates. We evaluate each contested situation by assessing the potential financial outcome for our clients as minority shareholders.
We may support board candidates nominated by a shareholder activist if the activist has demonstrated that their case for change enhances shareholder value, or if the incumbent board members do not demonstrate the relevant skills and expertise or have a poor track record of protecting shareholders’ interests.
Significant shareholders and related party transactions
Boards of companies with affiliated shareholders or directors should be able to demonstrate that the interests of all shareholders are given equitable consideration.
Transactions with related parties, such as significant shareholders or companies connected with the public company, should be disclosed in detail and conducted on terms similar to what would objectively have been agreed with a non-related party. Such transactions should be reviewed and approved by the independent members of the board, and if voted on, only disinterested shareholders should vote.
Corporate reporting, risk management and audit
Investors depend on corporate reporting, both regulatory and voluntary, to understand a company’s strategy, its implementation and financial performance, as well as to assess the quality of management and operations and potential for the company to create shareholder value over time. The board should oversee corporate reporting and the policies and procedures underpinning the internal audit function and external audit.
| BlackRock Active Investment Stewardship | Global Engagement and Voting Guidelines | 12 |
A company’s financial reporting should provide decision-useful information for investors and other stakeholders on its financial performance and position. It should provide an accurate and balanced assessment of the risks and opportunities the company faces in realizing its long-term strategy. Accordingly, the assumptions made by management and reviewed by the auditor in preparing the financial statements should be reasonable and justified. Financial statements should be prepared in accordance with globally developed reporting standards and any divergence from generally accepted accounting principles should be explained in detail and justified. Accounting restatements should be explained in detail and any remedial actions, and the implications of these, disclosed.
In this context, audit committees play a vital role in a company’s financial reporting system by providing independent oversight of the accounts, material financial and, where appropriate to the jurisdiction, nonfinancial information, internal control frameworks and Enterprise Risk Management systems. In our view, effective audit committee oversight strengthens the quality and reliability of a company’s financial statements and provides an important level of reassurance to shareholders. Audit committees should have a procedure in place for assessing the independence of the auditor and the quality of the external audit process annually.
Similarly, material sustainability-related factors that are integral to how a company manages risks or generates revenue should be disclosed. In our view, the standards developed by the International Sustainability Standards Board, can be helpful to companies in preparing such reports. 4
Companies should establish robust risk management and internal control processes appropriate to the company’s business, risk tolerance, and regulatory environment. A credible whistleblowing system for employees, and potentially other stakeholders, can be a useful mechanism for ensuring that senior management and the board are aware of potential misconduct or breaches in risk management and internal control processes.
A comprehensive audit conducted by an independent audit firm contributes to investor confidence in the quality of corporate reporting. It is helpful when the audit report gives some insight into the scope and focus of the audit, as well as any critical audit matters identified and how these were resolved. A comprehensive and effective audit is time and resource intensive, and the audit fee should be commensurate. Fees paid to the audit firm for non-audit consulting should not exceed the audit fee to a degree that may prompt concerns about the independence of the audit. The audit committee should explain its position on auditor tenure and how it confirmed that the auditor remained independent.
We may vote against the election of the responsible directors if corporate reporting is insufficient or there are material misstatements in financial reports. In markets where relevant, we may vote against a proposal to approve the financial statements or the discharge of the board when we are concerned about the quality of the reporting or the audit. We may vote against proposals to appoint the auditor, ratify the audit report, or approve the audit fee if we are concerned about the auditor’s independence, the quality of the audit, or there are material misstatements in financial reports and the board has not established reasonable remediation plans.
4 The objective of IFRS S1 General Requirements for Disclosure of Sustainability-related Financial Information is to require an entity to disclose information about its sustainability-related risks and opportunities that is useful to primary users of general-purpose financial reports in making decisions relating to providing resources to the entity. The objective of IFRS S2 Climate-related Disclosures is to require an entity to disclose information about its climate-related risks and opportunities that is useful to primary users of general-purpose financial reports in making decisions relating to providing resources to the entity.
| BlackRock Active Investment Stewardship | Global Engagement and Voting Guidelines | 13 |
Shareholder rights and protections
General shareholder meetings
Companies normally have an annual general meeting of shareholders at which routine and non-routine items of business are discussed and voted on by shareholders in attendance or submitting proxy votes. Companies should disclose materials relevant to the shareholder meeting sufficiently in advance so that shareholders can take them into consideration in their voting decisions. Many companies offer shareholders the option of participating in the meeting virtually which, whilst welcome, should not limit the rights of shareholders to participate as they would during an in-person meeting.
We may vote against directors when materials related to the business of the shareholder meeting are not provided in a timely manner or do not provide sufficient information for us to take an informed voting decision. We may vote against directors if the format of the shareholder meeting does not accommodate reasonable shareholder participation.
Bylaw amendments
We review bylaw amendments proposed by management on a case-by-case basis and will generally support those that are aligned with the interests of minority shareholders. Any material changes to the bylaws should be explained in detail and put to a shareholder vote.
We may vote against bylaw amendments that reduce shareholder rights and protections. We may vote against directors if material changes are made to the bylaws without shareholder approval.
If not provided for in the relevant corporate law, company bylaws should allow shareholders, individually or as a group, with a meaningful shareholding the right to call a special meeting of shareholders. The shareholding required to exercise this right should balance its utility with the cost to the company of holding special meetings.
If not provided for in the relevant corporate law, company bylaws should allow shareholders, individually or as a group, with a meaningful shareholding the right to nominate directors to the company’s board. The threshold for this right should be set so that shareholders can exercise it without being unduly disruptive to the board’s own nomination process.
Whilst we would not use either of these rights ourselves, we see them as important accountability mechanisms. We may vote for a shareholder proposal seeking the addition of either of these provisions to a company’s bylaws.
Change of domicile
We generally defer to management on proposals to change a company’s domicile as long as the rationale for doing so is consistent with the company’s long-term strategy and business model and the related costs are immaterial.
We may vote against directors or a proposal to change a company’s domicile where it does not seem aligned with our clients’ financial interests.
Changes to a company’s purpose or the nature of its business
Plans to materially change the nature of a company’s business or its purpose should be disclosed and explained in the context of long-term strategy and business dynamics. Such changes may significantly alter an investor’s views on the suitability of a company for their investment strategy or portfolio.
| BlackRock Active Investment Stewardship | Global Engagement and Voting Guidelines | 14 |
Where relevant, we may vote against proposals to change a company’s purpose or the nature of its business if the board has not provided a credible argument for change.
Shareholders in many markets, who meet certain eligibility criteria, have the right to submit proposals to the general shareholder meeting asking a company to take a particular course of action subject to the proposal being supported by a majority of votes cast at the meeting. The topics raised address a range of governance, social and environmental matters that may be relevant to a company’s business. Shareholder proposals are considered by many investors to be an escalation tool when a company is unresponsive to their engagement.
We vote on these proposals on a case-by-case basis. We assess the relevance of the topic raised to a company’s business and its current approach, whether the actions sought are consistent with shareholders’ interests, and what impact the proposal being acted upon might have on financial performance.
Our general approach where we have concerns about a company’s governance, disclosures or performance is to engage to understand the apparent difference in perspective. If we continue to believe the company is not acting in shareholders’ financial interests, we may vote against the election of directors. We may support a relevant shareholder proposal if doing so reinforces the points made in our engagement or is aligned with our clients’ financial interests. We generally do not support shareholder proposals that are legally binding on the company, seek to alter a company’s strategy or direct its operations, or are unrelated to how a company manages risk or generates financial returns.
BlackRock is subject to legal and regulatory requirements in the U.S. that place restrictions and limitations on how we can interact with the companies in which we invest on behalf of our clients, including our ability to submit shareholder proposals. We can vote on behalf of clients who authorize us to do so, on proposals put forth by others.
Corporate political activities
We seek to understand how companies ensure that their direct and indirect engagement in the policy making process is consistent with their public statements on policy matters important to the company’s long-term strategy. The board should be aware of the approach taken to corporate political activities as there can be reputational risks arising from inconsistencies. Companies should, as a minimum, meet all regulatory disclosure requirements on political activities, and ideally, provide accessible and clear disclosures to shareholders on policy positions, public policy engagement activities and political donations. To mitigate the risk of inconsistencies, companies can usefully assess the alignment between their policy priorities and the policy positions of the trade associations of which they are active members and any engagements undertaken by trade associations on behalf of members.
Generally, this is an engagement matter, although we may support a relevant shareholder proposal, or vote against directors, where a company’s disclosures are insufficient, or it becomes public that there is a material contradiction in a company’s public policy positions and its policy engagement.
| BlackRock Active Investment Stewardship | Global Engagement and Voting Guidelines | 15 |
Sustainability, or environmental and social, considerations
We seek to understand how companies manage the risks and opportunities inherent in their business operations. In our experience, sustainability-related factors5 that are relevant to a company’s business or material to its financial performance, are generally operational considerations embedded into day-to-day management systems. Certain sustainability issues may also inform long-term strategic planning, for example, investing in product innovation in anticipation of changing consumer demand or adapting supply chains in response to changing regulatory requirements.
We recognize that the specific sustainability-related factors that may be financially material or business relevant will vary by company business model, sector, key markets, and time horizon, amongst other considerations. From company disclosures and our engagement, we aim to understand how management is identifying, assessing and integrating material sustainability-related risks and opportunities into their business decision-making and practices. Doing so helps us undertake a more holistic assessment of a company’s potential financial performance and the likely risk-adjusted returns of an investment.
We may vote against directors or support a relevant shareholder proposal if we have concerns about how a company is managing or disclosing its approach to material sustainability-related risks that may impact financial returns.
In our view, companies should understand and take into consideration the interests of the various parties on whom they depend for their success over time. It is for each company to determine their key stakeholders based on what is material to their business and long-term financial performance. For many companies, key stakeholders include employees, business partners (such as suppliers and distributors), clients and consumers, regulators, and the communities in which they operate. Companies that appropriately balance the interests of investors and other stakeholders are, in our experience, more likely to be financially resilient over time.
5 By material sustainability-related risks and opportunities, we mean the drivers of risk and financial value creation in a company’s business model that have an environmental or social dependency or impact. Examples of environmental issues include, but are not limited to, water use, land use, waste management, and climate risk. Examples of social issues include, but are not limited to, human capital management, impacts on the communities in which a company operates, customer loyalty, and relationships with regulators. It is our view that well-managed companies will effectively evaluate and manage material sustainability-related risks and opportunities relevant to their businesses. Governance is the core means by which boards can oversee the creation of durable financial value over time. Appropriate risk oversight of business-relevant and material sustainability-related considerations is a component of a sound governance framework.
| BlackRock Active Investment Stewardship | Global Engagement and Voting Guidelines | 16 |
Climate and decarbonization investment objectives
Certain active BlackRock funds have climate and decarbonization objectives in addition to financial objectives. Consistent with the objectives of those investment strategies, our stewardship activity in relation to the holdings in those funds differs in some respects from BAIS’ benchmark guidelines, which are described above. Specifically, for those funds’ holdings, we look to investee companies to demonstrate that they are aligned with a decarbonization pathway that means their business model would be viable in a low-carbon economy, i.e., one in which global temperature rise is limited to 1.5°C above pre-industrial levels. This approach is only taken following BlackRock receiving the explicit approval from the applicable fund board.
The decarbonization stewardship guidelines focus on companies which produce goods and services that contribute to real world decarbonization or have a carbon intensive business model and face outsized impacts from the low carbon transition, based on reported and estimated scopes 1, 2, and 3 greenhouse gas emissions. These companies should provide disclosures that set out their governance, strategy, risk management processes and metrics and targets relevant to decarbonization. These disclosures should include an explanation of the decarbonization scenarios a company is using in its near- and long-term planning, as well as its scope 1, scope 2 and material scope 3 greenhouse gas (GHG) emissions and reduction targets for scope 1 and 2 emissions. As with the BAIS benchmark policies, we consider the climate-risk reporting standard issued by the International Sustainability Standards Board, IFRS S2, a useful reference for such reporting.
Under these climate- and decarbonization-specific guidelines, BAIS may recommend a vote against directors or support for a relevant shareholder proposal if a company does not appear to be adequately addressing or disclosing material climate-related risks. We may recommend supporting shareholder proposals seeking information relevant to a company’s stated low-carbon transition strategy and targets that the company does not currently provide and that would be helpful to investment decision-making. As under the BAIS benchmark approach, the active portfolio managers are ultimately responsible for voting consistent with their investment mandate and fund objectives.
| BlackRock Active Investment Stewardship | Global Engagement and Voting Guidelines | 17 |
Appendix 1: How we fulfil and oversee our active investment stewardship responsibilities
Oversight
The Global Head of BAIS has primary oversight of and responsibility for the team’s activities, including voting in accordance with the BlackRock Active Investment Stewardship Global Engagement and Voting Guidelines (“the Guidelines”), which require the application of professional judgment and consideration of each company’s unique circumstances, as well as input from active investors. BAIS is independent from BlackRock Investment Stewardship in our engagement and voting activities, reporting lines, and oversight.
The Active Investment Stewardship Oversight Committee, comprised of senior representatives of the active investment, legal and risk teams, reviews and advises on amendments to BAIS’ Global Engagement and Voting Guidelines. The Committee also considers developments in corporate governance, related public policy, and market norms and how these might influence BAIS’ policies and practices. The Committee does not determine voting decisions, which are the responsibility of BAIS and the relevant active equity investors.
In addition, there is a standing advisory group of senior active investors who counsel BAIS on complex or high-profile votes before a recommendation is finalized and escalated to the portfolio managers with holdings in the company under consideration. This group also formally reviews any revisions to the Engagement and Voting Guidelines proposed by BAIS as part of its annual review.
BAIS carries out engagement with companies in collaboration with active investment colleagues, executes proxy votes, and conducts vote operations (including maintaining records of votes cast) in a manner consistent with the Guidelines. BAIS also conducts research on corporate governance issues and participates in industry discussions to contribute to and keep abreast of important developments in the corporate governance field. BAIS may use third parties for certain of the foregoing activities and performs oversight of those third parties (see “Use and oversight of third-party vote services providers” below).
Voting guidelines and vote execution
BlackRock votes on proxy issues when our clients authorize us to do so. We carefully consider the voting items submitted to funds and other fiduciary account(s) (Fund or Funds) for which we have voting authority. BlackRock votes (or refrains from voting) for each Fund for which we have voting authority based on our evaluation of the alignment of the voting items with the long-term economic interests of our clients, in the exercise of our independent business judgment, and without regard to the relationship of the issuer (or any shareholder proponent or dissident shareholder) to the Fund, the Fund’s affiliates (if any), BlackRock or BlackRock’s affiliates, or BlackRock employees (see “Conflicts management policies and procedures,” below).
When exercising voting rights, BAIS will normally vote on specific proxy issues in accordance with the Guidelines, although portfolio managers have the right to vote differently on their holdings if they determine doing so is more aligned with the investment objective and financial interests of clients invested in the funds they manage.
The Guidelines are not intended to be exhaustive. BAIS applies the Guidelines on a case-by-case basis, in the context of the individual circumstances of each company and the specific issue under review. As such, the Guidelines do not indicate how BAIS will vote in every instance. Rather, they reflect our view about corporate governance issues generally, and provide insight into how we typically approach issues
| BlackRock Active Investment Stewardship | Global Engagement and Voting Guidelines | 18 |
that commonly arise on corporate ballots. The Guidelines are reviewed annually and updated as necessary to reflect changes in market practices, developments in corporate governance and feedback from companies and clients. In this way, BAIS aims to maintain policies that explain our approach to governance practices most aligned with clients’ long-term financial interests.
In certain markets, proxy voting involves logistical issues which can affect BAIS’ ability to vote such proxies, as well as the desirability of voting such proxies. These issues include, but are not limited to: i) untimely notice of shareholder meetings; ii) restrictions on a foreigner’s ability to exercise votes; iii) requirements to vote proxies in person; iv) “share-blocking” (requirements that investors who exercise their voting rights surrender the right to dispose of their holdings for some specified period in proximity to the shareholder meeting); v) potential difficulties in translating the proxy; vi) regulatory constraints; and vii) requirements to provide local agents with unrestricted powers of attorney to facilitate voting instructions. We are not supportive of impediments to the exercise of voting rights such as share-blocking or overly burdensome administrative requirements.
BlackRock votes proxies in these situations on a “best-efforts” basis. In addition, BAIS may determine that it is generally in the interests of BlackRock’s clients not to vote proxies (or not to vote our full allocation) if the costs (including but not limited to opportunity costs associated with share-blocking constraints) associated with exercising a vote are expected to outweigh the benefit the client would derive by voting on the proposal.
Voting Choice
BlackRock offers Voting Choice, a program that provides eligible clients with more opportunities to participate in the proxy voting process where legally and operationally viable.
Voting Choice is currently available for eligible clients invested in certain institutional pooled funds in the U.S., UK, and Canada that use systematic active equity (SAE) and multi-asset strategies. In addition, institutional clients in separately managed accounts (SMAs) are eligible for BlackRock Voting Choice regardless of their investment strategies.6
As a result, the shares attributed to BlackRock in company share registers may be voted differently depending on whether our clients have authorized BAIS to vote on their behalf, have authorized BlackRock to vote in accordance with a third-party policy, or have elected to vote shares in accordance with their own policy. Our clients have greater control over proxy voting because of Voting Choice. BlackRock does not disclose client information, including a client’s selection of proxy policy, without client consent.
Use and oversight of third-party vote services providers
Third-party vote services providers – or proxy research firms - provide research and recommendations on proxy votes, as well as voting infrastructure. As mentioned previously, BlackRock contracts primarily with the vote services provider ISS and leverages its online platform to supply research and support voting, record keeping, and reporting processes. We also use Glass Lewis’ research and analysis as an input into our voting process. It is important to note that, although proxy research firms provide important data and analysis, BAIS does not rely solely on their information or follow their voting recommendations. A
6 With Voting Choice, SMAs have the ability to select from a set of voting policies from third-party proxy advisers the policy that best aligns with their views and preferences. BlackRock can then use its proxy voting infrastructure to cast votes based on the client’s selected voting policy.
| BlackRock Active Investment Stewardship | Global Engagement and Voting Guidelines | 19 |
company’s disclosures, our past engagements and voting, investment colleagues’ insights and our voting guidelines are important inputs into our voting decisions on behalf of clients.
Given the large universe of actively held companies, BAIS employs the proxy services provider to streamline the voting process by making voting recommendations based on BAIS’ voting guidelines when the items on a shareholder meeting agenda are routine. Agenda items that are not routine are referred back to BAIS to assess, escalate as necessary to the relevant portfolio managers and vote. BAIS reviews and can override the recommendations of the vote services provider at any time prior to the vote deadline. Both BAIS and the vote services provider actively monitor securities filings, research reports, company announcements, and direct communications from companies to ensure awareness of supplemental disclosures and proxy materials that may require a modification of votes.
BAIS closely monitors the third-party vote services providers we contract with to ensure that they are meeting our service level expectations and have effective policies and procedures in place to manage potential conflicts of interest. Our oversight of service providers includes regular meetings with client service teams, systematic monitoring of vendor operations, as well as annual due diligence meetings in accordance with BlackRock’s firmwide policies.
Conflicts management policies and procedures
BAIS maintains policies and procedures that seek to prevent undue influence on BlackRock’s proxy voting activity. Such influence might stem from any relationship between the investee company (or any shareholder proponent or dissident shareholder) and BlackRock, BlackRock’s affiliates, a Fund or a Fund’s affiliates, or BlackRock employees. The following are examples of sources of perceived or potential conflicts of interest:
| ● | BlackRock clients who may be issuers of securities or proponents of shareholder resolutions |
| ● | BlackRock business partners or third parties who may be issuers of securities or proponents of shareholder resolutions |
| ● | BlackRock employees who may sit on the boards of public companies held in Funds managed by BlackRock |
| ● | Significant BlackRock, Inc. investors who may be issuers of securities held in Funds managed by BlackRock |
| ● | Securities of BlackRock, Inc. or BlackRock investment funds held in Funds managed by BlackRock |
| ● | BlackRock, Inc. board members who serve as senior executives or directors of public companies held in Funds managed by BlackRock |
BlackRock has taken certain steps to mitigate perceived or potential conflicts including, but not limited to, the following:
| ● | Adopted the Guidelines which are designed to advance our clients’ long-term economic interests in the companies in which BlackRock invests on their behalf |
| ● | Established a reporting structure that separates BAIS from employees with sales, vendor management, or business partnership roles. In addition, BlackRock seeks to ensure that all engagements with corporate issuers, dissident shareholders or shareholder proponents are managed consistently and without regard to BlackRock’s relationship with such parties. Clients or |
| BlackRock Active Investment Stewardship | Global Engagement and Voting Guidelines | 20 |
| business partners are not given special treatment or differentiated access. BAIS prioritizes engagements based on factors including, but not limited to, our need for additional information to make a voting decision or our view on the likelihood that an engagement could lead to positive outcome(s) over time for the economic value of the company. Within the normal course of business, BAIS may engage directly with BlackRock clients, business partners and/or third parties, and/or with employees with sales, vendor management, or business partnership roles, in discussions regarding our approach to stewardship, general corporate governance matters, client reporting needs, and/or to otherwise ensure that proxy-related client service levels are met |
| ● | Determined to engage, in certain instances, an independent third-party voting service provider to make proxy voting recommendations as a further safeguard to avoid potential conflicts of interest, to satisfy regulatory compliance requirements, or as may be otherwise required by applicable law. In such circumstances, the independent third-party voting service provider provides BlackRock with recommendations, in accordance with the Guidelines, as to how to vote such proxies. BlackRock uses an independent third-party voting service provider to make proxy voting recommendations for shares of BlackRock, Inc. and companies affiliated with BlackRock, Inc. BlackRock may also use an independent third-party voting service provider to make proxy voting recommendations for: |
| ○ | public companies that include BlackRock employees on their boards of directors |
| ○ | public companies of which a BlackRock, Inc. board member serves as a senior executive or a member of the board of directors |
| ○ | public companies that are the subject of certain transactions involving BlackRock Funds |
| ○ | public companies that are joint venture partners with BlackRock, and |
| ○ | public companies when legal or regulatory requirements compel BlackRock to use an independent third-party voting service provider |
In selecting an independent third-party voting service provider, we assess several characteristics, including but not limited to: independence, an ability to analyze proxy issues and make recommendations in the economic interest of our clients in accordance with the Guidelines, reputation for reliability and integrity, and operational capacity to accurately deliver the assigned recommendations in a timely manner. We may engage more than one independent third-party voting service provider, in part to mitigate potential or perceived conflicts of interest at a single voting service provider. The Active Investment Stewardship Oversight Committee appoints and reviews the performance of the independent third-party voting service providers, generally on an annual basis.
Securities lending
When so authorized, BlackRock acts as a securities lending agent on behalf of Funds. Securities lending is a well-regulated practice that contributes to capital market efficiency. It also enables funds to generate additional returns while allowing fund providers to keep fund expenses lower.
With regard to the relationship between securities lending and proxy voting, BlackRock cannot vote shares on loan and may determine to recall them for voting, as guided by our fiduciary duty as an asset manager to our clients in helping them achieve their investment goals. While this has occurred in a limited number of cases, the decision to recall securities on loan as part of BlackRock’s securities lending program in order to vote is based on an evaluation of various factors that include, but are not limited to,
| BlackRock Active Investment Stewardship | Global Engagement and Voting Guidelines | 21 |
assessing potential securities lending revenue alongside the potential long-term financial value to clients of voting those securities (based on the information available at the time of recall consideration). BAIS works with active portfolio managers, as well as colleagues in the Securities Lending and Risk and Quantitative Analysis teams, to evaluate the costs and benefits to clients of recalling shares on loan.
In almost all instances, BlackRock anticipates that the potential long-term financial value to clients of voting shares would not warrant recalling securities on loan. However, in certain instances, BlackRock may determine, in our independent business judgment as a fiduciary, that the value of voting outweighs the securities lending revenue loss to clients and would therefore recall shares to be voted in those instances.
Periodically, BlackRock reviews our process for determining whether to recall securities on loan in order to vote and may modify it as necessary.
Reporting and vote transparency
BAIS is committed to transparency in the stewardship work we do on behalf of clients. We inform clients about our engagement and voting policies and activities through direct communication and disclosure on our website.
| BlackRock Active Investment Stewardship | Global Engagement and Voting Guidelines | 22 |
Want to know more?
blackrock.com/stewardship | ContactActiveStewardship@blackrock.com
The document is provided for information purposes only and is subject to change. Reliance upon this information is at the sole discretion of the reader.
Prepared by BlackRock, Inc.
©2024 BlackRock, Inc. All rights reserved. BLACKROCK is a trademark of BlackRock, Inc., or its subsidiaries in the United States and elsewhere. All other trademarks are those of their respective owners.
| BlackRock Active Investment Stewardship | Global Engagement and Voting Guidelines | 23 |
BlackRock Energy and Resources Trust
Cusip: 09250U101
Ticker: BGR
| Record Date |
January 15, 2025 | |||||
| Pay Date |
January 31, 2025 | |||||
| Distribution Amount per share |
$ | 0.097300 | ||||
The following table sets forth the estimated amounts of the current distribution and the cumulative distributions paid this fiscal year to date from the following sources: net income, net realized short-term capital gains, net realized long-term capital gains and return of capital. All amounts are expressed per common share.
| Current Distribution | % Breakdown of the Current Distribution |
Total Cumulative Distributions for the Fiscal Year to Date |
% Breakdown of the Total Cumulative Distributions for the Fiscal Year to Date |
|||||||||||||||||||||||||
| Net Income |
$ | 0.010244 | 11% | $ | 0.010219 | 11% | ||||||||||||||||||||||
| Net Realized Short-Term Capital Gains |
$ | - | 0% | $ | - | 0% | ||||||||||||||||||||||
| Net Realized Long-Term Capital Gains |
$ | - | 0% | $ | - | 0% | ||||||||||||||||||||||
| Return of Capital |
$ | 0.087056 | 89% | $ | 0.087081 | 89% | ||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
| Total (per common share) |
$ | 0.097300 | 100% | $ | 0.097300 | 100% | ||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
| Average annual total return (in relation to NAV) for the 5-year period ending on December 31, 2024 |
|
8.37% | ||||||||||||||||||||||||||
|
|
|
|||||||||||||||||||||||||||
| Annualized current distribution rate expressed as a percentage of NAV as of December 31, 2024 |
|
8.48% | ||||||||||||||||||||||||||
|
|
|
|||||||||||||||||||||||||||
| Cumulative total return (in relation to NAV) for the fiscal year through December 31, 2024 |
|
3.93% | ||||||||||||||||||||||||||
|
|
|
|||||||||||||||||||||||||||
| Cumulative fiscal year distributions as a percentage of NAV as of December 31, 2024 |
|
0.00% | ||||||||||||||||||||||||||
|
|
|
|||||||||||||||||||||||||||
You should not draw any conclusions about the Trust’s investment performance from the amount of this distribution or from the terms of the Trust’s Managed Distribution Plan.
The Fund estimates that it has distributed more than its net income and net realized capital gains; therefore, a portion of your distribution may be a return of capital. A return of capital may occur, for example, when some or all of the money that you invested in the Fund is paid back to you. A return of capital does not necessarily reflect the Fund’s investment performance and should not be confused with ‘yield’ or ‘income’.
When distributions exceed total return performance, the difference will reduce the Fund’s net asset value per share.
The amounts and sources of distributions reported in this Notice are only estimates and are not being provided for tax reporting purposes.
The actual amounts and sources of the amounts for tax reporting purposes will depend upon the Fund’s investment experience during its fiscal year and may be subject to changes based on tax regulations. The Fund will send you a Form 1099-DIV for the calendar year that will tell you how to report these distributions for federal income tax purposes.
Contact Number: 800-882-0052